10576581.trn

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTADKO1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	DEC 01	ChemPort single article sales feature unavailable
NEWS	3	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS	4	APR 07	STN is raising the limits on saved answers
NEWS	5	APR 24	CA/CAplus now has more comprehensive patent assignee information
NEWS	6	APR 26	USPATFULL and USPAT2 enhanced with patent assignment/reassignment information
NEWS	7	APR 28	CAS patent authority coverage expanded
NEWS	8	APR 28	ENCOMPLIT/ENCOMPLIT2 search fields enhanced
NEWS	9	APR 28	Limits doubled for structure searching in CAS REGISTRY
NEWS	10	MAY 08	STN Express, Version 8.4, now available
NEWS	11	MAY 11	STN on the Web enhanced
NEWS	12	MAY 11	BEILSTEIN substance information now available on STN Easy
NEWS	13	MAY 14	DGENE, PCTGEN and USGENE enhanced with increased limits for exact sequence match searches and introduction of free HIT display format
NEWS	14	MAY 15	INPADOCDB and INPAFAMDB enhanced with Chinese legal status data
NEWS	15	MAY 28	CAS databases on STN enhanced with NANO super role in records back to 1992
NEWS	16	JUN 01	CAS REGISTRY Source of Registration (SR) searching enhanced on STN

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

10576581.trn

FILE 'HOME' ENTERED AT 13:35:47 ON 02 JUN 2009

=> file reg
FILE 'REGISTRY' ENTERED AT 13:35:58 ON 02 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 1 JUN 2009 HIGHEST RN 1151607-22-5
DICTIONARY FILE UPDATES: 1 JUN 2009 HIGHEST RN 1151607-22-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\11761274-55.str



chain nodes :
19 21
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 22 23 24 25 26 27
ring/chain nodes :
18 20 28 29 30 31
chain bonds :
3-30 5-31 6-7 9-19 10-18 11-12 15-29 19-20 19-21 21-22 21-28
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11 12-13 12-17 13-14
14-15 15-16 16-17 22-23 22-27 23-24 24-25 25-26 26-27

10576581.trn

exact/norm bonds :
6-7 7-8 7-11 8-9 9-10 10-11 19-20 19-21 21-22 22-23 22-27 23-24 24-25
25-26 26-27
exact bonds :
3-30 5-31 9-19 10-18 11-12 15-29 21-28
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:CLASS
29:CLASS 30:CLASS 31:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 13:36:25 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 48 TO ITERATE

100.0% PROCESSED 48 ITERATIONS 13 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 545 TO 1375

10576581.trn

PROJECTED ANSWERS: 44 TO 476

L2 13 SEA SSS SAM L1

=>
Uploading C:\Program Files\Stnexp\Queries\10576581.str



ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13
ring/chain nodes :
7
chain bonds :
1-8 4-7
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13
exact/norm bonds :
1-2 1-6 2-3 4-7
exact bonds :
1-8 3-4 4-5 5-6
normalized bonds :
8-9 8-13 9-10 10-11 11-12 12-13

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom

L3 STRUCTURE UPLOADED

=> d l13
L13 NOT FOUND
The L-number entered has not been defined in this session, or it
has been deleted. To see the L-numbers currently defined in this
session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s l3
SAMPLE SEARCH INITIATED 13:36:50 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 20587 TO ITERATE

```
  9.7% PROCESSED     2000 ITERATIONS                              50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       403148 TO   420332
PROJECTED ANSWERS:           13773 TO    17107

L4           50 SEA SSS SAM L3

=> s l3 full
FULL SEARCH INITIATED 13:36:59 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   411351 TO ITERATE

100.0% PROCESSED   411351 ITERATIONS                          16588 ANSWERS
SEARCH TIME: 00.00.06

L5        16588 SEA SSS FUL L3

=> FIL STNGUIDE
FILE 'STNGUIDE' ENTERED AT 13:43:45 ON 02 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 29, 2009 (20090529/UP).

=> FIL CAPLUS
FILE 'CAPLUS' ENTERED AT 13:49:42 ON 02 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 2 Jun 2009  VOL 150 ISS 23
FILE LAST UPDATED: 1 Jun 2009  (20090601/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Feb 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Feb 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.
```

```
=> FIL STNGUIDE
FILE 'STNGUIDE' ENTERED AT 13:49:49 ON 02 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 29, 2009 (20090529/UP).

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> FILE REGISTRY

FILE 'REGISTRY' ENTERED AT 13:55:44 ON 02 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    1 JUN 2009  HIGHEST RN 1151607-22-5
DICTIONARY FILE UPDATES:   1 JUN 2009  HIGHEST RN 1151607-22-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10576581-7777.str
```

10576581.trn





chain nodes :
14 21 23 24 25
ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13 15 16 17 18 19 20
ring/chain nodes :
7 22
chain bonds :
1-8 1-21 4-7 7-14 14-15 21-22 21-23 23-24 23-25
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13 15-16 15-20
16-17 17-18 18-19 19-20
exact/norm bonds :
1-2 1-6 2-3 4-7 7-14 21-22 21-23 23-24 23-25
exact bonds :
1-8 1-21 3-4 4-5 5-6 14-15
normalized bonds :
8-9 8-13 9-10 10-11 11-12 12-13 15-16 15-20 16-17 17-18 18-19 19-20

G1:CH3,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,H

Match level :

10576581.trn

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS

L6 STRUCTURE UPLOADED

=> d l6
L6 HAS NO ANSWERS
L6 STR



G1 Me,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,H

Structure attributes must be viewed using STN Express query preparation.

=> d his

(FILE 'HOME' ENTERED AT 13:35:47 ON 02 JUN 2009)

FILE 'REGISTRY' ENTERED AT 13:35:58 ON 02 JUN 2009
L1 STRUCTURE UPLOADED
L2 13 S L1
L3 STRUCTURE UPLOADED
L4 50 S L3
L5 16588 S L3 FULL

FILE 'STNGUIDE' ENTERED AT 13:43:45 ON 02 JUN 2009

FILE 'CAPLUS' ENTERED AT 13:49:42 ON 02 JUN 2009

FILE 'STNGUIDE' ENTERED AT 13:49:49 ON 02 JUN 2009

10576581.trn

```
     FILE 'REGISTRY' ENTERED AT 13:55:44 ON 02 JUN 2009
L6              STRUCTURE UPLOADED

=> s sub=l5 sam l6
SAMPLE SUBSET SEARCH INITIATED 13:56:16 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED -        1 TO ITERATE

100.0% PROCESSED        1 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):           ONLINE  **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):            1 TO       80
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):               0 TO        0

L7            0 SEA SUB=L5 SSS SAM L6

=>
Uploading C:\Program Files\Stnexp\Queries\10576581-99.str
```



```
chain nodes :
14  21
ring nodes :
1  2  3  4  5  6  8  9  10  11  12  13  15  16  17  18  19  20
ring/chain nodes :
7  22  23
chain bonds :
1-8  1-21  4-7  7-14  14-15  21-22  21-23
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  8-9  8-13  9-10  10-11  11-12  12-13  15-16  15-20
16-17  17-18  18-19  19-20
exact/norm bonds :
1-2  1-6  2-3  4-7  7-14  21-22  21-23
exact bonds :
1-8  1-21  3-4  4-5  5-6  14-15
normalized bonds :
8-9  8-13  9-10  10-11  11-12  12-13  15-16  15-20  16-17  17-18  18-19  19-20
```

10576581.trn

G1:CH3,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,H

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:CLASS 22:CLASS 23:CLASS

L8 STRUCTURE UPLOADED

=> d l8
L8 HAS NO ANSWERS
L8 STR



G1 Me,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,H

Structure attributes must be viewed using STN Express query preparation.

=> s sub=l5 sam l8
SAMPLE SUBSET SEARCH INITIATED 13:57:25 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED - 4 TO ITERATE

100.0% PROCESSED 4 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET): ONLINE **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET): 4 TO 200
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET): 0 TO 0

L9 0 SEA SUB=L5 SSS SAM L8

10576581.trn

```
=> d his

     (FILE 'HOME' ENTERED AT 13:35:47 ON 02 JUN 2009)

     FILE 'REGISTRY' ENTERED AT 13:35:58 ON 02 JUN 2009
L1             STRUCTURE UPLOADED
L2          13 S L1
L3             STRUCTURE UPLOADED
L4          50 S L3
L5       16588 S L3 FULL

     FILE 'STNGUIDE' ENTERED AT 13:43:45 ON 02 JUN 2009

     FILE 'CAPLUS' ENTERED AT 13:49:42 ON 02 JUN 2009

     FILE 'STNGUIDE' ENTERED AT 13:49:49 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 13:55:44 ON 02 JUN 2009
L6             STRUCTURE UPLOADED
L7           0 S SAM L6 SUB=L5
L8             STRUCTURE UPLOADED
L9           0 S SAM L8 SUB=L5

=> s sub=l5 full l8
FULL SUBSET SEARCH INITIATED 13:57:37 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -       74 TO ITERATE

100.0% PROCESSED       74 ITERATIONS                              16 ANSWERS
SEARCH TIME: 00.00.01

L10          16 SEA SUB=L5 SSS FUL L8

=> d scan
```

L10 16 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, N-[cis-4-(aminocarbonyl)-4-(2-chlorophenyl)cyclohexyl]-N-cyclopropyl-4-[[(5S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]-
MF C26 H28 Cl F3 N2 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1)-1

L10 16 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, N-[cis-4-(aminocarbonyl)-4-phenylcyclohexyl]-N-cyclopropyl-4-[[(5S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]-
MF C26 H29 F3 N2 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1)-1

L10 16 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Sulfanic acid, [1-[3-methoxyphenyl)-4-(phenylamino)cyclohexyl]carbonyl]-, 2,6-bis(1-methylethyl)phenyl ester
MF C32 H43 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1)-1

L10 16 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Cyclohexanecarboxamide, 4-[([1,1'-biphenyl]-4-ylmethyl)amino]-1-[3-methoxyphenyl]-N-[phenylmethyl]-, cis-
MF C34 H36 N2 O2

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1)-1

10576581.trn

L10 16 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Cyclohexanecarboxamide, N-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-1-phenyl-4-[(phenylmethyl)amino]-, trans-
MF C30 H30 F6 N2 O

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1)>1

L10 16 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Cyclohexanecarboxamide, N-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-1-phenyl-4-[(phenylmethyl)amino]-, cis-
MF C30 H30 F6 N2 O

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1)>1

L10 16 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, N-[cis-4-(aminocarbonyl)-4-[4-(aminocarbonyl)phenyl]cyclohexyl]-N-cyclopropyl-4-[(1S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]-
MF C27 H29 F3 N3 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1)>1

L10 16 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Sulfamic acid, N-[[1-(3-methoxyphenyl)-4-[(2-methoxyphenyl)amino]cyclohexyl]carbonyl]-, 2,6-bis(1-methylethyl)phenyl ester
MF C33 H42 N2 O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1)>1

10576581.trn

L10 16 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Cyclohexanecarboxamide, 1-[3-methoxyphenyl]-4-[[phenylmethyl]amino]-, cis-
MF C21 H26 N2 O2

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 16 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Cyclohexanecarboxamide, N-[3-[1,5-bis(trifluoromethyl)phenyl]ethyl]-4-[methyl(4-phenylbutyl)amino]-1-phenyl-, trans-
MF C34 H38 F6 N2 O

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 16 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Cyclohexanecarboxamide, N-[1-[3,5-bis[trifluoromethyl]phenyl]ethyl]-4-[methyl(phenylmethyl)amino]-1-phenyl-, trans-
MF C31 H32 F6 N2 O

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 16 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, N-[cis-4-(aminocarbonyl)-4-(4-fluorophenyl)cyclohexyl]-N-cyclopropyl-4-[[(1S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]-
MF C26 H28 F4 N2 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10576581.trn

L10 16 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, N-trans-4-(aminocarbonyl)-4-(2-fluorophenyl)cyclohexyl]-N-cyclopropyl-4-[(2S)-2,3,3-trifluoro-1-hydroxy-1-methylethyl]-
MF C26 H28 F4 N2 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1)-1

L10 16 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Cyclohexanecarboxamide, 4-[[(1,1'-biphenyl]-4-ylmethyl)amino]-1-[3-methoxyphenyl]-, cis-
MF C27 H30 N2 O2

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1)-1

L10 16 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzenebutanamide, N-[trans-4-[[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]amino]cyclohexyl]-
MF C33 H34 F6 N2 O2

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1)-1

L10 16 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Cyclohexanecarboxamide, N-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-1-phenyl-4-[[4-phenylbutyl]amino]-, trans-
MF C33 H36 F6 N2 O

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

10576581.trn

=> 1
1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> file caplus
FILE 'CAPLUS' ENTERED AT 13:58:03 ON 02 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 2 Jun 2009 VOL 150 ISS 23
FILE LAST UPDATED: 1 Jun 2009 (20090601/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

10576581.trn

```
     FILE 'REGISTRY' ENTERED AT 13:55:44 ON 02 JUN 2009
L6                STRUCTURE UPLOADED
L7              0 S SAM L6 SUB=L5
L8                STRUCTURE UPLOADED
L9              0 S SAM L8 SUB=L5
L10            16 S FULL L8 SUB=L5

     FILE 'CAPLUS' ENTERED AT 13:58:03 ON 02 JUN 2009

=> s l10
L11            4 L10

=> d cbib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 4 ANSWERS - CONTINUE? Y/(N):y
```

L11 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
2007:1454431 Document No. 148:79790 Preparation of benzamide derivatives useful in the treatment of hydroxysteroid dehydrogenase-mediated diseases and their preparation. Powers, Jay P.; DeGraffenreid, Michael; Julian, Lisa; Kaiserman, Jacoby McMinn; Dustin, New; Yoogy; Sun, Daqing; Yan, Xuelei; Wang, Zhulun (Amgen Inc., USA). PCT Int. Appl. WO 2007145835 A2 20071221, 133 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW, RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, GB, IE, IS, IT, LT, LU, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG. IN (English). CODEN: PIXXD2. APPLICATION: WO 2007-US12809 20070531. PRIORITY: US 2006-811758P 20060602; US 2007-879739P 20070110.

GI



I



II

AB Benzamide derivs. of formula I are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders. Compds. of formula I wherein n is 0, 1 and 2; R1 is OH, halo and C1-8 haloalkyl; R2 and R3 are independently halo, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 alkoxy, etc., and wherein no more than two of R1, R2 and R3 are halo; R4 is H, halo, C1-8 alkyl and C3-8 cycloalkyl; R5 is C1-8 (halo)alkyl, C2-8 hydroxyalkyl, and C3-8 (hetero)cycloalkyl; R6 is C1-8 (halo)alkyl, C2-8 alkenyl, aryl-C1-6 alkyl,

L11 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
Absolute stereochemistry.

RN 960368-94-9 CAPLUS
CN Benzamide, N-[cis-4-[aminocarbonyl]-4-[4-[aminocarbonyl]phenyl]cyclohexyl]-N-cyclopropyl-4-[[(2S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 960368-15-7 CAPLUS
CN Benzamide, N-[cis-4-[aminocarbonyl]-4-(4-fluorophenyl)cyclohexyl]-N-cyclopropyl-4-[[(2S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]- (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(un)substituted (hetero)aryl, etc.; and their pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof, are claimed. Example compd. 11 was prepd. by alkylation of cyclohexane-1,4-dione monoethylene ketal with (3-benzyloxypropyl)phosphonium bromide; the resulting 4-(3-benzyloxypropylidene)cyclohexanone ethylene ketal underwent debenzylation to give the corresponding alc., which underwent addn. of diethylaluminum cyanide followed by cyclopropanation to give 4-cyano-4-cyclopropylcyclohexanone ethylene ketal, which underwent hydrolysis to give the corresponding cyclohexanone, which underwent reductive amination with cyclopropylamine to give trans-4-(cyclopropylamino)-1-cyclopropylcyclohexanecarbonitrile, which underwent amidation with (3S)-4-(1,1,1-trifluoro-2-hydroxyprop-2-yl)benzoic acid to give compd. II. All the invention compds. were evaluated for their 11β-HSD1 enzyme activity. From the assay, it was det. that the tested compds. exhibited IC50 values ranging from 1000 nM to <1 nM.

IT 960368-94-9P 960368-97-0P 960368-98-7P
960369-15-7P 960369-84-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of benzamide derivs. useful in treatment and prevention of hydroxysteroid dehydrogenase-mediated diseases)

RN 960368-94-9 CAPLUS
CN Benzamide, N-[cis-4-[aminocarbonyl]-4-[2-fluorophenyl)cyclohexyl]-N-cyclopropyl-4-[[(2S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 960368-93-8 CAPLUS
CN Benzamide, N-[cis-4-(aminocarbonyl)-4-phenylcyclohexyl]-N-cyclopropyl-4-[[(2S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]- (CA INDEX NAME)

L11 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 960369-84-6 CAPLUS
CN Benzamide, N-[cis-4-(aminocarbonyl)-4-(2-chlorophenyl)cyclohexyl]-N-cyclopropyl-4-[[(2S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]- (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
2005:1123880 Document No. 143:4059230 Preparation of heterocycle- and benzene-containing sulfonamide derivatives as LDL receptor agonists. Ban, Hitoshi; Asano, Shigehiro (Sumitomo Pharmaceuticals Co., Ltd., Japan). PCT Int. Appl. WO 2005097738 A1 20051020, 233 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2005-JP6977 20050404. PRIORITY: JP 2004-112503 20040406.
GI



I



II

AB Enhancers for expression of low d. lipoprotein receptor containing the title compds. represented by the formula (I), prodrugs thereof, and their pharmaceutically acceptable salts [m, n, p = 0-4 and 3≤m+n≤8; X = O, S, each (un)substituted NH or CH2; R1 -R3 = H, each (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, arylsulfonyl, heteroarylsulfonyl, arylalkyl, or heteroarylalkyl; Y = SO2, optionally esterified P(O)(OH), CO; Z = O, S, (un)substituted NH, (CH2)q; q = 0-4; a, b, c, d, e, f = H, HO, each (un)substituted alkyl, alkoxy, alkoxycarbonyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, arylalkyl, heteroarylalkyl, arylalkyloxy, or heteroarylalkyloxy; or one or plural combination(s) of a and b, c and d, or e and f represent oxo; e and f

L11 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
represent thioxo; a and c represent alkylene] are disclosed. Drugs for treating hyperlipemia and arteriosclerosis contg. the compds. I are also disclosed. Thus, a soln. of 40 mg tert-Bu [[[2-[cis-4-amino-1-(3-methoxyphenyl)cyclohexyl]methyl]amino]sulfonyl]carbamate and 22.0 mg 1-benzyl-4-piperidone in 2 mL 1,2-dichloroethane was treated with 71.7 mg sodium triacetoxyborohydride and stirred overnight, followed by treatment of the product with CF3CO2H in CH2Cl2 to give N-[[cis-4-[(1-benzylpiperidin-4-yl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]sulfonamide (II) (R4 = NH2, R5 = 1-benzyl-4-piperidinyl) (III). III and II (R4 = Me, R5 = 1,1'-biphenyl-4-ylmethyl) at 10 μM increased the uptake of 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI)-labeled human low d. lipoprotein in HepG2 cells by 230 and 238%, resp.

IT 867263-27-2P 867263-28-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocycle- and benzene-containing sulfonamide derivs. as LDL receptor agonists for treatment of hyperlipemia and arteriosclerosis)

RN 867263-27-2 CAPLUS
CN Sulfamic acid, N-[[1-(3-methoxyphenyl)-4-(phenylamino)cyclohexyl]carbonyl]-, 2,6-bis(1-methylethyl)phenyl ester (CA INDEX NAME)



RN 867263-28-3 CAPLUS
CN Sulfamic acid, N-[[1-(3-methoxyphenyl)-4-[(2-methoxyphenyl)amino]cyclohexyl]carbonyl]-, 2,6-bis(1-methylethyl)phenyl ester (CA INDEX NAME)



L11 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

L11 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
2005:369273 Document No. 142:4302990 Preparation of novel piperidine and cyclohexanecarbonitrile derivatives effective in enhancing LDL receptor manifestation. Ban, Hitoshi; Ohnuma, Satoshi; Tsuboya, Norie; Asano, Shigehiro (Sumitomo Pharmaceuticals Co., Ltd., Japan). PCT Int. Appl. WO 2005037269 A1 20050428, 209 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2004-JP15773 20041019. PRIORITY: JP 2003-361256 20031021.
GI



I

AB Drugs for enhancing LDL receptor manifestation contains compds. represented by the following formula (I), prodrugs thereof, or pharmaceutically acceptable salts of either [m, n, p = 0-4, provided that 3≤m+n≤8; X = N, each (un)substituted CH; Y = each (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, or aromatic group, COY; R1 = H, each (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, 3- to 8-membered saturated heterocyclyl containing one (un)substituted NH or O, aromatic group, COR14; R14 = each (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, or aromatic group; R2-R7 = H, OH, each (un)substituted alkyl, alkoxy, alkoxycarbonyl, aralkyl, heteroarylalkyl, aralkyloxy, or heteroarylalkyloxy; or one or a plural combination of R2 and R3, R4 and R5, or R6 and R7 = oxo; or R2 and R4 together = alkylene; two of R2-R5 are on the adjacent carbon atom to form a double bond; Z = H, OH, CO2H, cyano, phthalimido, halo, each (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, or aromatic group, etc.] as active ingredients. These compds. are effective in enhancing low d. lipoprotein (LDL) receptor manifestation and lowering blood concentration of LDL cholesterol and are useful as therapeutic agents for treating hyperlipemia and arteriosclerosis. Thus, 0.019 mL benzyl bromide was added to a suspension of 40 mg 4-(3-methoxyphenyl)-1,4'-bipiperidine-4-carbonitrile dihydrochloride and 92.6 mg K2CO3 in 1.0 mL DMF under ice-cooling, and the resulting mixture was warmed to room temperature, stirred overnight, and quenched by adding water to

L11 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
cure, after workup and silica gel chromatog., 15.6 mg
1'-benzyl-4-(3-methoxyphenyl)-2,3',6'-thiopiperidine-4-carbonitrile (II). II
at 10 μM and N-benzyl-4-(3-methoxyphenyl)-3-(pyrimidin-2-yl)piperidine-
4-carbothioamide at 3 μM enhanced the LDL receptor activity by 135 and
1954, resp.
IT 850886-13-6P, cis-N-Benzyl-4-[(biphenyl-4-ylmethyl)amino]-1-(3-
methoxyphenyl)cyclohexanecarboxamide 850886-20-3P,
cis-1-Benzylamino-7-(3-methoxyphenyl)cyclohexanecarboxamide
850886-22-5P, cis-4-[(Biphenyl-4-ylmethyl)amino]-1-(3-
methoxyphenyl)cyclohexanecarboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); TWU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of novel piperidine and cyclohexanecarbonitrile delivs.
as
enhancers for LDL receptor manifestation, hypolipidemics, and
antiarteriosclerotics)
RN 850886-20-3 CAPLUS
CN Cyclohexanecarboxamide, 4-[(1,1'-biphenyl-4-ylmethyl)amino]-1-(3-
methoxyphenyl)-N-(phenylmethyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-29-3 CAPLUS
CN Cyclohexanecarboxamide, 1-(3-methoxyphenyl)-4-[(phenylmethyl)amino]-,
cis-
(CA INDEX NAME)

Relative stereochemistry.



RN 850886-22-5 CAPLUS
CN Cyclohexanecarboxamide, 4-[[(1,1'-biphenyl]-4-ylmethyl]amino]-1-(3-

L11 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
2001:851143 Document No. 136:57420 Preparation of cyclohexane derivatives
for therapeutic use in the treatment of disorders, such as depression,
anxiety, pain, inflammation, migraine, and vomiting. Castro Pineiro,
Jose
Luis; Dunmell, Kevin; Elliott, Jason Matthew; Hollingworth, Gregory John;
Shaw, Duncan Edward; Swain, Christopher John (Merck Sharp & Dohme
Limited,
UK). PCT Int. Appl. WO 2001087866 A1 20011122, 153 pp. DESIGNATED
STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CI, CM, CY,
DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE,
SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2001-GB2136
20010516. PRIORITY: GB 2000-12214 20000519.
GI



AB Cyclohexane derivs., such as I [R = substituted or unsubstituted Ph or
pyridinyl; R1 = H, SH, NH2, alkyl, alkenyl, cycloalkyl, alkoxy, amino,
alkylthio, etc.; R2 = H, halogen, alkyl, alkoxy; R3 = H, CN, SH, halogen,
alkyl, alkoxy, amino, carboxy, acyl, etc.; R4 = H, OH, alkyl; R7 = H, OH,
aminoalkyl, carboxyalkyl, carboxyalkyl, C-linked heterocyclyl; X = linking
group, such as -CONR1CH(CH3)-, -CH(CH3)NR1CO-; R13 = H, alkyl,
alkylcarboxyl; R14, R15 = H, OH, CHO, alkyl, alkenyl, aminoalkyl,
carboxyl; R14R15 = =(CH2)2-], were prepared for pharmaceutical use in the
treatment or prevention of depression, anxiety, pain, inflammation,
migraine, emesis or posttherpetic neuralgia, and treatment or prevention
of
physiol. disorders associated with an excess of tachykinins. Thus,
cyclohexane derivative II was prepared via a multistep synthetic
sequence which

L11 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.

L11 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
was concluded with the amination of the corresponding cyclohexanone with
4-(4-fluorophenyl)piperidine. Dosages of the prepd. cyclohexanes were
discussed, however, biol. activity data was not presented.
IT 374821-21-3P 374821-25-7P
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological
study, unclassified); RCT (Reactant); SPN (Synthetic preparation); TBU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT
(Reactant or reagent); USES (Uses)
(preparation of cyclohexane derivs. for therapeutic use in the
treatment of
disorders, such as depression, anxiety, pain, inflammation, migraine,
and vomiting)
RN 374821-21-3 CAPLUS
CN Cyclohexanecarboxamide, N-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-
[methyl(phenylmethyl)amino]-1-phenyl-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 374821-25-7 CAPLUS
CN Cyclohexanecarboxamide, N-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-1-
phenyl-4-[(4-phenylbutyl)amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.



IT 374821-20-2P 374821-32-4P 374821-33-7P
374821-35-9P
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological
study, unclassified); SYN (Synthetic preparation); TBU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclohexane derivs. for therapeutic use in the
treatment of
disorders, such as depression, anxiety, pain, inflammation, migraine,
and vomiting)
RN 374821-20-2 CAPLUS
CN Cyclohexanecarboxamide, N-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-1-

L11 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
phenyl-4-[(phenylmethyl)amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 374821-32-6 CAPLUS
CN Cyclohexanecarboxamide, N-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-1-phenyl-4-[(phenylmethyl)amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 374821-33-7 CAPLUS
CN Cyclohexanecarboxamide, N-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[methyl(4-phenylbutyl)amino]-1-phenyl-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 374821-39-9 CAPLUS
CN Benzenebutanamide, N-[trans-4-[[[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]amino]carbonyl]-4-phenylcyclohexyl]- (CA
INDEX NAME)

L11 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
Relative stereochemistry.



10576581.trn

```
=> s LDL receptor
         42410 LDL
           660 LDLS
         42513 LDL
                 (LDL OR LDLS)
        807893 RECEPTOR
        744344 RECEPTORS
        968120 RECEPTOR
                 (RECEPTOR OR RECEPTORS)
L12       6519 LDL RECEPTOR
                 (LDL(W)RECEPTOR)

=> file reg
FILE 'REGISTRY' ENTERED AT 14:02:44 ON 02 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    1 JUN 2009  HIGHEST RN 1151607-22-5
DICTIONARY FILE UPDATES:   1 JUN 2009  HIGHEST RN 1151607-22-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

<------User Break------>

TRANSFER ENDED BY USER:             921 ANSWERS PROCESSED

=> d his

     (FILE 'HOME' ENTERED AT 13:35:47 ON 02 JUN 2009)

     FILE 'REGISTRY' ENTERED AT 13:35:58 ON 02 JUN 2009
L1              STRUCTURE UPLOADED
L2           13 S L1
L3              STRUCTURE UPLOADED
L4           50 S L3
L5        16588 S L3 FULL

     FILE 'STNGUIDE' ENTERED AT 13:43:45 ON 02 JUN 2009
```

10576581.trn

FILE 'CAPLUS' ENTERED AT 13:49:42 ON 02 JUN 2009

FILE 'STNGUIDE' ENTERED AT 13:49:49 ON 02 JUN 2009

FILE 'REGISTRY' ENTERED AT 13:55:44 ON 02 JUN 2009
L6 STRUCTURE UPLOADED
L7 0 S SAM L6 SUB=L5
L8 STRUCTURE UPLOADED
L9 0 S SAM L8 SUB=L5
L10 16 S FULL L8 SUB=L5

FILE 'CAPLUS' ENTERED AT 13:58:03 ON 02 JUN 2009
L11 4 S L10
L12 6519 S LDL RECEPTOR

FILE 'REGISTRY' ENTERED AT 14:02:44 ON 02 JUN 2009

FILE 'CAPLUS' ENTERED AT 14:02:48 ON 02 JUN 2009

FILE 'REGISTRY' ENTERED AT 14:03:14 ON 02 JUN 2009

=> file hcaplus
FILE 'HCAPLUS' ENTERED AT 14:03:23 ON 02 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 2 Jun 2009 VOL 150 ISS 23
FILE LAST UPDATED: 1 Jun 2009 (20090601/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l5 and l12
3768 L5

```
         42410 LDL
           660 LDLS
         42513 LDL
                 (LDL OR LDLS)
        807893 RECEPTOR
        744344 RECEPTORS
        968120 RECEPTOR
                 (RECEPTOR OR RECEPTORS)
          6519 LDL RECEPTOR
                 (LDL(W)RECEPTOR)
L14          4 L5 AND L12

=> d his

     (FILE 'HOME' ENTERED AT 13:35:47 ON 02 JUN 2009)

     FILE 'REGISTRY' ENTERED AT 13:35:58 ON 02 JUN 2009
L1                STRUCTURE UPLOADED
L2           13 S L1
L3                STRUCTURE UPLOADED
L4           50 S L3
L5        16588 S L3 FULL

     FILE 'STNGUIDE' ENTERED AT 13:43:45 ON 02 JUN 2009

     FILE 'CAPLUS' ENTERED AT 13:49:42 ON 02 JUN 2009

     FILE 'STNGUIDE' ENTERED AT 13:49:49 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 13:55:44 ON 02 JUN 2009
L6                STRUCTURE UPLOADED
L7            0 S SAM L6 SUB=L5
L8                STRUCTURE UPLOADED
L9            0 S SAM L8 SUB=L5
L10          16 S FULL L8 SUB=L5

     FILE 'CAPLUS' ENTERED AT 13:58:03 ON 02 JUN 2009
L11           4 S L10
L12        6519 S LDL RECEPTOR

     FILE 'REGISTRY' ENTERED AT 14:02:44 ON 02 JUN 2009

     FILE 'CAPLUS' ENTERED AT 14:02:48 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 14:03:14 ON 02 JUN 2009

     FILE 'HCAPLUS' ENTERED AT 14:03:23 ON 02 JUN 2009
L14           4 S L5 AND L12

=> d cbib abs hist str 1-
'CBIB' IS NOT VALID HERE
For an explanation, enter "HELP DISPLAY HISTORY".

=> d cbib abs histr 1-
'HISTR' IS NOT A VALID FORMAT FOR FILE 'HCAPLUS'
```

10576581.trn

The following are valid formats:

```
ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs
```

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the

information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):end

=> d cbib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 4 ANSWERS - CONTINUE? Y/(N):y

10576581.trn

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
2005:1123880 Document No. 143:405923O Preparation of heterocycle- and benzene-containing sulfonamide derivatives as LDL receptor agonists. Ban, Hitoshi; Asano, Shigehiro (Sumitomo Pharmaceuticals Co., Ltd., Japan). PCT Int. Appl. WO 2005097738 A1 20051020, 233 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2005-JP6977 20050404. PRIORITY: JP 2004-112503 20040406.

GI



I



II

AB Enhancers for expression of low d. lipoprotein receptor containing the title compds. represented by the formula (I), prodrugs thereof, and their pharmaceutically acceptable salts [m, n, p = 0-4 and 3≤m+n≤8; X = O, S, each (un)substituted NH or CH2; R1 -R3 = H, each (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, arylsulfonyl, heteroarylsulfonyl, arylalkyl, or heteroarylalkyl; Y = SO2, optionally esterified P(O)(OH), CO; Z = O, S, (un)substituted NH, (CH2)q; q = 0-4; a, b, c, d, e, f = H, HO, each (un)substituted alkyl, alkoxy, alkoxycarbonyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, arylalkyl, heteroarylalkyl, arylalkyloxy, or heteroarylalkyloxy; or one or plural combination(s) of a and b, c and d, or e and f represent oxo; e and f

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
represent thioxo; a and c represent alkylene] are disclosed. Drugs for treating hyperlipemia and arteriosclerosis contg. the compds. I are also disclosed. Thus, a soln. of 40 mg tert-Bu [[[2-[cis-4-amino-1-(3-methoxyphenyl)cyclohexyl]methyl]amino]sulfonyl]carbamate and 22.0 mg 1-benzyl-4-piperidone in 2 mL 1,2-dichloroethane was treated with 71.7 mg sodium triacetoxyborohydride and stirred overnight, followed by treatment of the product with CF3CO2H in CH2Cl2 to give N-[[cis-4-[(1-benzylpiperidin-4-yl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]sulfonamide (II) (R4 = NH2, R5 = 1-benzyl-4-piperidinyl) (III). III and II (R4 = Me, R5 = 1,1'-biphenyl-4-ylmethyl) at 10 μM increased the uptake of 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI)-labeled human low d. lipoprotein in HepG2 cells by 230 and 238%, resp.

IT 850887-48-8P, tert-Butyl 4-[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]piperazine-1-carboxylate 867263-38-5P 867263-39-6P 867263-41-0P 867264-21-9P 867264-32-2P 867264-34-4P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of heterocycle- and benzene-containing sulfonamide derivs. as LDL receptor agonists for treatment of hyperlipemia and arteriosclerosis)

RN 850887-48-8 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Relative stereochemistry.



RN 867263-38-5 HCAPLUS
CN Methanesulfonamide, N-[[trans-1-(3-methoxyphenyl)-4-(1-piperazinyl)cyclohexyl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



●2 HCl

RN 867263-39-6 HCAPLUS
CN Methanesulfonamide, N-[[cis-1-(3-methoxyphenyl)-4-(4-piperidinylamino)cyclohexyl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 867263-41-0 HCAPLUS
CN Methanesulfonamide, N-[[cis-4-amino-1-(3-methoxyphenyl)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867264-21-9 HCAPLUS
CN Carbamic acid, [[[[cis-4-[([1,1'-biphenyl]-4-ylmethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]amino]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867264-32-2 HCAPLUS
CN Carbamic acid, [[[[cis-4-[([1,1'-biphenyl]-4-ylmethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]amino]sulfonyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867264-34-4 HCAPLUS
CN Carbamic acid, [[[[cis-1-(3-methoxyphenyl)-4-(4-methyl-1-piperazinyl)cyclohexyl]methyl]amino]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



IT 850296-15-6P 850898-16-7,
N-[(cis-4-{[biphenyl-4-ylmethyl)amino]-1-(3-methoxybenzyl)cyclohexyl]methyl}-4-methylbenzenesulfonamide
867263-37-1P 867263-38-2P 867263-39-3P
867263-44-1P 867263-46-5P 867263-47-6P
867263-49-8P 867263-50-1P 867263-51-2P
867263-52-3P 867263-53-4P 867263-56-7P
867263-57-8P 867263-59-0P 867263-60-3P
867263-61-4P 867263-62-5P 867263-63-6P
867263-64-7P 867263-65-8P 867263-66-9P
867263-67-0P 867263-68-1P 867263-69-2P
867263-70-5P 867263-71-6P 867263-72-7P
867263-73-8P 867263-74-9P 867263-77-2P
867263-78-3P 867263-82-9P 867263-85-2P
867264-08-2P 867264-15-1P 867264-17-3P
867264-22-0P 867264-23-1P 867264-27-5P
867264-29-7P 867264-30-0P 867264-33-1P
867264-37-5P 867264-38-6P 867264-77-7P
867264-44-0P 867264-41-7P 867264-44-0P
RLs PAC (Pharmacological activity); RPH (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclo- and benzene-containing sulfonamide derivs. as
LDL receptor agonists for treatment of hyperlipemia
and arteriosclerosis)

RN 850296-15-6 HCAPLUS
CN Methanesulfonamide, N-[[cis-4-{[(1,1'-biphenyl]-4-ylmethyl)amino]-1-(3-methoxybenzyl)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 867263-35-2 HCAPLUS
CN Methanesulfonamide, N-[[cis-1-(3-methoxyphenyl)-4-[1-piperazinyl)cyclohexyl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)

Relative stereochemistry.



● 2 HCl

RN 867263-44-3 HCAPLUS
CN Acetamide, N-[4-[[[cis-4-(3-methoxyphenyl)-4-[(methylsulfonyl)amino]methyl]cyclohexyl]amino]methyl]phenyl]- (CA INDEX NAME)

Relative stereochemistry.

RN 867263-46-5 HCAPLUS
CN Methanesulfonamide, N-[[trans-3-(3-methoxyphenyl)-4-[[[4-(methylsilyl)phenyl]methyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850296-16-7 HCAPLUS
CN Benzenesulfonamide, N-[[cis-4-{[(1,1'-biphenyl]-4-ylmethyl)amino]-1-(3-methoxybenzyl)cyclohexyl]methyl]-4-methyl- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-27-2 HCAPLUS
CN Sulfamic acid, N-[[1-(3-methoxyphenyl)-4-(phenylamino)cyclohexyl]carbonyl]-, 2,6-bis(1-methylethyl)phenyl ester (CA INDEX NAME)



RN 867263-28-3 HCAPLUS
CN Sulfamic acid, N-[[1-(3-methoxyphenyl)-4-[(2-methoxyethyl)amino]cyclohexyl]carbonyl]-, 2,6-bis(1-methylethyl)phenyl ester (CA INDEX NAME)

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Relative stereochemistry.



RN 867263-47-6 HCAPLUS
CN Methanesulfonamide, N-[[trans-1-(3-methoxyphenyl)-4-[4-methyl-1-piperazinyl)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-49-8 HCAPLUS
CN Methanesulfonamide, N-[[cis-1-(3-methoxyphenyl)-4-[[1-(1-methylethyl)-4-piperidinyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-50-1 HCAPLUS
CN Methanesulfonamide, N-[[cis-1-(3-methoxyphenyl)-4-[[1-methyl-4-piperidinyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867263-51-2 HCAPLUS
CN Acetamide, N-[4-[[4-[[cis-4-(3-methoxyphenyl)-4-[[(methylsulfonyl)amino]methyl]cyclohexyl]amino]-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-52-3 HCAPLUS
CN Methanesulfonamide, N-[[cis-1-[3-methoxyphenyl)-4-[[1-[[4-(methylsulfonyl)phenyl]methyl]-4-piperidinyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-53-4 HCAPLUS

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867263-59-0 HCAPLUS
CN Sulfamide, N-[[cis-4-[[4-(1H-imidazol-1-yl)phenyl]methyl]amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-60-3 HCAPLUS
CN Sulfamide, N-[[cis-1-(3-methoxyphenyl)-4-[[4-(1H-1,2,4-triazol-1-yl)phenyl]methyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867263-54-7 HCAPLUS
CN Methanesulfonamide, N-[cis-1-(3-methoxyphenyl)-4-(4-piperidinylamino)cyclohexyl)-, hydrochloride (1:2) (CA INDEX NAME)

Relative stereochemistry.



● 2 HCl

RN 867263-57-8 HCAPLUS
CN Sulfamide, N-[[cis-1-(3-methoxyphenyl)-4-[[1-(phenylmethyl)-4-piperidinyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 867263-61-4 HCAPLUS
CN Sulfamide, N-[[cis-4-[[[4-(2-hydroxyethoxy)phenyl]methyl]amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-62-5 HCAPLUS
CN Acetamide, N-[4-[[[cis-4-[[[aminosulfonyl)amino]methyl]-4-[3-methoxyphenyl)cyclohexyl]amino]methyl]phenyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-63-6 HCAPLUS
CN Sulfamide, N-[[cis-1-(3-methoxyphenyl)-4-[[4-quinolinylmethyl)amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867263-64-7 HCAPLUS
CN Sulfamide, N-[[cis-1-[3-methoxyphenyl)-4-
[[phenylmethyl)amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-65-8 HCAPLUS
CN Sulfamide, N-[[cis-1-[3-methoxyphenyl)-4-[[4-(4-
morpholinylphenyl)methyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867263-69-1 HCAPLUS
CN Sulfamide,
N-[[cis-4-[[(5-ehloro-1,2,3-thiadiazol-4-yl)methyl]amino]-1-(3-
methoxyphenyl)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-69-2 HCAPLUS
CN Sulfamide, N-[cis-1-(3-methoxyphenyl)-4-[[(1-methyl-1H-indol-5-
yl)methyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-70-5 HCAPLUS

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867263-66-9 HCAPLUS
CN Sulfamide, N-[[cis-4-[[4-butoxyphenyl)methyl]amino]-1-(3-
methoxyphenyl)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-67-0 HCAPLUS
CN Sulfamide, N-[[cis-4-[[1,3-benzodioxol-5-ylmethyl)amino]-1-(3-
methoxyphenyl)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN Sulfamide, N-[[cis-4-[[2-benzofurnylmethyl)amino]-1-(3-
methoxyphenyl)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-71-6 HCAPLUS
CN Sulfamide, N-[[cis-1-(3-methoxyphenyl)-4-[(1-methyl-4-
piperidinyl)amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-72-7 HCAPLUS
CN Sulfamide, N-[[cis-4-[[2-hydroxy-4-methoxyphenyl)methyl]amino]-1-(3-
methoxyphenyl)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-73-8 HCAPLUS
CN Sulfamide, N-[[cis-1-(3-methoxyphenyl)-4-[(1-

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
phenylethyl)amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867267-74-9 HCAPLUS
CN Sulfamide, N-[[cis-4-[[1-[1,1'-biphenyl]-4-ylethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 867263-77-2 HCAPLUS
CN Sulfamide, N-[[cis-4-[[1-[1,1'-biphenyl]-4-ylethyl]amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867263-85-2 HCAPLUS
CN Benzenesulfonamide, N-[[cis-4-[([1,1'-biphenyl]-4-ylmethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867264-08-2 HCAPLUS
CN Benzenesulfonamide, 4-[[[trans-4-[[(aminosulfonyl)amino]methyl]-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867263-78-3 HCAPLUS
CN Sulfamide, N-[2-[trans-4-[([1,1'-biphenyl]-4-ylmethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 867263-82-9 HCAPLUS
CN Sulfamide, N-[cis-4-[([1,1'-biphenyl]-4-ylmethyl)amino]-1-[3-methoxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 867264-15-1 HCAPLUS
CN Carbamic acid, [[[cis-1-(3-methoxyphenyl)-4-[[[4-(methylsulfonyl)phenyl]methyl]amino]cyclohexyl]methyl]amino]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867264-17-3 HCAPLUS
CN Methanesulfonamide, N-[[cis-4-[(1,1'-biphenyl]-4-ylmethyl)amino]-1-(3-ethoxyphenyl)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867264-22-0 HCAPLUS
CN Sulfamide, N-[[cis-4-[([1,1'-biphenyl]-4-ylmethyl)amino]-1-(2-methoxyphenyl)cyclohexyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 867264-23-1 HCAPLUS
CN Sulfamide, N-[[trans-4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 867264-27-5 HCAPLUS
CN Sulfamide, N-[[cis-4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-(3-ethoxyphenyl)cyclohexyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867264-31-1 HCAPLUS
CN Carbamic acid, [[[cis-4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867264-33-3 HCAPLUS
CN Sulfamide, N-[[cis-4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]-N'-methyl-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 867264-36-6 HCAPLUS

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 867264-29-7 HCAPLUS
CN Acetamide, N-[[[cis-4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]amino]sulfonyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867264-30-0 HCAPLUS
CN Propanamide, N-[[[cis-4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]amino]sulfonyl]-2-methyl- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

CN Sulfamide, N-[[cis-1-(3-methoxyphenyl)-4-(4-methyl-1-piperazinyl)cyclohexyl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)

Relative stereochemistry.



● 2 HCl

RN 867264-37-7 HCAPLUS
CN Methanesulfonamide, N-[[trans-1-(3-methoxyphenyl)-4-[[1-(phenylmethyl)-4-piperidinyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867264-40-2 HCAPLUS
CN Benzenesulfonamide, 4-[[4-[[cis-4-(3-methoxyphenyl)-4-[(methylsulfonyl)amino]methyl]cyclohexyl]amino]-1-piperidinyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 1 OF 4 ACAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867264-41-3 ACAPLUS
CN Sulfinide, N-[[trans-1-(3-methoxyphenyl)-4-[4-piperidinylamino]cyclohexyl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 867264-44-6 ACAPLUS
CN Sulfinide, N-[[trans-1-(3-methoxyphenyl)-4-[[1-(phenylmethyl)-4-piperidinyl]amino]cyclohexyl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 1 OF 4 ACAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867243-75-0 ACAPLUS
CN Cyclohexanecarbonitrile, 4-[[1-[1,1'-biphenyl]-4-ylethyl]amino]-1-(3-methoxyphenyl)-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 867264-25-3 ACAPLUS
CN Cyclohexanecarbonitrile, 4-[[(1,1'-biphenyl]-4-ylmethyl)amino]-1-(3-methoxyphenyl)-, trans- (CA INDEX NAME)

Relative stereochemistry.

IT 850895-23-1P, trans-1-(3-Methoxyphenyl)-4-piperazin-1-ylcyclohexanecarbonitrile dihydrochloride 850895-22-2P, cis-1-(3-Methoxyphenyl)-4-piperazin-1-ylcyclohexanecarbonitrile dihydrochloride 850895-24-4P, cis-4-[(Diphenylmethyl)amino]-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850895-40-3P, trans-4-[(Biphenylmethyl)amino]-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850895-46-4P, cis-4-Amino-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850895-48-6P, trans-4-Amino-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850896-02-1P, tert-Butyl

L14 ANSWER 1 OF 4 ACAPLUS COPYRIGHT 2009 ACS on STN (Continued)



●2 HCl

IT 850896-11-2, cis-4-(Aminomethyl)-N-(biphenyl-4-ylmethyl)-4-(3-methoxyphenyl)cyclohexanamine 850887-58-0, Methyl cis-4-[(diphenylmethyl)amino]-1-(3-methoxyphenyl)cyclohexanecarboxylate 867263-75-0 867264-25-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heterocycle- and benzene-containing sulfonamide derivs. as
LDL receptor agonists for treatment of hyperlipemia
and arteriosclerosis)
RN 850886-11-2 ACAPLUS
CN [1,1'-Biphenyl]-4-methanamine, N-[cis-4-(aminomethyl)-4-(3-methoxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850887-58-0 ACAPLUS
CN Cyclohexanecarboxylic acid, 4-[[diphenylmethyl)amino]-1-(3-methoxyphenyl)- , methyl ester, cis- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 1 OF 4 ACAPLUS COPYRIGHT 2009 ACS on STN (Continued)

4-[[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]piperidine-1-carboxylate 850886-03-2P,
cis-1-(3-Methoxyphenyl)-4-(piperidin-4-ylamino)cyclohexanecarbonitrile dihydrochloride 850886-05-4P,
cis-4-[[1-Benzylpiperidin-4-yl]amino]-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850886-33-8P
850887-47-7P, tert-Butyl 4-[trans-4-cyano-4-(3-methoxyphenyl)cyclohexyl]piperazine-1-carboxylate 850887-59-1P,
Methyl cis-4-[(tert-butoxycarbonyl)amino]-1-(3-methoxyphenyl)cyclohexanecarboxylate 850887-60-4P,
cis-4-[(tert-Butoxycarbonyl)amino]-1-(3-methoxyphenyl)cyclohexanecarboxylic acid 851067-35-1P
867262-90-6P 867262-91-7P 867262-92-8P
867262-93-9P 867262-94-0P 867262-95-1P
867262-96-2P 867263-36-3P 867263-37-4P
867263-42-1P 867263-43-2P 867263-54-4P
867263-55-6P 867263-58-9P 867263-76-1P
867263-79-4P 867263-80-7P 867263-81-8P
867263-83-0P 867263-84-1P 867264-09-3P
867264-10-6P 867264-11-7P 867264-12-8P
867264-14-0P 867264-16-2P 867264-18-4P
867264-19-5P 867264-20-8P 867264-24-2P
867264-26-4P 867264-28-6P 867264-35-5P
867264-36-6P 867264-42-4P 867264-43-5P
867264-45-7P
RL: RCT (Reactant); RPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of heterocycle- and benzene-containg. sulfonamide derivs. as
LDL receptor agonists for treatment of hyperlipemia
and arteriosclerosis)
RN 850885-21-1 ACAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-(1-piperazinyl)-, hydrochloride (1:2), trans- (CA INDEX NAME)

Relative stereochemistry.

●2 HCl

RN 850885-22-2 ACAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-(1-piperazinyl)-, hydrochloride (1:2), cis- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



●2 HCl

RN 850885-64-2 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[(diphenylmethyl)amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-65-3 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[(diphenylmethyl)amino]-1-(3-methoxyphenyl)-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-66-4 HCAPLUS
CN Cyclohexanecarbonitrile, 4-amino-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850885-68-6 HCAPLUS
CN Cyclohexanecarbonitrile, 4-amino-1-(3-methoxyphenyl)-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-02-1 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Relative stereochemistry.



RN 850886-03-2 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-(4-piperidinylamino)-, hydrochloride (1:2), cis- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



●2 HCl

RN 850886-05-4 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[1-(phenylmethyl)-4-piperidinyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-33-8 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[[(1,1'-biphenyl-4-ylmethyl)amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850887-47-7 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[trans-4-cyano-4-(3-methoxyphenyl)cyclohexyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850887-59-1 HCAPLUS
CN Cyclohexanecarboxylic acid, 4-[[(1,1-dimethylethoxy)carbonyl]amino]-1-(3-methoxyphenyl)-, methyl ester, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850887-60-4 HCAPLUS
CN Cyclohexanecarboxylic acid, 4-[[(1,1-dimethylethoxy)carbonyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 851047-35-1 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-(4-piperidinylamino)-, cis-
(CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867262-90-6 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[(diphenylmethyl)amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 867262-91-7 HCAPLUS
CN Cyclohexanemethanol, 4-[(diphenylmethyl)amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 867262-92-8 HCAPLUS
CN Cyclohexanemethanol, 4-[(diphenylmethyl)amino]-1-(3-methoxyphenyl)-, 1-methanesulfonate, cis- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867262-93-9 HCAPLUS
CN Cyclohexaneacetonitrile, 1-(3-methoxyphenyl)-4-(4-piperidinylamino)-, hydrochloride (1:2), cis- (CA INDEX NAME)

Relative stereochemistry.



● 2 HCl

RN 867262-94-0 HCAPLUS
CN Carbamic acid, [cis-4-amino-4-(3-methoxyphenyl)cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867262-95-1 HCAPLUS
CN Cyclohexanecarboxylic acid, 4-[(diphenylmethyl)amino]-3-(3-methoxyphenyl)-, methyl ester, trans- (CA INDEX NAME)

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Relative stereochemistry.



RN 867262-96-2 HCAPLUS
CN Carbamic acid, [cis-4-[[(1,1-dimethylethoxy)carbonyl]amino]-1-(3-methoxyphenyl)cyclohexyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867263-36-3 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[4-(triphenylmethyl)-1-piperazinyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-37-4 HCAPLUS
CN Piperazine, 1-(trans-4-(3-methoxyphenyl)-4-methylcyclohexyl]-4-(triphenylmethyl)- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867263-42-1 HCAPLUS
CN Methanesulfonamide, N-[[cis-4-[(diphenylmethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-43-2 HCAPLUS
CN Benzenemethanamine, N-[cis-4-(aminomethyl)-4-(3-methoxyphenyl)cyclohexyl]-N-phenyl- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-54-5 HCAPLUS
CN Carbamic acid, [cis-4-(3-methoxyphenyl)-4-[(methylsulfonyl)amino]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867263-55-6 HCAPLUS
CN Methanesulfonamide, N-[cis-4-amino-1-(3-methoxyphenyl)cyclohexyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 867263-58-9 HCAPLUS
CN Carbamic acid, [[[cis-4-amino-1-(3-methoxyphenyl)cyclohexyl]methyl]amino]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867263-76-1 HCAPLUS

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867263-81-8 HCAPLUS
CN Carbamic acid, [[[2-[cis-4-[[1,1'-biphenyl]-4-ylmethyl]amino]-1-(3-methoxyphenyl)cyclohexyl]ethyl]amino]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867263-83-0 HCAPLUS
CN Carbamic acid, [[[cis-4-[[(1,1-dimethylethoxy)carbonyl]amino]-1-(3-methoxyphenyl)cyclohexyl]amino]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867263-84-1 HCAPLUS
CN Sulfanide, N-[cis-4-amino-1-(3-methoxyphenyl)cyclohexyl]-, hydrochloride (1:1) (CA INDEX NAME)

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN Carbamic acid, [[[[trans-4-[(3-[1,1'-biphenyl]-4-ylethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]amino]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867263-79-4 HCAPLUS
CN Carbamic acid, [[[2-[cis-4-[(diphenylmethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]ethyl]amino]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867263-80-7 HCAPLUS
CN Carbamic acid, [[[2-[trans-4-amino-1-(3-methoxyphenyl)cyclohexyl]ethyl]amino]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Relative stereochemistry.



● HCl

RN 867264-09-3 HCAPLUS
CN Carbamic acid, [[cis-4-[(diphenylmethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867264-10-6 HCAPLUS
CN Carbamic acid, [[trans-4-amino-1-(3-methoxyphenyl)cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867264-11-7 HCAPLUS

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN Carbamic acid, [[cis-4-[[[4-(aminosulfonyl)phenyl]methyl]amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867264-12-9 HCAPLUS
CN Benzenesulfonamide, 4-[[[trans-4-(aminomethyl)-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]-, hydrochloride (1:2) (CA INDEX NAME)

Relative stereochemistry.



● 2 HCl

RN 867264-14-0 HCAPLUS
CN Carbamic acid, [[[[cis-4-[[[4-(aminosulfonyl)phenyl]methyl]amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]amino]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867264-16-2 HCAPLUS
CN Carbamic acid, [[[[cis-4-[(diphenylmethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]amino]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867264-18-4 HCAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867264-19-5 HCAPLUS

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN [1,1'-Biphenyl]-4-carboxamide, N-[cis-4-cyano-4-(3-hydroxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867264-20-8 HCAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[cis-4-cyano-4-(3-ethoxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867264-24-2 HCAPLUS
CN [1,1'-Biphenyl]-4-methanamine, N-[trans-4-(aminomethyl)-4-(3-methoxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867264-26-4 HCAPLUS
CN Carbamic acid, [[[trans-4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]amino]sulfonyl]-, 1,1-dimethylethyl ester

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867264-28-6 HCAPLUS
CN Carbamic acid, [[[[cis-4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-(3-ethoxyphenyl)cyclohexyl]methyl]amino]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867264-35-5 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[cis-4-(aminomethyl)-4-(3-methoxyphenyl)cyclohexyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Relative stereochemistry.



RN 867264-38-8 HCAPLUS

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN 4-0-guanidinoace,
N-[trans-4-(aminomethyl)-4-[3-methoxyphenyl)cyclohexyl]-
1-[phenylmethyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867264-42-4 HCAPLUS
CN Cyclohexanecarbonitrile, 1-[3-methoxyphenyl)-4-[[1-(triphenylmethyl)-4-
piperidinyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 867264-43-5 HCAPLUS
CN Carbamic acid, [[[cis-1-[3-methoxyphenyl)-4-[[1-(triphenylmethyl)-4-
piperidinyl]amino]cyclohexyl]methyl]amino]sulfonyl]-, 1,1-dimethylethyl
ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 867264-45-7 HCAPLUS
CN Carbamic acid, [[[trans-1-[3-methoxyphenyl)-4-[[1-(phenylmethyl)-4-
piperidinyl]amino]cyclohexyl]methyl]amino]sulfonyl]-, 1,1-dimethylethyl

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
2005:369373 Document No. 142:430299M Preparation of novel piperidine and
cyclohexanecarbonitrile derivatives effective in enhancing LDL
receptor manifestation. Ban, Hitoshi; Ohnuma, Satoshi; Tsuboya,
Norio; Asano, Shigehiro (Sumitomo Pharmaceuticals Co., Ltd., Japan). PCT
Int. Appl. WO 2005037229 A1 20050428, 209 pp. DESIGNATED STATES: W: AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR,
CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,
SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK,
ES, FI, FR, GA, GB, GR, GW, HU, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD,
TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2004-JP15773
20041019. PRIORITY: JP 2003-361256 20031021.

GI

AB Drugs for enhancing LDL receptor manifestation
contain compds. represented by the following formula (I), prodrugs
thereof, or pharmaceutically acceptable salts of either [m, n, p = 0-4,
provided that 3≤m+n+p≤5; X = N, each (un)substituted CH; Y =
each (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, or aromatic
group,
CO?, N1 = N, each (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, 3-
to 8-membered saturated heterocyclyl containing one (un)substituted NR
or O, aromatic
group, CONR4; R14 = each (un)substituted alkyl, alkenyl, alkynyl,
cycloalkyl, or aromatic group; R2-R7 = H, OH, each (un)substituted alkyl,
alkoxy, alkoxycarbonyl, aralkyl, heteroarylalkyl, aralkyloxy, or
heteroarylalkyloxy, or one or a pair(s) combination of R2 and R3, R4 and
R5, or R6 and R7 = oxo; or R2 and R4 together = alkylene; two of R2-R5
are
on the adjacent carbon atom to form a double bond; Z = H, OH, CO2H,
cyano,
phthalimido, halo, each (un)substituted alkyl, alkenyl, alkynyl,
cycloalkyl, or aromatic group, etc.] as active ingredients. These
compds.
are effective in enhancing low d. lipoprotein (LDL)
receptor manifestation and lowering blood concentration of LDL
cholesterol and are useful as therapeutic agents for treating
hyperlipemia
and arteriosclerosis. Thus, 0.019 mL benzyl bromide was added to a
suspension of 40 mg 4-[3-methoxyphenyl)-1,4'-bipiperidine-4-carbonitrils
dihydrochloride and 92.6 mg K2CO3 in 1.0 mL DMF under ice-cooling, and
the
resulting mixture was warmed to room temperature, stirred overnight, and
quenched
by adding water to give, after workup and silica gel chromatog., 15.6 mg

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
1'-benzyl-4-(3-methoxyphenyl)-1,1'-bipiperidine-4-carbonitrile (I). II
at 10 μM and N-benzyl-4-(3-methoxyphenyl)-1-(pyrimidin-2-yl)piperidine-
4-carbothioamide at 3 μM enhanced the LDL receptor
activity by 125 and 195%, resp.
IT 850885-21-1P, trans-1-[3-Methoxyphenyl)-4-(piperazin-1-
yl)cyclohexanecarbonitrile dihydrochloride 850885-12-2P,
cis-1-[3-Methoxyphenyl)-4-(piperazin-1-yl)cyclohexanecarbonitrile
dihydrochloride 850885-24-4P,
4-[[4-Benzylphenyl)amino]-1-(3-methoxyphenyl)cyclohexanecarbonitrile
850885-86-8P, Ethyl 4-[[cis-4-cyano-4-(3-
methoxyphenyl)cyclohexyl]amino]benzoate 850885-94-8P,
3-(Heinsulfonyl)-4-chloro-N-[cis-4-cyano-4-(3-
methoxyphenyl)cyclohexyl]benzamide 850886-02-2P,
cis-1-(3-Methoxyphenyl)-4-[(piperidin-4-ylamino]cyclohexanecarbonitrile
dihydrochloride 850886-11-2P,
cis-4-(Malonemthyl)-N-(biphenyl-4-ylmethyl)-4-(3-
methoxyphenyl)cyclohexanamine 850886-33-8P 850887-57-9P
, 4-[[[cis-4-Cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]benzoic
acid
hydrochloride
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of novel piperidine and cyclohexanecarbonitrile derivs.
as
enhancers for LDL receptor manifestation,
hypolipidemics, and antiarteriosclerotics)
RN 850885-21-1 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-(1-piperazinyl)-,
hydrochloride (1:2), trans- (CA INDEX NAME)

Relative stereochemistry.



● 2 HCl

RN 850885-22-2 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-(1-piperazinyl)-,
hydrochloride (1:2), cis- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● 2 HCl

RN 850855-24-4 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[(4-benzylphenyl)amino]-1-(3-methoxyphenyl)- (CA INDEX NAME)

RN 850885-86-3 HCAPLUS
CN Benzoic acid, 4-[(cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl)amino]-, ethyl ester (CA INDEX NAME)

Relative stereochemistry.

RN 850885-94-3 HCAPLUS
CN Benzamide, 2-(ethylsulfonyl)-4-chloro-N-[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850884-33-8 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[[(3,1'-biphenyl]-4-ylmethyl)amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850887-57-9 HCAPLUS
CN Benzoic acid, 4-[[[trans-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.

● HCl

IT 43383-56-2P, Methyl cis-4-(benzylamino)-1-(3-methoxyphenyl)cyclohexanecarboxylate 773000-44-9P, Methyl

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

trans-4-(benzylamino)-1-(3-methoxyphenyl)cyclohexanecarboxylate 850885-14-2P, cis-1-(3-Methoxyphenyl)-4-(piperidin-1-yl)cyclohexanecarboxamide 850885-20-0P, cis-1-(3-Methoxyphenyl)-4-[4-[(3-methoxyphenyl)piperazin-1-yl]cyclohexanecarbonitrile 850885-23-3P, 4-[4-[Diphenylmethyl]piperazin-1-yl]-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850885-25-5P, 4-[[4-(Hydroxyphenylmethyl]phenyl]amino]-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850885-26-6P, cis-4-(4-Acetylpiperazin-1-yl)-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850885-27-7P, cis-4-(4-Benzoylpiperazin-1-yl)-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850885-28-8P, cis-4-(4-Benzylpiperazin-1-yl)-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850885-29-9P, cis-1-(3-Methoxyphenyl)-4-[4-(methylsulfonyl)piperazin-1-yl]cyclohexanecarbonitrile 850885-30-2P, cis-1-(3-Methoxyphenyl)-4-[4-[(4-methylphenyl)sulfonyl]piperazin-1-yl]cyclohexanecarbonitrile 850885-31-3P, cis-1-(3-Methoxyphenyl)-4-[4-methylpiperazin-1-yl]cyclohexanecarbonitrile 850885-32-4P, cis-1-(3-Methoxyphenyl)-4-[4-pyrimidin-2-ylpiperazin-1-yl]cyclohexanecarbonitrile 850885-33-5P, cis-1-(3-Methoxyphenyl)-4-[4-(4-methoxypyrimidin-2-yl)piperazin-1-yl]cyclohexanecarbonitrile 850885-34-6P, cis-4-[4-(1,3-Benzoxazol-2-yl)piperazin-1-yl]-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850885-35-7P, cis-4-[4-(1,3-Benzothiazol-2-yl)piperazin-1-yl]-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850885-36-8P, cis-4-Anilino-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850885-37-9P, cis-1-(3-Methoxyphenyl)-4-[(2-phenylethyl)amino]cyclohexanecarbonitrile 850885-38-0P, cis-1-(3-Methoxyphenyl)-4-[(3-phenylpropyl)amino]cyclohexanecarbonitrile 850885-39-1P, trans-4-(Benzylamino)-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850885-40-4P, trans-4-[Benzyl(methyl)amino]-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850885-41-5P, N-Benzyl-N-[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]methanesulfonamide 850885-42-6P, N-Benzyl-N-[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]acetamide 850885-43-7P, N-Benzyl-N-[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]-4-methylbenzenesulfonamide 850885-44-8P, N-Benzyl-N-[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]benzamide 850885-45-9P, cis-4-(Butylamino)-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850885-46-0P, trans-4-(4-Benzylpiperazin-1-yl)-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850885-47-1P, 1-(3-Methoxyphenyl)-4-[4-(pyrimidin-2-yl)piperazin-1-yl]cyclohexanecarbonitrile 850885-49-3P, cis-4-(Benzylbutylamino)-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850885-57-3P, trans-1-(3-Methoxyphenyl)-4-(piperazin-1-yl)cyclohexanecarbonitrile dihydrochloride 850885-58-4P, trans-4-(Piperazin-1-yl)-1-(3-propoxyphenyl)cyclohexanecarbonitrile dihydrochloride 850885-59-5P, trans-1-[3-(Cyclopentyloxy)phenyl]-4-(piperazin-1-yl)cyclohexanecarbonitrile dihydrochloride 850885-60-8P, trans-1-(3-Isopropoxyphenyl)-4-(piperazin-1-yl)cyclohexanecarbonitrile dihydrochloride 850885-61-9P, trans-1-(3-Benzyloxyphenyl)-4-(piperazin-1-yl)cyclohexanecarbonitrile dihydrochloride 850885-62-0P, cis-4-(Cyclohexylamino)-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850885-63-1P, trans-4-(Cyclohexylamino)-1-(3-

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-07-2 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-(4-piperidinylamino)-, hydrochloride (1:2), cis- (CA INDEX NAME)

Relative stereochemistry.

● 2 HCl

RN 850886-11-2 HCAPLUS
CN [1,1'-Biphenyl]-4-methanamine, N-[cis-4-(aminomethyl)-4-(3-methoxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 2 OF 4 ACAPLUS COPYRIGHT 2009 ACS on STN (Continued)
methoxyphenyl)cyclohexanecarbonitrile 850885-64-1P,
cis-4-[(biphenylmethyl)amino]-1-[3-methoxyphenyl)cyclohexanecarbonitrile
850885-65-2P, trans-4-[(biphenylmethyl)amino]-1-[3-
methoxyphenyl)cyclohexanecarbonitrile 850885-67-5P,
cis-1-(4-Methoxyphenyl)-4-(piperidin-1-yl)cyclohexanecarbonitrile
850885-69-7P, cis 1-(3-Methoxyphenyl)-4-(morpholin-4-
yl)cyclohexanecarbonitrile 850885-70-0P,
cis-4-[(4-Chlorophenyl)amino]-1-[3-methoxyphenyl)cyclohexanecarbonitrile
850885-71-1P, cis-1-(3-Methoxyphenyl)-4-[[3-
methylphenyl)amino]cyclohexanecarbonitrile 850885-72-2P,
cis-1-(3-Methoxyphenyl)-4-[[4-methylphenyl)amino]cyclohexanecarbonitrile
850885-73-3P, cis-1-(3-Methoxyphenyl)-4-[[2-
methylphenyl)amino]cyclohexanecarbonitrile 850885-74-4P,
cis-4-[(3,5-Dimethylphenyl)amino]-1-[3-
methoxyphenyl)cyclohexanecarbonitrile 850885-75-5P,
4-[[cis-4-Cyano-4-(3-methoxyphenyl)cyclohexyl]amino]benzenesulfonamide
850885-76-6P, 1-[3-Methoxyphenyl)-4-[[4-(piperidin-1-
yl)sulfonyl]phenyl]amino]cyclohexanecarbonitrile 850885-77-7P,
2-[[cis-4-Cyano-4-(3-methoxyphenyl)cyclohexyl]amino]benzenesulfonamide
850885-78-8P, 4-[[cis-4-Cyano-4-(3-
methoxyphenyl)cyclohexyl]amino]methyl]benzenesulfonamide
850885-79-9P, Methyl 4-[[trans-4-cyano-4-(3-
methoxyphenyl)cyclohexyl]amino]methyl]benzoate 850885-80-2P,

4-[[[trans-4-Cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]benzenesulfo
namide 850885-83-3P, cis-1-(3-Methoxyphenyl)-4-[(4-
methylbenzyl)amino]cyclohexanecarbonitrile 850885-82-4P,

trans-1-(3-Methoxyphenyl)-4-[(4-methylbenzyl)amino]cyclohexanecarbonitrile
850885-83-5P, cis-4-[(4-Methoxybenzyl)amino]-1-(3-
methoxyphenyl)cyclohexanecarbonitrile 850885-84-6P,
trans-4-[(4-Methoxybenzyl)amino]-1-(3-
methoxyphenyl)cyclohexanecarbonitrile 850885-85-7P,
cis-1-(3-Methoxyphenyl)-4-[[(pyridin-4-
yl)methyl]amino]cyclohexanecarbonitrile 850885-87-9P,
4-[[cis-4-Cyano-4-(3-methoxyphenyl)cyclohexyl]amino]benzoic acid
850885-88-0P, cis-1-(3-Methoxyphenyl)-4-[[(pyridin-2-
yl)amino]cyclohexanecarbonitrile 850885-90-4P,
4-[[[cis-4-Cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]benzoic acid
850885-91-5P, 4-[[[cis-4-Cyano-4-(3-
methoxyphenyl)cyclohexyl]amino]methyl]benzamide 850885-92-6P,
4-[[[cis-4-Cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]-N,N-
dimethylbenzamide 850885-97-7P,

3-[[[cis-4-Cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]benzenesulfona
mide 850885-93-9P, 3-[Aminosulfonyl)-N-[cis-4-cyano-4-(3-
methoxyphenyl)cyclohexyl]benzamide 850885-96-0P,
N-[cis-4-Cyano-4-(3-methoxyphenyl)cyclohexyl]acetamide
850885-97-1P, N-[cis-4-Cyano-4-(3-
methoxyphenyl)cyclohexyl]benzamide 850885-98-2P, tert-Butyl
[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]carbamate 850885-99-3P
,

N-[cis-4-Cyano-4-(3-methoxyphenyl)cyclohexyl]-4-methylbenzenesulfonamide
850886-01-0P, 4-Benzylamino-1-(3-methoxyphenyl)cyclohexanol
850886-02-1P, tert-Butyl 4-[[cis-4-cyano-4-(3-

L14 ANSWER 3 OF 4 ACAPLUS COPYRIGHT 2009 ACS on STN (Continued)
850886-95-2P 850886-96-3P 850886-97-4P
850886-98-5P 850886-99-6P 850887-00-2P
850887-01-3P 850887-02-4P 850887-09-1P
850887-44-8P, Methyl 4-[[[cis-4-cyano-4-(3-
methoxyphenyl)cyclohexyl]amino]methyl]benzoate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preps. of novel piperidine and cyclohexanecarbonitrile derivs. as
enhancers for LDL receptor manifestation,
hypolipidemics, and antiarteriosclerotics)
RN 62383-56-2 ACAPLUS
CN Cyclohexanecarboxylic acid, 1-(3-methoxyphenyl)-4-[(phenylmethyl)amino]-,
methyl ester, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 773002-64-9 ACAPLUS
CN Cyclohexanecarboxylic acid, 1-(3-methoxyphenyl)-4-[(phenylmethyl)amino]-,
methyl ester, trans- (CA INDEX NAME)

Relative stereochemistry.

RN 850885-14-2 ACAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-(1-piperidinyl)-, cis- (CA
INDEX NAME)

Relative stereochemistry.

L14 ANSWER 4 OF 4 ACAPLUS COPYRIGHT 2009 ACS on STN (Continued)
methoxyphenyl)cyclohexyl]amino]piperidine-1-carboxylate
850886-04-3P, cis-1-(3-Methoxyphenyl)-4-[[1-methylpiperidin-4-
yl]amino]cyclohexanecarbonitrile 850886-05-4P,
cis-4-[[1-Benzylpiperidin-4-yl]amino]-1-(3-
methoxyphenyl)cyclohexanecarbonitrile 850886-06-5P,
cis-1-(3-Methoxyphenyl)-4-[[1-(methanesulfonyl)piperidin-4-
yl]amino]cyclohexanecarbonitrile 850886-07-6P,
cis-1-(3-Methoxyphenyl)-4-[[1-[(4-methylphenyl)sulfonyl]piperidin-4-
yl]amino]cyclohexanecarbonitrile 850886-08-7P,
cis-4-[[1-Acetylpiperidin-4-yl]amino]-1-(3-
methoxyphenyl)cyclohexanecarbonitrile 850886-09-8P,
cis-1-(3-Methoxyphenyl)-4-[[1-(pyridin-2-yl)piperidin-4-
yl]amino]cyclohexanecarbonitrile 850886-10-1P,
cis-4-(Aminoethyl)-N-benzyl-4-(3-methoxyphenyl)cyclohexanamine
850886-12-3P, cis-N-Benzyl-4-(3-methoxyphenyl)-4-[(piperidin-1-
ylmethyl)cyclohexanamine 850886-13-4P,
cis-N-(Biphenyl-4-ylmethyl)-4-[ethylamino)methyl]-4-(3-
methoxyphenyl)cyclohexanol 850886-14-5P,
Benzyl[cis-4-[(biphenyl-4-ylmethyl)amino]-1-(3-
methoxyphenyl)cyclohexylmethyl]amine 850886-15-6P
850886-16-7P, N-[[cis-4-[(Biphenyl-4-ylmethyl)amino]-1-(3-
methoxyphenyl)cyclohexyl]methyl]-4-methylbenzenesulfonamide
850886-17-8P 850886-18-9P,
N-[[cis-4-[(Biphenyl-4-ylmethyl)amino]-1-(3-
methoxyphenyl)cyclohexyl]methyl]benzamide 850886-19-0P,
cis-N-Benzyl-4-[(biphenyl-4-ylmethyl)amino]-1-(3-
methoxyphenyl)cyclohexanecarboxamide 850886-20-3P,
cis-4-Benzylamino-1-(3-methoxyphenyl)cyclohexanecarboxamide
850886-21-4P, trans-1-(3-Methoxyphenyl)-4-(piperidin-1-
yl)cyclohexanecarboxamide 850886-22-5P,
cis-4-[(Biphenyl-4-ylmethyl)amino]-1-(3-
methoxyphenyl)cyclohexanecarboxamide 850886-23-6P
850886-24-7P 850886-25-8P 850886-26-9P
850886-27-0P 850886-28-1P 850886-29-2P
850886-30-5P 850886-31-6P 850886-32-7P
850886-34-9P 850886-35-0P 850886-36-1P
850886-37-2P 850886-38-3P 850886-39-4P
850886-40-7P 850886-41-8P 850886-42-9P
850886-43-0P 850886-45-2P 850886-46-3P
850886-47-4P 850886-48-5P 850886-49-6P
850886-50-9P 850886-51-0P 850886-52-1P
850886-53-2P 850886-54-3P 850886-55-4P
850886-56-5P 850886-57-6P 850886-58-7P
850886-59-8P 850886-60-1P 850886-61-2P
850886-62-3P 850886-63-4P 850886-64-5P
850886-65-6P 850886-66-7P 850886-67-8P
850886-68-9P 850886-69-0P 850886-70-3P
850886-71-4P 850886-72-5P 850886-73-6P
850886-74-7P 850886-75-8P 850886-76-9P
850886-77-0P 850886-78-1P 850886-79-2P
850886-80-5P 850886-81-6P 850886-82-7P
850886-83-8P 850886-84-9P 850886-85-0P
850886-86-1P 850886-87-2P 850886-88-3P
850886-89-4P 850886-90-7P 850886-91-8P
850886-92-9P 850886-93-0P 850886-94-1P

RN 850885-20-0 ACAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[4-(2-methoxyphenyl)-2-
piperazinyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-23-3 ACAPLUS
CN Cyclohexanecarbonitrile, 4-[4-(diphenylmethyl)-1-piperazinyl]-1-(3-
methoxyphenyl)- (CA INDEX NAME)

RN 850885-25-5 ACAPLUS
CN Cyclohexanecarbonitrile, 4-[[4-(hydroxyphenylmethyl)phenyl]amino]-1-(3-
methoxyphenyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850885-26-6 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[4-acetyl-1-piperazinyl]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-27-7 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[4-benzoyl-1-piperazinyl]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-28-8 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[4-(phenylmethyl)-1-piperazinyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-32-4 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[4-(2-pyrimidinyl)-1-piperazinyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-33-5 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[4-(4-methoxy-2-pyrimidinyl)-1-piperazinyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.



L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850885-29-9 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[4-(methylsulfonyl)-1-piperazinyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-30-2 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[4-[(4-methylphenyl)sulfonyl]-1-piperazinyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-31-3 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-(4-methyl-1-piperazinyl)-,

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 850885-34-6 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[4-(2-benzoxazolyl)-1-piperazinyl]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-35-7 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[4-(2-benzothiazolyl)-1-piperazinyl]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-36-8 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-(phenylamino)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-37-9 HCAPLUS

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN Cyclohexanecarbonitrile, 1-[3-methoxyphenyl)-4-[(2-phenylethyl)amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-78-0 HCAPLUS
CN Cyclohexanecarbonitrile, 1-[3-methoxyphenyl)-4-[[3-phenylpropyl)amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-79-1 HCAPLUS
CN Cyclohexanecarbonitrile, 1-[3-methoxyphenyl)-4-[(phenylmethyl)amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-40-4 HCAPLUS
CN Cyclohexanecarbonitrile, 1-[3-methoxyphenyl)-4-[methyl(phenylmethyl)amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850885-41-5 HCAPLUS
CN Methanesulfonamide, N-[cis-4-cyano-4-[3-methoxyphenyl)cyclohexyl]-N-(phenylmethyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-42-6 HCAPLUS
CN Acetamide, N-[cis-4-cyano-4-[3-methoxyphenyl)cyclohexyl]-N-(phenylmethyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-43-7 HCAPLUS
CN Benzenesulfonamide, N-[cis-4-cyano-4-[3-methoxyphenyl)cyclohexyl]-4-methyl-

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
N-(phenylmethyl)- (CA INDEX NAME)

Relative stereochemistry.

RN 850885-44-8 HCAPLUS
CN Benzamide, N-[cis-4-cyano-4-[3-methoxyphenyl)cyclohexyl]-N-(phenylmethyl)- (CA INDEX NAME)

Relative stereochemistry.

RN 850885-48-2 HCAPLUS
CN Cyclohexanecarbonitrile, 4-(diethylamino)-1-[3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.

RN 850885-46-0 HCAPLUS
CN Cyclohexanecarbonitrile, 1-[3-methoxyphenyl)-4-[4-(phenylmethyl)-1-piperazinyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850885-41-5 HCAPLUS
CN Methanesulfonamide, N-[cis-4-cyano-4-[3-methoxyphenyl)cyclohexyl]-N-(phenylmethyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-42-6 HCAPLUS
CN Acetamide, N-[cis-4-cyano-4-[3-methoxyphenyl)cyclohexyl]-N-(phenylmethyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-43-7 HCAPLUS
CN Benzenesulfonamide, N-[cis-4-cyano-4-[3-methoxyphenyl)cyclohexyl]-4-methyl-

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 850885-47-1 HCAPLUS
CN Cyclohexanecarbonitrile, 1-[3-methoxyphenyl)-4-[4-[2-pyrimidinyl)-1-piperazinyl]- (CA INDEX NAME)



RN 850885-49-3 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[butyl(phenylmethyl)amino]-1-[3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-57-3 HCAPLUS
CN Cyclohexanecarbonitrile, 1-[3-ethoxyphenyl)-4-(1-piperazinyl)-, hydrochloride (1:2), trans- (CA INDEX NAME)

Relative stereochemistry.



● 2 HCl

RN 850885-58-4 HCAPLUS
CN Cyclohexanecarbonitrile, 4-(3-piperazinyl)-1-(3-propoxyphenyl)-, hydrochloride (1:2), trans- (CA INDEX NAME)

Relative stereochemistry.



● 2 HCl

RN 850885-59-5 HCAPLUS
CN Cyclohexanecarbonitrile, 1-[3-(cyclopentyloxy)phenyl]-4-(1-piperazinyl)-, hydrochloride (1:2), trans- (CA INDEX NAME)

Relative stereochemistry.



● 2 HCl

RN 850885-62-8 HCAPLUS
CN Cyclohexanecarbonitrile, 4-(cyclohexylamino)-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-63-1 HCAPLUS
CN Cyclohexanecarbonitrile, 4-(cyclohexylamino)-1-(3-methoxyphenyl)-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-64-2 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[(diphenylmethyl)amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



● 2 HCl

RN 850885-60-0 HCAPLUS
CN Cyclohexanecarbonitrile, 1-[3-(1-methylethoxy)phenyl]-4-(1-piperazinyl)-, hydrochloride (1:2), trans- (CA INDEX NAME)

Relative stereochemistry.



● 2 HCl

RN 850885-61-9 HCAPLUS
CN Cyclohexanecarbonitrile, 1-[3-(phenylmethoxy)phenyl]-4-(1-piperazinyl)-, hydrochloride (1:2), trans- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-65-3 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[(diphenylmethyl)amino]-1-(3-methoxyphenyl)-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-67-5 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-(4-piperidinyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-69-7 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-(4-morpholinyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-70-9 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[(4-chlorophenyl)amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-71-1 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[(3-methylphenyl)amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-72-2 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[(4-methylphenyl)amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-76-6 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[4-[(1-piperidinylsulfonyl)phenyl]amino]- (CA INDEX NAME)



RN 850885-77-7 HCAPLUS
CN Benzenesulfonamide, 2-[(cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-78-8 HCAPLUS
CN Benzenesulfonamide, 4-[[[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-73-3 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[(2-methylphenyl)amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-74-4 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[(3,5-dimethylphenyl)amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-75-5 HCAPLUS
CN Benzenesulfonamide, 4-[[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-79-9 HCAPLUS
CN Benzoic acid, 4-[[[trans-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]-, methyl ester (CA INDEX NAME)

Relative stereochemistry.



RN 850885-80-2 HCAPLUS
CN Benzenesulfonamide, 4-[[[trans-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-81-3 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[(4-methylphenyl)methyl]amino]-, cis- (CA INDEX NAME)

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Relative stereochemistry.



RN 850885-82-4 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[(4-methylphenyl)methyl]amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-83-5 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[(4-methoxyphenyl)methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-84-6 HCAPLUS

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(CA INDEX NAME)

Relative stereochemistry.



RN 850885-90-4 HCAPLUS
CN Benzoic acid, 4-[[[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-91-5 HCAPLUS
CN Benzamide, 4-[[[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-92-6 HCAPLUS
CN Benzamide, 4-[[[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]-N,N-dimethyl- (CA INDEX NAME)

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[(4-methoxyphenyl)methyl]amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-85-7 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[(4-pyridinylmethyl)amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-87-9 HCAPLUS
CN Benzoic acid, 4-[[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-88-0 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-(2-pyrimidinylamino)-, cis-

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
Relative stereochemistry.



RN 850885-93-7 HCAPLUS
CN Benzenesulfonamide, 3-[[[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-95-9 HCAPLUS
CN Benzamide, 3-(aminosulfonyl)-N-[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-96-0 HCAPLUS
CN Acetamide, N-[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850885-97-7 HCAPLUS
CN Benzamide, N-[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-98-2 HCAPLUS
CN Carbamic acid, [cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 850885-99-3 HCAPLUS
CN Benzenesulfonamide, N-[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]-4-methyl- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-05-4 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[1-(phenylmethyl)-4-piperidinyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-06-5 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[1-(methylsulfonyl)-4-piperidinyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-07-6 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[1-[(4-methylphenyl)sulfonyl]-4-piperidinyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-01-0 HCAPLUS
CN Cyclohexanol, 1-[3-methoxyphenyl)-4-[(phenylmethyl)amino]- (CA INDEX NAME)



RN 850886-02-1 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Relative stereochemistry.



RN 850886-04-3 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[(1-methyl-4-piperidinyl)amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-08-7 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[(1-acetyl-4-piperidinyl)amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-09-8 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[1-(2-pyrimidinyl)-4-piperidinyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-10-1 HCAPLUS
CN Benzenethanamine, N-[cis-4-(aminomethyl)-4-(3-methoxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-12-3 HCAPLUS
CN Benzenemethanamine, N-[cis-4-(3-methoxyphenyl)-4-(1-piperidinylmethyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-13-4 HCAPLUS
CN [1,1'-Biphenyl]-4-methanamine, N-[cis-4-[(ethylamino)methyl]-4-(3-methoxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-14-5 HCAPLUS
CN [1,1'-Biphenyl]-4-methanamine, N-[cis-4-(3-methoxyphenyl)-4-[[(phenylmethyl)amino]methyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-15-6 HCAPLUS
CN Methanesulfonamide, N-[cis-4-[[[3,1'-biphenyl]-4-ylmethyl]amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]- (CA INDEX NAME)

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 850886-19-9 HCAPLUS
CN Benzamide, N-[[cis-4-[[[3,1'-biphenyl]-4-ylmethyl]amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-19-0 HCAPLUS
CN Cyclohexanecarboxamide, 4-[[[3,1'-biphenyl]-4-ylmethyl]amino]-1-[3-methoxyphenyl]-N-(phenylmethyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-20-3 HCAPLUS
CN Cyclohexanecarboxamide, 1-(3-methoxyphenyl)-4-[(phenylmethyl)amino]-, cis-
(CA INDEX NAME)

Relative stereochemistry.



RN 850886-21-4 HCAPLUS
CN Cyclohexanecarboxamide, 1-(3-methoxyphenyl)-4-(1-piperazinyl)-, trans-
(CA INDEX NAME)

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Relative stereochemistry.



RN 850886-16-7 HCAPLUS
CN Benzenesulfonamide, N-[[cis-4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]-4-methyl- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-17-8 HCAPLUS
CN Acetamide, N-[[cis-4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Relative stereochemistry.



RN 850886-22-5 HCAPLUS
CN Cyclohexanecarboxamide, 4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-23-6 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[(9H-fluoren-2-ylmethyl)amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-24-7 HCAPLUS
CN Benzonitrile, 4-[[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]-
(CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-25-8 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-fluorophenyl]methyl]amino]-1-[3-methoxyphenyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-26-9 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-chlorophenyl]methyl]amino]-1-[3-methoxyphenyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-27-0 HCAPLUS
CN Acetamide, N-[4-[[[cis-4-cyano-4-[3-methoxyphenyl]cyclohexyl]amino]methyl]phenyl]- (CA INDEX NAME)

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
naphthalenylmethyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-31-6 HCAPLUS
CN Cyclohexanecarbonitrile, 1-[3-methoxyphenyl]-4-[[2-naphthalenylmethyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-32-7 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[[3,5-benzodioxol-5-ylmethyl]amino]-1-[3-methoxyphenyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
Relative stereochemistry.



RN 850886-28-1 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-(dimethylamino)phenyl]methyl]amino]-1-[3-methoxyphenyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-29-2 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[4-phenoxyphenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-30-5 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[1-

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-34-9 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[4-(methylthio)phenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-35-0 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[4-(trifluoromethyl)phenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-36-1 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[4-(1-methylethyl)phenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-37-2 HCAPLUS
CN 2-Propenoic acid, 3-[4-[[[cis-4-cyano-4-[3-methoxyphenyl]cyclohexyl]amino]methyl]phenyl]- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 850886-38-3 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-(dimethylamino)-1-naphthalenyl]methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-39-4 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[4-(2-propen-1-yloxy)phenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-40-7 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[4-(1-pyrrolidinyl)phenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 850886-41-8 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[(3,7-benzodioxol-4-ylmethyl)amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-42-9 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[4-(trifluoromethoxy)phenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-43-0 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 850886-45-2 HCAPLUS
CN Benzenesulfonamide, N-[4-[[[cis-4-cyano-4-[3-methoxyphenyl]cyclohexyl]amino]methyl]-3-hydroxyphenyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-46-3 HCAPLUS
CN Cyclohexanecarbonitrile, 1-[3-methoxyphenyl]-4-[[[4-[methylsulfonyl]phenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-47-4 HCAPLUS
CN Cyclohexanecarbonitrile, 1-[3-methoxyphenyl]-4-[[2,4,6-trimethoxyphenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-51-0 HCAPLUS
CN Cyclohexanecarbonitrile, 1-[3-methoxyphenyl]-4-[[[4-[phenylmethoxy]phenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-52-1 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-ethoxyphenyl]methyl]amino]-1-[3-methoxyphenyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-53-2 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-(butoxyphenyl]methyl]amino]-1-[3-methoxyphenyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-48-5 HCAPLUS
CN Cyclohexanecarbonitrile, 1-[3-methoxyphenyl]-4-[[[2,4,6-trimethylphenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-49-6 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-bromophenyl]methyl]amino]-1-[3-methoxyphenyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-50-9 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-(diethylamino)phenyl]methyl]amino]-1-[3-methoxyphenyl]-, cis- (CA INDEX NAME)

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-54-3 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-ethylphenyl]methyl]amino]-1-[3-methoxyphenyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-55-4 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-[3-(dimethylamino)propoxy]phenyl]methyl]amino]-1-[3-methoxyphenyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-56-5 HCAPLUS
CN Cyclohexanecarbonitrile, 1-[3-methoxyphenyl]-4-[[[4-propoxyphenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850826-57-6 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[4-[pentyloxy]phenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850826-58-7 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[(2,3,4,5,6-pentamethylphenyl)methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-59-8 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[[(4-[1,1-dimethylethyl]phenyl)methyl]amino]-1-

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-62-3 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[(4-[1-methylethoxy]phenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-63-4 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-(dibutylamino)phenyl]methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-64-5 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[4-(2-methylpropyl)phenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 850886-65-6 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-(diphenylamino)phenyl]methyl]amino]-1-(3-

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-6Q-1 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[[[2-[(1,1-dimethylethyl)thio]phenyl]methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.

RN 850886-61-2 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[[(4-butylphenyl)methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-66-7 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[(1-methyl-1H-imidazol-2-yl)methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-67-8 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[(2-phenyl-1H-imidazol-5-yl)methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-68-9 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[(4-methyl-1H-imidazol-5-yl)methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-69-0 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[(2-phenyl-1H-indol-3-yl)methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-70-3 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[3-(phenylsulfonyl)-1H-pyrrol-2-yl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-71-4 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-75-8 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[[(1H-indol-3-ylmethyl)amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-76-9 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[(3-methylbenzo[b]thien-2-yl)methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-77-0 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[[(2,2'-bithiophen]-5-ylmethyl)amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-72-5 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[5-(methylthio)-2-thienyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-73-6 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[(1H-indazol-5-ylmethyl)amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-74-7 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[(1H-pyrazol-3-ylmethyl)amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-78-1 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[[(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-79-2 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[(2-benzofuranylmethyl)amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-80-5 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[(1-methyl-1H-indol-2-yl)methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-81-6 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[(3-furanylmethyl)amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-82-7 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[(4-quinolinylmethyl)amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-85-0 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[(3-thienylmethyl)amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-86-1 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[(2-furanylmethyl)amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-87-2 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-83-8 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[(3-pyridinylmethyl)amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-84-9 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[(2-pyridinylmethyl)amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-88-3 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[4-(2-phenylethenyl)phenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 850886-89-4 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[[4-(2-hydroxyethoxy)phenyl]methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-90-7 HCAPLUS
CN Benzenesulfonic acid, 4-[[[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]- (CA INDEX NAME)

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Relative stereochemistry.



RN 850886-91-8 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[[(3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-92-9 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[(2-quinolinylmethyl)amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-96-3 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-(1H-imidazol-1-yl)phenyl]methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-97-4 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-(1-hexyn-1-yl)phenyl]methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-98-5 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[4-(4-methyl-1-

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 850886-93-0 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[[[5-chloro-1,3-dimethyl-1H-pyrazol-4-yl]methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-94-1 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-(1,1-dimethylethoxy)phenyl]methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-95-2 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-(4-(1,1-dimethylethyl)-2-thiazolyl)phenyl]methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
piperazinyl)phenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-99-6 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[4-(4-morpholinyl)phenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850887-00-2 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-[(2-hydroxyethyl)methylamino]phenyl]methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850887-01-3 HCAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-acetylphenyl)methyl]amino]-1-[3-methoxyphenyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850887-02-4 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[4-(1H-1,2,4-triazol-1-yl)phenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
methoxyphenyl)cyclohexanecarbonitrile 850887-63-7,
trans-1-(3-Methoxyphenyl)-4-[(piperazin-1-yl)cyclohexanecarbonitrile
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of novel piperidine and cyclohexanecarbonitrile derivs. as enhancers for LDL receptor manifestation, hypolipidemics, and antiarteriosclerotics)
RN 850885-66-4 HCAPLUS
CN Cyclohexanecarbonitrile, 4-amino-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-68-6 HCAPLUS
CN Cyclohexanecarbonitrile, 4-amino-1-(3-methoxyphenyl)-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-89-1 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[(phenylmethyl)amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850887-63-7 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-(1-piperazinyl)-, trans- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 850887-09-1 HCAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[6-[(4-methylphenyl)thio]imidazo[2,1-b]thiazol-5-yl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850887-64-8 HCAPLUS
CN Benzoic acid, 4-[[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl-, methyl ester (CA INDEX NAME)

Relative stereochemistry.



IT 850885-66-4, cis-4-Amino-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850885-68-6, trans-4-Amino-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850885-89-1, cis-4-Benzylamino-1-(3-

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



IT 850887-47-7P, tert-Butyl 4-[trans-4-cyano-4-(3-methoxyphenyl)cyclohexyl]piperazine-1-carboxylate 850887-48-8P, tert-Butyl 4-[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]piperazine-1-carboxylate 850887-49-9P 850887-53-5P, tert-Butyl 4-[trans-4-[3-(benzyloxy)phenyl]-4-cyanocyclohexyl]piperazine-1-carboxylate 850887-54-6P, tert-Butyl 4-[cis-4-[3-(benzyloxy)phenyl]-4-cyanocyclohexyl]piperazine-1-carboxylate 850887-55-7P, tert-Butyl 4-[trans-4-cyano-4-[3-hydroxyphenyl)cyclohexyl]piperazine-1-carboxylate 850887-58-8P, tert-Butyl 4-[trans-4-cyano-4-[3-ethoxyphenyl)cyclohexyl]piperazine-1-carboxylate 850887-59-0P, Methyl cis-4-[[diphenylmethyl)amino]-1-(3-methoxyphenyl)cyclohexanecarboxylate 850887-59-1P, Methyl cis-4-[[tert-butoxycarbonyl)amino]-1-[3-methoxyphenyl)cyclohexanecarboxylate 850887-60-4P, cis-4-[[tert-Butoxycarbonyl)amino]-1-[3-methoxyphenyl)cyclohexanecarboxylic acid 850887-61-5P, tert-Butyl [cis-4-[(benzylamino)carbonyl]-4-[3-methoxyphenyl)cyclohexyl]carbamate 850887-62-6P, cis-4-Amino-N-benzyl-1-(3-methoxyphenyl)cyclohexanecarboxamide
RL: RCT (Reactant); SNH (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of novel piperidine and cyclohexanecarbonitrile derivs. as
enhancers for LDL receptor manifestation, hypolipidemics, and antiarteriosclerotics)
RN 850887-47-7 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[trans-4-cyano-4-(3-methoxyphenyl)cyclohexyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Relative stereochemistry.



L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 850887-48-8 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]-, 1,1-dimethylethyl ester (CA INDEX NAMES)

Relative stereochemistry.



RN 850887-49-9 HCAPLUS
CN Butanamide, N-[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]-N-(phenylmethyl)- (CA INDEX NAMES)

Relative stereochemistry.



RN 850887-53-5 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[trans-4-cyano-4-[3-(phenylmethoxy)phenyl]cyclohexyl]-, 1,1-dimethylethyl ester (CA INDEX NAMES)

Relative stereochemistry.

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850887-56-8 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[trans-4-cyano-4-(3-ethoxyphenyl)cyclohexyl]-, 1,1-dimethylethyl ester (CA INDEX NAMES)

Relative stereochemistry.



RN 850887-59-1 HCAPLUS
CN Cyclohexanecarboxylic acid, 4-[[(1,1-dimethylethoxy)carbonyl](diphenylmethyl)amino]-1-(3-methoxyphenyl)-, methyl ester, cis- (CA INDEX NAMES)

Relative stereochemistry.



RN 850887-59-2 HCAPLUS
CN Cyclohexanecarboxylic acid, 4-[[(1,1-dimethylethoxy)carbonyl]amino]-1-(3-methoxyphenyl)-, methyl ester, cis- (CA INDEX NAMES)

Relative stereochemistry.

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850887-54-6 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[cis-4-cyano-4-[3-(phenylmethoxy)phenyl]cyclohexyl]-, 1,1-dimethylethyl ester (CA INDEX NAMES)

Relative stereochemistry.



RN 850887-55-7 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[trans-4-cyano-4-(3-hydroxyphenyl)cyclohexyl]-, 1,1-dimethylethyl ester (CA INDEX NAMES)

Relative stereochemistry.

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850887-60-4 HCAPLUS
CN Cyclohexanecarboxylic acid, 4-[[(1,1-dimethylethoxy)carbonyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAMES)

Relative stereochemistry.



RN 850887-61-5 HCAPLUS
CN Carbamic acid, [cis-4-(3-methoxyphenyl)-4-[[(phenylmethyl)amino]carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAMES)

Relative stereochemistry.



RN 850887-62-6 HCAPLUS
CN Cyclohexanecarboxamide, 4-amino-1-(3-methoxyphenyl)-N-(phenylmethyl)-, cis- (CA INDEX NAMES)

Relative stereochemistry.

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L14 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
2004:467697 Document No. 141:386230 A preparation of fused bicyclic nitrogen-containing heterocycles, useful in the treatment or prevention of metabolic and cell proliferative diseases. Fox, Brian M.; Furukawa, Noboru; Hao, Xiaolin; Iio, Kiyosei; Inaba, Takashi; Jackson, Simon M.; Kayser, Frank; Labelle, Marc; Li, Kexue; Matsui, Takuya; McMinn, Dustin L.; Ogawa, Nobuya; Rubenstein, Steven M.; Sagawa, Shoichi; Sugimoto, Kazuyuki; Suzuki, Masahiro; Tanaka, Masahiro; Ye, Guosen; Yoshida, Atsuhito; Zhang, Jian (Tularik Inc., USA; Japan Tobacco, Inc.). PCT Int. Appl. WO 2004047755 A2 20040610, 176 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-US37574 20031121. PRIORITY: US 2002-428600P 20021122.
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to fused bicyclic nitrogen-containing heterocycles of formula I [wherein: X is C(R6) or N; Y is C(R6)1-2, N(R6)0-1; Z is O or S; W1 and W2 are independently selected from (un)substituted (hetero)cycloalkyl or (hetero)aryl; L1 and L2 are independently selected from bond, alkylene, or alkenylene, etc.; R1, R2, R3, and R4 are independently selected from H, alk(en/yn)yl, CHO, or C(O)-alkyl, etc.; R3 and R4 may be combined with the nitrogen to form a 5-, 6-, or 7-membered rings; R5 is H, (halo)alkyl, alk(en/yn)yl, OH, or alkoxy, etc.; R6 is H, alk(en/yn)yl, fluoroalkyl, or aryl, etc.], useful in the treatment or prevention of metabolic and cell proliferative diseases. The invention provides compds. which modulate the activity of proteins involved in lipid metabolism and cell proliferation. For instance, pyrimidine derivative II (hDGAT1 IC50 < 0.01 μM) was prepared via heterocyclization of 4,5-diamino-6-hydroxypyrimidine and bromoketone III (example 2, no yield data).
IT 701234-22-2P 701234-23-3P 701234-38-0P
701235-39-4P 701235-40-7P 701235-50-9P
701235-56-5P 701235-64-5P 701235-81-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of fused bicyclic nitrogen-containing heterocycles, useful in the treatment or prevention of metabolic and cell proliferative diseases)
RN 701234-22-2 HCAPLUS

L14 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN 7H-Pyrimido[4,5-b][1,4]oxazin-4-amine, 7,7-dimethyl-6-[4-[4-(1-pyrrolidinyl)cyclohexyl]phenyl]- (CA INDEX NAME)



RN 701234-23-3 HCAPLUS
CN 7H-Pyrimido[4,5-b][1,4]oxazin-4-amine, 7,7-dimethyl-6-[4-[4-(1-piperidinyl)cyclohexyl]phenyl]- (CA INDEX NAME)



RN 701234-38-0 HCAPLUS
CN Acetamide, N-[trans-4-[4-(4-amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]cyclohexyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

Relative stereochemistry.



RN 701235-39-4 HCAPLUS
CN Acetamide, N-[trans-4-[4-(4-amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 701235-40-7 HCAPLUS
CN Benzenesulfonamide, N-[trans-4-[4-(4-amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]cyclohexyl]-4-methyl- (CA INDEX NAME)

Relative stereochemistry.



RN 701235-50-9 HCAPLUS
CN Methanesulfonamide, N-[trans-4-[4-(4-amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



L14 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 701235-56-5 HCAPLUS
CN Sulfanilic, N-[trans-4-[4-[4-amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl]phenyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 701235-64-5 HCAPLUS
CN Sulfanic6,
N-[trans-4-[4-[4-amino-6,7-dihydro-7,7-dimethyl-5H-pyrimido[4,5-b][1,4]oxazin-6-yl]phenyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 701235-81-6 HCAPLUS
CN Acetamide, N-[trans-4-[4-[4-amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl]phenyl]cyclohexyl]-2-hydroxy- (CA INDEX NAME)

Relative stereochemistry.

L14 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
2003:807414 Document No. 139:333083 Method of identifying transmembrane protein-interacting compounds. O'Dowd, Brian F.; George, Susan R. (Can.)
PCT Int. Appl. WO 2003087836 A1 20031023, 108 pp. DESIGNATED STATES: W:
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; NH= AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GH, GI, IT, LU, MC, ML, MR, NL, PT, SE, SK, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-CA542 20030411. PRIORITY: US 2002-371704P 20020412; US 2002-379419P 20020513; US 2002-387570P 20021011; US 2003-442556P 20030127.
AB The invention provides a method for screening a candidate compound for its
ability to interact with at least one transmembrane protein comprising: transfecting a cell with at least one nucleotide sequence encoding a protein comprising a transmembrane protein containing at least one nuclear
localization sequence (NLS) and a detectable moiety and permitting expression of the encoded protein in the cell; contacting the cell with a candidate compound; and determining the distribution of the expressed protein in
the cell by detecting the distribution of the detectable moiety in the cell; wherein detection of an altered distribution of the detectable moiety in the cell relative to the distribution of the detectable moiety in a control cell not contacted with the candidate compound indicates that
the compound interacts with the transmembrane protein. The invention provides a method for determining whether a first protein and a second protein
are able to oligomerize comprising: transfecting a cell with a first nucleotide sequence encoding a first protein containing an NLS and a second
nucleotide sequence encoding a second protein comprising a detectable moiety and permitting expression of the encoded first and second proteins in the cell; and determining the distribution of the detectable moiety in the
cell; wherein detection of the detectable moiety in or adjacent to the nucleus of the cell or detection of a reduced level of the detectable moiety at the cell surface, relative to a control cell, indicates that the
first and second proteins interact. Transmembrane proteins have been classified in several major classes, including G protein coupled receptors, transporters, tyrosine kinase receptors, cytokine receptors and
LDL receptors.
IT 79617-96-2, Sertraline
RL: PAC (Pharmacological activity); BIOL (Biological study)
(serotonin transporter ligand; determining interacting compds. and oligomerization of transmembrane proteins using transfected fusion proteins containing nuclear localization sequences and detectable moieties
and determining nuclear localization)
RN 79617-96-2 HCAPLUS
CN 1-Naphthalenamine, 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-,

L14 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(1S,4S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L14 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



10576581.trn

=>
Uploading C:\Program Files\Stnexp\Queries\10576581-55.str



ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13
ring/chain nodes :
7
chain bonds :

```
L14  ANSWER 1 OF 4  HCAPLUS  COPYRIGHT 2009 ACS on STN
AN   2005:1123880  HCAPLUS
DN   143:405923
TI   Preparation of heterocycle- and benzene-containing sulfonamide
derivatives
     as LDL receptor agonists
IN   Ban, Hitoshi; Asano, Shigehiro
PA   Sumitomo Pharmaceuticals Co., Ltd., Japan
SO   PCT Int. Appl., 233 pp.
     CODEN: PIXXD2
DT   Patent
LA   Japanese
FAN.CNT 1
     PATENT NO.          KIND   DATE       APPLICATION NO.         DATE
     ---------------     ----   --------   --------------------    --------
PI   WO 2005097738        A1    20051020   WO 2005-JP6977          20050404
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
             NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
             SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
             ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
     EP 1736467           A1    20061227   EP 2005-728832          20050404
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
     US 20080096922       A1    20080424   US 2006-547626          20061005
PRAI JP 2004-112503       A     20040406
     WO 2005-JP6977       W     20050404
OS   MARPAT 143:405923
RE.CNT  10    THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

10576581.trn

```
=> d l15
L15 HAS NO ANSWERS
L15             STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.


=> d his

     (FILE 'HOME' ENTERED AT 13:35:47 ON 02 JUN 2009)

     FILE 'REGISTRY' ENTERED AT 13:35:58 ON 02 JUN 2009
L1              STRUCTURE UPLOADED
L2           13 S L1
L3              STRUCTURE UPLOADED
L4           50 S L3
L5        16588 S L3 FULL

     FILE 'STNGUIDE' ENTERED AT 13:43:45 ON 02 JUN 2009

     FILE 'CAPLUS' ENTERED AT 13:49:42 ON 02 JUN 2009

     FILE 'STNGUIDE' ENTERED AT 13:49:49 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 13:55:44 ON 02 JUN 2009
L6              STRUCTURE UPLOADED
L7             0 S SAM L6 SUB=L5
L8              STRUCTURE UPLOADED
L9             0 S SAM L8 SUB=L5
L10           16 S FULL L8 SUB=L5

     FILE 'CAPLUS' ENTERED AT 13:58:03 ON 02 JUN 2009
L11            4 S L10
L12         6519 S LDL RECEPTOR

     FILE 'REGISTRY' ENTERED AT 14:02:44 ON 02 JUN 2009

     FILE 'CAPLUS' ENTERED AT 14:02:48 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 14:03:14 ON 02 JUN 2009

     FILE 'HCAPLUS' ENTERED AT 14:03:23 ON 02 JUN 2009
L14            4 S L5 AND L12
L15             STRUCTURE UPLOADED

=> file reg
FILE 'REGISTRY' ENTERED AT 14:07:39 ON 02 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.
```

10576581.trn

```
STRUCTURE FILE UPDATES:    1 JUN 2009  HIGHEST RN 1151607-22-5
DICTIONARY FILE UPDATES:   1 JUN 2009  HIGHEST RN 1151607-22-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d l156
L156 NOT FOUND
The L-number entered has not been defined in this session, or it
has been deleted.  To see the L-numbers currently defined in this
session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> d l15
L15 HAS NO ANSWERS
L15             STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.


=> d his

     (FILE 'HOME' ENTERED AT 13:35:47 ON 02 JUN 2009)

     FILE 'REGISTRY' ENTERED AT 13:35:58 ON 02 JUN 2009
L1              STRUCTURE UPLOADED
L2           13 S L1
L3              STRUCTURE UPLOADED
L4           50 S L3
L5        16588 S L3 FULL

     FILE 'STNGUIDE' ENTERED AT 13:43:45 ON 02 JUN 2009

     FILE 'CAPLUS' ENTERED AT 13:49:42 ON 02 JUN 2009

     FILE 'STNGUIDE' ENTERED AT 13:49:49 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 13:55:44 ON 02 JUN 2009
L6              STRUCTURE UPLOADED
L7            0 S SAM L6 SUB=L5
L8              STRUCTURE UPLOADED
L9            0 S SAM L8 SUB=L5
```

10576581.trn

```
L10          16 S FULL L8 SUB=L5

     FILE 'CAPLUS' ENTERED AT 13:58:03 ON 02 JUN 2009
L11           4 S L10
L12        6519 S LDL RECEPTOR

     FILE 'REGISTRY' ENTERED AT 14:02:44 ON 02 JUN 2009

     FILE 'CAPLUS' ENTERED AT 14:02:48 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 14:03:14 ON 02 JUN 2009

     FILE 'HCAPLUS' ENTERED AT 14:03:23 ON 02 JUN 2009
L14           4 S L5 AND L12
L15             STRUCTURE UPLOADED

     FILE 'REGISTRY' ENTERED AT 14:07:39 ON 02 JUN 2009

=> s sub=15 sam l15
SAMPLE SUBSET SEARCH INITIATED 14:08:14 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED -      811 TO ITERATE

100.0% PROCESSED      811 ITERATIONS                              50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):          ONLINE  **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):       14512 TO    17928
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):          14512 TO    17928

L16          50 SEA SUB=L5 SSS SAM L15

=> FIL STNGUIDE
FILE 'STNGUIDE' ENTERED AT 14:18:03 ON 02 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 29, 2009 (20090529/UP).

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> FILE REGISTRY

FILE 'REGISTRY' ENTERED AT 14:20:55 ON 02 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
```

10576581.trn

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 1 JUN 2009 HIGHEST RN 1151607-22-5
DICTIONARY FILE UPDATES: 1 JUN 2009 HIGHEST RN 1151607-22-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10576581-444.str

10576581.trn





chain nodes :
16
ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13
ring/chain nodes :
7 18
chain bonds :
1-8 4-7 7-18
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13
exact/norm bonds :
1-2 1-6 2-3 4-7
exact bonds :
1-8 3-4 4-5 5-6 7-18
normalized bonds :
8-9 8-13 9-10 10-11 11-12 12-13

10576581.trn

G1:CH3,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,H

G2:OH,SH,MeO,EtO,n-PrO,i-PrO,n-BuO,i-BuO,t-BuO

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 16:CLASS 17:Atom 18:CLASS

L17 STRUCTURE UPLOADED

=> d l17
L17 HAS NO ANSWERS
L17 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> file reg
FILE 'REGISTRY' ENTERED AT 14:21:18 ON 02 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 1 JUN 2009 HIGHEST RN 1151607-22-5
DICTIONARY FILE UPDATES: 1 JUN 2009 HIGHEST RN 1151607-22-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s l17
SAMPLE SEARCH INITIATED 14:21:21 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 19511 TO ITERATE

10.3% PROCESSED 2000 ITERATIONS 18 ANSWERS

10576581.trn

```
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:       381855 TO   398585
PROJECTED ANSWERS:            2716 TO     4306

L18          18 SEA SSS SAM L17

=> d his

     (FILE 'HOME' ENTERED AT 13:35:47 ON 02 JUN 2009)

     FILE 'REGISTRY' ENTERED AT 13:35:58 ON 02 JUN 2009
L1              STRUCTURE UPLOADED
L2           13 S L1
L3              STRUCTURE UPLOADED
L4           50 S L3
L5        16588 S L3 FULL

     FILE 'STNGUIDE' ENTERED AT 13:43:45 ON 02 JUN 2009

     FILE 'CAPLUS' ENTERED AT 13:49:42 ON 02 JUN 2009

     FILE 'STNGUIDE' ENTERED AT 13:49:49 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 13:55:44 ON 02 JUN 2009
L6              STRUCTURE UPLOADED
L7            0 S SAM L6 SUB=L5
L8              STRUCTURE UPLOADED
L9            0 S SAM L8 SUB=L5
L10          16 S FULL L8 SUB=L5

     FILE 'CAPLUS' ENTERED AT 13:58:03 ON 02 JUN 2009
L11           4 S L10
L12        6519 S LDL RECEPTOR

     FILE 'REGISTRY' ENTERED AT 14:02:44 ON 02 JUN 2009

     FILE 'CAPLUS' ENTERED AT 14:02:48 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 14:03:14 ON 02 JUN 2009

     FILE 'HCAPLUS' ENTERED AT 14:03:23 ON 02 JUN 2009
L14           4 S L5 AND L12
L15             STRUCTURE UPLOADED

     FILE 'REGISTRY' ENTERED AT 14:07:39 ON 02 JUN 2009
L16          50 S SAM L15 SUB=L5

     FILE 'STNGUIDE' ENTERED AT 14:18:03 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 14:20:55 ON 02 JUN 2009
L17             STRUCTURE UPLOADED
```

10576581.trn

```
     FILE 'REGISTRY' ENTERED AT 14:21:18 ON 02 JUN 2009
L18          18 S L17

=> s sub=l5 sam l18
SAMPLE SUBSET SEARCH INITIATED 14:21:35 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED -      718 TO ITERATE

100.0% PROCESSED      718 ITERATIONS                              50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):          ONLINE  **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):       12753 TO    15967
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):           2318 TO     3802

L19          50 SEA SUB=L5 SSS SAM L17

=> s sub=l5 sam l17
SAMPLE SUBSET SEARCH INITIATED 14:21:42 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED -      718 TO ITERATE

100.0% PROCESSED      718 ITERATIONS                              50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):          ONLINE  **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):       12753 TO    15967
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):           2318 TO     3802

L20          50 SEA SUB=L5 SSS SAM L17

=> d scan
```

L20 50 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Urea, N-(3,4-difluorophenyl)-N'-[(5aS,8R,9aS)-5a-(3,4-dimethoxyphenyl)octahydro-1-propyl-1H-indol-6-yl]-, hydrochloride (1:1)
MF C26 H33 F2 N3 O3 . Cl H

Absolute stereochemistry. Rotation (+).



● AC1

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L20 50 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Methanesulfonamide, N-[(cis-1-[3-methoxyphenyl)-4-[(1-methyl-4-piperidinyl)amino]cyclohexyl]methyl]-
MF C21 H35 N3 O3 S

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L20 50 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 1H-Indole-3-acetamide, N-[5S,5aS,8aR,9R)-5,5a,6,8,8a,9-hexahydro-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxofuro[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-5-yl]-4-ethoxy-a-oxo-1-[phenylmethyl]-
MF C39 H34 N2 O10

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L20 50 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Urea, N-(3-bromophenyl)-N'-[(3aR,6S,7aR)-1-cyclobutyl-3a-(3,4-dimethoxyphenyl)octahydro-1H-indol-6-yl]-, rel-
MF C27 H34 Br N3 O3
CI COM

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10576581.trn

L10 50 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Urea, N-(2,5-difluorophenyl)-N'-[(3aR,6S,7aR)-3a-(3,4-dimethoxyphenyl)octahydro-1-methyl-1H-indol-6-yl]-
MF C24 H29 F2 N3 O3
CI COM

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1)-50

10576581.trn

=>
Uploading C:\Program Files\Stnexp\Queries\10576581-55555.str





chain nodes :
16
ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13
ring/chain nodes :
7 18
chain bonds :
1-8 4-7 7-18
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13
exact/norm bonds :
4-7
exact bonds :
1-2 1-6 1-8 2-3 3-4 4-5 5-6 7-18
normalized bonds :

10576581.trn

8-9 8-13 9-10 10-11 11-12 12-13
isolated ring systems :
containing 1 :

G1:CH3,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,H

G2:OH,SH,MeO,EtO,n-PrO,i-PrO,n-BuO,i-BuO,t-BuO

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 16:CLASS 17:Atom 18:CLASS

L21 STRUCTURE UPLOADED

=> d l21
L21 HAS NO ANSWERS
L21 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l21
SAMPLE SEARCH INITIATED 14:22:40 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3976 TO ITERATE

50.3% PROCESSED 2000 ITERATIONS 26 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 75739 TO 83301
PROJECTED ANSWERS: 602 TO 1464

L22 26 SEA SSS SAM L21

=> s sub=l5 sam l122
L122 NOT FOUND
The L-number entered has not been defined in this session, or it
has been deleted. To see the L-numbers currently defined in this
session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s sub=l5 sam l22
SAMPLE SUBSET SEARCH INITIATED 14:22:52 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED - 605 TO ITERATE

100.0% PROCESSED 605 ITERATIONS 42 ANSWERS
SEARCH TIME: 00.00.01

10576581.trn

```
PROJECTIONS (WITHIN SPECIFIED SUBSET):            ONLINE  **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):        10625 TO    13575
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):             451 TO     1227

L23          42 SEA SUB=L5 SSS SAM L21

=> d scan
```

10576581.trn

L23 42 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Pyrrolidineacetamide, 1-[(4-chlorophenyl)methyl]-N-[cis-4-(2,4-dihydroxyphenyl)cyclohexyl]-5-oxo-
MF C24 H27 Cl N2 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1)-1

L23 42 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Carbamic acid, [[[[cis-4-[(diphenylmethyl)amino]-1-(2-methoxyphenyl)cyclohexyl]methyl]amino]sulfonyl]-, 1,1-dimethylethyl ester (9CI)
MF C32 H41 N3 O5 S

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1)-1

L23 42 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Phenol, 4-[trans-4-[[3-[4-methoxyphenyl]propyl]amino]cyclohexyl]-, hydrochloride (1:1)
MF C22 H29 N O2 . Cl H

Relative stereochemistry.



● HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1)-1

L23 42 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Methanesulfonamide, N-[[cis-1-[3-methoxyphenyl)-4-[(1-methyl-4-piperidinyl)amino]cyclohexyl]methyl]-
MF C21 H35 N3 O3 S

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1)-1

10576581.trn

L23 42 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzenebutanol, β-[[trans-4-[4-hydroxyphenyl]cyclohexyl]amino]-
MF C22 H29 N O2

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1)-1

L23 42 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[(2,4,6-trimethylphenyl)methyl]amino]-, cis-
MF C24 H30 N2 O

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

10576581.trn

```
=> d his

     (FILE 'HOME' ENTERED AT 13:35:47 ON 02 JUN 2009)

     FILE 'REGISTRY' ENTERED AT 13:35:58 ON 02 JUN 2009
L1                STRUCTURE UPLOADED
L2             13 S L1
L3                STRUCTURE UPLOADED
L4             50 S L3
L5          16588 S L3 FULL

     FILE 'STNGUIDE' ENTERED AT 13:43:45 ON 02 JUN 2009

     FILE 'CAPLUS' ENTERED AT 13:49:42 ON 02 JUN 2009

     FILE 'STNGUIDE' ENTERED AT 13:49:49 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 13:55:44 ON 02 JUN 2009
L6                STRUCTURE UPLOADED
L7              0 S SAM L6 SUB=L5
L8                STRUCTURE UPLOADED
L9              0 S SAM L8 SUB=L5
L10            16 S FULL L8 SUB=L5

     FILE 'CAPLUS' ENTERED AT 13:58:03 ON 02 JUN 2009
L11             4 S L10
L12          6519 S LDL RECEPTOR

     FILE 'REGISTRY' ENTERED AT 14:02:44 ON 02 JUN 2009

     FILE 'CAPLUS' ENTERED AT 14:02:48 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 14:03:14 ON 02 JUN 2009

     FILE 'HCAPLUS' ENTERED AT 14:03:23 ON 02 JUN 2009
L14             4 S L5 AND L12
L15               STRUCTURE UPLOADED

     FILE 'REGISTRY' ENTERED AT 14:07:39 ON 02 JUN 2009
L16            50 S SAM L15 SUB=L5

     FILE 'STNGUIDE' ENTERED AT 14:18:03 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 14:20:55 ON 02 JUN 2009
L17               STRUCTURE UPLOADED

     FILE 'REGISTRY' ENTERED AT 14:21:18 ON 02 JUN 2009
L18            18 S L17
L19            50 S SAM L18 SUB=L5
L20            50 S SAM L17 SUB=L5
L21               STRUCTURE UPLOADED
L22            26 S L21
L23            42 S SAM L22 SUB=L5

=> s sub=l5 full l22
```

10576581.trn

FULL SUBSET SEARCH INITIATED 14:23:27 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 12606 TO ITERATE

100.0% PROCESSED 12606 ITERATIONS 781 ANSWERS
SEARCH TIME: 00.00.01

L24 781 SEA SUB=L5 SSS FUL L21

=> file caplus
FILE 'CAPLUS' ENTERED AT 14:23:31 ON 02 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 2 Jun 2009 VOL 150 ISS 23
FILE LAST UPDATED: 1 Jun 2009 (20090601/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d cbib abs hitstr l-
YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:y

'CBIB' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'
'ABS' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'
'HITSTR' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

The following are valid formats:

Substance information can be displayed by requesting individual
fields or predefined formats. The predefined substance formats
are: (RN = CAS Registry Number)

10576581.trn

```
REG    - RN
SAM    - Index Name, MF, and structure - no RN
FIDE   - All substance data, except sequence data
IDE    - FIDE, but only 50 names
SQIDE  - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD    - Protein sequence data, includes RN
SQD3   - Same as SQD, but 3-letter amino acid codes are used
SQN    - Protein sequence name information, includes RN

EPROP  - Table of experimental properties
PPROP  - Table of predicted properties
PROP   - EPROP, ETAG, PPROP and SPEC

Any CA File format may be combined with any substance format to
obtain CA references citing the substance.  The substance formats
must be cited first.  The CA File predefined formats are:

ABS  -- Abstract
APPS -- Application and Priority Information
BIB  -- CA Accession Number, plus Bibliographic Data
CAN  -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND  -- Index Data
IPC  -- International Patent Classification
PATS -- PI, SO
STD  -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when
it is available.
The MAX format is the same as ALL.
The IALL format is the same as ALL with BIB ABS and IND indented,
with text labels.

For additional information, please consult the following help
messages:

HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.
ENTER DISPLAY FORMAT (IDE):end

=> d cbib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:n
```

10576581.trn

```
=> d his

     (FILE 'HOME' ENTERED AT 13:35:47 ON 02 JUN 2009)

     FILE 'REGISTRY' ENTERED AT 13:35:58 ON 02 JUN 2009
L1                STRUCTURE UPLOADED
L2             13 S L1
L3                STRUCTURE UPLOADED
L4             50 S L3
L5          16588 S L3 FULL

     FILE 'STNGUIDE' ENTERED AT 13:43:45 ON 02 JUN 2009

     FILE 'CAPLUS' ENTERED AT 13:49:42 ON 02 JUN 2009

     FILE 'STNGUIDE' ENTERED AT 13:49:49 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 13:55:44 ON 02 JUN 2009
L6                STRUCTURE UPLOADED
L7              0 S SAM L6 SUB=L5
L8                STRUCTURE UPLOADED
L9              0 S SAM L8 SUB=L5
L10            16 S FULL L8 SUB=L5

     FILE 'CAPLUS' ENTERED AT 13:58:03 ON 02 JUN 2009
L11             4 S L10
L12          6519 S LDL RECEPTOR

     FILE 'REGISTRY' ENTERED AT 14:02:44 ON 02 JUN 2009

     FILE 'CAPLUS' ENTERED AT 14:02:48 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 14:03:14 ON 02 JUN 2009

     FILE 'HCAPLUS' ENTERED AT 14:03:23 ON 02 JUN 2009
L14             4 S L5 AND L12
L15               STRUCTURE UPLOADED

     FILE 'REGISTRY' ENTERED AT 14:07:39 ON 02 JUN 2009
L16            50 S SAM L15 SUB=L5

     FILE 'STNGUIDE' ENTERED AT 14:18:03 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 14:20:55 ON 02 JUN 2009
L17               STRUCTURE UPLOADED

     FILE 'REGISTRY' ENTERED AT 14:21:18 ON 02 JUN 2009
L18            18 S L17
L19            50 S SAM L18 SUB=L5
L20            50 S SAM L17 SUB=L5
L21               STRUCTURE UPLOADED
L22            26 S L21
L23            42 S SAM L22 SUB=L5
L24           781 S FULL L22 SUB=L5
```

10576581.trn

FILE 'CAPLUS' ENTERED AT 14:23:31 ON 02 JUN 2009

FILE 'REGISTRY' ENTERED AT 14:23:42 ON 02 JUN 2009

FILE 'CAPLUS' ENTERED AT 14:23:45 ON 02 JUN 2009

```
=> file caplus
FILE 'CAPLUS' ENTERED AT 14:24:02 ON 02 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 2 Jun 2009  VOL 150 ISS 23
FILE LAST UPDATED: 1 Jun 2009  (20090601/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Feb 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Feb 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l24
L25           75 L24

=> s l25 and py<=2004
      25140316 PY<=2004
L26           59 L25 AND PY<=2004

=> s l25 and prd<=2004
       4606383 PRD<=2004
                 (PRD<=20049999)
L27           52 L25 AND PRD<=2004

=> s l25 and pry<=2004
       4606382 PRY<=2004
L28           52 L25 AND PRY<=2004

=> s l26 or l27 or l28
```

10576581.trn

L29 63 L26 OR L27 OR L28

=> d cbib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 63 ANSWERS - CONTINUE? Y/(N):y

L29 ANSWER 1 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
2006:100777 Document No. 144:192410 Preparation of aminotropane derivatives
and their therapeutic applications. Braun, Alain; Cornet, Bruno; Courtemanche, Gilles; Crespin, Olivier; Pascal, Cecile (Sanofi-Synthelabo, Fr.). Fr. Demande FR 2873693 A1 20060203, 52 pp. (French). CODEN: FRXXBL. APPLICATION: FR 2004-8372 20040729.
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to aminotropane derivs. I [Ra, Ra', R5 = H, alkyl, cycloalkyl; R1 = H, alkyl, cycloalkyl, heterocycloalkyl, aryl; R2 = (CH2)x(CO)y, (CO)y(CH2)x; Y = H, OH, alkyl, cycloalkyl, alkoxy, aryl, heteroaryl, NR11R12; R3 = 1 to 3 groups chosen among halogen, alkyl, cycloalkyl, OR, NRR', CO-NRR', NR-CO-R', NR-CO-NRR', NR-COOR', NO2, CN, CO2R; R4 = Z1, Z2, Z3 or Z4, A-R18, A-CH=N-R19, A-N(R20)-A'-R19, A-CO-N(R20)-A'-R19, A-CH(NH2)-R19, A-N(R20)-COO-A', (CH2)6-heteroaryl; R11, R12 = H, alkyl, cycloalkyl, alkoxy, NR13R14; NR11R12 = mono- or bicyclic 4- to 10-membered ring (optionally containing 1 - 3 addnl. heteroatoms, 1 - 3 ethylenic or acetylenic bonds); R13, R14 = H, alkyl, cycloalkyl, alkoxy; NR13R14 = mono- or bicyclic 4- to 10-membered ring; R19 = H, OH, Ph, CH2Ph, heteroaryl; R20 = H, CH2Ph; R, R' = alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylaryl, alkylheteroaryl; A, A' = linear or branched alkyl; U, V, W = N, CH2 chain;
X1 = (CH2)a; X2 = (CH2)r; a, p = 0 - 3; m = 0 - 2; r = 1 - 3; s= 0, 1; x =
0 - 4; y = 0, 1], their acid addition salts as well as their hydrates or solvates, procedures for their preparation and their therapeutic applications.
The procedure for their preparation is characterized by reductive amination of
amide II with ketones. Thus, tropanamine III·HCl was prepared from N-Boc-tropinone via reductive amination with N-[8-(4-chloro-D-phenylalanyl)-8-azabicyclo[3.2.1]oct-8-yl]-N-cyclohexyl-N',N'-diethylurea in CH2Cl2 containing Na(AcO)3BH and N-deprotection with aqueous
HCl. The agonistic activity of vs. melanocortin receptors was determined [IC50
= 770 nM vs. MC3 and IC50 = 150 nM vs. MC4].
IT 874891-83-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminotropane derivs. and their therapeutic applications)
RN 874891-83-5 CAPLUS
CN Urea, N-[(3-endo)-8-[(2R)-3-(4-chlorophenyl)-2-[[4-(4-
hydroxyphenyl)cyclohexyl]amino]-1-oxopropyl]-8-azabicyclo[3.2.1]oct-3-yl]-N-cyclohexyl-N',N'-diethyl-, hydrochloride (1:1) (CA INDEX NAME)

L29 ANSWER 1 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Absolute stereochemistry.



L29 ANSWER 2 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
2006:100772 Document No. 144:192940 Preparation of oxopiperidines, particularly piperidino-D-phenylalanine derivatives, as melanocortin receptor agonists. Braun, Alain; Courtemanche, Gilles; Crespin, Olivier; Fett, Eykmar; Pascal, Cecile (Sanofi-Synthelabo, Fr.). Fr. Demande FR 2873690 A1 20060203, 59 pp. (French). CODEN: FRXXBL. APPLICATION: FR 2004-8369 20040729.
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = (CH2)n; n = 0-1; Ra, Ra', Rb, Rb' = independently H, cyclo/alkyl; or Rb, Rb' can form a bridge together with the carbons they are attached; R1 = cyclo/alkyl; R2 = heteroaryl; R3 = 1-3 groups independently selected from halo, cyclo/alkyl, OH and derivs., NH2 and derivs., etc.; R5 = H, cyclo/alkyl; R4 = substituted tetrahydrofuranyl, cyclopentyl, adamantyl, etc.; their free bases, and acid addition salts, and
their hydrates and solvates] were prepared as ligands, particularly agonists, of melanocortin MC3 and/or MC4 receptors. Thus, II (m.p. = 60°) was prepared by reductive amination of cyclohexanone with amine III (preparation given). In a radioligand assay, I exhibited binding affinity
towards MC3 and MC4 receptors [IC50 for II = 250 nM towards MC4 receptor].
II displayed an EC50 of 209 nM and 52 nM towards MC3 and MC4 receptors in a test evaluating the agonistic activity by monitoring the cAMP formation stimulated by MC3 or MC4 receptors. I are useful for treating obesity, diabetes, and sexual dysfunctions.
IT 874909-27-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of oxopiperidine-D-phenylalanine derivs. as
melanocortin receptor agonists)
RN 874909-27-0 CAPLUS
CN 1-Propanone, 3-(4-chlorophenyl)-1-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)-1-piperidinyl]-2-[[4-(4-hydroxyphenyl)cyclohexyl]amino]-, (2R)-
(CA INDEX NAME)

Absolute stereochemistry.

L29 ANSWER 2 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
2005:1123880 Document No. 143:4059230 Preparation of heterocycle- and benzene-containing sulfonamide derivatives as LDL receptor agonists.
Ban,
Hitoshi; Asano, Shigehiro (Sumitomo Pharmaceuticals Co., Ltd., Japan).
PCT Int. Appl. WO 2005097738 A1 20051020, 233 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2005-JP6977 20050404. PRIORITY: JP 2004-112503 20040406.
GI



I



II

AB Enhancers for expression of low d. lipoprotein receptor containing the title
compds. represented by the formula (I), prodrugs thereof, and their pharmaceutically acceptable salts [m, n, p = 0-4 and $3 \leq m+n \leq 8$; X = O, S, each (un)substituted NH or CH2; R1 -R3 = H, each (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, arylsulfonyl, heteroarylsulfonyl, arylalkyl, or heteroarylalkyl; Y = SO2, optionally esterified P(O)(OH), CO; Z = O, S, (un)substituted NH, (CH2)q; q = 0-4; a,
b, c, d, e, f = H, HO, each (un)substituted alkyl, alkoxy, alkoxycarbonyl,
aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, arylalkyl, heteroarylalkyl, arylalkyloxy, or heteroarylalkyloxy; or one or plural combination(s) of a and b, c and d, or e and f represent oxo; e and f

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
represent thioxo; a and c represent alkylene] are disclosed. Drugs for treating hyperlipemia and arteriosclerosis contg. the compds. I are also disclosed. Thus, a soln. of 40 mg tert-Bu

[[[2-[cis-4-amino-1-(3-methoxyphenyl)cyclohexyl]methyl]amino]sulfonyl]carbamate and 22.0 mg 1-benzyl-4-piperidone in 2 mL 1,2-dichloroethane was treated with 71.7 mg sodium triacetoxyborohydride and stirred overnight, followed by treatment of the product with CF3CO2H in CH2Cl2 to give N-[[cis-4-[(1-benzylpiperidin-4-yl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]sulfonamide (II) (R4 = NH2, R5 = 1-benzyl-4-piperidinyl) (III). III and II (R4 = Me, R5 = 1,1'-biphenyl-4-ylmethyl) at 10 μM increased the uptake of 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI)-labeled human low d. lipoprotein in HepG2 cells by 230 and 238%, resp.
IT 867263-39-6P 867263-41-0P 867264-21-9P
867264-32-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of heterocycle- and benzene-containing sulfonamide derivs. as LDL
receptor agonists for treatment of hyperlipemia and arteriosclerosis)
RN 867263-39-6 CAPLUS
CN Methanesulfonamide, N-[[cis-1-(3-methoxyphenyl)-4-(4-piperidinylamino)cyclohexyl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)

Relative stereochemistry.



● 2 HCl

RN 867263-41-0 CAPLUS
CN Methanesulfonamide,
N-[[cis-4-amino-1-(3-methoxyphenyl)cyclohexyl]methyl]-
(CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867264-21-9 CAPLUS
CN Carbamic acid, [[[[cis-4-[([1,1'-biphenyl]-4-ylmethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]amino]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867264-32-2 CAPLUS
CN Carbamic acid, [[[[cis-4-[([1,1'-biphenyl]-4-ylmethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]amino]sulfonyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 850886-15-6P 850886-16-7P,
N-[[cis-4-[(Biphenyl-4-ylmethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]-4-methylbenzenesulfonamide
867263-27-2P 867263-28-3P 867263-44-3P
867263-46-5P 867263-49-8P 867263-50-1P
867263-51-2P 867263-52-3P 867263-53-4P

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
867263-56-7P 867263-57-8P 867263-59-0P
867263-60-3P 867263-61-4P 867263-62-5P
867263-63-6P 867263-64-7P 867263-65-8P
867263-66-9P 867263-67-0P 867263-68-1P
867263-69-2P 867263-70-5P 867263-71-6P
867263-72-7P 867263-73-8P 867263-74-9P
867263-77-2P 867263-78-3P 867263-82-9P
867263-85-2P 867264-08-2P 867264-15-1P
867264-17-3P 867264-22-0P 867264-23-1P
867264-27-5P 867264-29-7P 867264-30-0P
867264-31-1P 867264-33-3P 867264-37-7P
867264-40-2P 867264-41-3P 867264-44-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heterocycle- and benzene-contg. sulfonamide derivs. as LDL receptor agonists for treatment of hyperlipemia and arteriosclerosis)
RN 850886-15-6 CAPLUS
CN Methanesulfonamide, N-[[cis-4-[([1,1'-biphenyl]-4-ylmethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-16-7 CAPLUS
CN Benzenesulfonamide, N-[[cis-4-[([1,1'-biphenyl]-4-ylmethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]-4-methyl- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-27-2 CAPLUS
CN Sulfamic acid,
N-[[1-(3-methoxyphenyl)-4-(phenylamino)cyclohexyl]carbonyl]-

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
, 2,4-bis(1-methylethyl)phenyl ester (CA INDEX NAME)



RN 867263-28-3 CAPLUS
CN Sulfamic acid, N-[[1-(3-methoxyphenyl)-4-[(2-methoxyphenyl)amino]cyclohexyl]carbonyl]-, 2,4-bis(1-methylethyl)phenyl ester (CA INDEX NAME)



RN 867263-44-3 CAPLUS
CN Acetanide, N-(4-[[[cis-4-(3-methoxyphenyl)-4-[[methylsulfonyl]amino]methyl]cyclohexyl]amino]methyl]phenyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-46-5 CAPLUS
CN Methanesulfonamide, N-[[trans-1-(3-methoxyphenyl)-4-[[4-[methylsulfonyl]phenyl]methyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Relative stereochemistry.



RN 867263-52-3 CAPLUS
CN Methanesulfonamide, N-[[cis-1-(3-methoxyphenyl)-4-[[1-[[4-[methylsulfonyl]phenyl]methyl]-4-piperidinyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-53-4 CAPLUS
CN Methanesulfonamide, N-[cis-4-[[2,3'-bipheny1]-4-ylmethyl]amino]-1-(3-methoxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-54-7 CAPLUS
CN Methanesulfonamide, N-[cis-1-[3-methoxyphenyl)-4-[4-piperidinylamino]cyclohexyl]-, hydrochloride (1:2) (CA INDEX NAME)

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867263-49-8 CAPLUS
CN Methanesulfonamide, N-[[cis-1-(3-methoxyphenyl)-4-[[1-(1-methylethyl)-4-piperidinyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-50-1 CAPLUS
CN Methanesulfonamide, N-[[cis-1-(3-methoxyphenyl)-4-[[1-methyl-4-piperidinyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-51-2 CAPLUS
CN Acetanide, N-[4-[[4-[[cis-4-(3-methoxyphenyl)-4-[[methylsulfonyl]amino]methyl]cyclohexyl]amino]-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Relative stereochemistry.



● 2 HCl

RN 867263-57-8 CAPLUS
CN Sulfanide, N-[[cis-1-(3-methoxyphenyl)-4-[[1-(phenylmethyl)-4-piperidinyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-59-0 CAPLUS
CN Sulfanide, N-[[cis-4-[[[4-(1H-imidazol-1-yl)phenyl]methyl]amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867263-60-3 CAPLUS
CN Sulfamide, N-[[cis-1-[3-methoxyphenyl)-4-[[(4-[H-1,2,4-triazol-1-yl]phenyl]methyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-61-4 CAPLUS
CN Sulfamide, N-[[cis-4-[[4-(2-hydroxyethoxy)phenyl]methyl]amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867263-64-7 CAPLUS
CN Sulfamide, N-[[cis-1-[3-methoxyphenyl)-4-[(phenylmethyl)amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-65-8 CAPLUS
CN Sulfamide, N-[[cis-1-(3-methoxyphenyl)-4-[[4-(4-morpholinylphenyl)methyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867263-62-5 CAPLUS
CN Acetamide, N-[4-[[[cis-4-[[aminosulfonyl)amino]methyl]-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]phenyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-63-6 CAPLUS
CN Sulfamide, N-[[cis-1-(3-methoxyphenyl)-4-[[4-quinolinylmethyl)amino)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867263-66-9 CAPLUS
CN Sulfamide, N-[[cis-4-[[(4-butoxyphenyl)methyl]amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-67-0 CAPLUS
CN Sulfamide, N-[[cis-4-[[1,3-benzodioxol-5-ylmethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 867263-68-3 CAPLUS
CN Sulfamide,
N-[[cis-4-[[5-chloro-1,2,3-thiadiazol-4-yl]methyl]amino]-1-(3-
methoxyphenyl)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-69-2 CAPLUS
CN Sulfamide, N-[[cis-1-(3-methoxyphenyl)-4-[[1-methyl-1H-indol-5-
yl]methyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-70-5 CAPLUS
CN Sulfamide, N-[[cis-4-[(2-benzofuranylmethyl)amino]-1-(3-
methoxyphenyl)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
phenylethyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-74-9 CAPLUS
CN Sulfamide, N-[[cis-4-[[1-[1,1'-biphenyl]-4-ylethyl]amino]-1-(3-
methoxyphenyl)cyclohexyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 867263-77-2 CAPLUS
CN Sulfamide, N-[[cis-4-[[1-[1,1'-biphenyl]-4-ylethyl]amino]-1-(3-
methoxyphenyl)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867263-71-6 CAPLUS
CN Sulfamide, N-[[cis-1-(3-methoxyphenyl)-4-[[1-methyl-4-
piperidinyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-72-7 CAPLUS
CN Sulfamide, N-[[cis-4-[[2-hydroxy-4-methoxyphenyl]methyl]amino]-1-(3-
methoxyphenyl)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-73-8 CAPLUS
CN Sulfamide, N-[[cis-1-(3-methoxyphenyl)-4-[(1-

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867263-78-3 CAPLUS
CN Sulfamide, N-[2-[trans-4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-(3-
methoxyphenyl)cyclohexyl]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 867263-82-9 CAPLUS
CN Sulfamide, N-[cis-4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-(3-
methoxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 867263-85-2 CAPLUS
CN Benzenesulfonamide, N-[[cis-4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-[(3-methoxyphenyl)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867264-00-2 CAPLUS
CN Benzenesulfonamide, 4-[[[trans-4-[[(aminosulfonyl)amino]methyl]-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 867264-15-1 CAPLUS
CN Carbamic acid, [[[cis-1-(3-methoxyphenyl)-4-[[[4-[methylsulfonyl]phenyl]methyl]amino]cyclohexyl]methyl]amino]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 867264-23-1 CAPLUS
CN Sulfamide, N-[[trans-4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-[3-methoxyphenyl]cyclohexyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 867264-27-5 CAPLUS
CN Sulfamide, N-[[cis-4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-(3-ethoxyphenyl)cyclohexyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867264-17-3 CAPLUS
CN Methanesulfonamide, N-[[cis-4-[[1,1'-biphenyl]-4-ylmethyl)amino]-1-[3-ethoxyphenyl)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867264-22-0 CAPLUS
CN Sulfamide, N-[[cis-4-[[1,1'-biphenyl]-4-ylmethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 867264-29-7 CAPLUS
CN Acetamide, N-[[[[cis-4-[[[1,1'-biphenyl]-4-ylmethyl)amino]-1-[(3-methoxyphenyl)cyclohexyl]methyl]amino]sulfonyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867264-30-0 CAPLUS
CN Propanamide, N-[[[[cis-4-[[[1,1'-biphenyl]-4-ylmethyl)amino]-1-[(2-methoxyphenyl)cyclohexyl]methyl]amino]sulfonyl]-2-methyl- (CA INDEX NAME)

Relative stereochemistry.



RN 867264-31-1 CAPLUS
CN Carbamic acid, [[[[cis-4-[[[1,1'-biphenyl]-4-ylmethyl)amino]-1-[(3-

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
methoxyphenyl)cyclohexyl]methyl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867264-32-3 CAPLUS
CN Sulfamide, N-[[cis-4-[[1,1'-biphenyl]-4-ylmethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]-N'-methyl-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 867264-37-7 CAPLUS
CN Methanesulfonamide, N-[[trans-1-(3-methoxyphenyl)-4-[[1-(phenylmethyl)-4-piperidinyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



●2 HCl

RN 867264-44-6 CAPLUS
CN Sulfamide, N-[[trans-1-(3-methoxyphenyl)-4-[[1-(phenylmethyl)-4-piperidinyl]amino]cyclohexyl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

IT 850886-11-2, cis-4-(Aminomethyl)-N-(biphenyl-4-ylmethyl)-4-(3-methoxyphenyl)cyclohexanamine 850887-58-0, Methyl cis-4-[(diphenylmethyl)amino]-1-(3-methoxyphenyl)cyclohexanecarboxylate 867263-75-0 867264-25-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heterocyclo- and benzene-containing sulfonamide derivs. as LDL
receptor agonists for treatment of hyperlipemia and arteriosclerosis)

RN 850886-11-2 CAPLUS
CN [1,1'-Biphenyl]-4-methanamine, N-[cis-4-(aminomethyl)-4-(3-methoxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867264-40-2 CAPLUS
CN Benzenesulfonamide, 4-[[4-[[cis-4-(3-methoxyphenyl)-4-[[(methylsulfonyl)amino]methyl]cyclohexyl]amino]-1-piperidinyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867264-41-3 CAPLUS
CN Sulfamide, N-[[trans-1-(3-methoxyphenyl)-4-(4-piperidinylamino)cyclohexyl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850887-58-0 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[(diphenylmethyl)amino]-1-(3-methoxyphenyl)-, methyl ester, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-75-0 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[1-[1,1'-biphenyl]-4-ylethyl)amino]-1-(3-methoxyphenyl)-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 867264-25-3 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[[1,1'-biphenyl]-4-ylmethyl)amino]-1-(3-methoxyphenyl)-, trans- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



IT 850885-64-2P, cis-4-[(Diphenylmethyl)amino]-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850885-65-3P, trans-4-[(Diphenylmethyl)amino]-1-[3-methoxyphenyl)cyclohexanecarbonitrile 850885-66-4P, cis-4-Amino-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850886-02-1P, cis-1-Piperidinecarboxylic acid, 4-[[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]-, 3,3-dimethylethyl ester 850886-02-2P, cis-4-(4-Piperidylamino)-1-(3-methoxyphenyl)cyclohexanecarbonitrile dihydrochloride 850886-03-4P, cis-4-[(1-Benzylpiperidin-4-yl)amino]-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850886-33-8P 850887-59-1P, Methyl cis-4-[(tert-butoxycarbonyl)amino]-1-(3-methoxyphenyl)cyclohexanecarboxylate 850887-60-4P, cis-4-[(tert-Butoxycarbonyl)amino]-1-(3-methoxyphenyl)cyclohexanecarboxylic acid 851067-35-1P 867262-90-4P 867262-91-5P 867262-92-6P 867262-93-7P 867262-94-8P 867262-95-1P 867262-96-2P 867263-42-1P 867263-43-2P 867263-54-3P 867263-55-4P 867263-58-8P 867263-76-1P 867263-79-4P 867263-80-7P 867263-81-8P 867263-83-0P 867263-84-1P 867264-09-7P 867264-10-0P 867264-11-7P 867264-12-8P 867264-14-0P 867264-16-2P 867264-19-4P 867264-19-5P 867264-20-8P 867264-24-2P 867264-26-4P 867264-28-6P 867264-33-3P 867264-42-4P 867264-43-5P 867264-44-6P

RLs RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of heteroycle- and benzene-containing sulfonamide derivs. as LSL

receptor agonists for treatment of hyperlipemia and arteriosclerosis)

RN 850885-64-2 CAPLUS
CN Cyclohexanecarbonitrile, 4-[(diphenylmethyl)amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-02-1 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]-, 3,3-dimethylethyl ester (CA INDEX NAME)

Relative stereochemistry.



RN 850886-02-2 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-(4-piperidylamino)-, hydrochloride (1:2), cis- (CA INDEX NAME)

Relative stereochemistry.



● 2 HCl

RN 850886-05-4 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[1-(phenylmethyl)-4-piperidinyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850885-65-3 CAPLUS
CN Cyclohexanecarbonitrile, 4-[(diphenylmethyl)amino]-1-(3-methoxyphenyl)-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-66-4 CAPLUS
CN Cyclohexanecarbonitrile, 4-amino-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-68-6 CAPLUS
CN Cyclohexanecarbonitrile, 4-amino-1-(3-methoxyphenyl)-, trans- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-33-8 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[(1,1'-biphenyl]-4-ylmethyl)amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850887-59-1 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[[(1,1-dimethylethoxy)carbonyl]amino]-1-(3-methoxyphenyl)-, methyl ester, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850887-60-4 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[[(1,1-dimethylethoxy)carbonyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 851067-35-5 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-(4-piperidinylamino)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 867262-90-6 CAPLUS
CN Cyclohexaneacetonitrile, 4-[(diphenylmethyl)amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 867262-91-7 CAPLUS
CN Cyclohexanemethanol, 4-[(diphenylmethyl)amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867262-95-1 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[(diphenylmethyl)amino]-3-(3-methoxyphenyl)-, methyl ester, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 867262-96-2 CAPLUS
CN Carbamic acid, [cis-4-[[(1,1-dimethylethoxy)carbonyl]amino]-1-(3-methoxyphenyl)cyclohexyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867263-42-2 CAPLUS
CN Methanesulfonamide, N-[[cis-4-[(diphenylmethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867262-92-8 CAPLUS
CN Cyclohexanemethanol, 4-[(diphenylmethyl)amino]-1-(3-methoxyphenyl)-, 1-methanesulfonate, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 867262-93-9 CAPLUS
CN Cyclohexaneacetonitrile, 1-(3-methoxyphenyl)-4-(4-piperidinylamino)-, hydrochloride (1:2), cis- (CA INDEX NAME)

Relative stereochemistry.



● 2 HCl

RN 867262-94-0 CAPLUS
CN Carbamic acid, [cis-4-amino-4-(3-methoxyphenyl)cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867263-43-2 CAPLUS
CN Benzeneethanamine, N-[cis-4-(aminomethyl)-4-(3-methoxyphenyl)cyclohexyl]-a-phenyl- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-54-5 CAPLUS
CN Carbamic acid, [cis-4-(3-methoxyphenyl)-4-[(methylsulfonyl)amino]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867263-55-6 CAPLUS
CN Methanesulfonamide, N-[cis-4-amino-3-(3-methoxyphenyl)cyclohexyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 867267-58-9 CAPLUS
CN Carbamic acid, [[[cis-4-amino-1-[3-methoxyphenyl)cyclohexyl]methyl]amino]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867267-76-1 CAPLUS
CN Carbamic acid, [[[[trans-4-[[1-[1,1'-biphenyl]-4-ylethyl]amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]amino]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867263-83-0 CAPLUS
CN Carbamic acid, [[cis-4-[[(5,1-dimethylethoxy)carbonyl]amino]-1-[3-methoxyphenyl)cyclohexyl]methyl]amino]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867263-84-1 CAPLUS
CN Sulfamide, N-[cis-4-amino-1-(3-methoxyphenyl)cyclohexyl]-, hydrochloride (2:1) (CA INDEX NAME)

Relative stereochemistry.



RN 867263-79-4 CAPLUS
CN Carbamic acid, [[[2-[cis-4-[(diphenylmethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]ethyl]amino]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867263-80-7 CAPLUS
CN Carbamic acid, [[[2-[trans-4-amino-1-(3-methoxyphenyl)cyclohexyl]ethyl]amino]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867263-81-8 CAPLUS



● HCl

RN 867264-09-3 CAPLUS
CN Carbamic acid, [[cis-4-[(diphenylmethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867264-10-6 CAPLUS
CN Carbamic acid, [[trans-4-amino-1-(3-methoxyphenyl)cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867264-11-7 CAPLUS
CN Carbamic acid, [[cis-4-[[[4-(aminosulfonyl)phenyl]methyl]amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
INDEX NAME)

Relative stereochemistry.



RN 867264-12-9 CAPLUS
CN Benzenesulfonamide, 4-[[[trans-4-(aminomethyl)-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]-, hydrochloride (1:2) (CA INDEX NAME)

Relative stereochemistry.



● 2 HCl

RN 867264-14-0 CAPLUS
CN Carbamic acid, [[[cis-4-[[[4-(aminosulfonyl)phenyl]methyl]amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]amino]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN [1,1'-Biphenyl]-4-carboxamide, N-[cis-4-cyano-4-(3-hydroxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867264-20-8 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[cis-4-cyano-4-(3-ethoxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867264-24-2 CAPLUS
CN [1,1'-Biphenyl]-4-methanamine, N-[trans-4-(aminomethyl)-4-(3-methoxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867264-26-4 CAPLUS
CN Carbamic acid, [[[trans-4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]amino]sulfonyl]-, 1,1-dimethylethyl ester

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867264-16-2 CAPLUS
CN Carbamic acid, [[[cis-4-[(diphenylmethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]amino]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867264-18-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867264-19-5 CAPLUS

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867264-28-6 CAPLUS
CN Carbamic acid, [[[cis-4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-(3-ethoxyphenyl)cyclohexyl]methyl]amino]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867264-38-8 CAPLUS
CN 4-Piperidinamine, N-[trans-4-(aminomethyl)-4-(3-methoxyphenyl)cyclohexyl]-1-(phenylmethyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 867264-42-4 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[1-(triphenylmethyl)-4-piperidinyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867264-43-5 CAPLUS
CN Carbamic acid, 1[[(cis-1-(3-methoxyphenyl)-4-[[1-(triphenylmethyl)-4-piperidinyl]amino]cyclohexyl]methyl]amino]aminoxyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867264-45-7 CAPLUS
CN Carbamic acid, 1[[(trans-1-(3-methoxyphenyl)-4-[[1-(phenylmethyl)-4-piperidinyl]amino]cyclohexyl]methyl]amino]aminoxyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
92.6 mg K2CO3 in 1.0 mL DMF under ice-cooling, and the resulting mixt. was

warmed to room temp., stirred overnight, and quenched by adding water to give, after workup and silica gel chromatog., 15.6 mg 1'-benzyl-4-(3-methoxyphenyl)-1,1'-bipiperidine-4-carbonitrile (II). II at 10 μM and N-benzyl-4-(3-methoxyphenyl)-1-(pyrimidin-2-yl)piperidine-4-carbothioamide at 3 μM enhanced the LDL receptor activity by 135 and 193%, resp.

IT 850885-24-4P, 4-[[4-Benzoylphenyl]amino]-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850885-86-8P, Ethyl 4-[[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]benzoate 850885-94-8P, 3-(Acetoxiffonyl)-4-chloro-N-[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]benzamide 850886-03-2P, cis-1-(3-Methoxyphenyl)-4-(1-pyridin-4-ylaminocyclohexaneacarbonitrile dihydrochloride 850886-11-2P, cis-4-(Aminomethyl)-N-(naphenyl-4-ylmethyl)-4-(3-methoxyphenyl)cyclohexanine 850886-33-8P 850887-57-9P , 4-[[cis-4-Cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]benzoic acid

hydrochloride
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of novel piperidine and cyclohexaneacabonitrile derivs. as

as

enhancers for LDL receptor manifestation, hypellpidemics, and antiarteriosclerotics)

RN 850885-24-4 CAPLUS
CN Cyclohexaneacarbonitrile, 4-[(4-benzoylphenyl)amino]-1-(3-methoxyphenyl)- (CA INDEX NAME)



RN 850885-86-8 CAPLUS
CN Benzoic acid, 4-[[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]-, ethyl
ester (CA INDEX NAME)

Relative stereochemistry.



RN 850885-94-8 CAPLUS
CN Benzamide, 3-(aminoxiforyl)-4-chloro-N-[cis-4-cyano-4-(3-

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
methoxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-03-2 CAPLUS
CN Cyclohexaneacarbonitrile, 1-[3-methoxyphenyl)-4-(4-piperidinylamino)-, hydrochloride (1:2), cis- (CA INDEX NAME)

Relative stereochemistry.



● 2 HCl

RN 850886-11-2 CAPLUS
CN [1,1'-Biphenyl]-4-methanamine, N-[cis-4-(aminomethyl)-4-(3-methoxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 850885-37-8 CAPLUS
CN Benzoic acid, 4-[[trans-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.

IT 63383-56-2P, Methyl cis-4-(benzylamino)-1-(3-methoxyphenyl)cyclohexanecarboxylate 773000-64-9P, Methyl trans-4-(benzylamino)-1-(3-methoxyphenyl)cyclohexanecarboxylate 850885-22-3P, 4-[[4-[Hydroxy(phenyl)methyl]phenyl]amino]-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850885-36-7P, cis-4-Anilino-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850885-37-8P, cis-1-(3-Methoxyphenyl)-4-[[2-phenylethyl]amino]cyclohexanecarbonitrile 850885-38-9P, cis-1-(3-Methoxyphenyl)-4-[(3-phenylpropyl)amino]cyclohexanecarbonitrile 850885-39-1P, trans-4-(Benzylamino)-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850885-62-0P,

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

850885-63-1P, trans-4-(Cyclohexylamino)-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850885-64-2P, cis-4-[(Diphenylmethyl)amino]-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850885-65-3P, trans-4-[(Diphenylmethyl)amino]-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850885-70-0P, cis-4-[[4-Chlorophenyl)amino]-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850885-71-1P, cis-1-(3-Methoxyphenyl)-4-[[3-methylphenyl)amino]cyclohexanecarbonitrile 850885-72-2P, cis-1-(3-Methoxyphenyl)-4-[[4-methylphenyl)amino]cyclohexanecarbonitrile 850885-73-3P, cis-1-(3-Methoxyphenyl)-4-[(2-methylphenyl)amino]cyclohexanecarbonitrile 850885-74-4P, cis-4-[(3,5-Dimethylphenyl)amino]-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850885-75-5P, 4-[[cis-4-Cyano-4-(3-methoxyphenyl)cyclohexyl]amino]benzenesulfonamide 850885-76-6P, 1-(3-Methoxyphenyl)-4-[4-[(pyridin-1-yl)sulfonyl]phenyl]aminocyclohexanecarbonitrile 850885-77-7P, 2-[[cis-4-Cyano-4-(3-methoxyphenyl)cyclohexyl]amino]benzenesulfonamide 850885-78-8P, 4-[[cis-4-Cyano-4-(3-methoxyphenyl)cyclohexyl]amino]benzenesulfonamide 850885-79-9P, Methyl 4-[[[trans-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]benzoate 850885-80-2P,

4-[[[trans-4-Cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]benzenesulfonamide 850885-81-3P, cis-1-(3-Methoxyphenyl)-4-[[4-methylbenzyl)amino]cyclohexanecarbonitrile 850885-82-4P,

trans-1-(3-Methoxyphenyl)-4-[[4-methylbenzyl)amino]cyclohexanecarbonitrile 850885-83-5P, cis-4-[[4-Methoxyphenyl)amino]-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850885-84-6P, trans-4-[[4-Methoxyphenyl)amino]-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850885-85-7P, cis-1-(3-Methoxyphenyl)-4-[[(pyridin-4-yl)methyl]amino]cyclohexanecarbonitrile 850885-87-9P, 4-[[cis-4-Cyano-4-(3-methoxyphenyl)cyclohexyl]amino]benzoic acid 850885-88-0P, cis-1-(3-Methoxyphenyl)-4-[(pyrimidin-2-yl)amino]cyclohexanecarbonitrile 850885-90-4P, 4-[[[cis-4-Cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]benzoic acid 850885-91-5P, 4-[[[cis-4-Cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]benzamide 850885-92-6P, 4-[[[cis-4-Cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]-N,N-dimethylbenzamide 850885-93-7P,

3-[[[cis-4-Cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]benzenesulfonamide 850885-95-9P, 3-(Aminosulfonyl)-N-[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]benzamide 850885-96-0P, N-[cis-4-Cyano-4-(3-methoxyphenyl)cyclohexyl]acetanside 850885-97-1P, N-[cis-4-Cyano-4-(3-methoxyphenyl)benzamide 850885-98-2P, tert-Butyl [cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]carbamate 850885-99-3P ,

N-[cis-4-Cyano-4-(3-methoxyphenyl)cyclohexyl]-4-methylbenzenesulfonamide 850886-01-0P, 4-Benzylamino-1-(3-methoxyphenyl)cyclohexanol 850886-02-1P, tert-Butyl 4-[[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]piperidine-1-carboxylate

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

850886-04-3P, cis-1-(3-Methoxyphenyl)-4-[[1-methylpiperidin-4-yl]amino]cyclohexanecarbonitrile 850886-05-4P, cis-4-[[1-Benzylpiperidin-4-yl]amino]-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850886-06-5P, cis-1-(3-Methoxyphenyl)-4-[[1-(methanesulfonyl)piperidin-4-yl]amino]cyclohexanecarbonitrile 850886-07-6P, cis-1-(3-Methoxyphenyl)-4-[[1-[(4-methylphenyl)sulfonyl]piperidin-4-yl]amino]cyclohexanecarbonitrile 850886-08-7P, cis-4-[[1-Acetylpiperidin-4-yl]amino]-1-(3-methoxyphenyl)cyclohexanecarbonitrile 850886-09-8P, cis-1-(3-Methoxyphenyl)-4-[[1-(pyrimidin-2-yl)piperidin-4-yl]amino]cyclohexanecarbonitrile 850886-10-1P, cis-4-(Aminomethyl)-N-benzyl-4-(3-methoxyphenyl)cyclohexanamine 850886-11-2P, cis-N-Benzyl-4-(3-methoxyphenyl)-4-[(piperidin-3-yl)methyl]cyclohexanamine 850886-13-4P, N-[cis-4-[(Biphenyl-4-ylmethyl)amino]methyl]-4-(3-methoxyphenyl)cyclohexanamine 850886-14-5P, Benzyl [cis-4-[(biphenyl-4-ylmethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]methylcarbamate 850886-15-6P 850886-16-7P, N-[cis-4-[(Biphenyl-4-ylmethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]-4-methylbenzenesulfonamide 850886-17-8P 850886-18-9P, N-[[cis-4-[(Biphenyl-4-ylmethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]benzamide 850886-19-0P, cis-N-Benzyl-4-[(biphenyl-4-ylmethyl)amino]-1-(3-methoxyphenyl)cyclohexanecarboxamide 850886-20-3P, cis-4-Benzylamino-1-(3-methoxyphenyl)cyclohexanecarboxamide 850886-22-5P, cis-4-[(Biphenyl-4-ylmethyl)amino]-1-(3-methoxyphenyl)cyclohexanecarboxamide 850886-23-6P 850886-24-7P 850886-25-8P 850886-26-9P 850886-27-0P 850886-28-1P 850886-29-2P 850886-30-3P 850886-31-4P 850886-32-5P 850886-34-7P 850886-35-8P 850886-36-1P 850886-37-2P 850886-38-3P 850886-39-4P 850886-40-7P 850886-41-8P 850886-42-9P 850886-43-0P 850886-44-1P 850886-45-2P 850886-47-4P 850886-48-5P 850886-49-6P 850886-50-9P 850886-51-0P 850886-52-1P 850886-53-2P 850886-54-3P 850886-55-4P 850886-56-5P 850886-57-6P 850886-58-7P 850886-59-8P 850886-60-1P 850886-61-2P 850886-62-3P 850886-63-4P 850886-64-5P 850886-65-6P 850886-66-7P 850886-67-8P 850886-68-9P 850886-69-0P 850886-70-3P 850886-71-4P 850886-72-5P 850886-73-6P 850886-74-7P 850886-75-8P 850886-76-9P 850886-77-0P 850886-78-1P 850886-79-2P 850886-80-5P 850886-81-6P 850886-82-7P 850886-83-8P 850886-84-9P 850886-85-0P 850886-86-1P 850886-87-2P 850886-88-3P 850886-89-4P 850886-90-7P 850886-91-8P 850886-92-9P 850886-93-0P 850886-94-1P 850886-95-2P 850886-96-3P 850886-97-4P 850886-98-5P 850886-99-6P 850887-00-2P 850887-01-3P 850887-02-4P 850887-03-5P 850887-04-6P, Methyl 4-[[[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]benzoate

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological activity); PREP (Preparation); USES

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

(Uses)

Iprep. of novel piperidine and cyclohexanecarbonitrile derivs. as enhancers for LDL receptor manifestation, hypolipidemics, and antiarteriosclerotics)

RN 63383-56-2 CAPLUS
CN Cyclohexanecarboxylic acid, 1-(3-methoxyphenyl)-4-[(phenylmethyl)amino]-, methyl ester, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 773000-64-9 CAPLUS
CN Cyclohexanecarboxylic acid, 1-(3-methoxyphenyl)-4-[(phenylmethyl)amino]-, methyl ester, trans- (CA INDEX NAME)

Relative stereochemistry.

RN 850885-25-5 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[4-(hydroxyphenylmethyl)phenyl]amino]-1-(3-methoxyphenyl)- (CA INDEX NAME)

RN 850885-36-8 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-(phenylamino)-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850885-37-9 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[(2-phenylethyl)amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-38-0 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[(3-phenylpropyl)amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-39-1 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[(phenylmethyl)amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850885-40-4 CAPLUS
CN Cyclohexanecarbonitrile, 4-[(diphenylmethyl)amino]-1-(3-methoxyphenyl)-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-41-5 CAPLUS
CN Cyclohexanecarbonitrile, 4-[(4-chlorophenyl)amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-71-1 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[(3-methylphenyl)amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850885-42-0 CAPLUS
CN Cyclohexanecarbonitrile, 4-(cyclohexylamino)-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-43-1 CAPLUS
CN Cyclohexanecarbonitrile, 4-(cyclohexylamino)-1-(3-methoxyphenyl)-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-44-2 CAPLUS
CN Cyclohexanecarbonitrile, 4-[(diphenylmethyl)amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 850885-72-2 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[(4-methylphenyl)amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-73-3 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[(2-methylphenyl)amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-74-4 CAPLUS
CN Cyclohexanecarbonitrile, 4-[(3,5-dimethylphenyl)amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-75-5 CAPLUS
CN Benzenesulfonamide, 4-[[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850885-76-6 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[4-[(2-pyridinylmethyl)oxy]phenyl]amino]- (CA INDEX NAME)



RN 850885-77-7 CAPLUS
CN Benzenesulfonamide, 2-[[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-78-8 CAPLUS
CN Benzenesulfonamide, 4-[[[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850885-79-9 CAPLUS
CN Benzoic acid, 4-[[[trans-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]-, methyl ester (CA INDEX NAME)

Relative stereochemistry.



RN 850885-80-2 CAPLUS
CN Benzenesulfonamide, 4-[[[trans-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]- (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 850885-81-3 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[4-methylphenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-82-4 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[4-methylphenyl]methyl]amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-83-5 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[4-methoxyphenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-84-6 CAPLUS

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[(4-methoxyphenyl)methyl]amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-85-7 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[(4-pyridinylmethyl)amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-87-9 CAPLUS
CN Benzoic acid, 4-[[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-88-0 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-(2-pyrimidinylamino)-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850885-90-4 CAPLUS
CN Benzoic acid, 4-[[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-91-5 CAPLUS
CN Benzamide, 4-[[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-92-6 CAPLUS
CN Benzamide, 4-[[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]-N,N-dimethyl- (CA INDEX NAME)

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 850885-96-0 CAPLUS
CN Acetamide, N-[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

RN 850885-97-1 CAPLUS
CN Benzamide, N-[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-98-2 CAPLUS
CN Carbamic acid, [cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 850885-99-3 CAPLUS
CN Benzenesulfonamide, N-[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]-4-methyl- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Relative stereochemistry.



RN 850885-93-7 CAPLUS
CN Benzenesulfonamide, 3-[[[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850885-95-9 CAPLUS
CN Benzamide, 3-(aminosulfonyl)-N-[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-01-0 CAPLUS
CN Cyclohexanol, 1-(3-methoxyphenyl)-4-[(phenylmethyl)amino]- (CA INDEX NAME)

RN 850886-02-1 CAPLUS
CN 1-Pyridinecarboxylic acid, 4-[[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Relative stereochemistry.



RN 850886-04-3 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[(1-methyl-4-piperidinyl)amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 850886-05-4 CAPLUS
CN Cyclohexanecarbonitrile, 1-[3-methoxyphenyl]-4-[[1-(phenylmethyl)-4-piperidinyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-06-5 CAPLUS
CN Cyclohexanecarbonitrile, 1-[3-methoxyphenyl]-4-[[1-(methylsulfonyl)-4-piperidinyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-07-6 CAPLUS
CN Cyclohexanecarbonitrile, 1-[3-methoxyphenyl]-4-[[1-[(4-methylphenyl)sulfonyl]-4-piperidinyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-08-7 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[1-acetyl-4-piperidinyl]amino]-1-[3-methoxyphenyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-13-4 CAPLUS
CN [1,1'-Biphenyl]-4-methanamine, N-[cis-4-[(ethylamino)methyl]-4-[3-methoxyphenyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-14-5 CAPLUS
CN [1,1'-Biphenyl]-4-methanamine, N-[cis-4-[3-methoxyphenyl]-4-[[(phenylmethyl)amino]methyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-15-6 CAPLUS
CN Methanesulfonamide, N-[[cis-4-[[1,1'-biphenyl]-4-ylmethyl]amino]-1-[3-methoxyphenyl]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-09-8 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[1-(2-pyrimidinyl)-4-piperidinyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-10-1 CAPLUS
CN Benzenemethanamine, N-[cis-4-(aminomethyl)-4-(3-methoxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-12-3 CAPLUS
CN Benzenemethanamine, N-[cis-4-[3-methoxyphenyl)-4-[(1-piperidinylmethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-16-7 CAPLUS
CN Benzenesulfonamide, N-[[cis-4-[[1,1'-biphenyl]-4-ylmethyl]amino]-1-[3-methoxyphenyl]cyclohexyl]methyl]-4-methyl- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-17-8 CAPLUS
CN Acetamide, N-[[cis-4-[[1,1'-biphenyl]-4-ylmethyl]amino]-1-[3-methoxyphenyl]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-18-9 CAPLUS
CN Benzamide, N-[[cis-4-[[1,1'-biphenyl]-4-ylmethyl)amino]-1-[3-methoxyphenyl]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-19-2 CAPLUS
CN Cyclohexanecarboxamide, 4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-[3-methoxyphenyl]-N-[phenylmethyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-20-7 CAPLUS
CN Cyclohexanecarboxamide, 1-[3-methoxyphenyl]-4-[[phenylmethyl]amino]-, cis-
(CA INDEX NAME)

Relative stereochemistry.



RN 850886-22-5 CAPLUS
CN Cyclohexanecarboxamide, 4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-[3-methoxyphenyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Relative stereochemistry.



RN 850886-26-9 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-chlorophenyl]methyl]amino]-1-[3-methoxyphenyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-27-0 CAPLUS
CN Acetamide, N-[4-[[[cis-4-cyano-4-[3-methoxyphenyl]cyclohexyl]amino]methyl]phenyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-28-1 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-(dimethylamino)phenyl]methyl]amino]-1-[3-methoxyphenyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-23-6 CAPLUS
CN Cyclohexanecarbonitrile, 4-[(9H-fluoren-2-ylmethyl)amino]-1-[3-methoxyphenyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-24-7 CAPLUS
CN Benzonitrile, 4-[[[cis-4-cyano-4-[3-methoxyphenyl]cyclohexyl]amino]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-25-8 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-fluorophenyl]methyl]amino]-1-[3-methoxyphenyl]-, cis- (CA INDEX NAME)

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-29-2 CAPLUS
CN Cyclohexanecarbonitrile, 1-[3-methoxyphenyl]-4-[[[4-phenoxyphenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-30-5 CAPLUS
CN Cyclohexanecarbonitrile, 1-[3-methoxyphenyl]-4-[[(1-naphthalenylmethyl)amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-31-6 CAPLUS
CN Cyclohexanecarbonitrile, 1-[3-methoxyphenyl]-4-[[2-naphthalenylmethyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.

RN 850886-32-7 CAPLUS
CN Cyclohexanecarbonitrile, 4-[(3,3-benzodioxol-5-ylmethyl)amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 850886-34-9 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[4-(methylthio)phenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.

RN 850886-35-0 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[4-(trifluoromethyl)phenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.

RN 850886-36-1 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[4-(1-methylethyl)phenyl]methyl]amino]-, cis- (CA INDEX NAME)

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
Relative stereochemistry.

RN 850886-37-2 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]phenyl]- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.

RN 850886-38-3 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-(dimethylamino)-1-naphthalenyl]methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-39-4 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[4-(2-propen-1-yloxy)phenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.

RN 850886-40-7 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[4-(1-pyrrolidinyl)phenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A

PAGE 2-A

RN 850886-41-3 CAPLUS
CN Cyclohexanecarbonitrile, 4-[(1,3-benzodioxol-4-ylmethyl)amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-42-4 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[(4-trifluoromethoxyphenyl)methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-43-5 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-45-2 CAPLUS
CN Benzenesulfonamide, N-[4-[[(cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]-3-hydroxyphenyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-46-3 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[(4-methylsulfonylphenyl)methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-47-4 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[(2,4,6-trimethoxyphenyl)methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-48-5 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[(2,4,6-trimethylphenyl)methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-49-6 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[(4-bromophenyl)methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-50-9 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-(diethylamino)phenyl]methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-51-0 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[4-(phenylmethoxy)phenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-52-1 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-ethoxyphenyl)methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-53-2 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-butoxyphenyl)methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 850886-56-5 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[4-propoxyphenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-57-6 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[4-(pentyloxy)phenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-58-7 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[(2,3,4,5,6-pentamethylphenyl)methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Relative stereochemistry.



RN 850886-54-3 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-ethylphenyl)methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-55-4 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-(3-(dimethylamino)propoxy]phenyl]methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 850886-59-8 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-(1,1-dimethylethyl)phenyl]methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-60-1 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[[2-[(1,1-dimethylethyl)thio]phenyl]methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-61-2 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-butylphenyl)methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-62-3 CAPLUS

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN Cyclohexanecarbonitrile, 1-[3-methoxyphenyl)-4-[[[4-(1-methylethoxy)phenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-63-4 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-(dibutylamino)phenyl]methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-64-5 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[4-(2-methylpropyl)phenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 850886-66-7 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[1-methyl-1H-imidazol-2-yl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-67-8 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[2-phenyl-1H-imidazol-5-yl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 850886-69-9 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[4-methyl-1H-imidazol-5-yl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-69-0 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[2-phenyl-1H-indol-3-yl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-70-3 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[1-(phenylsulfonyl)-1H-pyrrol-2-yl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-71-4 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 850886-65-6 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-(diphenylamino)phenyl]methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-68-9 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[5-(methylthio)-2-thienyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-72-5 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[5-(methylthio)-2-thienyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-73-6 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[1H-imidazol-5-ylmethyl)amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-74-7 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[1H-pyrazol-3-ylmethyl)amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-73-8 CAPLUS
CN Cyclohexanecarbonitrile, 4-[(1H-indol-3-ylmethyl)amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-76-9 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[(3-methylbenzo[b]thien-2-yl)methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-77-0 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[(2,2'-bithiophen]-5-ylmethyl)amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Relative stereochemistry.



RN 850886-81-6 CAPLUS
CN Cyclohexanecarbonitrile, 4-[(3-furanylmethyl)amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-82-7 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[(4-quinolinylmethyl)amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Relative stereochemistry.



RN 850886-78-1 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-79-2 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[2-benzofuranylmethyl)amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-80-5 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[(1-methyl-1H-indol-3-yl)methyl]amino]-, cis- (CA INDEX NAME)

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Relative stereochemistry.



RN 850886-83-8 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[(3-pyridinylmethyl)amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-84-9 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[(2-pyridinylmethyl)amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850826-85-0 CAPLUS
CN Cyclohexanecarbonitrile, 1-[3-methoxyphenyl)-4-[(3-thienylmethyl)amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-86-1 CAPLUS
CN Cyclohexanecarbonitrile, 4-[(2-furanylmethyl)amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-87-2 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850886-88-3 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[4-(2-phenylethenyl)phenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 850886-89-4 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-(2-hydroxyethoxy)phenyl]methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 850886-90-7 CAPLUS
CN Benzenesulfonic acid, 4-[[[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-91-8 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]amino]-1-[3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-92-9 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[(2-quinolinylmethyl)amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 850886-93-0 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-94-1 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-(1,1-dimethylethoxy)phenyl]methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-95-2 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-(4,1-dimethylethyl)-2-thiazolyl]phenyl]methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850806-96-3 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-(1H-1ntdazol-1-yl)phenyl]methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850806-97-4 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-(1-hexyn-1-yl)phenyl]methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850887-00-2 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-[(2-hydroxyethyl)methylamino]phenyl]methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850887-01-3 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[[4-acetylphenyl)methyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850887-02-4 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[4-(1H-1,2,4-triazol-1-

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850806-98-5 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[4-(4-methyl-1-piperazinyl)phenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850806-99-6 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[4-(4-morpholinyl)phenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

yl)phenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850887-09-1 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[[[6-[(4-methylphenyl)thio]imidazo[2,1-b]thiazol-5-yl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850887-64-8 CAPLUS
CN Benzoic acid, 4-[[[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]-, methyl ester (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



IT 850885-66-4, cis-4-Amino-1-[3-methoxyphenyl]cyclohexanecarbonitrile 850885-68-6, trans-4-Amino-1-[3-methoxyphenyl]cyclohexanecarbonitrile 850885-89-1, cis-4-Benzylamino-1-[3-methoxyphenyl]cyclohexanecarbonitrile
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of novel piperidine and cyclohexanecarbonitrile derivs. as
enhancers for LDL receptor manifestation, hypolipidemics, and antiarteriosclerotics)

RN 850885-66-4 CAPLUS
CN Cyclohexanecarbonitrile, 4-amino-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.

RN 850885-68-6 CAPLUS
CN Cyclohexanecarbonitrile, 4-amino-1-(3-methoxyphenyl)-, trans- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850885-89-1 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3-methoxyphenyl)-4-[(phenylmethyl)amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



IT 850887-58-0P, Methyl cis-4-[(diphenylmethyl)amino]-1-(3-methoxyphenyl)cyclohexanecarboxylate 850887-59-1P, Methyl cis-4-[(tert-Butoxycarbonyl)amino]-1-(3-methoxyphenyl)cyclohexanecarboxylate 850887-60-4P, cis-4-[(tert-Butoxycarbonyl)amino]-1-(3-methoxyphenyl)cyclohexanecarboxylic acid 850887-61-5P, tert-Butyl [cis-4-[(benzylamino)carbonyl]-4-(3-methoxyphenyl)cyclohexyl]carbamate 850887-62-6P, cis-4-Amino-N-benzyl-1-(3-methoxyphenyl)cyclohexanecarboxamide
RLs RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of novel piperidine and cyclohexanecarbonitrile derivs. as
enhancers for LDL receptor manifestation, hypolipidemics, and antiarteriosclerotics)

RN 850887-58-0 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[(diphenylmethyl)amino]-1-(3-methoxyphenyl)-, methyl ester, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850887-59-1 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[[(1,1-dimethylethoxy)carbonyl]amino]-1-(3-methoxyphenyl)-, methyl ester, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850887-60-4 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[[(1,1-dimethylethoxy)carbonyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850887-61-5 CAPLUS
CN Carbamic acid, [cis-4-(3-methoxyphenyl)-4-[[(phenylmethyl)amino]carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 850887-62-6 CAPLUS
CN Cyclohexanecarboxamide, 4-amino-1-(3-methoxyphenyl)-N-(phenylmethyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 5 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
2004:182658 Document No. 140:235738 Preparation of pyrazolopyrimidines as calcium receptor modulators. Yasuma, Tsuneo; Mori, Akira; Kawase, Masahiro; Kimura, Hiroyuki; Yoshida, Masato; Gyorkos, Albert Charles; Pratt, Scott Alan; Corrette, Christopher Peter (Takeda Chemical Industries, Ltd., Japan; Takeda Pharmaceutical Company Limited). PCT Int. Appl. WO 2004017908 A2 20040304, 460 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-US26317 20030821. PRIORITY: US 2002-406012P 20020826; US 2003-466129P 20030428.
GI



AB The title compds. [I; ring A = (un)substituted 5-7 membered ring; ring B = (un)substituted 5-7 membered heterocyclic ring; X1 = (un)substituted CH, CH2, N or NH; X2 = N or (un)substituted NH; Y = C, (un)substituted CH or N; Z = (un)substituted CH, CH2, N or NH; Ar = (un)substituted cyclic group; R = H, (un)substituted alkyl, etc.; and their salts], useful as calcium receptor modulators, were provided. The compds. II, III [wherein ring A = (un)substituted 5-7 membered ring; Q = C, CR5 (R5 = H, alkyl, hydroxyalkyl, etc.), or N; X1 = CR1 (R1 = H, alkyl, hydroxyalkyl, etc.), CR1R2 (R1 as above; R2 = H, heterocyclyl, etc.); R3 = H, alkyl, hydroxyalkyl, aminoalkyl, etc.; Y = C, CR4 (R4 = H, alkyl, hydroxyalkyl, etc.), or N; R8-R12 = H, (un)substituted alkyl, etc.; X3 = a bond, O, (un)oxidized S, N, (un)substituted NH, C1-2 alkylene; or their salts], were also provided. Thus, reacting amidation of the acid IV [R = H] with 4-(F3C)C6H4C(Et)2NH2 afforded 31% IV [R = 4-(F3C)C6H4C(Et)2NH]. Biol data were given for selected compds. The pharmaceutical compn. comprising the compd. I is claimed.

L29 ANSWER 5 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

IT 667928-55-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyrimidines as calcium receptor modulators)
RN 667928-55-4 CAPLUS
CN Pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-[1-ethyl-4-(4-methoxyphenyl)cyclohexyl]-4,5,6,7-tetrahydro-7,7-dimethyl-5-phenyl- (CA INDEX NAME)



L29 ANSWER 6 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
2004:77908 Document No. 140:417862 Anti-inflammatory and utero-relaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitors. Oger, Stephanie; Mehats, Celine; Barnette, Mary S.; Ferre, Francoise; Cabrol, Dominique; Leroy, Marie-Josephe (INSERM U-361, Maternite Port-Royal-Cochin, Universite Paris V, Rene Descartes, Paris, 75014, Fr.). Biology of Reproduction, 70(2), 458-464 (English) 2004. CODEN: BIREBV. ISSN: 0006-3363. Publisher: Society for the Study of Reproduction.
AB The anti-inflammatory and utero-relaxant effects of two potent phosphodiesterase 4 (PDE4) inhibitors of the latest generation: cilomilast (one of the most advanced PDE4 inhibitors in clin. development, reportedly more selective for PDE4D) and compound A (which displays 12-fold greater selectivity toward PDE4B and/or PDE4A than toward PDE4D) were evaluated in human uterine smooth muscle. We first established that these compds. exhibit greater efficacy in inhibiting total cAMP-PDE activity in pregnant vs. nonpregnant myometrium (Emax = 78.0% ± 3.6% and 80.3% ± 2.2% in pregnant vs. 57% ± 4.7% and 70.5% ± 5.9% in nonpregnant women for compound A and cilomilast, resp.; $P < 0.05$ for both compds.), confirming the prominent participation of PDE4 isoforms in cAMP hydrolysis in the near-term pregnant myometrium. Using pregnant myometrial explants, we have shown that both these drugs and also rolipram, the prototype PDE4 inhibitor, produce concentration-dependent inhibition of lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNFα) release with similar potency in each case (pD2 = 8.0 ± 0.5, 7.9 ± 0.2, and 7.6 ± 0.2 for compound A, cilomilast, and rolipram, resp.). The maximum inhibition produced is 65%. Pretreatment with forskolin or 8-bromo-cAMP mimics the PDE4 inhibitor effect. Furthermore, compound A and cilomilast both produce concentration-dependent inhibition of the spontaneous contractions of myometrial strips and are more potent in pregnant than in nonpregnant myometrium (pD2 = 7.3 ± 0.7 and 8.1 ± 0.3 in pregnant vs. 6.2 ± 0.9 and 6.6 ± 0.1 in nonpregnant myometrium for compound A and cilomilast, resp.; $P < 0.05$ for both compds.). This demonstrates that the PDE4 isoforms involved in the mechanism of contraction are different in the pregnant and nonpregnant myometrium. Our study highlights the importance of developing PDE4 inhibitors for the pharmacol. management of infection-induced preterm labor.
IT 180529-65-1
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PDE-4 inhibitors anti-inflammatory and utero-relaxant effects in human myometrium)
RN 180529-65-1 CAPLUS
CN 2-Pyrimidinamine, 5-[[trans-4-amino-1-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexyl]ethynyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 6 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L29 ANSWER 7 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
2003:950983 Document No. 140:165630 Phenylcyclohexylpropanolamine derivatives, and the production and use thereof in therapeutics as β3 receptor agonists Bovy, Philippe R.; Cecchi, Roberto; Croci, Tiziano; Venier, Olivier (Sanofi-Synthelabo, Fr.). PCT Int. Appl. WO 2003099772 A1
20031204, 42 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (French). CODEN: PIXXD2. APPLICATION: WO 2003-FR1580 20030526. PRIORITY: FR 2002-6561 20020529.
GI



I



II

AB The invention relates to title compds. I [wherein: R1 = H, alkyl, alkanoyl, (un)substituted phenylalkyl, (un)substituted COPh; R2 = H, halo,
-S(O)m-alkyl, -NHSO2-alkyl, (un)substituted -NHSO2Ph or -NHSO2-alkyl-Ph; m
= 0, 1, or 2; R3 = -X-R4, Ph (optionally substituted or fused with dioxolane), or CONR8R9; X = bond, O, or CH2; R4 = H or CR5R6COOR7; R4 ≠ H when X = bond; R5, R6, R7 = H or alkyl; R8 = H, alkyl, or alkylalkoxy; R9 = alkylalkoxy, -(CH2)n-A, (un)substituted NHPh, -CH(R10)-(CH2)n-COOR11; n = 0, 1, 2, or 3; A = indolyl, fluorene, or substituted Ph; R10 = H, alkyl, (un)substituted CH2Ph, or COOR12; R11, R12
= H or alkyl; including bases, acid addition salts, hydrates, and/or

L29 ANSWER 7 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
solvates]. The invention also relates to a method for the prodn. of I, and the use of I in therapeutics. A table of 35 compds. I is given, and prepns. of several I and various intermediates are described. Usage of I in a wide variety of specific therapeutic applications is claimed. For instance, reductive amination of 4-(4-hydroxyphenyl)cyclohexanone with benzylamine gave 48% trans-4-[4-(benzylamino)cyclohexyl]phenol. This amine underwent N-protection with BOC (68.2%), conversion to the triflate ester (97%), removal of BOC (98%), N-alkylation with a corresponding BOC- and benzyl-protected epoxide (72%), removal of BOC (98%), arylation of the
triflate with PhB(OH)2 in the presence of Pd(PPh3)4 (60%), and hydrogenolytic debenzylation of two benzyl groups (68%), to give title compd. II. In an assay for β3 receptor agonism in human neuroblastoma cells SKNMC, in the presence of the selective β1 and β2 antagonists CGP 20712 and ICI 118551, compds. I had a pKa of ≥ 6.0, generally 6.0-7.6. The efficacy of I was generally 60-90%. Tests against β1 and β2 receptor subtypes showed that I were at least 50 times more selective for β3 receptors.
IT 629672-32-8P, trans-N-[2-Hydroxy-5-[[(2S)-2-hydroxy-3-[[4-(4-hydroxyphenyl)cyclohexyl]amino]propyl]oxy]phenyl]methanesulfonamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of phenylcyclohexylpropanolamine derivs. as
β3 adrenoceptor agonists)
RN 629672-32-8 CAPLUS
CN Methanesulfonamide, N-[2-hydroxy-5-[(2S)-2-hydroxy-3-[[trans-4-(4-hydroxyphenyl)cyclohexyl]amino]propoxy]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 370860-26-7P, trans-4-[4-(Benzylamino)cyclohexyl]phenol
370861-02-2P, trans-4-[4-(Benzylamino)cyclohexyl]phenol hydrochloride
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of phenylcyclohexylpropanolamine derivs. as
β3 adrenoceptor agonists)
RN 370860-26-7 CAPLUS
CN Phenol, 4-[trans-4-[(phenylmethyl)amino]cyclohexyl]- (CA INDEX NAME)

L29 ANSWER 7 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Relative stereochemistry.



RN 370861-02-2 CAPLUS
CN Phenol, 4-[trans-4-[(phenylmethyl)amino]cyclohexyl]-, hydrochloride (1:1)
(CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 8 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
2003:610206 Document No. 139:164542O Preparation of cycloalkyl inhibitors of
potassium channel function for preventing/treating arrhythmia and IKur-associated conditions. Lloyd, John; Jeon, Yoon T.; Finlay, Heather; Yan, Lin; Gross, Michael F.; Beaudoin, Serge (Bristol-Myers Squibb Company, USA; Icagen, Inc.). PCT Int. Appl. WO 2003063797 A2 20030807, 312 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-US3170 20030131. PRIORITY: US 2002-353884P 20020201.
GI



AB Claimed are novel cycloalkyl compds. (shown as I; variables defined below;
e.g. cis- and trans-N-(4-hydroxy-1-thiophen-2-ylcyclohexylmethyl)-2-methoxybenzamide and trans-N-[[4-[N'-cyano-N''-ethyl-N-(furan-2-ylmethyl)guanidino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide) useful as inhibitors of K channel function (especially inhibitors of the Kv1 subfamily
of voltage gated K+ channels, especially inhibitors Kv1.5 which was linked to
the ultra-rapidly activating delayed rectifier K+ current IKur; no data), methods of using such compds. in the prevention and treatment of arrhythmia and IKur-associated conditions, and pharmaceutical compns. containing
such compds. For I: dashed line = an optional double bond, provided that R1a is absent when a double bond is present; m and p = 0-3; R1 = H, NR8C(:W)NR6R7 (W = NR8a2, NCO2R8a2, NC(O)R8a2, NCN, NSO2R8a2), NR8SO2NR6R7, etc.; R1a = H, RX; or R1 and R1a together form oxo; or R1 and
R1a together with the C atom to which they are attached combine to form an
(un)substituted spiro-fused heterocyclo group; or R1 and R1a together combine to form :CR8R9. R2 is heteroaryl, (heteroaryl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, alkyl, alkenyl or cycloalkyl; J is a bond, C1-4 alkylene or C1-4 alkenylene; R3 = R5 (R5 = NR6aR7a, heteroaryl, (heteroaryl)alkyl, aryl, arylalkyl, alkyl, etc.), OR5, C(:Z1)R5, OC(:Z1)R5, C(:Z1)OR5, NR8a1C(:Z1)R5, etc.; RX is one or more optional substituents, attached to any available ring carbon atom; addnl. details including provisos are given in the claims. Although the methods of preparation are not claimed, >600 example prepns. are included.

L29 ANSWER 8 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
IT 577036-69-2P 577036-70-5P,
trans-2-Methoxy-N-[[4-[N'-allyl-N''-cyanoguanidino]-1-[2-
methoxyphenyl]cyclohexyl]methyl]benzamide 577036-71-6P,
cis-2-Methoxy-N-[[4-(N'-allyl-N''-cyanoguanidino)-1-[2-
methoxyphenyl]cyclohexyl]methyl]benzamide 577036-72-7P,
trans-2-Methoxy-N-[[4-(N'-(cyclopropylmethyl)-N''-cyanoguanidino)-1-[2-
methoxyphenyl]cyclohexyl]methyl]benzamide 577036-73-8P,
cis-2-Methoxy-N-[[4-(N'-(cyclopropylmethyl)-N''-cyanoguanidino)-1-[2-
methoxyphenyl]cyclohexyl]methyl]benzamide 577036-74-9P,
cis-2-Methoxy-N-[[4-(N'-ethyl-N''-cyanoguanidino)-1-[2-
methoxyphenyl]cyclohexyl]methyl]benzamide 577036-75-0P,
trans-2-Methoxy-N-[[4-(N'-methyl-N''-cyanoguanidino)-1-[2-
methoxyphenyl]cyclohexyl]methyl]benzamide 577036-76-1P,
trans-2-Methoxy-N-[[4-(N'-allyl-N''-cyanoguanidino)-1-[2-
methoxyphenyl]cyclohexyl]methyl]benzamide 577036-77-2P,
cis-2-Methoxy-N-[[4-[[[pyridin-2-yl]methyl]amino]sulfonyl]amino]-1-[2-
methoxyphenyl]cyclohexyl]methyl]benzamide 577036-78-3P
577036-79-4P, trans-2-Methoxy-N-[[4-[[[(S)-1-(methoxymethyl)-2-
phenylethyl]amino]sulfonyl]amino]-1-[2-
methoxyphenyl]cyclohexyl]methyl]benzamide 577036-80-7P,
cis-2-Methoxy-N-[[4-[[benzylamino]sulfonyl]amino]-1-[2-
methoxyphenyl]cyclohexyl]methyl]benzamide 577036-81-8P,
trans-2-Methoxy-N-[[4-[[benzylamino]sulfonyl]amino]-1-[2-
methoxyphenyl]cyclohexyl]methyl]benzamide 577036-82-9P,

trans-2-Methoxy-N-[[4-[[[pyridin-2-yl]methyl]amino]sulfonyl]amino]-1-[2-
methoxyphenyl]cyclohexyl]methyl]benzamide
RL: PAC (Pharmacological activity); RPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(drug candidate; preparation of cyclohexyl inhibitors of potassium
channel
function for preventing/treating arrhythmia and IKur-associated
conditions)
RN 577036-69-2 CAPLUS
CN Benzamide, N-[[cis-4-[[cyanoamino](methylimino)methyl]amino]-1-[2-
methoxyphenyl]cyclohexyl]methyl]-2-methoxy- (CA INDEX NAME)

Relative stereochemistry.



RN 577036-70-5 CAPLUS
CN Benzamide, N-[[trans-4-[[cyanoamino](2-propen-1-ylimino)methyl]amino]-1-

L29 ANSWER 8 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 577036-73-9 CAPLUS
CN Benzamide,
N-[[cis-4-[[cyanoamino][cyclopropylmethyl]imino]methyl]amino]-
1-[2-methoxyphenyl]cyclohexyl]methyl]-2-methoxy- (CA INDEX NAME)

Relative stereochemistry.



RN 577036-74-9 CAPLUS
CN Benzamide, N-[[cis-4-[[cyanoamino](ethylimino)methyl]amino]-1-[2-
methoxyphenyl]cyclohexyl]methyl]-2-methoxy- (CA INDEX NAME)

Relative stereochemistry.



RN 577036-75-0 CAPLUS
CN Benzamide, N-[[trans-4-[[[cyanoamino](methylimino)methyl]amino]-1-[2-
methoxyphenyl]cyclohexyl]methyl]-2-methoxy- (CA INDEX NAME)

L29 ANSWER 8 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(2-methoxyphenyl)cyclohexyl]methyl]-2-methoxy- (CA INDEX NAME)

Relative stereochemistry.



RN 577036-71-6 CAPLUS
CN Benzamide,
N-[[cis-4-[[cyanoamino](2-propen-1-ylimino)methyl]amino]-1-[2-
methoxyphenyl]cyclohexyl]methyl]-2-methoxy- (CA INDEX NAME)

Relative stereochemistry.



RN 577036-72-7 CAPLUS
CN Benzamide,
N-[[trans-4-[[[cyanoamino][cyclopropylmethyl]imino]methyl]amin
o]-1-[2-methoxyphenyl]cyclohexyl]methyl]-2-methoxy- (CA INDEX NAME)

Relative stereochemistry.



RN 577036-76-1 CAPLUS
CN Benzamide, N-[[trans-4-[[[cyanoamino](ethylimino)methyl]amino]-1-[2-
methoxyphenyl]cyclohexyl]methyl]-2-methoxy- (CA INDEX NAME)

Relative stereochemistry.



RN 577036-77-2 CAPLUS
CN Benzamide, 2-methoxy-N-[[cis-1-[2-methoxyphenyl]-4-[[[2-
pyridinylmethyl]amino]sulfonyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 577036-78-3 CAPLUS
CN Benzamide, 2-methoxy-N-[[cis-4-[[[1-(methoxymethyl)-2-
phenylethyl]amino]sulfonyl]amino]-1-[2-methoxyphenyl]cyclohexyl]methyl]-
(CA INDEX NAME)

Relative stereochemistry.



RN 577036-79-4 CAPLUS
CN Benzamide, 2-methoxy-N-[[trans-4-[[[[1-(methoxymethyl)-2-phenylethyl]amino]sulfonyl]amino]-1-(2-methoxyphenyl)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 577036-80-7 CAPLUS
CN Benzamide, 2-methoxy-N-[[cis-1-(2-methoxyphenyl)-4-[[[(phenylmethyl)amino]sulfonyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 577036-81-8 CAPLUS
CN Benzamide, 2-methoxy-N-[[trans-1-(2-methoxyphenyl)-4-[[[(phenylmethyl)amino]sulfonyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 577036-82-9 CAPLUS
CN Benzamide, 2-methoxy-N-[[trans-1-(2-methoxyphenyl)-4-[[[(2-pyridinylmethyl)amino]sulfonyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



2003:356431 Document No. 138:368915 Preparation of 2(1H)-quinoxalinones as analgesics. Sattlegger, Michael; Buschmann, Helmut; Przewosny, Michael; Englberger, Werner; Koegel, Babette-Yvonne; Schick, Hans (Gruenenthal G.m.b.H., Germany). PCT Int. Appl. WO 2003037879 A1 20030508, 89 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (German). CODEN: PIXXD2. APPLICATION: WO 2002-EP11832 20021023. PRIORITY: DE 2001-10153345 20011029.
GI



I

AB Title compds. [I; R1-R4 = H, halo, OH, (branched) (saturated) C1-10 aliphatic group, C3-7 cycloaliph. group; whereby the both aliphatic and cycloaliph. groups are bonded by an ether bridge; A = (CH2)n+2, (CH2)nCH:CH, (CH2)nCO2, (CH2)nCONH, (CH2)n+1O(CH2)pCO, (CH2)n+1O, (CH2)n+1NR8, NH(CH2)r; p = 0, 1; n = 0-3; r = 0-2; R8 = H, (branched) (saturated) C1-10 aliphatic group, C3-7 cycloaliph. group, (hetero)aryl; X = (substituted) phenylcyclohexyl, etc.], were prepared. Thus, 6,7-dimethyl-3-oxo-3,4-dihydroquinoxaline-2-carboxylic acid (preparation given) was reacted with 4-amino-2-(N,N-dimethylaminomethyl)-1-(3-methoxyphenyl)cyclohexan-1-ol in the presence of N-methylmorpholine, dicyclohexylcarbodiimide, and hydroxybenzotriazole in DMF to give 69% (6,7-dimethyl-3-oxo-3,4-dihydroquinoxalin-2-yl)-N-[3-(N,N-dimethylaminomethyl)-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]carboxamide. The latter at 10 mg/kg i.v. in mice gave 72% inhibition of phenylquinone-induced writhing.
IT 521292-62-6P 521292-63-7P 521292-66-0P
521292-67-1P 521292-71-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinoxalinones as analgesics)
RN 521292-62-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]-3,4-dihydro-6,7-dimethyl-3-oxo-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

RN 521292-63-7 CAPLUS
CN 2-Quinoxalinecarboxamide, 6,7-dichloro-N-[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]-3,4-dihydro-3-oxo- (CA INDEX NAME)



RN 521292-66-0 CAPLUS
CN 2-Quinoxalinepropanamide, 6,7-dichloro-N-[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]-3,4-dihydro-3-oxo- (CA INDEX NAME)



RN 521292-67-1 CAPLUS
CN 2-Quinoxalinepropanamide, N-[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]-3,4-dihydro-6,7-dimethyl-3-oxo- (CA INDEX NAME)

L29 ANSWER 9 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 521292-73-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]-3,4-dihydro-6,7-dimethyl-3-oxo- (CA INDEX NAME)



IT 412931-30-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of quinoxalinones as analgesics)
RN 412931-76-7 CAPLUS
CN Cyclohexanol, 4-amino-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)- (CA INDEX NAME)



IT 521292-69-3P 521292-70-6P
RL: RCT (Reactant); SYN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinoxalinones as analgesics)
RN 521292-69-3 CAPLUS
CN Cyclohexanol, 4-amino-1-(3-methoxyphenyl)- (CA INDEX NAME)

L29 ANSWER 10 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
2003:356425 Document No. 138:353450 Preparation of 2H-1-benzazepin-2-ones as analgesics. Sattelegger, Michael; Braschwanz, Helmut; Przewosny, Michael; Engelberger, Werner; Voegel, Babette-Yvonne; Schick, Hans (Grunenthal G.m.b.H., Germany). PCT Int. Appl. WO 2003037879 A1 20030508, 73 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CI, CM, GA, GH, GM, GN, GQ, GW, ML, MR, NE, SN, TD, TG. (German). CODEN: PIXXD2. APPLICATION: WO 2002-EP12830 20021023. PRIORITY: DE 2001-10153348 20011029.
GI



AB Title compds. [I; X1-X4 = N, halo, OR, (branched) (saturated) C1-10 aliphatic group, C3-7 cycloaliph. group; whereby the both aliphatic and cycloaliph. groups are bonded by an ether bridge; R5 = H, (branched) (saturated) C1-10 aliphatic group, (hetero)aryl; R6 = OH, CH2NR7R8; R7 = (branched) (saturated) C1-4 aliphatic group, C3-6 cycloaliph. group; or NR7 = 3-8 membered cyclyl; A = (CH2)n=2, (CH2)nCH=CH, (CH2)nCO2, (CH2)nCONH, (CH2)n+1O(CH2)pCO, (CH2)n+1O, (CH2)n+1NR9; n = 0, 1; n + n = 0-3; R8 = H, (branched) (saturated) C1-20 aliphatic group, C3-7 cycloaliph. group, (hetero)aryl; X = (substituted) phenylcyclohexyl, etc.], were prepared Thus, 4-amino-2-(N,N-dimethylaminomethyl)-1-(3-methoxyphenyl)cyclohexan-1-ol was reacted with (8-chloro-1-methyl-2-oxo-2,3-dihydro-1H-1-benzazepin-5-yl)acetic acid (analog preparation given) in the presence of dicyclohexylcarbodiimide, N-methylmorpholine, and 1-hydroxybenzotriazole in DMF to give 75% (8-chloro-1-methyl-2-oxo-3,3-dihydro-1H-1-benzazepin-5-yl)-N-(3,N-dimethylaminomethyl)-4-hydroxy-4-(3-methoxyphenyl)cyclohexylacetamide. The latter at 30 mg/kg i.v. in mice gave 23% inhibition of phenylquinone-induced writhing.
IT 521058-18-4P 521058-19-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzazepinones as analgesics)
RN 521058-18-4 CAPLUS
CN 1H-1-Benzazepine-5-acetamide, 8-chloro-N-[3-[(dimethylamino)methyl]-4-

L29 ANSWER 9 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 521292-70-6 CAPLUS
CN Phenol, 3-(4-amino-1-hydroxycyclohexyl)- (CA INDEX NAME)

L29 ANSWER 10 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
hydroxy-4-(3-methoxyphenyl)cyclohexyl]-2,3-dihydro-1-methyl-2-oxo- (CA INDEX NAME)

RN 521058-19-5 CAPLUS
CN 1H-1-Benzazepine-5-acetamide, 8-chloro-N-[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]-2,3-dihydro-2-oxo- (CA INDEX NAME)



IT 412931-30-7
RL: RCT (Reactant); RACT (Reactant or reagent)

L29 ANSWER 10 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(prep. of benzazepinones as analgesics)

RN 412931-30-7 CAPLUS

CN Cyclohexanol, 4-amino-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)- (CA INDEX NAME)

L29 ANSWER 11 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(Cont.)
(prep. of quinolinones as analgesics)

RN 521057-87-4 CAPLUS

CN 3-Quinolinecarboxamide, 7-chloro-N-[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]-1,2-dihydro-4-hydroxy-2-oxo- (CA INDEX NAME)

RN 521057-90-9 CAPLUS

CN 3-Quinolinecarboxamide, 7-chloro-N-[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]-1,2-dihydro-4-methoxy-2-oxo- (CA INDEX NAME)

IT 412931-30-7

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of quinolinones as analgesics)

RN 412931-30-7 CAPLUS

CN Cyclohexanol, 4-amino-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)- (CA INDEX NAME)

L29 ANSWER 11 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

AB Title compds. [I; R1-R4 = H, halo, OH, (branched) (saturated) C1-10 aliphatic group, C3-7 cycloaliph. group; whereby the both aliphatic and cycloaliph. groups are bonded by an ether bridge; R5 = H, (branched) (saturated) C1-10 aliphatic group, (hetero)aryl; R6 = OH, OR7; R7 = (branched) (saturated) C1-10 aliphatic group, C3-6 cycloaliph. group; A = (CH2)3, CHCCH2CH, CH2CO2, CH2CONH, (CH2)2O(CH2)pCO, (CH2)2O, (CH2)2NR8; p = 0, 1; R8 = H, (branched) (saturated) C1-10 aliphatic group, C3-7 cycloaliph. group, (hetero)aryl; X = (substituted) phenylcyclohexyl, etc.], were prepared Thus, (7-chloro-4-hydroxy-2-oxo-1,2-dihydroquinolin-3-yl)acetic acid [preparation given] was reacted with 4-amino-2-(N,N-dimethylaminomethyl)-1-(3-methoxyphenyl)cyclohexan-1-ol in the presence of N-methylmorpholine, dicyclohexylcarbodiimide, and hydroxybenzotriazole in DMF to 2-(7-chloro-4-hydroxy-2-oxo-1,2-dihydroquinolin-3-yl)-N-[3-(N,N-dimethylaminomethyl)-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]acetamide with a yield of 49%. The latter at 10 mg/kg i.v. in mice gave 60% inhibition of phenylquinone-induced writhing.

IT 521057-87-4P 521057-90-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

L29 ANSWER 12 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN

AB Title compds. I [R1, R2, R3, R4 = (un)substituted alkyl, cycloalkyl; R5 = H, (un)substituted alkyl, cycloalkyl; etc.; R6 = OH, halo, CN, etc.; A = -(CH2)nCOO-, -(CH2)nCONR9-, -(CH2)nO-; n = 0-3; X = (un)substituted piperidin-1-yl, cyclohexyl, dihydro-1H-isoquinolin-2-yl, etc.] and their pharmaceutically acceptable salts were prepared For example, reductive amination condensation of cyclohexylamine II and 5-methyl-3-formyl-1H-indol-2-carboxylic acid Me ester afforded indole III in 82% yield. In phenylquinone-induced writhing studies with mice, 6-examples of I exhibited 68-100% inhibition at 10 mg/kg i.v. dosage, e.g., indole III displayed 68% inhibition. Compds. I provided medium-strong to strong analgesic effects.

IT 522647-69-4P 522647-70-7P 522647-71-8P 522647-85-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of indole carboxylic acids and related compds.

L29 ANSWER 12 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
for the treatment of pain)
RN 522647-69-4 CAPLUS
CN 1H-Indole-2-carboxylic acid, 3-[[[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]-4,6-dimethyl-, ethyl ester (CA INDEX NAME)



RN 522647-70-7 CAPLUS
CN 1H-Indole-2-carboxylic acid, 5-chloro-3-[[[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]-, ethyl ester (CA INDEX NAME)



RN 522647-71-8 CAPLUS
CN 1H-Indole-2-carboxylic acid, 4,6-dichloro-3-[[[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]-, ethyl ester (CA INDEX NAME)



RN 522647-80-4 CAPLUS
CN 1H-Indole-2-carboxylic acid, 4,6-dichloro-3-[[[4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]-, ethyl ester (CA INDEX NAME)

L29 ANSWER 12 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 522647-82-1 CAPLUS
CN 1H-Indole-2-carboxylic acid, 4,6-dichloro-3-[[[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]- (CA INDEX NAME)



RN 522648-18-6 CAPLUS
CN 1H-Indole-1,2-dicarboxylic acid, 4,6-dichloro-3-[[[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]-, 1-(1,1-dimethylethyl) 2-ethyl ester (CA INDEX NAME)



RN 522648-18-7 CAPLUS
CN 1H-Indole-2-carboxylic acid, 4,6-dichloro-3-[[[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]-1-methyl-, ethyl ester (CA INDEX NAME)

L29 ANSWER 12 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



IT 522647-79-6P 522647-80-9P 522647-81-0P
522647-82-1P 522648-18-6P 522648-19-7P
522648-20-0P 522648-21-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of indole carboxylic acids and related compds.
for the treatment of pain)
RN 522647-79-6 CAPLUS
CN 1H-Indole-2-carboxylic acid, 3-[[[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]-5-methyl- (CA INDEX NAME)



RN 522647-80-9 CAPLUS
CN 1H-Indole-2-carboxylic acid, 5-chloro-3-[[[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]- (CA INDEX NAME)



RN 522647-81-0 CAPLUS
CN 1H-Indole-2-carboxylic acid, 3-[[[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]-4,6-dimethyl- (CA INDEX NAME)

L29 ANSWER 12 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 522648-20-0 CAPLUS
CN 1H-Indole-2-carboxylic acid, 4,6-dichloro-3-[[[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]-1-(phenylmethyl)-, ethyl ester (CA INDEX NAME)



RN 522648-21-1 CAPLUS
CN 1H-Indole-2-carboxylic acid, 5-chloro-3-[[[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]-1-(phenylmethyl)-, ethyl ester (CA INDEX NAME)



IT 522647-68-3P
RL: PAC (Pharmacological activity); PCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidates; preparation of indole carboxylic acids and related compds.
for the treatment of pain)
RN 522647-68-3 CAPLUS
CN 1H-Indole-2-carboxylic acid, 3-[[[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]amino]methyl]-5-methyl-, methyl ester (CA INDEX NAME)

L29 ANSWER 12 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



IT 413931-76-7, 4-Amino-2-(N,N-dimethylaminomethyl)-3-(3'-methoxyphenyl)cyclohexan-1-ol 413589-36-3, 2-(N,N-Dimethylaminomethyl)-1-(3'-methoxyphenyl)-4-(N-methylamino)cyclohexan-1-ol 521292-69-3 530084-27-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of indole carboxylic acids and related compds. for the treatment of pain)

RN 413931-76-7 CAPLUS
CN Cyclohexanol, 4-amino-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)- (CA INDEX NAME)

RN 413589-36-3 CAPLUS
CN Cyclohexanol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-4-(methylamino)- (CA INDEX NAME)

RN 521292-69-3 CAPLUS
CN Cyclohexanol, 4-amino-1-(3-methoxyphenyl)- (CA INDEX NAME)

RN 530084-27-6 CAPLUS
CN Cyclohexanol, 1-(3-methoxyphenyl)-4-(methylamino)- (CA INDEX NAME)

L29 ANSWER 12 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L29 ANSWER 13 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN

2002:803519 Document No. 137:337790 Resorcinol derivatives as skin lightening agents. Browning, Andrea Francis; Collington, Eric William; Proetter, Martin James; Geden, Joanna Victoria (Pfizer Inc., Swed.). U.S. Pat. Appl. Pub. US 2002161041 A1 20021031, 54 pp., Cont.-in-part of U.S. Ser. No. 526,287, abandoned. (English). CODEN: USXXCO. APPLICATION: US 2001-20037 20011221. PRIORITY: US 1999-125534P 19990322; US 2000-522287 20000315.

AB 2,4-(HO)2C6H3R (R = substituted cycloalkyl, cycloalkenyl) were prepared for use as skin lightening agents. Thus, 3-methoxy-2-cyclopenten-1-one was treated with 2,4-(MeCOCH2)2C6H3Br to give 3-(2,4-bis(methoxymethoxy)phenyl)-2-cyclopenten-1-one (13%) which was reduced to the cyclopentanone (16%), demethoxymethoxylated (70%), and converted to 3-(2,4-dihydroxyphenyl)cyclopentanone oxime (71%). This compound had an IC50 for tyrosinase inhibition of 2 μM.

IT 296765-78-8P, Acetamide, N-[4-(2,4-dihydroxyphenyl)cyclohexyl]- 296765-24-7P, 1,3-Benzenediol, 4-[4-(hydroxyamino)cyclohexyl]- 296765-23-8P, 1,3-Benzenediol, 4-[trans-4-(methoxyamino)cyclohexyl]-
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dihydroxyphenylcycloalkane derivs. as skin lightening agents)

RN 296764-78-6 CAPLUS
CN Acetamide, N-[4-(2,4-dihydroxyphenyl)cyclohexyl]- (CA INDEX NAME)

RN 296765-24-7 CAPLUS
CN 1,3-Benzenediol, 4-[4-(hydroxyamino)cyclohexyl]- (CA INDEX NAME)



RN 296765-25-8 CAPLUS
CN 1,3-Benzenediol, 4-[trans-4-(methoxyamino)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 13 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

L29 ANSWER 14 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
2002:139595 Document No. 136:123595 Substituted cyclohexylmethylamine derivatives as analgesics. Sundermann, Bernd; Mazl, Corinna; Buschmann, Helmut; Fiskan, Wilfried; Koespel, Babette-Yvonne (Grunenthal GmbH, Germany). PCT Int. Appl. WO 2002008870 A2 20020418, 153 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW; RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG. (German). CODEN: PIXKD2. APPLICATION: WO 2001-EP11246 20010928. PRIORITY: DE 2000-10047451 20000923.

GI

AB The title compds. were prepared as tramadol analogs for use as analgesics (no data). Thus, 700 mg 4-benzyloxy-2-dimethylaminomethylcyclohexanone was subjected to Grignard reaction with 4-IC6H4Br to give 190 mg of the hydrochloride I.

IT 412933-36-7P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted cyclohexylmethylamine deriva. as analgesics)

RN 412933-36-7 CAPLUS
CN Cyclohexanol, 4-amino-2-[(dimethylamino)methyl]-1-[3-methoxyphenyl]- (CA INDEX NAME)

L29 ANSWER 14 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 413587-29-8 CAPLUS
CN Benzenepropanamide, N-[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 413587-30-1 CAPLUS
CN Benzamide, N-[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]-4-nitro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 413587-31-2 CAPLUS
CN Benzamide, N-[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]-4-methyl-3-nitro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 413587-32-3 CAPLUS
CN Benzamide, N-[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-

L29 ANSWER 14 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
IT 413587-27-4P 413587-28-5P 413587-29-6P
413587-30-1P 413587-31-2P 413587-32-3P
413587-33-4P 413587-34-5P 413587-35-6P
413587-36-7P 413587-37-8P 413587-38-9P
413589-36-2P 413590-16-6P 413590-19-9P
413590-22-4P 413590-25-7P 413590-28-0P
413590-30-4P 413590-32-6P 413590-34-8P
413590-35-9P 413590-36-0P 413590-37-1P
413590-39-3P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted cyclohexylmethylamine derivs. as analgesics)

RN 413587-27-4 CAPLUS
CN Benzamide, 3,4-dichloro-N-[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 413587-28-7 CAPLUS
CN 2-Naphthalenecarboxamide, N-[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L29 ANSWER 14 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
methoxyphenyl)cyclohexyl]-3,4,5-trimethoxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 413587-33-4 CAPLUS
CN Acetamide, 2-(4-chlorophenoxy)-N-[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 413587-34-5 CAPLUS
CN Benzamide, N-[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]-3-nitro-, hydrochloride (1:1) (CA INDEX NAME)

L29 ANSWER 14 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 413587-75-6 CAPLUS
CN 2-Furancarboxamide, N-[3-[(dimethylamino)methyl]-6-hydroxy-4-(3-methoxyphenyl)cyclohexyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 413587-36-7 CAPLUS
CN Acetamide, N-[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]-2-phenoxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L29 ANSWER 14 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 413590-23-9 CAPLUS
CN 2-Naphthalenesulfonamide, N-[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]- (CA INDEX NAME)



RN 413590-22-4 CAPLUS
CN Benzenepropanamide, N-[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]- (CA INDEX NAME)



RN 413590-25-7 CAPLUS
CN Benzamide, N-[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]-4-nitro- (CA INDEX NAME)



RN 413590-28-0 CAPLUS

L29 ANSWER 14 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 413587-37-8 CAPLUS
CN Benzamide, N-[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 413587-38-9 CAPLUS
CN Benzamide, N-[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]-4-methoxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 413589-36-3 CAPLUS
CN Cyclohexanol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-4-(methylamino)- (CA INDEX NAME)



RN 413590-16-6 CAPLUS
CN Benzamide, 3,4-dichloro-N-[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]- (CA INDEX NAME)

L29 ANSWER 14 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 413590-30-4 CAPLUS
CN Benzamide, N-[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]-3,4,5-trimethoxy- (CA INDEX NAME)



RN 413590-32-6 CAPLUS
CN Acetamide, 2-(4-chlorophenoxy)-N-[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]- (CA INDEX NAME)



RN 413590-24-8 CAPLUS
CN Benzamide, N-[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]-3-nitro- (CA INDEX NAME)

L29 ANSWER 14 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 413549-35-9 CAPLUS
CN 2-furancarboxamide, N-[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]- (CA INDEX NAME)



RN 413549-36-0 CAPLUS
CN Acetamide, N-[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]-2-phenoxy- (CA INDEX NAME)



RN 413549-37-1 CAPLUS
CN Benzamide, N-[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]-4-(trifluoromethyl)- (CA INDEX NAME)

L29 ANSWER 15 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
2002:240693 Document No. 136:279398Q Preparation of resorcinol derivatives as inhibitors of tyrosinase for use as skin-lightening agents. Bradley, Stuart Edward; Collington, Eric William; Fyfe, Matthew Colin Thor; Gattrell, William Thomas; Geden, Joanna Victoria; Murray, Peter John; Procter, Martin James; Rowley, Robert John; Williams, Jonathan Gareth (Pfizer Products, Inc., USA). PCT Int. Appl. WO 2002024613 A2 20020328, 87 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RN: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2001-IB1677 20010913. PRIORITY: US 2000-234468P 20000921.

GI



AB Title compds. I [R = cycloalkyl, cycloalkenyl ring substituted by (1) NR1CONR2R3 wherein R1-3 = H, alkyl, arylalkyl; R3 = H, alkyl, arylalkyl, aryl; (2) NR1CONY wherein R1 = H, alkyl, arylalkyl, OR; R3 = alkyl, aryl, arylalkyl, Oaryl, OCF3, heterocycloalkyl, alkylheterocycloalkyl, alkenylheterocycloalkyl, heteroaryl, alkylheteroaryl, alkenylheteroaryl, alkenylaryl, alkenyl-CO-aryl, alkyl(OH)-CO-aryl, alkyl-CO-aryl, alkylhydroxyaryl, alkyl-X-aryl, alkoxyl, benzylhydryl, 5-hydroxyacenidinyl, tetrahydronaphthalenyl; X = O, SO2-2 or NR1; (3) NR1OCOaryl; (4) 1CH2CH2, etc., with the proviso that the cycloalkenyl ring is not aromatic] were prepared. For instance, trans-4-[2,6-bis[[tert-butyldimethylsilyl]oxy]phenyl]cyclohexanol (preparation given) was coupled to N-(tert-butoxycarbonyl)-L-phenylalanine (OCH2CL2, DCC, DMAP) and the resulting ester treated with TFA to afford II. II had IC50 = 2 uM for human tyrosinase. I are useful as skin lightening agents.

IT 405517-90-0P, cis-N-[4-(2,4-Dihydroxyphenyl)cyclohexyl]benzamide 405517-94-4P, cis-N-[4-(2,4-Dihydroxyphenyl)cyclohexyl]-N'-phenylurea 405517-95-5P 405518-10-7P, trans-N-[4-(2,4-Dihydroxyphenyl)cyclohexyl]-3-nitrobenzamide 405518-11-8P, trans-N'-[4-(2,4-Dihydroxyphenyl)cyclohexyl]-N'-phenylurea 405518-12-9P 405518-17-4P

L29 ANSWER 14 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 413549-39-7 CAPLUS
CN Benzamide, N-[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]-4-methoxy- (CA INDEX NAME)



L29 ANSWER 15 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
405518-18-5P 405518-19-6P 405518-20-9P
405518-21-0P 405518-22-1P 405518-23-2P
405518-24-3P 405518-25-4P 405518-26-5P
405518-27-6P 405518-28-7P 405518-29-8P
405518-30-1P 405518-31-2P 405518-32-3P
405518-33-4P 405518-34-5P 405518-35-6P
405518-36-7P 405518-37-8P 405518-38-9P
405518-39-0P 405518-40-3P 405518-41-4P
405518-42-5P 405518-43-6P 405518-44-7P
405518-45-8P 405518-46-9P 405518-47-0P
405518-48-1P 405518-49-2P
BL PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; prepn. of resorcinol deriva. as inhibitors of tyrosinase for use as skin-lightening agents)
RN 405517-90-0 CAPLUS
CN Benzamide, N-[cis-4-(2,4-dihydroxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

RN 405517-94-4 CAPLUS
CN Urea, N-[cis-4-(2,4-dihydroxyphenyl)cyclohexyl]-N'-phenyl- (CA INDEX NAME)

Relative stereochemistry.



RN 405517-95-5 CAPLUS
CN Carbamic acid, [trans-4-(2,4-dihydroxyphenyl)cyclohexyl]-, phenyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 405518-10-7 CAPLUS
CN Benzamide, N-[trans-4-[2,4-dihydroxyphenyl)cyclohexyl]-3-nitro- (CA INDEX
NAME)

Relative stereochemistry.



RN 405518-11-8 CAPLUS
CN Urea, N-[trans-4-[2,4-dihydroxyphenyl)cyclohexyl]-N'-phenyl- (CA INDEX
NAME)

Relative stereochemistry.



RN 405518-12-9 CAPLUS
CN Acetamide, N-[trans-4-[2,4-dihydroxyphenyl)cyclohexyl]-2,2,2-trifluoro- (CA INDEX NAME)

Relative stereochemistry.



RN 405518-20-9 CAPLUS
CN 3-Pyridineacetamide, N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]- (CA INDEX
NAME)

Relative stereochemistry.



RN 405518-21-0 CAPLUS
CN 1H-Indole-3-acetamide, N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 405518-22-1 CAPLUS
CN 2-Pyridinecarboxamide, N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 405518-17-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 405518-18-5 CAPLUS
CN 1H-Indole-2-carboxamide, N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 405518-19-6 CAPLUS
CN Benzamide, N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]-3-nitro- (CA INDEX NAME)

Relative stereochemistry.



RN 405518-23-2 CAPLUS
CN 1H-Indole-3-butanamide, N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 405518-24-3 CAPLUS
CN 3-Benzofuranacarboxamide, N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]-4,5,6,7-tetrahydro-4-oxo- (CA INDEX NAME)

Relative stereochemistry.



RN 405518-25-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]-2-(methylthio)- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 15 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 405518-26-5 CAPLUS
CN 2-Thiophenecarboxamide,
3-chloro-N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]-
4-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 405518-27-6 CAPLUS
CN 3-Pyridinecarboxamide,
N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]-1,4,5,6-
tetrahydro-6-oxo- (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 15 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 405518-31-2 CAPLUS
CN Benzeneacetamide, N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]-3-methoxy-
(CA INDEX NAME)

Relative stereochemistry.



RN 405518-32-3 CAPLUS
CN Benzeneacetamide, N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]-4-methoxy-
(CA INDEX NAME)

Relative stereochemistry.



RN 405518-33-4 CAPLUS
CN Cyclohexaneacetamide, N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]- (CA
INDEX NAME)

Relative stereochemistry.

L29 ANSWER 15 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 405518-28-7 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]-1-
(1,1-dimethylethyl)-3-methyl- (CA INDEX NAME)

Relative stereochemistry.



RN 405518-29-8 CAPLUS
CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide,
N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]-2,7-dimethyl- (CA INDEX NAME)

Relative stereochemistry.



RN 405518-30-1 CAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[(4-chlorophenyl)methyl]-N-[cis-4-[2,4-
dihydroxyphenyl)cyclohexyl]-5-oxo- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 15 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 405518-34-5 CAPLUS
CN Benzeneacetamide, N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]-2-methyl-
(CA
INDEX NAME)

Relative stereochemistry.



RN 405518-35-6 CAPLUS
CN Benzamide, N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]-2-methyl- (CA INDEX
NAME)

Relative stereochemistry.



RN 405518-36-7 CAPLUS
CN Benzamide, 4-bromo-N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]- (CA INDEX
NAME)

Relative stereochemistry.

L29 ANSWER 15 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 405518-37-0 CAPLUS
CN 2-Furancarboxamide, N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]tetrahydro- (CA INDEX NAME)

Relative stereochemistry.



RN 405518-38-9 CAPLUS
CN 7-Oxabicyclo[2.2.1.1]heptane-1-carboxamide, N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

RN 405518-39-0 CAPLUS
CN 1H-Pyrazole-1-carboxamide, 4-bromo-N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]-1-ethyl-3-methyl- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 15 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(CA INDEX NAME)

Relative stereochemistry.



RN 405518-43-6 CAPLUS
CN Benzamide, 3-cyano-N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 405518-44-7 CAPLUS
CN Benzamide, N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]-3-iodo- (CA INDEX NAME)

Relative stereochemistry.



RN 405518-45-8 CAPLUS
CN Benzamide, 2-bromo-N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]- (CA INDEX NAME)

L29 ANSWER 15 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 405518-40-3 CAPLUS
CN Benzamide, N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]-4-nitro- (CA INDEX NAME)

Relative stereochemistry.



RN 405518-41-4 CAPLUS
CN 1-Cyclohexene-1-carboxamide, N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 405518-42-5 CAPLUS
CN Benzamide, N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]-3-(trifluoromethyl)-

L29 ANSWER 15 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
Relative stereochemistry.



RN 405518-46-9 CAPLUS
CN Benzamide, 3-bromo-N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 405518-47-0 CAPLUS
CN Benzamide, 4-bromo-2-chloro-N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 405518-48-1 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]amino]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 15 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 405518-49-2 CAPLUS
CN Benzamide, N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]-2-fluoro-6-iodo- (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 16 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(prepn. and formulation of resorcinol deriv. for pharmaceutical use as skin lightening agents)
RN 403854-85-9 CAPLUS
CN Benzenesulfonamide, 3-cyano-N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 403854-75-1 CAPLUS
CN Benzoic acid, 3-[[[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]amino]sulfonyl]-, methyl ester (CA INDEX NAME)

Relative stereochemistry.



RN 403854-76-2 CAPLUS
CN Benzoic acid, 4-[[[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]amino]sulfonyl]-, methyl ester (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 16 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 403854-77-3 CAPLUS
CN Benzoic acid, 3-[[[trans-4-[2,4-dihydroxyphenyl)cyclohexyl]amino]sulfonyl]-, methyl ester (CA INDEX NAME)

Relative stereochemistry.



RN 403854-98-8 CAPLUS
CN Benzoic acid, 3-[[[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]amino]sulfonyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 403855-01-6 CAPLUS
CN L-Phenylalanine, N-[3-[[[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]amino]sulfonyl]benzoyl]-, phenylmethyl ester

L29 ANSWER 16 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
2002:185071 Document No. 136:247740 Preparation and formulation of resorcinol derivatives for pharmaceutical use as skin lightening agents. Bradley, Stuart Edward; Collington, Eric William; Fyfe, Matthew Colin Thor; Procter, Martin James; Sambrook Smith, Colin Peter (Pfizer Products Inc., USA). PCT Int. Appl. WO 2002010114 A2 20020214, 69 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: AT, BE, CH, CY, DE, DK, EA, ES, FI, FR, GB, GH, GM, GR, IE, IT, LU, MC, MW, NL, PT, SD, SE, SL, SZ, TR, TZ, UG, ZW. (English). CODEN: PIXXD2. APPLICATION: WO 2001-IB1605 20010831. PRIORITY: US 2000-231623P 20000911.

GI



AB Resorcinol derivs., such as I [R = cycloalkyl, cycloalkenyl, sulfonylaminocycloalkyl, etc.], were prepared for pharmaceutical use as skin lightening agents. Thus, N-[cis-4-(2,4-Dihydroxyphenyl)cyclohexyl]benzenesulfonamide (II) was prepared via reaction of cis-4-[2,4-bis[(tert-butyldimethylsilyl)oxy]phenyl]cyclohexylamine and Benzenesulfonyl chloride followed by desilylation with 64% yield using TFA in DCE and H2O. The prepared resorcinol derivs. were assayed for tyrosinase activity using SPMEL 188 human melanoma cells and for inhibition of melanin synthesis in human primary melanocytes.
IT 403854-65-9P, 3-Cyano-N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]benzenesulfonamide 403854-75-1P, Methyl 3-[[[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]amino]sulfonyl]benzoate 403854-76-2P 403854-77-3P, Methyl 3-[[[trans-4-[2,4-dihydroxyphenyl)cyclohexyl]amino]sulfonyl]benzoate 403854-98-8P, 3-[[[cis-4-[2,4-Dihydroxyphenyl)cyclohexyl]amino]sulfonyl]benzoic acid 403855-01-6P, Benzyl (2S)-2-[[3-[[[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]amino]sulfonyl]benzoyl]amino]-3-phenylpropanoate 403855-03-8P, Benzyl 3-[[3-[[[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]amino]sulfonyl]benzoyl]amino]propanoate
RLs COS (Cosmetic use); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

L29 ANSWER 16 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(CA INDEX NAME)

Absolute stereochemistry.



RN 402855-07-8 CAPLUS
CN β-Alanine, N-[3'-[[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]amino]sulfonyl]benzoyl]-, phenylmethyl ester (CA INDEX NAME)

Relative stereochemistry.



IT 402854-57-9P, N-[cis-4-[2,4-Dihydroxyphenyl)cyclohexyl]benzenesulfonanide 402854-58-0P, 4-Chloro-N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]benzenesulfonanide 402854-59-1P, 3-Chloro-N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]-4-fluorobenzenesulfonanide 402854-60-4P, N-[cis-4-[2,4-Dihydroxyphenyl)cyclohexyl]-2-thiophenesulfonanide 402854-61-5P, 5-Chloro-N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]-2-thiophenesulfonanide 402854-62-6P, N-[cis-4-[2,4-Dihydroxyphenyl)cyclohexyl]-3-nitrobenzenesulfonanide 402854-63-7P, N-[cis-4-[2,4-Dihydroxyphenyl)cyclohexyl]-4-nitrobenzenesulfonanide 402854-64-8P, N-[cis-4-[2,4-Dihydroxyphenyl)cyclohexyl]-2,4-dinitrobenzenesulfonanide 402854-66-0P, N-[cis-4-[2,4-Dihydroxyphenyl)cyclohexyl]-4-(methylsulfonyl)benzenesulfonanide 402854-67-1P, N-[trans-4-[2,4-Dihydroxyphenyl)cyclohexyl]benzenesulfonanide 402854-68-2P, N-[cis-4-[2,4-Dihydroxyphenyl)cyclohexyl]-2-naphthalenesulfonanide 402854-69-3P, N-[cis-4-[2,4-Dihydroxyphenyl)cyclohexyl]-4-methylbenzenesulfonanide

L29 ANSWER 16 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
402854-70-6P, N-[trans-4-[2,4-Dihydroxyphenyl)cyclohexyl]-4-methylbenzenesulfonanide 402854-71-7P, N-[cis-4-[2,4-Dihydroxyphenyl)cyclohexyl]-4-methoxybenzenesulfonanide 402854-72-8P, N-[cis-4-[2,4-Dihydroxyphenyl)cyclohexyl]-5-(dimethylamino)-1-naphthalenesulfonanide 402854-73-9P, N-[cis-4-[2,4-Dihydroxyphenyl)cyclohexyl]-4-methyl-1H-imidazole-4-sulfonamide 402854-74-0P, N-[cis-4-[2,4-Dihydroxyphenyl)cyclohexyl]-5-(3-isoxazolyl)-2-thiophenesulfonamide 402854-78-4P, Methyl 4-[[trans-4-[2,4-dihydroxyphenyl)cyclohexyl]amino]sulfonyl]benzoate 402854-79-5P, 4-Cyano-N-[trans-4-[2,4-dihydroxyphenyl)cyclohexyl]benzenesulfonamide 402854-80-8P, N-(2-Chloro-4-[[[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]amino]sulfonyl]phenyl]acetamide 402854-81-9P, 6-Amino-3-chloro-N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]benzenesulfonamide 402854-82-0P, 6-Acetyl-N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]benzenesulfonanide 402854-83-1P, N-[cis-4-[2,4-Dihydroxyphenyl)cyclohexyl]-4-(trifluoromethoxy)benzenesulfonanide 402854-84-2P, N-[trans-4-[2,4-Dihydroxyphenyl)cyclohexyl]-4-fluorobenzenesulfonanide 402854-85-3P, N-[trans-4-[2,4-Dihydroxyphenyl)cyclohexyl]-2,4-difluorobenzenesulfonanide 402854-86-4P, N-[trans-4-[2,4-Dihydroxyphenyl)cyclohexyl]-3,3,4,5,6-pentafluorobenzenesulfonanide 402854-87-5P, N-[trans-4-[2,4-Dihydroxyphenyl)cyclohexyl]-3-(trifluoromethyl)benzenesulfonanide 402854-88-6P, N-[trans-4-[2,4-Dihydroxyphenyl)cyclohexyl]-3,5-bis(trifluoromethyl)benzenesulfonanide 402854-89-7P 402854-90-0P, 2-Chloro-N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]-5-(trifluoromethyl)benzenesulfonanide 402854-91-1P, 3,5-Dichloro-N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]benzenesulfonanide 402854-92-2P, 4-Bromo-N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]-2,5-difluorobenzenesulfonanide 402854-93-3P, N-[cis-4-[2,4-Dihydroxyphenyl)cyclohexyl]-3,5-bis(trifluoromethyl)benzenesulfonanide 402854-94-4P, N-[cis-4-[2,4-Dihydroxyphenyl)cyclohexyl]-1-naphthalenesulfonanide 402854-95-5P, N-[cis-4-[2,4-Dihydroxyphenyl)cyclohexyl]-3-(hydroxymethyl)benzenesulfonamide 402854-96-6P, N-[cis-4-[2,4-Dihydroxyphenyl)cyclohexyl]-4-(hydroxymethyl)benzenesulfonanide 402854-97-7P, 4-[[[cis-4-[2,4-Dihydroxyphenyl)cyclohexyl]amino]sulfonyl]benzoic acid 402854-99-9P, 4-[[[trans-4-[2,4-Dihydroxyphenyl)cyclohexyl]amino]sulfonyl]benzoic acid 402855-00-5P, 3-[[[trans-4-[2,4-Dihydroxyphenyl)cyclohexyl]amino]sulfonyl]benzoic acid 402855-02-7P, (2S)-2-[[3-[[[cis-4-[2,4-Dihydroxyphenyl)cyclohexyl]amino]sulfonyl]benzoyl]amino]-3-phenylpropanoic acid 402855-04-9P, N-[3-[[[cis-4-[2,4-Dihydroxyphenyl)cyclohexyl]amino]sulfonyl]benzoyl]-β-alanine 402855-05-0P, N-[cis-4-[2,4-Dihydroxyphenyl)cyclohexyl]-4-(hydrazinosulfonyl)benzenesulfonanide 402855-06-1P, N-[cis-4-[2,4-Dihydroxyphenyl)cyclohexyl]-7-(1H-tetrazol-5-yl)benzenesulfonanide
RLs COS (Cosmetic use); PAC (Pharmacological activity); SPN (Synthetic

L29 ANSWER 16 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
preparation); TMU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and formulation of resorcinol deriva. for pharmaceutical use as
skin lightening agents)

RN 402854-57-9 CAPLUS
CN Benzenesulfonamide, N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

RN 402854-58-0 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 402854-59-1 CAPLUS
CN Benzenesulfonamide, 3-chloro-N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]-4-fluoro- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 16 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 402854-60-4 CAPLUS
CN 2-Thiophenesulfonamide, N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

RN 402854-61-5 CAPLUS
CN 2-Thiophenesulfonamide, 5-chloro-N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

RN 402854-62-6 CAPLUS
CN Benzenesulfonamide, N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]-3-nitro- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 16 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 403854-63-7 CAPLUS
CN Benzenesulfonamide, N-[cis-4-[2,4-dihydroxyphenyl]cyclohexyl]-4-nitro- (CA INDEX NAME)

Relative stereochemistry.



RN 403854-64-8 CAPLUS
CN Benzenesulfonamide, N-[cis-4-[2,4-dihydroxyphenyl]cyclohexyl]-2,4-dinitro- (CA INDEX NAME)

Relative stereochemistry.



RN 403854-66-0 CAPLUS
CN Benzenesulfonamide, N-[cis-4-[2,4-dihydroxyphenyl]cyclohexyl]-4-

L29 ANSWER 16 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 403854-69-3 CAPLUS
CN Benzenesulfonamide, N-[cis-4-[2,4-dihydroxyphenyl]cyclohexyl]-4-methyl- (CA INDEX NAME)

Relative stereochemistry.



RN 403854-70-6 CAPLUS
CN Benzenesulfonamide, N-[trans-4-[2,4-dihydroxyphenyl]cyclohexyl]-4-methyl- (CA INDEX NAME)

Relative stereochemistry.



RN 403854-71-7 CAPLUS
CN Benzenesulfonamide, N-[cis-4-[2,4-dihydroxyphenyl]cyclohexyl]-4-methoxy- (CA INDEX NAME)

Relative stereochemistry.



RN 403854-72-8 CAPLUS

L29 ANSWER 16 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(methylsulfonyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 403854-67-1 CAPLUS
CN Benzenesulfonamide, N-[trans-4-[2,4-dihydroxyphenyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 403854-68-2 CAPLUS
CN 2-Naphthalenesulfonamide, N-[cis-4-[2,4-dihydroxyphenyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 16 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN 1-Naphthalenesulfonamide, N-[cis-4-[2,4-dihydroxyphenyl]cyclohexyl]-5-(dimethylamino)- (CA INDEX NAME)

Relative stereochemistry.



RN 403854-73-9 CAPLUS
CN 1H-Indazole-6-sulfonamide, N-[cis-4-[2,4-dihydroxyphenyl]cyclohexyl]-1-methyl- (CA INDEX NAME)

Relative stereochemistry.



RN 403854-74-0 CAPLUS
CN 2-Thiophenesulfonamide, N-[cis-4-[2,4-dihydroxyphenyl]cyclohexyl]-5-(3-isoxazolyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 403854-78-4 CAPLUS
CN Benzoic acid, 4-[[[trans-4-[2,4-dihydroxyphenyl]cyclohexyl]amino]sulfonyl]-, methyl ester (CA INDEX NAME)

L29 ANSWER 16 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
Relative stereochemistry.



RN 403854-78-5 CAPLUS
CN Benzenesulfonamide, 6-cyano-N-[trans-4-(2,4-dihydroxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 403854-80-9 CAPLUS
CN Acetamide, N-[2-chloro-4-[[[cis-4-(2,4-dihydroxyphenyl)cyclohexyl]amino]sulfonyl]phenyl]- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 16 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 403854-81-9 CAPLUS
CN Benzenesulfonamide, 4-amino-3-chloro-N-[cis-4-(2,4-dihydroxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 403854-82-0 CAPLUS
CN Benzenesulfonamide, 4-acetyl-N-[cis-4-(2,4-dihydroxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 16 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 403854-83-1 CAPLUS
CN Benzenesulfonamide, N-[cis-4-(2,4-dihydroxyphenyl)cyclohexyl]-4-(trifluoromethoxy)- (CA INDEX NAME)

Relative stereochemistry.



RN 403854-84-2 CAPLUS
CN Benzenesulfonamide, N-[trans-4-(2,4-dihydroxyphenyl)cyclohexyl]-4-fluoro- (CA INDEX NAME)

Relative stereochemistry.



RN 403854-85-3 CAPLUS
CN Benzenesulfonamide, N-[trans-4-(2,4-dihydroxyphenyl)cyclohexyl]-2,4-difluoro- (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 16 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 403854-86-4 CAPLUS
CN Benzenesulfonamide, N-[trans-4-(2,4-dihydroxyphenyl)cyclohexyl]-2,3,4,5,6-pentafluoro- (CA INDEX NAME)

Relative stereochemistry.



RN 403854-87-5 CAPLUS
CN Benzenesulfonamide, N-[trans-4-(2,4-dihydroxyphenyl)cyclohexyl]-3-(trifluoromethyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 403854-88-6 CAPLUS
CN Benzenesulfonamide, N-[trans-4-(2,4-dihydroxyphenyl)cyclohexyl]-3,5-bis(trifluoromethyl)- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 16 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 403854-89-7 CAPLUS
CN Benzenemethanesulfonamide, N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]- (CA INDEX NAMES)

Relative stereochemistry.



RN 403854-90-2 CAPLUS
CN Benzenesulfonamide, 2-chloro-N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]-5-(trifluoromethyl)- (CA INDEX NAMES)

Relative stereochemistry.



L29 ANSWER 16 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 403854-94-4 CAPLUS
CN 1-Naphthalenesulfonamide, N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]- (CA INDEX NAMES)

Relative stereochemistry.



RN 403854-95-5 CAPLUS
CN Benzenesulfonamide, N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]-3-(hydroxymethyl)- (CA INDEX NAMES)

Relative stereochemistry.



RN 403854-96-6 CAPLUS
CN Benzenesulfonamide, N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]-4-(hydroxymethyl)- (CA INDEX NAMES)

Relative stereochemistry.

L29 ANSWER 16 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 403854-91-1 CAPLUS
CN Benzenesulfonamide, 3,5-dichloro-N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]- (CA INDEX NAMES)

Relative stereochemistry.



RN 403854-92-2 CAPLUS
CN Benzenesulfonamide, 4-bromo-N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]-2,5-difluoro- (CA INDEX NAMES)

Relative stereochemistry.



RN 403854-93-3 CAPLUS
CN Benzenesulfonamide, N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]-3,5-bis(trifluoromethyl)- (CA INDEX NAMES)

Relative stereochemistry.

L29 ANSWER 16 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 403854-97-7 CAPLUS
CN Benzoic acid, 4-[[[cis-4-(2,4-dihydroxyphenyl)cyclohexyl]amino]sulfonyl]- (CA INDEX NAMES)

Relative stereochemistry.



RN 403854-99-9 CAPLUS
CN Benzoic acid, 4-[[[trans-4-(2,4-dihydroxyphenyl)cyclohexyl]amino]sulfonyl]- (CA INDEX NAMES)

Relative stereochemistry.



RN 403855-00-5 CAPLUS
CN Benzoic acid, 3-[[[trans-4-(2,4-dihydroxyphenyl)cyclohexyl]amino]sulfonyl]- (CA INDEX NAMES)

L29 ANSWER 16 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
Relative stereochemistry.

RN 403855-02-7 CAPLUS
CN L-Phenylalanine, N-[3-[[[cis-4-[2,4-dihydroxyphenyl]cyclohexyl]amino]sulfonyl]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 403855-04-9 CAPLUS
CN D-Alanine, N-[3-[[[cis-4-[2,4-dihydroxyphenyl]cyclohexyl]amino]sulfonyl]benzoyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 403855-05-0 CAPLUS
CN Benzoic acid, 4-[[[cis-4-(2,4-dihydroxyphenyl)cyclohexyl]amino]sulfonyl]-,

L29 ANSWER 17 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
2002:174796 Document No. 137:3700450 Synthesis of isotopically labeled phosphodiesterase type 4 inhibitors, SB 222418 and SB 242126.
Mokhallalati, Mohamed K.; Shu, Arthur Y. L.; Villani, Anthony J. (Radiochemistry Department, SmithKline Beecham Pharmaceuticals, King of Prussia, PA, 19406, USA). Synthesis and Applications of Isotopically Labelled Compounds, Proceedings of the International Symposium, 7th, Dresden, Germany, June 18-22, 2000, Meeting Date 2000, 264-267. Editor(s): Pleiss, Ulrich Voges, Rolf. John Wiley & Sons Ltd.: Chichester, UK. ISBN: 0-471-49501-8 (English) 2001. CODEN: 69CIJC. OTHER SOURCES: CASREACT 137:3700450.

AB Carbon-14 labeled SB 222418 and SB 242126, which are potential phosphodiesterase type 4 inhibitors for the treatment of asthma, were synthesized. Two routes were proposed for potentially rapid production of SB 222418-[14C]. The first route was based on the use of the readily available [14C]methyl iodide as the carbon-14 source, while the second involved preparation of 5-bromo-2-aminopyrimidine in C-14 labeled form starting from [14C]guanidine. SB 242216-[14C] was obtained by converting SB 222418-[14C] using Mitsunobu type chemical. Deuterium labeled SB 222418 and tritium labeled SB 242126 were also prepared

IT 475230-81-4P
RL: RPH (Synthetic preparation); PREP (Preparation)
(synthesis of isotopically labeled phosphodiesterase type 4 inhibitors)

SB 222418 and SB 242126)

RN 475230-81-4 CAPLUS
CN 2-Pyrimidinamine-2-14C, 5-[3-(cyclopentyloxy)-4-methoxyphenyl]-(cyclohexylethenyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 16 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
hydrazide (CA INDEX NAME)

Relative stereochemistry.



RN 403855-06-1 CAPLUS
CN Benzenesulfonamide, N-[cis-4-[2,4-dihydroxyphenyl)cyclohexyl]-3-(2H-tetrazol-5-yl)- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 18 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
2002:173949 Document No. 136:217050 Preparation of cyclic peptides having melanocortin-4 receptor (MC4-R) agonist activity. Chen, Li; Cheung, Adrian Wai-hing; Chu, Kin-yje; Danbo, Waleedy Swistok, Joseph; Wang, Yao; Yagaloff, Keith Alan (F. Hoffmann-La Roche Ag, Switz.). PCT Int. Appl. WO 2002018437 A2 20020307, 230 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, GA, GB, GH, GM, GN, GQ, GW, ML, MR, NE, SD, SL, SZ, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-EP8630 20010721. PRIORITY: US 2000-PV229184 20000830.

GI



AB The invention refers to peptides I [R1XYR12 is benzo or R1 is H, R2(NH)nCONH (R2 = alkyl, alkenyl, alkynyl; n = 0 or 1), or R2CONHCR3(4CONH (R3(4 is alkyl); R12 is H; XY is C<C or CHCH; Q is (un)substituted methylene or phenylimino; X7 = O, NH; X8, X10 = H, Me; X9 is 3-indenylalkyl, 1- or 2-naphthyl; p = 0 or 1; s = 0-2; Z = CONH or S(2), cyclized via disulfide or lactam bridges; having melanocortin-4 receptor (MC4-R) agonist activity and useful for treatment of obesity. Thus, BuCO-cyclo(Asp-Hpg)-Asp-Apc-D-Phe-Arg-Trp-Lys-NH2 (Apc = 1-amino-4-phenylcyclohexanecarboxylic acid residue, Asp-Lys forms a lactam bridge) was prepared by the solid-phase method and showed EC50 = 9.2 and 654 nM, resp., in the MC-4 and MC-1 agonist assays.

IT 365550-45-8P 365550-47-0P 365550-49-2P
365550-71-4P 365550-77-2P 365553-45-3P
402788-82-2P 402788-83-4P 402788-84-5P
402788-85-6P 402788-86-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of cyclic peptides having melanocortin-4 receptor (MC4-R)

L29 ANSWER 18 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
agonist activity)

RN 365550-65-8 CAPLUS
CN Cyclohexanecarboxylic acid,
1-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-
(4-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A

RN 365550-67-0 CAPLUS
CN Cyclohexanecarboxylic acid, 4-(4-ethoxyphenyl)-1-[[(9H-fluoren-9-
ylmethoxy)carbonyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 18 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 365550-69-2 CAPLUS
CN Cyclohexanecarboxylic acid,
1-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-
(4-hydroxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 18 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 365550-71-6 CAPLUS
CN Cyclohexanecarboxylic acid,
1-[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-
[4-(1-methylethoxy)phenyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 18 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 365550-73-2 CAPLUS
CN Cyclohexanecarboxylic acid,
1-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-
(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 19 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 365553-45-3 CAPLUS
CN Cyclohexanecarboxylic acid, 1-amino-4-(4-hydroxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 402788-82-3 CAPLUS
CN L-Lysinamide, N-(1-oxopentyl)-L-α-aspartyl-cis-1-amino-4-[4-hydroxyphenyl]cyclohexanecarbonyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L29 ANSWER 18 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

OH

RN 402788-83-4 CAPLUS
CN L-Lysinamide, N-(1-oxopentyl)-L-α-aspartyl-cis-1-amino-4-[4-methoxyphenyl]cyclohexanecarbonyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (CA INDEX NAME)

Absolute stereochemistry.

L29 ANSWER 19 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

OMe

RN 402788-84-5 CAPLUS
CN L-Lysinamide, N-(1-oxopentyl)-L-α-aspartyl-cis-1-amino-4-[4-ethoxyphenyl]cyclohexanecarbonyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L29 ANSWER 18 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

OEt

RN 402788-85-6 CAPLUS
CN L-Lysinamide, N-(1-oxopentyl)-L-α-aspartyl-cis-1-amino-4-[4-(2-methylethoxy)phenyl]cyclohexanecarbonyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L29 ANSWER 19 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



OPr-i

RN 402788-86-7 CAPLUS
CN L-tyrosinamide, N-(1-oxopentyl)-L-α-aspartyl-cis-1-amino-4-[3-methoxyphenyl]cyclohexanecarbonyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L29 ANSWER 19 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
2001:886087 Document No. 136:200030 Preparation of aminocycloheptenzarolones as NMDA receptor antagonists. Hikam, Sham Shridhar; Scott, Ian Leslie; Sherer, Brian Alan; Wise, Lawrence David (Warner-Lambert Company, USA). PCT Int. Appl. WO 2001092239 A1 20011206, 156 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXMD2. APPLICATION: WO 2001-US14703 20010508. PRIORITY: US 2000-208241P 20000531.

GI



AB Title compds. [I; Ar = (substituted) aryl, heteroaryl; X = (CR1R2)n, O2C, OSO2, etc.; n = 1-6; R = H, alkyl, CONH2, CO2R6, COHNR6, aralkyl, hydroxyalkyl, aminoalkyl, etc.; R6 = alkyl, aralkyl; Y = H, electron withdrawing group; m = 0-2; EY = CH=CHNH, CH2CH2NH, CHCHNH, SCONH, NCHNH, CH=CHNH, etc.; dotted line = optional double bond], were prepared Thus, a mixture of 6-(1-oxocyclohexyl)benzoxazolin-2-one (preparation given), PhCH2CH2NH2, and 3A mol. sieves were stirred 4 h in MeOCH2OH; NaBH4 was added followed by stirring overnight to give 41% 6-[trans-4-[3-phenylpropylamino]cyclohexyl]-3H-benzoxazol-2-one (II). II inhibited NR1A/NR2B receptors in oocytes with IC50 = 0.03 μM. A II drug formulation is given.

IT 377084-76-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aminocycloheptenzarolones as NMDA receptor antagonists)
RN 377084-76-9 CAPLUS
CN 2(3H)-Benzoxazolone, 5-methoxy-6-[trans-4-(methylamino)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 18 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



OMe

L29 ANSWER 18 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

L29 ANSWER 20 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
2001:850920 Document No. 135:366766 Method for enhancing cognitive function with phosphodiesterase-4 inhibitors. Hagan, James (Smithkline Beecham P.L.C., UK). PCT Int. Appl. WO 2001087281 A2 20011122, 20 pp.
DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-GB2134 20010515. PRIORITY: GB 2000-11802 20000516.

AB A method for enhancing cognitive function by administering to a patient in need thereof an effective amount of a PDE4 inhibitor.

IT 180529-65-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(enhancing cognitive function with phosphodiesterase-4 inhibitors)

RN 180529-65-1 CAPLUS
CN 2-Pyrimidinamine, 5-[[trans-4-amino-1-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexyl]ethynyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 21 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
2001:809680 Document No. 136:857980
trans-4-[4-(Methoxyphenyl)cyclohexyl]-1-arylpiperazines: A New Class of Potent and Selective 5-HT1A Receptor Ligands as Conformationally Constrained Analogues of 4-[3-(5-Methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]-1-arylpiperazines. Perrone, Roberto; Berardi, Francesco; Colabufo, Nicola A.; Leopoldo, Marcello; Lacivita, Enza; Tortorella, Vincenzo; Leonardi, Amedeo; Poggesi, Elena; Testa, Rodolfo (Dipartimento Farmaco-Chimico, Bari, 70126, Italy). Journal of Medicinal Chemistry, 44(25), 4431-4442 (English) 2001. CODEN: JMCMAR. ISSN: 0022-2623. OTHER SOURCES: CASREACT 136:85798. Publisher: American Chemical Society.

AB The influence of conformational parameters on the recognition by rat 5-HT1A receptors of derivs. of 4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]-1-(2-pyridinyl)piperazine (I) and 3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)-N-[2-(2-pyridyloxy)ethyl]propanamine (II), two highly potent and selective 5-HT1A receptor ligands, is addressed. Fifteen flexible and rigid analogs were prepared following several synthetic routes and were tested in binding assays with radioligands at 5-HT1A, D2, and α1 receptors from rat brain membranes. Among the new derivs. trans-4-[4-(3-methoxyphenyl)cyclohexyl]-1-(2-pyridinyl)piperazine (III) and trans-N-[4-(3-methoxyphenyl)cyclohexyl]-2-(2-pyridyloxy)ethylamine (IV) emerged as active compds. These compds. can be considered as conformationally constrained analogs of I and II, resp. In fact, III and IV showed a marked enhancement in 5-HT1A receptor affinity when compared to their cis isomers. Because III was a potent and selective 5-HT1A ligand (Ki, nM: 5-HT1A = 0.028, D2 = 2194, α1 = 767), it was chosen as a lead to prepare other analogs that were tested at 5-HT1A, D2, and α1 receptors from rat brain membranes, showing high affinity at the 5-HT1A and selectivity vs D2 and α1 receptors. Selected compds. were tested for their affinity at the human cloned 5-HT1A, α1a, α1b, α1d receptor subtypes. They were also submitted to the [35S]GTPγS binding assay stimulating the 5-HT1A receptor-mediated G-protein activation, therefore behaving as full or as partial agonists. Finally, the ability of iv administration of III to induce fore-paw treading in rats was evaluated in comparison with 8-OH-DPAT. Although the affinity (Ki) and in vitro activity (pD'2) of III at the 5-HT1A receptor were higher than those of 8-OH-DPAT, the compound was less potent than the reference standard in inducing the symptom.

IT 385811-59-6P 385811-60-9P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(trans-4-[4-(methoxyphenyl)cyclohexyl]-1-arylpiperazines as potent and selective 5-HT1A receptor agonists)

RN 385811-59-6 CAPLUS
CN Cyclohexanamine, 4-(3-methoxyphenyl)-N-[2-(2-pyridinyloxy)ethyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 21 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 385811-60-9 CAPLUS
CN Cyclohexanamine, 4-(3-methoxyphenyl)-N-[2-(2-pyridinyloxy)ethyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 22 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
2001:798181 Document No. 135:3442730 Preparation of 4-arylcyclohexylamines as subtype selective NMDA receptor antagonists.. Deorazio, Russell Joseph; Nikam, Sham Shridhar; Scott, Ian Leslie; Sherer, Brian Alan; Wise, Lawrence David (Warner-Lambert Company, USA). PCT Int. Appl. WO 2001081295 A1 20011101, 75 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US13176 20010424. PRIORITY: US 2000-PV199762 20000426.

GI



I

AB Title compds. [I; Ar = substituted aryl, heteroaryl; Z = (CR1R2)n, (CR1R2)qV, etc.; V = (CH2)n, CO, SO, SO2; n = 1-6; q = 0-6; R = H, OH, alkyl, COR6, CO2R6, CONHR6, aralkyl, hydroxyalkyl, etc.; R6 = alkyl, aralkyl; Y = hydrogen bond donor group; X = H, electron withdrawing group; m = 1, 2], were prepared Thus, a mixture of Ph(CH2)4NH2, 4-(4-hydroxyphenyl)cyclohexanone, NaBH(OAc)3, and HOAc were stirred in ClCH2CH2Cl to give 12% cis-4-[4-(4-phenylbutylamino)cyclohexyl]phenol and 4% trans-isomer. Tested I antagonized NR1A/NR1B NMDA receptors in oocytes with IC50 = 0.02-301 μM. I are antagonists of NMDA receptor channel complexes useful for treating cerebrovascular disorders such as cerebral ischemia, cardiac arrest, stroke, and Parkinson's disease.

IT 259662-54-9P 259662-55-0P 259662-59-4P
259662-80-1P 259662-81-2P 259662-98-1P
259662-99-2P 370860-24-5P 370860-25-6P
370860-27-8P 370860-28-9P 370860-29-0P
370860-30-3P 370860-31-4P 370860-32-5P
370860-33-6P 370860-34-7P 370860-35-8P
370860-36-9P 370860-37-0P 370860-38-1P
370860-39-2P 370860-40-5P 370860-41-6P
370860-42-7P 370860-43-8P 370860-44-9P
370860-45-0P 370860-51-8P 370860-52-9P
370860-53-0P 370860-54-1P 370860-55-2P
370860-59-6P 370860-60-9P 370860-61-0P
370860-62-1P 370860-63-2P 370860-64-3P
370860-65-4P 370860-66-5P 370860-67-6P
370860-68-7P 370860-69-8P 370860-70-1P
370860-71-2P 370860-77-8P 370860-78-9P
370860-79-0P 370860-80-3P 370860-81-4P
370860-82-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

L29 ANSWER 22 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 4-arylcyclohexylamines as subtype selective NMDA receptor antagonists)

RN 259662-54-9 CAPLUS
CN Phenol, 4-[cis-4-[[2-phenylethyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 259662-55-0 CAPLUS
CN Phenol, 4-[trans-4-[[2-phenylethyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 259662-53-8 CAPLUS
CN Phenol, 4-[trans-4-[[4-phenylbutyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 259662-90-1 CAPLUS
CN Phenol, 4-[cis-4-[[2-phenoxyethyl]amino]cyclohexyl]- (CA INDEX NAME)

L29 ANSWER 22 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
Relative stereochemistry.

RN 259662-81-2 CAPLUS
CN Phenol, 4-[trans-4-[(2-phenoxyethyl)amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

RN 259662-98-1 CAPLUS
CN Phenol, 4-[trans-4-[(1-methyl-3-phenylpropyl)amino]cyclohexyl]- (CA INDEX
NAME)

Relative stereochemistry.

RN 259662-99-2 CAPLUS
CN Phenol, 4-[cis-4-[(1-methyl-3-phenylpropyl)amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 22 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 370860-24-5 CAPLUS
CN Phenol, 4-[cis-4-[(4-phenylbutyl)amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 370860-25-6 CAPLUS
CN Phenol, 4-[cis-4-[(3-phenylpropyl)amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 370860-27-8 CAPLUS
CN Phenol, 4-[cis-4-[(phenylmethyl)amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 22 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 370860-28-9 CAPLUS
CN Phenol, 4-[trans-4-[[2-(4-fluorophenyl)ethyl]amino]cyclohexyl]- (CA INDEX
NAME)

Relative stereochemistry.

RN 370860-29-0 CAPLUS
CN Phenol, 4-[cis-4-[[2-(4-fluorophenyl)ethyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

RN 370860-30-3 CAPLUS
CN Phenol, 4-[trans-4-[[(1R)-1-methyl-3-phenylpropyl]amino]cyclohexyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 370860-31-4 CAPLUS
CN Phenol, 4-[trans-4-[[(1S)-1-methyl-3-phenylpropyl]amino]cyclohexyl]- (CA INDEX NAME)

Absolute stereochemistry.

L29 ANSWER 21 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 370860-32-5 CAPLUS
CN Phenol, 4-[trans-4-[(3-pyridinylmethyl)amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 370860-33-6 CAPLUS
CN Phenol, 4-[cis-4-[(3-pyridinylmethyl)amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 370860-34-7 CAPLUS
CN Phenol, 4-[trans-4-[[2-(4-methoxyphenyl)ethyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 22 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 370860-38-1 CAPLUS
CN Benzenepropanol, β-[[cis-4-(4-hydroxyphenyl)cyclohexyl]amino]-, (βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 370860-39-2 CAPLUS
CN Phenol, 4-[trans-4-[[3-(4-pyridinyl)propyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 370860-40-5 CAPLUS
CN Phenol, 4-[cis-4-[[3-(4-pyridinyl)propyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 22 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 370860-35-8 CAPLUS
CN Phenol, 4-[cis-4-[[2-(4-methoxyphenyl)ethyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 370860-36-9 CAPLUS
CN Phenol, 4-[trans-4-[(5-phenylpentyl)amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 370860-37-0 CAPLUS
CN Benzenepropanol, β-[[trans-4-(4-hydroxyphenyl)cyclohexyl]amino]-, (βR)- (CA INDEX NAME)

Absolute stereochemistry.

L29 ANSWER 22 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 370860-41-6 CAPLUS
CN Phenol, 4-[trans-4-[[(1S)-1-methyl-2-phenylethyl]amino]cyclohexyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 370860-42-7 CAPLUS
CN Phenol, 4-[trans-4-[[3-(3-pyridinyl)propyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 370860-43-8 CAPLUS
CN Phenol, 4-[cis-4-[[3-(3-pyridinyl)propyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 21 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 370860-44-9 CAPLUS
CN Phenol, 4-[trans-4-[[3-(2-pyridinyl)propyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 370860-45-0 CAPLUS
CN Phenol, 4-[cis-4-[[3-(2-pyridinyl)propyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 370860-51-8 CAPLUS
CN Benzenepropanamide, N-[trans-4-(4-hydroxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 22 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 370860-52-9 CAPLUS
CN Butanamide, N-[trans-4-(4-hydroxyphenyl)cyclohexyl]-3-methyl-3-phenoxy- (CA INDEX NAME)

Relative stereochemistry.



RN 370860-53-0 CAPLUS
CN Phenol, 4-[trans-4-[(3-phenyl-2-propyn-1-yl)amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 370860-54-1 CAPLUS
CN Phenol, 4-[trans-4-[[2-(phenylthio)ethyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 22 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 370860-55-2 CAPLUS
CN Phenol, 4-[trans-4-[[3-(4-methoxyphenyl)propyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 370860-59-6 CAPLUS
CN Phenol, 4-[trans-4-[[5-phenylpentyl]amino]cyclohexyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 370860-60-9 CAPLUS
CN Benzenepropanol, β-[[cis-4-(4-hydroxyphenyl)cyclohexyl]amino]-, hydrochloride (1:1), (βR)- (CA INDEX NAME)

Absolute stereochemistry.

L29 ANSWER 22 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 370860-61-0 CAPLUS
CN Benzenepropanol, β-[[trans-4-(4-hydroxyphenyl)cyclohexyl]amino]-, hydrochloride (1:1), (βR)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 370860-62-1 CAPLUS
CN Phenol, 4-[cis-4-[[3-(4-pyridinyl)propyl]amino]cyclohexyl]-, hydrochloride (1:2) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 21 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● xHCl

RN 370860-63-2 CAPLUS
CN Phenol, 4-[trans-4-[[3-[4-pyridinyl)propyl]amino]cyclohexyl]-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 370860-39-2
CMF C20 H26 N2 O

Relative stereochemistry.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.

L29 ANSWER 22 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.

RN 370860-66-5 CAPLUS
CN Phenol, 4-[cis-4-[[3-(2-pyridinyl)propyl]amino]cyclohexyl]-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 370860-45-0
CMF C20 H26 N2 O

Relative stereochemistry.

CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.

L29 ANSWER 22 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 370860-64-3 CAPLUS
CN Phenol, 4-[cis-4-[[3-(3-pyridinyl)propyl]amino]cyclohexyl]-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 370860-43-8
CMF C20 H26 N2 O

Relative stereochemistry.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.

RN 370860-65-4 CAPLUS
CN Phenol, 4-[trans-4-[[3-[3-pyridinyl)propyl]amino]cyclohexyl]-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 370860-42-7
CMF C20 H26 N2 O

Relative stereochemistry.

L29 ANSWER 22 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 370860-67-6 CAPLUS
CN Phenol, 4-[trans-4-[[3-[2-pyridinyl)propyl]amino]cyclohexyl]-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 370860-44-9
CMF C20 H26 N2 O

Relative stereochemistry.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.

RN 370860-68-7 CAPLUS
CN Propanamide, N-[trans-4-(4-hydroxyphenyl)cyclohexyl]-2-methyl-2-phenoxy- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 21 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 370860-69-8 CAPLUS
CN Phenol, 4-[trans-4-[[3-phenyl-2-propynyl)amino]cyclohexyl]-, [2S]-2-hydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 370860-53-0
CMF C21 H23 N O

Relative stereochemistry.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.

RN 370860-70-1 CAPLUS
CN Phenol, 4-[trans-4-[[2-[phenylamino)ethyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 22 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 370860-78-9 CAPLUS
CN Phenol, 4-[trans-4-[[2-(4-fluorophenyl)ethyl]amino]cyclohexyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 370860-79-0 CAPLUS
CN Phenol, 4-[cis-4-[[1-methyl-3-phenylpropyl)amino]cyclohexyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 370860-80-3 CAPLUS
CN Phenol, 4-[trans-4-[[1-methyl-3-phenylpropyl)amino]cyclohexyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 22 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 370860-71-2 CAPLUS
CN Phenol, 4-[trans-4-[[3-(4-methoxyphenyl)propyl]amino]cyclohexyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 370860-77-8 CAPLUS
CN Phenol, 4-[cis-4-[[2-(4-fluorophenyl)ethyl]amino]cyclohexyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

L29 ANSWER 22 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 370860-81-4 CAPLUS
CN Phenol, 4-[cis-4-[(3-pyridinylmethyl)amino]cyclohexyl]-, hydrochloride (1:2) (CA INDEX NAME)

Relative stereochemistry.



● 2 HCl

RN 370860-82-5 CAPLUS
CN Phenol, 4-[trans-4-[(3-pyridinylmethyl)amino]cyclohexyl]-, hydrochloride (1:2) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 21 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● 2 HCl

IT 259402-57-2 370960-26-7 370960-90-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 4-arylcyclohexylamines as subtype selective NMDA receptor antagonists)
RN 259402-57-2 CAPLUS
CN Phenol, 4-[trans-4-[[3-phenylpropyl)amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 370960-26-7 CAPLUS
CN Phenol, 4-[trans-4-[(phenylmethyl)amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 22 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

L29 ANSWER 22 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 370960-90-5 CAPLUS
CN Phenol, 4-[4-[[2-phenoxyethyl)amino]cyclohexyl]- (CA INDEX NAME)



IT 143507-41-5P 370960-83-6P 370961-02-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 4-arylcyclohexylamines as subtype selective NMDA receptor antagonists)
RN 143507-41-5 CAPLUS
CN Phenol, 4-(trans-4-aminocyclohexyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 370960-83-6 CAPLUS
CN Acetamide, N-[trans-4-[4-hydroxyphenyl)cyclohexyl]-2-(phenylthio)- (CA INDEX NAME)

Relative stereochemistry.



RN 370961-02-2 CAPLUS
CN Phenol, 4-[trans-4-[(phenylmethyl)amino]cyclohexyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
2001:747815 Document No. 135:3041430 Preparation of selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity. Chen, Li; Cheung, Adrian Wai-hing; Chu, Xin-jie; Danho, Waleed; Swistok, Joseph; Yagaloff, Keith Alan (F. Hoffmann-La Roche Ag, Switz.). PCT Int. Appl. WO 2001074844 A2 20011011, 265 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG. (English). CODEN: PIXD2. APPLICATION: WO 2001-EP3529 20010327. PRIORITY: US 2000-PV194450 20000404.

GI



I



II

AB Peptides I [m, n = 0, 1; R1 = (un)substituted alkyl, phenylalkyl, oxabenzalkyl or phenyl; X = phenylmethylene or alkoxyphenylmethylene, cyclohexyl-, cyclohexylpl- or alkylmethylene, or (un)substituted phenylimino; R6, R8 = H, Me; R7 = 3-indolyl, 1- or 2-naphthyl; Y = CH2, CH2CH2, CONH, CHNCSNH-m or p- or o-C6H4 (with provisos)] or an analog in which X-CHI is (un)substituted benzo were prepared as MC4-R agonists. Thus, pentapeptide II [pentaAspo-D-Phe-Arg-Trp-Gly-NH2] was prepared by the solid-phase method using a Fmoc-Linker-RHA resin.
IT 365551-40-6P 365551-42-8P 365551-45-1P 365551-48-4P 365551-71-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity)
RN 365551-40-6 CAPLUS

L29 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN Glycinamide, cis-4-[4-hydroxyphenyl)-1-[(1-

oxopentyl)amino]cyclohexanecarbonyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

OH

RN 365551-62-8 CAPLUS
CN Glycinamide, cis-4-[4-methoxyphenyl)-1-[(1-

oxopentyl)amino]cyclohexanecarbonyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L29 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

OMe

RN 365551-68-4 CAPLUS
CN Glycinamide, cis-4-[4-ethoxyphenyl)-1-[(1-

oxopentyl)amino]cyclohexanecarbonyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L29 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

OMe

RN 365551-63-1 CAPLUS
CN Glycinamide, cis-4-[3-methoxyphenyl)-1-[(1-

oxopentyl)amino]cyclohexanecarbonyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L29 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

OEt

RN 365551-71-9 CAPLUS
CN Glycinamide, cis-4-[4-(1-methylethoxy)phenyl]-1-[(1-

oxopentyl)amino]cyclohexanecarbonyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OEt-i

IT 365550-65-8P 365550-67-0P 365550-69-2P
365550-71-4P 365550-75-2P 365553-43-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity)

RN 365550-65-8 CAPLUS
CN Cyclohexanecarboxylic acid,
1-[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-
(4-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 365550-67-0 CAPLUS
CN Cyclohexanecarboxylic acid, 4-(4-ethoxyphenyl)-1-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 365550-69-2 CAPLUS
CN Cyclohexanecarboxylic acid,
1-[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-
(4-hydroxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 365550-71-4 CAPLUS
CN Cyclohexanecarboxylic acid,
1-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-
(4-(1-methylethoxy)phenyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 365550-77-2 CAPLUS
CN Cyclohexanecarboxylic acid, 1-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-[3-methoxyphenyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 365553-45-3 CAPLUS
CN Cyclohexanecarboxylic acid, 1-amino-4-[4-hydroxyphenyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 24 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
2001:114937 Document No. 134:162890 Preparation of 1,4-substituted 4,4-diaryl cyclohexanes as PDE IV and TNF production inhibitors. Christensen, Siegfried B., IV (SmithKline Beecham Corp., USA). PCT Int. Appl. WO 2001007393 A2 20010201, 23 pp. DESIGNATED STATES: W: AE, AG, AL, AM, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, CH, CY, DE, DK, EA, ES, FI, FR, GB, GH, GM, GR, IE, IT, LU, MC, MW, NL, OA, PT, SE, SL, SZ, TR, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM (English). CODEN: PIXD2. APPLICATION: WO 2000-US21867 20000810. PRIORITY: US 1999-PV148034 19990810.

GI



AB The title compds. [I; R3 = (CR4R5)nCO2(CR4R5)nR6, (CR4R5)nCONR4(CR4R5)nR6, (CR4R5)nO(CR4R5)mR6, etc.; n = 0-2; n + m = 1-4; R4, R5 = H, alkyl; R6 = H, Me, OH, etc.; X = CH2, S, NR4R5, formyl amine; Y = O, SO2; p = 0-2; X1 = O, NR8; R2 = Me, Et optionally substituted by halogens; R8 = H, alkyl optionally substituted by 1-3 F atoms; Rz = (un)substituted Ph; Z = OH, NH2, O, etc.] which can be used in treating conditions which are mediated by the inhibition of PDE4, particularly in treating allergic and inflammatory diseases and for inhibiting the production of Tumor Necrosis Factor (TNF), were prepared E.g., a multi-step synthesis of cis-1 and trans-2 (R) - cyclopentyl; X2 = O; X = OMe; Rz = 4-(2-aminopyrimidin-4-yl)phenyl; Z = OH] was given. The exemplified compds. I showed pos. IC50's in the nM to uM range against PDE. IT 323770-77-2P 323770-78-3P
RLs RAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1,4-substituted 4,4-diaryl cyclohexanes as PDE IV and TNF production inhibitors)
RN 323770-77-2 CAPLUS
CN 2-Pyrimidinamine, 5-[4-[trans-4-amino-1-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexyl]phenyl]- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 24 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 323770-78-3 CAPLUS
CN 2-Pyrimidinamine, 5-[4-[cis-4-amino-1-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexyl]phenyl]- (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 25 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
2000:688208 Document No. 133:266592O Resorcinol derivatives as skin lightening agents. Collington, Eric William; Procter, Martin James; Geden, Joanna Victoria; Browning, Andrew Francis (Pfizer Inc., USA). PCT Int. Appl. WO 2000056702 A1 20000928, 98 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-IB286 20000316. PRIORITY: US 1999-PV125534 19990322.

AB 2,4-(HO)2C6H3R [R = substituted cycloalkyl, cycloalkenyl] were prepared for use as skin lightening agents. Thus, 3-methoxy-2-cyclopenten-1-one was treated with 2,4-(MeOCH2O)2C6H3Br to give 3-[2,4-bis(methoxymethoxy)phenyl]-2-cyclopenten-1-one which was reduced to the cyclopentanone, demethoxymethoxylated, and converted to 3-(2,4-dihydroxyphenyl)cyclopentanone oxime. This compound had an IC50 for tyrosinase inhibition of 2 μM.

IT 296764-76-6P 296765-24-7P 296765-25-8P
RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dihydroxyphenylcycloalkane derivs. as skin lightening agents)

RN 296764-76-6 CAPLUS
CN Acetamide, N-[4-(2,4-dihydroxyphenyl)cyclohexyl]- (CA INDEX NAME)



RN 296765-24-7 CAPLUS
CN 1,3-Benzenediol, 4-[4-(hydroxyamino)cyclohexyl]- (CA INDEX NAME)



RN 296765-25-8 CAPLUS
CN 1,3-Benzenediol, 4-[trans-4-(methoxyamino)cyclohexyl]- (CA INDEX NAME)

L29 ANSWER 25 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Relative stereochemistry.



L29 ANSWER 26 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
2000:351506 Document No. 132:347581O Preparation of pyrimidinediones as alpha 1a adrenoceptor antagonists. Nerenberg, Jennie B.; Bock, Mark G. (Merck & Co., Inc., USA). PCT Int. Appl. WO 2000029386 A1 20000525, 103 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-US26362 19991109. PRIORITY: US 1998-PV108146 19981112.
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; Q = II, III; Z = C, N (when Z = N, R2 is absent); X = CRaRb, NRa; Y = CH, N (provided that when Y = N, Z = C and X = CRaRb; and when Y = CH, X = NRa); R1 = (un)substituted Ph, pyridyl, thienyl, etc.; R2 = H, CN, OH, etc.; R3 = alkyl; R4, R5, R10, R11 = H, alkyl, cycloalkyl; R6, R7 = H, alkyl, fluorinated alkyl; R6 and R7 are taken together to form oxo; R8, R9 = H, halo, CN, etc.; R12 = H, alkyl, cycloalkyl, etc.; Ra, Rb = H, alkyl, cycloalkyl; m = 0-4; n = 2-4, when X = NRa; n = 1-3, when X = CRaRb; o, p = 0-2 (wherein o + p ≤ 3); q = 0-2], useful as alpha 1a adrenergic receptor antagonists, were prepared Thus, reacting 4-(4-fluorophenyl)piperidine.HCl with 1-benzyl-3-(3-bromopropyl)-5-methyl-1H-pyrimidine-2,4-dione in the presence of NaI and K2CO3 in MeCN afforded 61% IV which showed Ki of < 30 nM against alpha 1a adrenergic receptor binding. One application of compds. I is in the treatment of benign prostatic hyperplasia. The compds.I are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compds. is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compds. is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved.

IT 270077-13-9P 270077-25-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidinediones as alpha 1a adrenoceptor antagonists)

RN 270077-13-9 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[3-[3,6-dihydro-5-methyl-2,6-dioxo-3-(phenylmethyl)-1(2H)-pyrimidinyl]propyl]amino]-1-(2-methoxyphenyl)-, hydrochloride (1:1), cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 26 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 270077-25-3 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 3-[3-[[trans-4-(2-methoxyphenyl)cyclohexyl]amino]propyl]-5-methyl-1-(phenylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

IT 270077-56-0 270077-61-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrimidinediones as alpha 1a adrenoceptor antagonists)

RN 270077-56-0 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 3-[3-[[trans-4-(2-methoxyphenyl)cyclohexyl]amino]propyl]-5-methyl-1-(phenylmethyl)- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 26 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 270077-61-7 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[3-[3,6-dihydro-5-methyl-2,6-dioxo-3-[phenylmethyl]-1(2H)-pyrimidinyl]propyl]amino]-1-(2-methoxyphenyl)-, cis-
(CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 27 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 259662-59-4 CAPLUS
CN Phenol, 4-[trans-4-[(4-phenylbutyl)amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 259662-81-2 CAPLUS
CN Phenol, 4-[trans-4-[(2-phenoxyethyl)amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 259662-88-9 CAPLUS
CN Benzeneethanol, a-[[trans-4-(4-hydroxyphenyl)cyclohexyl]amino]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 259662-98-1 CAPLUS
CN Phenol, 4-[trans-4-[[1-methyl-3-phenylpropyl]amino]cyclohexyl]- (CA INDEX
NAME)

Relative stereochemistry.

L29 ANSWER 27 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN

2000:144521 Document No. 132:190870 Preparation of phenylalkylaminocyclohexylphenols and related compounds as NMDA receptor blockers. Alanine, Alexander; Buettelmann, Bernd; Reitz, Reichart Marie-paule; Pinard, Emmanuel; Wyler, Rene (F. Hoffmann-La Roche A.-G., Switz.). Eur. Pat. Appl. EP 983026 A2 20000301, 36 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO. (English). CODEN: EPXXDW. APPLICATION: EP 1999-115114 19990809. PRIORITY: EP 1998-115484 19980518.

GI

AB Title compds. [I; Ar1, Ar2 = (un)substituted Ph, naphthyl, tetrahydronaphthyl; A = -, CH2, C(OH), N; Y = CH2, CH, O, SCH2, CHMe, CMe2; R1 = H, alkyl Ar; A = CO, (CHR3)n; R2 = H, alkyl, hydroxyalkyl; R3 = (CH2)n, O, CH(OH)(CH2)n, CH(CH2OH)(CH2)n, (CH2)nCH(OH), CH(CH2OH); n = 0-4; dotted line = optional double bond], were prepared. Thus, trans-4-[4-[[3-(4-fluorophenyl)propyl]methylamino]cyclohexyl]phenol (preparation given) showed IC50 = 0.004 nM in 3H-Ro 25-6981 binding expts.
IT 259662-57-2P 259662-59-4P 259662-81-2P
259662-89-0P 259662-98-1P 259663-00-8P
259663-02-0P 259663-06-4P 259663-10-0P
259663-11-1P 259663-14-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylalkylaminocyclohexylphenols and related compds. as
NMDA receptor blockers)
RN 259662-57-2 CAPLUS
CN Phenol, 4-[trans-4-[[3-phenylpropyl)amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 27 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 259663-00-8 CAPLUS
CN Phenol, 4-[trans-4-[[3-[4-methylphenyl)propyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 259663-02-0 CAPLUS
CN Phenol, 4-[trans-4-[[3-(4-fluorophenyl)propyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 259663-06-4 CAPLUS
CN Benzenebutanol, β-[[trans-4-(4-hydroxyphenyl)cyclohexyl]amino]- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 27 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 259663-30-0 CAPLUS
CN Benzenepropanol, β-[[[trans-4-(4-hydroxyphenyl)cyclohexyl]amino]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 259663-11-1 CAPLUS
CN Phenol, 4-[cis-1-hydroxy-4-[(3-phenylpropyl)amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 259663-34-4 CAPLUS
CN Phenol, 4-[(1S,3S,4R)-3-methyl-4-[(3-phenylpropyl)amino]cyclohexyl]-, rel-
(CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 27 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Relative stereochemistry.



● RC1

RN 259662-58-3 CAPLUS
CN Phenol, 4-[cis-4-[(4-phenylbutyl)amino]cyclohexyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 259662-82-3 CAPLUS
CN Phenol, 4-[cis-4-[(2-phenoxyethyl)amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 259662-99-2 CAPLUS
CN Phenol, 4-[cis-4-[(2-methyl-3-phenylpropyl)amino]cyclohexyl]- (CA INDEX NAME)

L29 ANSWER 27 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



3T 259662-54-9P 259662-55-0P 259662-56-1P
259662-58-3P 259662-80-1P 259662-99-2P
259663-04-2P 259663-08-6P 259663-12-2P
259664-16-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of phenylalkylaminocyclohexylphenols and related compds. as
NMDA receptor blockers)
RN 259662-54-9 CAPLUS
CN Phenol, 4-[cis-4-[(2-phenylethyl)amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 259662-55-0 CAPLUS
CN Phenol, 4-[trans-4-[(2-phenylethyl)amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 259662-56-1 CAPLUS
CN Phenol, 4-[cis-4-[(3-phenylpropyl)amino]cyclohexyl]-, hydrochloride (1:1)
(CA INDEX NAME)

L29 ANSWER 27 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Relative stereochemistry.



RN 259663-04-2 CAPLUS
CN Benzenemethanol, α-[2-[[trans-4-(4-hydroxyphenyl)cyclohexyl]amino]ethyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 259663-08-6 CAPLUS
CN Benzenemethanol, β-[2-[[trans-4-(4-hydroxyphenyl)cyclohexyl]amino]ethyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 259663-12-2 CAPLUS
CN Phenol, 4-[trans-1-hydroxy-4-[(3-phenylpropyl)amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 27 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 259664-36-9 CAPLUS
CN Benzenemethanol, a-[[cis-4-[4-hydroxyphenyl)cyclohexyl]amino]methyl]- (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 28 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1999:753239 Document No. 131:353450 Preparation of arylcyclohexylaminopyrimidines and related compounds as pesticides. Jakobi, Harald; Eckhardt, Matthias; Schaper, Wolfgang; Kraus, Ralf; Krautstrunk, Gerhard; Ort, Oswald; Sanft, Ulrich; Thenessen, Maria-Theresia; Benin, Werner (Bayer Aktiengesellschaft, Germany). PCT Int. Appl. WO 9956979 A1 19991111, 99 pp. DESIGNATED STATES: W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HR, HU, ID, IL, IN, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, NL, PT, SE, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG (English). CODEN: PIXD2. APPLICATION: WO 1999-EP3126 19990506. PRIORITY: GB 1998-10862 19980520.

GI



AB Title compds. [I; R1 = H, halo, alkyl, haloalkyl, alkoxy, cycloalkyl; R2, R3 = H, (substituted) alkyl, alkenyl, alkynyl, alkoxy, alkylthio, halo, CN, cyano, NO2, etc.; R2R3 atoms to form (substituted) carbocyclyl, heterocyclyl rings; R4, R41 = H, halo, alkyl, haloalkyl, alkoxy, alkylthio; R5 = substituted Ph; q = 0-2; A = CR, D = N+X.1/n Qn-; or A = N, D = N+R.1/n Qn-; or A = CR, N and D = N; or A = N+R.1/n Qn- and D = N; R = CHRETHAR9; R6 = H, halo, alkyl, cyano; R7 = H, halo cyano, NO2, alkoxycarbonyl, alkylaminocarbonyl, etc.; R8 = H, cyano, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, etc.; Z = bond, imino, O, S, SO, SO2, etc.; Qn- = (in)organic anion; n = 1-4; X is NR, O, S, SO, SO2], were prepared Thus, 5-chloro-6-ethylpyrimidine, cis-4-(4-hydroxyphenyl)cyclohexylamine, and Et3N were heated in DMF at 85° for 7 h to give 5-chloro-6-ethyl-4-[cis-4-(4-hydroxyphenylcyclohexylamine]pyrimidine. The latter at 700 ppm gave 90-100% control of tetranychus urticae in bean plants.

IT 1099588-53-0 1099589-39-5 1129624-22-1
1129624-30-1 1129624-34-5 1129624-38-9
1129624-45-9 1129624-95-8 1129625-32-6
1129625-43-9 1129627-11-7 1129627-49-1
1129627-71-9
RL: PRPH (Prophetic)
(Preparation of arylcyclohexylaminopyrimidines and related compounds as pesticides)

RN 1099588-53-0 CAPLUS

L29 ANSWER 29 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN 4-Pyrimidinamine, 5-chloro-6-ethyl-N-[cis-4-(4-propoxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 1099589-39-5 CAPLUS
CN Phenol, 4-[cis-4-[[5-bromo-6-ethyl-4-pyrimidinyl)amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 1129624-22-1 CAPLUS
CN Pyrimidinium, 1-[2-[4-(benzoyloxy)phenyl]-2-oxoethyl]-5-chloro-6-ethyl-4-[[cis-4-[4-hydroxyphenyl)cyclohexyl]amino]-, bromide (1:1) (CA INDEX NAME)

Relative stereochemistry.



● Br⁻

L29 ANSWER 28 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 1129624-30-1 CAPLUS
CN Pyrimidinium, 1-[(benzoyloxy)methyl]-5-chloro-6-ethyl-4-[[cis-4-[4-hydroxyphenyl)cyclohexyl]amino]-, iodide (1:1) (CA INDEX NAME)

Relative stereochemistry.



● I⁻

RN 1129624-34-5 CAPLUS
CN Pyrimidinium, 5-chloro-1-[2-[4-(2,2-dimethyl-1-oxopropoxy)phenyl]-2-oxoethyl]-6-ethyl-4-[[cis-4-[4-hydroxyphenyl)cyclohexyl]amino]-, bromide (1:1) (CA INDEX NAME)

Relative stereochemistry.



● Br⁻

RN 1129624-38-9 CAPLUS
CN Pyrimidinium, 5-chloro-6-ethyl-4-[[cis-4-(4-hydroxyphenyl)cyclohexyl]amino]-1-[2-[4-(2-methyl-1-oxopropoxy)phenyl]-2-oxoethyl]-, bromide (1:1) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 29 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● Br⁻

RN 1129624-88-3 CAPLUS
CN Pyridinium, 1-[2-[2-(benzoyloxy)phenyl]-2-oxoethyl]-5-chloro-6-ethyl-4-[[cis-4-(4-hydroxyphenyl)cyclohexyl]amino]-, bromide (1:1) (CA INDEX NAME)

Relative stereochemistry.

● Br⁻

RN 1129624-93-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.

L29 ANSWER 28 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● I⁻

RN 1129625-32-6 CAPLUS
CN Pyridinium, 5-chloro-6-ethyl-4-[[cis-4-(4-hydroxyphenyl)cyclohexyl]amino]-1-[[4-(1-oxopropoxy)phenyl]methyl]-, bromide (1:1) (CA INDEX NAME)

Relative stereochemistry.



● Br⁻

RN 1129625-43-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.

L29 ANSWER 28 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

● Br⁻

RN 1129627-71-7 CAPLUS
CN Pyridinium, 1-[2-[3-(benzoyloxy)phenyl]-2-oxoethyl]-5-chloro-6-ethyl-4-[[cis-4-(4-hydroxyphenyl)cyclohexyl]amino]-, bromide (1:1) (CA INDEX NAME)

Relative stereochemistry.



● Br⁻

RN 1129627-49-1 CAPLUS
CN Pyridinium, 5-chloro-6-ethyl-4-[[cis-4-[4-hydroxyphenyl)cyclohexyl]amino]-2-[2-oxo-2-[4-(trifluoromethoxy)phenyl]ethyl]-, bromide (1:1) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 28 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

● Br⁻

RN 1129627-71-9 CAPLUS
CN Pyridinium, 1-[2-[4-(benzoyloxy)-2,5-dichlorophenyl]-2-oxoethyl]-5-chloro-6-ethyl-4-[[cis-4-(4-hydroxyphenyl)cyclohexyl]amino]-, bromide (1:1) (CA INDEX NAME)

Relative stereochemistry.

● Br⁻

IT 250706-96-8P 250707-06-9P 250707-08-5P
250707-09-6P 250707-10-9P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylcyclohexylaminopyrimidines and related compds. as pesticides)
RN 250706-96-8 CAPLUS
CN Phenol, 4-[cis-4-[[5-chloro-6-ethyl-4-pyrimidinyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 28 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 256707-06-3 CAPLUS
CN Phenol, 4-[cis-4-[[5-bromo-6-chloro-4-pyrimidinyl)amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 256707-08-5 CAPLUS
CN Phenol, 4-[cis-4-[[6-ethyl-4-pyrimidinyl)amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 256707-09-6 CAPLUS
CN Phenol, 4-[cis-4-[[5-chloro-6-methyl-4-pyrimidinyl)amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 29 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1999:220202 Document No. 130:237396G Substituted triazines for use as pest control agent and fungicides. Schaper, Wolfgang; Braun, Ralf, Jakobi, Harald; Krautstrunk, Gerhard; Maerkl, Martin; Ort, Oswald; Stark, Herbert; Kern, Manfred; Sanft, Ulrich; Bonin, Werner (Hoechst Schering AgrEvo G.m.b.H., Germany). Ger. Offen. DE 19741654 A1 19990325, 28 pp. (German). CODEN: GWXXBX. APPLICATION: DE 1997-19741654 19970922.

GI

AB Triazines I [R1, R2 = H, alkyl, cycloalkyl, haloalkyl, halocycloalkyl, halo, alkoxyalkyl, alkenyl, alkynyl, cyanoalkyl; X = O, NH; Q = (un)substituted carbocycle, heterocycle] were prepared ZTna, 2,4-dichloro-6-methyl-1,3,5-triazine was treated with cis-4-tert.-butylcyclohexylamine to give the 2-(cis-4-tert.-butylcyclohexylamino) derivative which was dehalogenated over Pd. I [XQ = cis-4-tert.-butylcyclohexylamino, R1 = Et, R2 = H] at 300 ppm gave 290% control of Tetranychus urticae on beans.
IT 1098985-77-3 1098986-22-1 1098986-32-3
RL: PEP (Prophetic)
(Substituted triazines for use as pest control agent and fungicides)
RN 1098985-77-3 CAPLUS
CN 1,3,5-Triazin-2-amine, 4-ethylhexahydro-N-[4-[4-(1-methylethoxy)phenyl]cyclohexyl]- (CA INDEX NAME)

RN 1098986-22-1 CAPLUS
CN 1,3,5-Triazin-2-amine, N-[4-(4-methoxyphenyl)cyclohexyl]-4-ethylhexahydro- (CA INDEX NAME)

L29 ANSWER 28 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 256707-10-9 CAPLUS
CN Phenol, 4-[cis-4-[(2,5-dichloro-6-ethyl-4-pyrimidinyl)amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



IT 149506-77-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of arylcyclohexylaminopyrimidines and related compds. as pesticides)
RN 149506-77-4 CAPLUS
CN Phenol, 4-(cis-4-aminocyclohexyl)- (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 29 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1098986-32-3 CAPLUS
CN 1,3,5-Triazin-2-amine, 4-ethylhexahydro-N-[4-(4-methoxyphenyl)cyclohexyl]- (CA INDEX NAME)



L29 ANSWER 30 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1999:19702 Document No. 130:214032 Preparation of acylphenylcycloalkylaminoalkylpiperidines and related compounds as ala adrenergic receptor antagonists.. Patane, Michael A.; Bock, Mark G. (Merck & Co., Inc., USA). PCT Int. Appl. WO 9857639 A1 19981223 , 83 pp. DESIGNATED STATES: W. AL, AM, AT, AU, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AL, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1998-US12659 19980617. PRIORITY: US 1997-50137 19970618; GB 1998-416 19980109.

GI



AB Title compds. [I; R = H, cyano, CR7, CO2R7, SO2R7, tetrazolyl, isoxazolinonyl, [substituted] Ph, thienyl, pyridyl, furyl, naphthyl; R1 = [substituted] Ph, pyridyl, pyrazinyl, thienyl, thiazolyl, furyl, quinazolinyl, thiazolyl, naphthyl, etc.; R2, R3, R4 = H, alkyl, cycloalkyl, [CH2]0-4CO2R7, [CH2]0-4OR7, [CH2]1-4CN, [CH2]1-4CF3, etc.; R4 = H, COR7, [CH2]0-4CF3, [CH2]0-4CN, [CH2]0-4CO2R17, etc.; R5 = H, alkyl, cycloalkyl, [CH2]1-4OR7, [CH2]0-4CF3, R7 = H, alkyl, cycloalkyl, [CH2]1-4CF3; R8-R10 = H, alkyl, cycloalkyl, [CH2]2-4OR7, [CH2]0-4CF3; R13 = H, alkyl, cycloalkyl, [CH2]2-4OR7, OR7, [CH2]0-4CF3; R14-R16 = H, alkyl, cycloalkyl, [CH2]2-4OR7, [CH2]0-4CF3; R17 = H, alkyl, cycloalkyl, [CH2]1-4CF3; X, Q, L, M = H, alkyl, cycloalkyl, [CH2]0-4OR7, [CH2]0-4CF3, [CH2]0-4CO2R7, etc.; R26 = H, OR28; R28 = H, alkyl, cycloalkyl, [CH2]0-4OR7, [CH2]0-4CF3; J = H, alkyl, cycloalkyl, [CH2]1-4OR7,

L29 ANSWER 31 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1999:9695 Document No. 130:215070 Preparation of N-cycloalkylaminoalkyl oxazolidonecarboxamides and related compounds as ala adrenergic receptor antagonists.. Patane, Michael A.; Bock, Mark G.; Nagarathnam, Dhanapalan; Lagu, Bharat; Wang, Wei C. (Merck & Co., Inc., USA; Synaptic Pharmaceutical Corporation). PCT Int. Appl. WO 9857632 A1 19981223, 94 pp. DESIGNATED STATES: W. AL, AM, AT, AU, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GN, GR, IE, IT, LU, MC, ML, MR, NE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1998-US12573 19980617. PRIORITY: US 1997-50136 19970618; GB 1998-219 19980107.

GI

AB Title compds. [I; Q = Q1, Q2, etc.; X, Q, L, M = H, alkyl, cycloalkyl, [CH2]0-4OR15, [CH2]0-4CN, [CH2]0-4CF3, etc.; J = H, alkyl, cycloalkyl, [CH2]0-4OR15, [CH2]1-4CN, [CH2]0-4CF3, etc.; R = H, cyano, OR15, CO2R15, tetrazolyl, [substituted] Ph, pyridyl, thienyl, furyl, naphthyl; R1 = [substituted] Ph, pyridyl, pyrazinyl, thienyl, furyl, naphthyl, etc.; R2, R7 = H, alkyl, cycloalkyl, [CH2]1-4CN, [CH2]2-4CONR15, etc.; R3, R6 = H, alkyl, cycloalkyl, [CH2]1-4OR15, [CH2]0-4CF3; R15 = H, alkyl, cycloalkyl, [CH2]0-4CF3; R = halo, cyano, NO2, alkyl, cycloalkyl, [CH2]0-4CF3, etc.; n, p, q = 0-4], were prepared as selective relaxants of smooth muscle tissue enriched in the ala receptor subtype (e.g. urethral tissue) without inducing hypotension (no data). Thus, 1-[(2-aminoethyl)amino]-4-cyano-4-phenylcyclohexane and 4-nitrophenyl 4-(3,4,5-trifluorophenyl)-2-oxooxazolidine-3-carboxylate were stirred 2 h in THF to give (+)-2-oxo-4-[3,4,5-trifluorophenyl]oxazolidine-3-carboxylic acid [2-[4-cyano-4-phenylcyclohexylamino]ethyl]amide.

IT 218789-71-0P 218789-74-5P 218932-09-1P

L29 ANSWER 32 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
[CH2]1-4CN, [CH2]0-4CF3, [CH2]0-4CO2R17, etc.; Q = Q1, Q2, etc.; X = halo, cyano, NO2, alkyl, cycloalkyl, [CH2]0-4OR17, [CH2]0-4CF3; n, p, q1 = 0-2; n, n2, q = 0-4;], were prepd. as selective relaxants of smooth muscle tissue enriched in the ala receptor subtype without at the same time inducing hypotension (no data). Thus, 4-nitrophenyl 4-(3,4-difluorophenyl)-2-oxooxazolidine-3-carboxylate and tert-Bu (4-cyano-4-phenylcyclohexyl)piperidin-4-ylcarbamate were stirred 12 h in THF to give 4-[3-[4-(3,4-difluorophenyl)-2-oxooxazolidine-3-carbonyl]piperidin-4-ylamino]-1-phenylcyclohexanecarbonitrile.

IT 218605-64-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of acylphenylcycloalkylamino/piperidines and related compds. as ala adrenergic receptor antagonists.)

RN 218605-64-0 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[1-(diphenylmethyl)-3-azetidinyl]methylamino]-1-(2-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 33 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-cycloalkylaminoalkyl oxazolidonecarboxamides and related compds. as ala adrenergic receptor antagonists)

RN 218789-71-0 CAPLUS
CN 3-Oxazolidinecarboxamide, N-[2-[(cis-4-cyano-4-[2-ethoxyphenyl)cyclohexyl]amino]ethyl]-4-(3,4-difluorophenyl)-2-oxo-, (4S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 218789-74-5 CAPLUS
CN 3-Oxazolidinecarboxamide, N-[2-[(cis-4-cyano-4-[2-methoxyphenyl)cyclohexyl]amino]ethyl]-4-(3,4-difluorophenyl)-2-oxo-, hydrochloride (1:1), (4S)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 218932-09-1 CAPLUS
CN 3-Oxazolidinecarboxamide, N-[2-[(cis-4-cyano-4-[2-ethoxyphenyl)cyclohexyl]amino]ethyl]-4-(3,4-difluorophenyl)-2-oxo-, hydrochloride (1:1), (4S)- (CA INDEX NAME)

L29 ANSWER 31 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Absolute stereochemistry. Rotation (+).



● HCl

IT 218790-61-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-cyclohexylaminoalkyl oxazolidonecarboxamides and related
compds. as ala adrenergic receptor antagonists)
RN 218790-61-5 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[2-aminoethyl]amino]-1-[2-methoxyphenyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.



IT 218790-58-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-cyclohexylaminoalkyl oxazolidonecarboxamides and related
compds. as ala adrenergic receptor antagonists)
RN 218790-58-0 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[2-aminoethyl]amino]-1-(2-ethoxyphenyl)-, cis-
(CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 32 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1998:386301 Document No. 129:2831150 Original Reference No. 129:585a,586a
Liquid-crystal compound with high negative dielectric anisotropy, its composition, and display device using it. Yamada, Keiro; Yano, Hitoshi (Chisso Corp., Japan). Jpn. Kokai Tokkyo Koho JP 10237035 A
19980908 Heisei, 26 pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 1997-58457 19970220.

GI

I

AB The title compound has -CH:N- and/or -N:CH-, trans-cyclohexane-1,4-diyl, and
halophenylene I (W1, W2 = F, Cl; atoms in the compound may be substituted by
isotopes) in the structure. The liquid-crystal composition containing 21 of
the above compound and composed of 22 components and the display
device using the composition are also claimed. The compound has low viscosity
and controlled optical anisotropy.
IT 213844-44-1P
RL: PNU (Preparation, unclassified); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(in preparation of liquid-crystal compound having high neg. dielec. anisotropy
for display device)
RN 213844-44-1 CAPLUS
CN Cyclohexanamine, 4-(2,3-difluoro-4-propoxyphenyl)-, trans- (CA INDEX NAME)

Relative stereochemistry.



n-PrO

L29 ANSWER 33 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L29 ANSWER 33 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1998:394035 Document No. 129:410770 Original Reference No. 129:863a,864a
Preparation of N-aralkyl-2-(substituted-aryl)indole-3-alkanamines and analogs as gonadotropin releasing hormone antagonists. Goulet, Mark; Chu,
Lin; Ashton, Wallace T.; Fisher, Michael H.; Wyvratt, Matthew J.; Smith, Roy G.; Hoplamel, Robert L.; Pongipon, Mutree M.; Yang, Yi Tien; Lin, Peter (Merck and Co., Inc., USA). U.S. US 5756507 A 19980526, 53 pp. (English). CODEN: USXXAM. APPLICATION: US 1996-760851 19961205.

GI



II

AB Title compds. I [R = H, (ar)alkyl, aryl, etc.; R4 = (CR9R9)mCR10R10aNR2SR1; R1 = (un)substituted Ph, -naphthyl, -biphenylyl, etc.; R2 = H, (ar)alkyl, aryl, etc.; R3 = Ph with 2-3 substituents; R5 = H, halo, OR7, OR8, NR7R8, COR7, COR8, etc.; R6 = H, halo, (perfluoro)alkyl, aryl, etc.; R7 = H or (un)substituted alkyl; R8 = H, OCOR derivs., NR1 or derivs., etc.; R9, R9a = H, (ar)alkyl, aryl, etc., R10, R10a = H, (ar)alkyl, aryl, etc.; X = (un)substituted alk(en/yn)ylene, etc.; NR2S = heterocyclene; m = 0-3] and their pharmaceutically acceptable
salts are antagonists of GnRH (gonadotropin releasing hormone), and are useful for the treatment of a variety of sex-hormone-related and other conditions in both men and women (no data). Almost 300 invention compds. were prepared and/or claimed. For instance, sulfation of
3-(4-hydroxyphenyl)propionic acid with
2-[2-(3,4-dimethoxyphenyl)-1H-indol-3-yl]ethylamine using EDC and HOBt gave title compound II.
IT 192772-29-5P 192772-30-8P 192772-95-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-aralkyl-2-arylindole-3-alkanamines and analogs as gonadotropin releasing hormone antagonists)
RN 192772-29-5 CAPLUS
CN Phenol, 4-[cis-4-[[2-(3,4-dimethoxyphenyl)-1H-indol-3-yl]ethyl]aminolcyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 33 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 192772-30-8 CAPLUS
CN Phenol, 4-[trans-4-[[2-[2-(3,4-dimethoxyphenyl)-1H-indol-3-yl]ethyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 192772-95-5 CAPLUS
CN Phenol, 4-[4-[[2-[2-(3,5-dimethylphenyl)-1H-indol-3-yl]ethyl]amino]cyclohexyl]- (CA INDEX NAME)





L29 ANSWER 33 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

L29 ANSWER 34 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1997:516361 Document No. 127:1216330 Original Reference No. 127:23461a,23464a Preparation of N-aralkyl-2-arylindole-3-alkanamines and analogs as gonadotropin releasing hormone antagonists. Goulet, Mark; Bugianesi, Robert L.; Ashton, Wallace T.; Chu, Lin; Fisher, Michael H.; Lin, Peter; Smith, Roy G.; Ponpipom, Mitree M.; Wyvratt, Matthew J.; Yang, Yi Tien (Merck & Co., Inc., USA; Goulet, Mark; Bugianesi, Robert L.; Ashton, Wallace T.; Chu, Lin; Fisher, Michael H.; Lin, Peter; Smith, Roy G.; Ponpipom, Mitree M.; et al.). PCT Int. Appl. WO 9721435 A1 19970619, 147 pp. DESIGNATED STATES: W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1996-US20004 19961210. PRIORITY: US 1995-8632 19951214; GB 1996-3370 19960216.
GI


I


II

AB Title compds. [I; R = H, (ar)alkyl, aryl, etc.; R3 = (un)substituted Ph; R4 = (CR9R9a)m CR10R10aNR2ZR1; R1 = (un)substituted Ph, -naphthyl, -biphenylyl, etc.; R2 = H, (ar)alkyl, aryl, etc.; R5 = H, halo, OR7, OR8, NR7R8, COR7, COR8, etc.; R6 = H, halo, (perfluoro)alkyl, aryl, etc.; R7 = H or (un)substituted alkyl; R9,R9a = H, (ar)alkyl, aryl, etc.; R10,R10a = H, (ar)alkyl, aryl, etc.; Z = (un)substituted alk(en)ylene, etc.; NR2Z = heterocyclene; m = 0-3] were prepared as gonadotropin releasing hormone antagonists (no data). Thus, indole-3-ethanamine was N-protected and the brominated product arylated with 3,5-Me2C6H3B(OH)2 to give, after deprotection, 2-(3,5-dimethylphenyl)indole-3-ethanamine which was condensed with 3-benzyloxyphenyl glycidyl ether to give, after deprotection, title compound II.
IT 192772-29-5P 192772-30-8P 192772-95-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-aralkyl-2-arylindole-3-alkanamines and analogs as gonadotropin releasing hormone antagonists)
RN 192772-29-5 CAPLUS
CN Phenol, 4-[cis-4-[[2-[2-(3,4-dimethoxyphenyl)-1H-indol-3-yl]ethyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 34 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 192772-30-8 CAPLUS
CN Phenol, 4-[trans-4-[[2-[2-(3,4-dimethoxyphenyl)-1H-indol-3-yl]ethyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 192772-95-5 CAPLUS
CN Phenol, 4-[4-[[2-[2-(3,5-dimethylphenyl)-1H-indol-3-yl]ethyl]amino]cyclohexyl]- (CA INDEX NAME)





L29 ANSWER 35 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1997:163162 Document No. 126:239010 Original Reference No. 126:46085a,46085a Preparation of novel phenylcycloheaeene-yildene derivatives for treating inflammatory diseases and inhibiting production of tumor necrosis factor. Christensen, Siegfried B., IV; Forster, Cornelia J. (SmithKline Beecham Corporation, USA). U.S. US 5605923 A 19970225, 16 pp., Cont.-in-part of U.S. Ser. No. 968,761, abandoned. (English). CODEN: USXAAM. APPLICATION: US 1994-352093, 19941209. PRIORITY: US 1992-821113 19920401; US 1992-968761 19921030; WO 1993-US9516 19931005.

GI

AB The title compds. [I; R1 = (CR4R5)nC(O)O(CR4R5)mR6, (CR4R5)nC(O)NR4(CR4R5)mR6; wherein R4, R5 = H, C1-2 alkyl; R6 = H, Me, OR, etc.; n = 0-2; m = 1-4), etc.; X = halo, NO2, NR4R5, etc.; R2 = O, NR8 (wherein R8 = H, C1-4 alkyl); R7 = H, X; R2 = Me, Et optionally substituted by 1 or more halogens; R3 = CN, C(:S)NH2, S = CH2, NH, OC1-6 alkyl, etc.; s = 0-4), useful for inhibiting the production of Tumor Necrosis Factor, and enzymic or catalytic activity of phosphodiesterase IV, and in the treatment of an allergic or inflammatory disease state, were prepared Thus, treatment of 4-cyano-4-[3-cyclopentyloxy-4-methoxyphenyl]cyclohexan-1-one with NaBH4 in 2,2-dimethoxethane afforded 79% cis-I [R1 = cyclopentyl; X2 = O; X = MeO; X3, X5, R2 = H; R3 = CN; I = OH] and 20% trans-I. Compds. I are effective at 0.01-40 mg/kg/day.

IT 154284-41-0P 154284-42-1P 154284-51-2P
154284-60-7P 154284-62-5P 154284-64-7P
154284-66-9P 154284-69-2P 154284-70-5P
154284-71-6P 154284-72-7P 154284-73-8P
154284-74-9P 154284-84-1P 154284-85-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel phenylcycloheaeene-yildene deriva. for treating inflammatory diseases and inhibiting production of tumor necrosis factor)

RN 154284-41-0 CAPLUS
CN Cyclohexanecarbonitrile, 4-amino-1-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 35 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 154284-42-1 CAPLUS
CN Cyclohexanecarbonitrile, 4-amino-1-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.

RN 154284-51-2 CAPLUS
CN Urea, [4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 35 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 154284-60-7 CAPLUS
CN Acetamide, N-[4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 35 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 154284-62-5 CAPLUS
CN Acetic acid, [[4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexyl]amino]oxo-, methyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 35 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 154284-64-7 CAPLUS
CN Ethanediamide, [4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 154284-66-9 CAPLUS
CN Acetic acid, [[4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexyl]amino]oxo-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 154284-69-2 CAPLUS
CN Cyclohexanecarbonitrile, 1-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-(hydroxyamino)-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 33 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 154284-79-5 CAPLUS
CN Cyclohexanecarbonitrile, 1-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-(hydroxyamino)-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 154284-71-6 CAPLUS
CN Cyclohexanecarbonitrile, 1-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-4-(hydroxyamino)-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 34 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 154284-74-9 CAPLUS
CN Cyclohexanecarbonitrile, 1-[3-[(4-fluorophenyl)methoxy]-4-methoxyphenyl]-4-(hydroxyamino)-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 154284-84-1 CAPLUS
CN Cyclohexanecarbonitrile, 4-amino-1-[3-(cyclopentyloxy)-4-methoxyphenyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 35 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 154284-72-7 CAPLUS
CN Cyclohexanecarbonitrile, 1-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-4-(hydroxyamino)-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 154284-73-8 CAPLUS
CN Cyclohexanecarbonitrile, 1-[3-[(4-fluorophenyl)methoxy]-4-methoxyphenyl]-4-(hydroxyamino)-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 36 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 154284-85-2 CAPLUS
CN Cyclohexanecarbonitrile, 4-amino-1-[3-(cyclopentyloxy)-4-methoxyphenyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 36 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1997:113375 Document No. 126:113788Z Original Reference No. 126:22777a,22780a Preparation of 4,4-(disubstituted)cyclohexan-1-ols monomers and related compounds as antiallergic and antiinflammatory agents, and the production of Tumor Necrosis Factor (TNF) inhibitors. Christensen, Siegfried B., Iv; Karpinski, Joseph M.; Ryan, M. Dominic; Bender, Paul E. (Smithkline Beecham Corporation, USA; Christensen, Siegfried B., Iv; Karpinski, Joseph M.; Ryan, M. Dominic; Bender, Paul E.) PCT Int. Appl., WO 9628150 A1 19960919, 79 pp. DESIGNATED STATES: W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1996-US2480 19960220. PRIORITY: US 1995-405866 19950321.

GI



AB The title compds. [I; R1 = (CR4R5)mC(O)O(CR4R5)mR6 (wherein R4, R5 = H, C1-2 alkyl; R6 = H, Me, OH, etc.; m = 0-2; m = 1-4), (CR4R5)mC(O)NR4(CR4R5)mR6, etc.; R2 = Me, Et (optionally substituted by 1 or more halogens); R3 = COOH, N-disubstituted C(O)NR2, etc.; R = F, NR4R5, formyl amine, OR2, S(O)n*R2 (wherein n* = 0-2); X2 = O, (un)substituted NR; X3 = N, X; W = C1-6 alkyl, C1-6 alkenyl, C1-6 alkynyl; Y = CH, NH, etc.; z = 0-4], useful in treating asthma, allergy and inflammatory diseases, and for inhibiting the production of Tumor Necrosis Factor (TNF), were prepared. Thus, reaction of trans-[4-[3-cyclopentyloxy-4-methoxyphenyl]-1-(2-propyldiethyl)cyclohexan-1-ol] with 2-bromopyridine in the presence of Pd(PPh3)4, CuI, PPh3 in piperidine afforded 84% the title compound cis-II. In general, compds. I demonstrated a pos. in vivo response in reducing serum levels of TNF induced by the injection of endotoxin.

IT 180529-49-1P 180529-50-4P 180529-53-7P
180529-54-8P 186186-46-7P 186186-47-0P
186186-48-1P 186186-49-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L29 ANSWER 36 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 180529-54-8 CAPLUS
CN Formamide, N-[4-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-(2-pyridinylethyl)cyclohexyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 186186-44-7 CAPLUS
CN Cyclohexanamine, 4-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-[2-[5-(5-methyl-1,2,4-oxadiazol-2(3H)-yl)-2-thienyl]ethynyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 186186-45-8 CAPLUS
CN Sulfamic acid, N-cyclohexyl-, trans-compd. with 4-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-[2-[5-(5-methyl-1,2,4-oxadiazol-

L29 ANSWER 36 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(prepn. of 4,4-(disubstituted)cyclohexan-1-ols monomers and related compds. as antiallergic and antiinflammatory agents, and the prodn. of Tumor Necrosis Factor (TNF) inhibitors)

RN 180529-49-1 CAPLUS
CN Cyclohexanamine, 4-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-[2-pyridinylethynyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180529-50-4 CAPLUS
CN Formamide, N-[4-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-(2-pyridinylethynyl)cyclohexyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180529-53-7 CAPLUS
CN Cyclohexanamine, 4-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-[2-pyridinylethynyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 36 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
2(3H)-yl)-2-thienyl]ethynyl]cyclohexanamine (1:1) (CA INDEX NAME)

CM 1

CRN 186186-44-7
CMF C27 H33 N3 O3 S

Relative stereochemistry.



CM 2

CRN 100-88-9
CMF C6 H13 N O3 S

RN 186186-46-9 CAPLUS
CN Cyclohexanamine, 4-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-[2-[5-(5-methyl-1,2,4-oxadiazol-2(3H)-yl)-2-thienyl]ethynyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 186186-47-0 CAPLUS
CN Sulfamic acid, N-cyclohexyl-, cis-compd. with

L29 ANSWER 36 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
4-[3-(cyclopentyloxy)-4-methoxyphenyl]-6-[2-[5-(5-methyl-1,2,4-oxadiazol-2(3H)-yl)-2-thienyl]ethyl]cyclohexanamine (1:1) (CA INDEX NAME)

CM 1

CRN 186186-46-9
CMF C27 H33 N3 O3 S

Relative stereochemistry.



CM 2

CRN 1Q0-88-9
CMF C6 H13 N O3 S

IT 180529-92-4P 180529-95-7P 180529-97-9P
180529-98-0P 180682-87-5P 186186-50-5P
186186-51-6P
RL: BCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 4,4-(disubstituted)cyclohexan-1-ols monomers and related
compds. as antiallergic and antiinflammatory agents, and the production of
Tumor Necrosis Factor (TNF) inhibitors)
RN 180529-92-4 CAPLUS
CN Cyclohexanamine, 4-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-ethynyl-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 36 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 180682-87-5 CAPLUS
CN Cyclohexanamine,
4,4'-(1,3-butadiyne-1,4-diyl)bis[4-[3-(cyclopentyloxy)-4-methoxyphenyl]-, (4S)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 186186-50-5 CAPLUS
CN Carbamic acid, [4-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-[[5-(5-methyl-1,2,4-oxadiazol-2(3H)-yl)-2-thienyl]ethynyl]cyclohexyl]-, 1,1-dimethylethyl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 36 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 180529-95-7 CAPLUS
CN Carbamic acid, [4-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-(2-pyridinylethynyl)cyclohexyl]-, 1,1-dimethylethyl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180529-97-9 CAPLUS
CN Cyclohexanone, 4-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-ethynyl-, trans-
(CA INDEX NAME)

Relative stereochemistry.



RN 180529-98-0 CAPLUS
CN Carbamic acid, [4-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-ethynylcyclohexyl]-, 1,1-dimethylethyl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 36 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 186186-51-6 CAPLUS
CN Carbamic acid, [4-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-[[5-(5-methyl-1,2,4-oxadiazol-2(3H)-yl)-2-thienyl]ethynyl]cyclohexyl]-, 1,1-dimethylethyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 37 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1997:88770 Document No. 126:104015O Original Reference No.
126:20069a,20072a
Preparation of substituted 2,3-cycloalkanopyridines as pesticides and fungicides.. Jakobi, Harald; Schaper, Wolfgang; Preuss, Rainer; Braun, Peter; Sachse, Burkhard; Luemmen, Peter (Hoechst Schering AgrEvo GmbH, Germany; Jakobi, Harald; Schaper, Wolfgang; Preuss, Rainer; Braun, Peter; Sachse, Burkhard; Luemmen, Peter). PCT Int. Appl. WO 9637473 A1 19961128, 74 pp. DESIGNATED STATES: W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (German). CODEN: PIXXD2.
APPLICATION: WO 1995-EP2006 19950523.
GI


I

AB Title compds. [I; Q = (CR5R6)n; n = 1-8; R1 = H, (substituted) alkyl, alkoxy, cycloalkoxy, alkylthio, alkylsulfinyl, alkysulfonyl, cycloalkyl, acyl, Ph, PhO; R2 = H, alkyl, cycloalkyl, alkoxy, cycloalkoxy, acyl, CO2H, CN, halo; R1R2 = CH2(CH2)mCH2; m = 1-3; R3-R8 = H, alkyl, alkoxy, cycloalkoxy, alkylthio, (substituted) cycloalkyl, haloalkyl, haloalkoxy, Ph, alkoxycarbonyl, CO2H, halo, CN, haloalkoxycarbonyl, PhO, PhS; vicinal or geminal pairs of R3-R8 = atoms to form 5-6 membered rings; X = O, S, (substituted) imino; YZ = (heteroatom-interrupted) aliphatic residue, or Y = bond, (substituted) bivalent residue and Z = (substituted) aryl, aryloxy, cycloalkyl, cycloalkenyl], were prepared Thus, 4-chloro-5,6,7,8-tetrahydroquinoline and cis-4-tert-amylcyclohexylamine were heated with catalytic NH4Cl at 170° for 7 h to give 4-(cis-4-tert-amylcyclohexylamino)-5,6,7,8-tetrahydroquinoline. The latter as a 250 mg/L spray gave complete control of Botrytis cinerea on bean plants.

IT 168086-38-2P 168086-42-8P 168086-43-9P 168086-48-4P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted 2,3-cycloalkanopyridines as pesticides and fungicides)

RN 168086-38-2 CAPLUS
CN 4-Quinolinamine, 5,6,7,8-tetrahydro-N-[4-[4-(1-methylethoxy)phenyl]cyclohexyl]-, cis- (9CI) (CA INDEX NAME)

L29 ANSWER 37 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
Relative stereochemistry.



RN 168086-42-8 CAPLUS
CN 4-Quinolinamine, 5,6,7,8-tetrahydro-2-methyl-N-[4-[4-(1-methylethoxy)phenyl]cyclohexyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 168086-43-9 CAPLUS
CN 4-Quinolinamine, 5,6,7,8-tetrahydro-2-methyl-N-[4-[4-(1-methylethoxy)phenyl]cyclohexyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 37 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 168086-48-4 CAPLUS
CN 4-Quinolinamine, N-[4-(4-ethoxyphenyl)cyclohexyl]-5,6,7,8-tetrahydro-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 38 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1996:531791 Document No. 125:195045O Original Reference No.
125:36527a,36530a 4,4-(Disubstituted)cyclohexan-1-ol derivatives useful as PDE IV and TNF inhibitors. Christensen, Siegfried B., IV; Karpinski, Joseph M.; Ryan, M. Dominic; Bender, Paul E. (Smithkline Beecham Corporation, USA). PCT Int. Appl. WO 9619988 A1 19960704, 45 pp. DESIGNATED STATES: W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, PT, RO, RU, SD, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2.
APPLICATION: WO 1995-US16711 19951221. PRIORITY: US 1994-363506 19941223.
GI


I


II

AB The invention relates to novel 4,4-disubstituted cyclohexan-1-ol derivs. I [R1 = various sidechains; X = YR2, F, (un)substituted NH2; Y = O, S(O)m; m = 0, 1, 2; X2 = O, (un)substituted NH; X3 = H, as given for X; R2 = (poly)(halo)methyl or -ethyl; s = 0-4; W = alk(en/yn)yl; R3 = CO2H or esters or amides, (hetero)aryl(alkyl), etc.; Z = OH, SH, NH2, and their derivs.; with provisos]. The compds. are useful for treating allergic and inflammatory diseases (especially asthma), for inhibiting the production of tumor necrosis factor (TNF), as antivirals and antifungals, and for reducing toxicity of antimicrobials such as amphotericin B (no data). For example, 4-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-ethynylcyclohexan-1-one was reduced by NaBH4, and the resulting cis- and trans-cyclohexanol derivs. were separated by flash chromatog. The trans-isomer was coupled with 4-bromopyridine using Pd(PPh3)4 and CuI to give title compound II. Prepns. of addnl. I and several related 3,3-disubstituted cyclohexanone derivs. are given.

IT 180530-06-7P 180682-87-5P
RL: BYP (Byproduct); PREP (Preparation)
(byproduct; preparation of cyclohexanol derivs. as PDE IV and TNF inhibitors)

RN 180530-06-7 CAPLUS
CN Cyclohexanamine, 4,4'-(1,3-butadiyne-1,4-diyl)bis[4-[3-(cyclopentyloxy)-4-methoxyphenyl]-, [trans(trans)]- (9CI) (CA INDEX NAME)

L29 ANSWER 39 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Relative stereochemistry.



RN 180602-87-5 CAPLUS
CN Cyclohexanamine, 4,4'-[1,7-butadiyne-1,4-diyl]bis[4-[3-(cyclopentyloxy)-4-methoxyphenyl]-, (cis,cis)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 180529-92-4P 180529-94-6P 180529-95-7P
180529-96-8P 180529-97-9P 180529-98-0P
180529-99-1P 180530-00-1P 180530-03-4P

L29 ANSWER 39 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 180529-96-8 CAPLUS
CN Carbamic acid, [4-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-[[5-(5-methyl-1,2,4-oxadiazol-3-yl)-2-thienyl]ethynyl]cyclohexyl]-, 1,1-dimethylethyl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180529-97-9 CAPLUS
CN Cyclohexanamine, 4-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-ethynyl-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 180529-98-0 CAPLUS
CN Carbamic acid, [4-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-ethynylcyclohexyl]-, 1,1-dimethylethyl ester, trans- (9CI) (CA INDEX NAME)

L29 ANSWER 38 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
180530-04-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate prepn. of cyclohexanol derivs. as PDE IV and TNF inhibitors)
RN 180529-92-4 CAPLUS
CN Cyclohexanamine, 4-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-ethynyl-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 180529-94-6 CAPLUS
CN Carbamic acid, [4-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-ethynylcyclohexyl]-, 1,1-dimethylethyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180529-95-7 CAPLUS
CN Carbamic acid, [4-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-[2-pyridinylethynyl]cyclohexyl]-, 1,1-dimethylethyl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 38 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
Relative stereochemistry.



RN 180529-99-1 CAPLUS
CN Carbamic acid, [4-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-[2-pyridinylethynyl]cyclohexyl]-, 1,1-dimethylethyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180530-00-1 CAPLUS
CN Carbamic acid, [4-[5-(cyclopentyloxy)-4-methoxyphenyl]-4-[[5-[5-methyl-1,2,4-oxadiazol-3-yl]-2-thienyl]ethynyl]cyclohexyl]-, 1,1-dimethylethyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180530-03-4 CAPLUS
CN Carbamic acid, [4-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-[[2-[[(aminocarbonyl)amino]-5-pyrimidinyl]ethynyl]cyclohexyl]-, 1,1-dimethylethyl

L29 ANSWER 29 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180570-04-5 CAPLUS
CN Carbamic acid,
[4-[[2-anino-5-pyrimidinyl)ethynyl]-6-[3-(cyclopentyloxy)-6-
methoxyphenyl]cyclohexyl]-, 1,1-dimethylethyl ester, trans- (9CI) (CA
INDEX NAME)

Relative stereochemistry.



IT 180529-33-7P
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological
study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT
(Reactant or reagent); USES (Uses)

L29 ANSWER 30 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 180529-51-5 CAPLUS
CN Cyclohexanamine, 4-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-[[5-(5-methyl-
1,2,4-oxadiazol-3-yl)-2-thienyl]ethynyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180529-52-6 CAPLUS
CN Sulfamic acid, cyclohexyl-, compd. with
trans-4-[5-[cyclopentyloxy]-4-methoxyphenyl]-4-[[5-(5-methyl-1,2,4-
oxadiazol-3-yl)-2-thienyl]ethynyl]cyclohexanamine (1:1) (9CI) (CA INDEX
NAME)

CM 1

CRN 180529-51-5
CMF C27 H31 N3 O3 S

Relative stereochemistry.

L29 ANSWER 30 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(prepn. of cyclohexanol derivs. as PDE IV and TNF inhibitors)

RN 180529-53-7 CAPLUS
CN Cyclohexanamine, 4-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-[2-
pyridinylethynyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 180529-49-1P 180529-50-4P 180529-51-5P
180529-52-6P 180529-54-8P 180529-55-9P
180529-56-0P 180529-65-1P 180529-66-2P
180529-68-4P
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclohexanol derivs. as PDE IV and TNF inhibitors)
RN 180529-49-1 CAPLUS
CN Cyclohexanamine, 4-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-[2-
pyridinylethynyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180529-50-4 CAPLUS
CN Formamide, N-[4-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-[2-
pyridinylethynyl]cyclohexyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 30 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



CM 2

CRN 100-88-9
CMF C6 H13 N O3 S

RN 180529-54-8 CAPLUS
CN Formamide, N-[4-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-[2-
pyridinylethynyl]cyclohexyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180529-55-9 CAPLUS
CN Cyclohexanamine, 4-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-[[5-(5-methyl-
1,2,4-oxadiazol-3-yl)-2-thienyl]ethynyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 39 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 180529-56-0 CAPLUS
CN Sulfamic acid, cyclohexyl-, compd. with

cis-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-[[5-(5-methyl-1,2,4-oxadiazol-3-yl)-2-thienyl]ethynyl]cyclohexanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 180529-55-9
CMF C27 H31 N3 O3 S

Relative stereochemistry.



CM 2

CRN 100-88-9
CMF C6 H13 N O3 S

L29 ANSWER 39 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CMF C6 H13 N O3 S

RN 180529-68-4 CAPLUS
CN Sulfamic acid, cyclohexyl-, compd. with

cis-5-[[4-amino-1-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexyl]ethynyl]-2-pyrimidinamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 180529-67-3
CMF C24 H30 N4 O2

Relative stereochemistry.



CM 2

CRN 100-88-9
CMF C6 H13 N O3 S

IT 180529-97-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of cyclohexanol deriva. as PDE IV and TNF inhibitors)
RN 180529-97-9 CAPLUS
CN Cyclohexanamine, 4-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-ethynyl-, trans-

L29 ANSWER 38 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 180529-65-1 CAPLUS
CN 2-Pyrimidinamine, 5-[[trans-4-amino-1-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexyl]ethynyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180529-66-2 CAPLUS
CN Sulfamic acid, cyclohexyl-, compd. with trans-5-[[4-amino-1-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexyl]ethynyl]-2-pyrimidinamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 180529-65-1
CMF C24 H30 N4 O2

Relative stereochemistry.



CM 2

CRN 100-88-9

L29 ANSWER 38 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 39 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1996:425252 Document No. 125:963190 Original Reference No. 125:5626a,1628a
Preparation and formulation of N-(4-phenylcyclohexyl)alkanamides and analogs as cholesterol biosynthesis inhibitors. Maier, Roland; Moeller, Peter; Molton, Eberhard; Strnad, Rudolf; Mark, Michael; Risele, Bernhard
Boehringer, Ralph-Michael (Dr. Karl Thomae GmbH, Germany). Ger. Offen. DE 4437999 A1 19960502, 40 pp. (German). CODEN: GWXXBX.
APPLICATION: DE 1994-4437999 19941025.

GI



AB Title compds. [I; R1 = substituted Ph, pyridyl, pyrimidinyl, etc.; Z = (CR2R2)q; R2a-R2b = H, alk(en)yl; R3 = alk(en)yl, alkynyl, Ph, cyclohexyl(methyl); R4 = (O- or S-interrupted) alkyl, alkenyl, phenyl(alkyl), etc.; X = O, S, NPh, NSO2C6H4Me-4; n = 0 or 1] were prepared
Thus, I, e.g., prepared 4-[4-[2-diethylaminoethoxy]-3-methylphenyl]-N-hexanoyl-N-methylcyclohexylamine gave 2504 inhibition of cholesterol biosynthesis in human hepatoma cells at 10-6M in vitro.
IT 178542-14-2P 178542-68-0P 178542-24-6P
178542-15-3P 178542-23-5P 178542-24-6P
178542-25-1P 178542-26-2P 178542-29-5P
178542-30-8P 178542-31-9P 178542-32-0P
178542-33-1P 178542-34-2P 178542-37-5P
178542-38-6P 178542-39-7P 178542-40-0P
178542-41-1P 178542-42-2P 178542-43-3P
178542-46-6P 178542-47-7P 178542-48-8P
178542-49-9P 178542-50-2P 178542-51-3P
178542-52-4P 178542-53-5P 178542-54-6P
178542-56-8P 178542-61-5P 178542-62-6P
178542-63-7P 178542-64-8P 178542-65-9P
178542-66-0P 178737-97-8P 178737-98-9P
178737-99-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and formulation of N-(4-phenylcyclohexyl)alkanamides and analogs as cholesterol biosynthesis inhibitors)
RN 178162-68-0 CAPLUS
CN Cyclohexanamine, 4-[4-methoxy-3-methylphenyl]-N-methyl-, trans- (CA INDEX NAME)

L29 ANSWER 39 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 178542-23-9 CAPLUS
CN Cyclohexanamine, 4-(4-methoxy-3-methylphenyl)-N-pentyl-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 178542-24-0 CAPLUS
CN Cyclohexanamine, 4-(4-methoxy-3-methylphenyl)-N-pentyl-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 178542-25-1 CAPLUS
CN Cyclohexanemethanamine, N-[4-(4-methoxy-3-methylphenyl)cyclohexyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 39 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Relative stereochemistry.



RN 178162-68-0 CAPLUS
CN Cyclohexanamine, 4-[4-methoxy-3-methylphenyl]-N-methyl-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 178542-14-8 CAPLUS
CN Cyclohexanamine, 4-[4-methoxyphenyl]-N-methyl-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 178542-15-9 CAPLUS
CN Cyclohexanamine, 4-[4-methoxyphenyl]-N-methyl-, trans- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 39 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 178542-26-2 CAPLUS
CN Cyclohexanamine, 4-[4-methoxy-3-methylphenyl]-N,2-dimethyl-, (1e,2e,4e)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 178542-29-5 CAPLUS
CN Cyclohexanamine, 4-[3-methoxyphenyl]-N-methyl-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 178542-30-8 CAPLUS
CN Cyclohexanamine, 4-[3-methoxyphenyl]-N-methyl-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 178542-31-9 CAPLUS
CN Cyclohexanamine, 4-(3,4-dimethoxyphenyl)-N-methyl-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 178542-32-0 CAPLUS
CN Cyclohexanamine, 4-(3,4-dimethoxyphenyl)-N-methyl-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 178542-33-1 CAPLUS
CN Cyclohexanamine, 4-(4-methoxy-3-methylphenyl)-N-methyl-2-(2-propen-1-yl)- (CA INDEX NAME)





RN 178542-40-0 CAPLUS
CN Cyclohexanamine, 4-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-N-methyl-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 178542-41-1 CAPLUS
CN Cyclohexanamine, 4-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-N-methyl-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 178542-42-2 CAPLUS
CN Cyclohexanamine, 4-(4-methoxy-2-methylphenyl)-N-methyl-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 178542-36-4 CAPLUS
CN Cyclohexanamine, 4-[3-ethyl-4-methoxyphenyl]-N-methyl-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 178542-37-5 CAPLUS
CN Cyclohexanamine, 4-[3-ethyl-4-methoxyphenyl]-N-methyl-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 178542-38-6 CAPLUS
CN Cyclohexanamine, 4-(4-methoxy-3-propylphenyl)-N-methyl-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 178542-39-7 CAPLUS
CN Cyclohexanamine, 4-(4-methoxy-3-propylphenyl)-N-methyl-, trans- (CA INDEX NAME)

Relative stereochemistry.

RN 178542-43-3 CAPLUS
CN Cyclohexanamine, 4-(4-methoxy-2-methylphenyl)-N-methyl-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 178542-46-6 CAPLUS
CN Cyclohexanamine, N-ethyl-4-(4-methoxy-3-methylphenyl)-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 178542-47-7 CAPLUS
CN Cyclohexanamine, 4-(4-methoxy-3-methylphenyl)-N-propyl-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 178542-48-8 CAPLUS
CN Cyclohexanamine, N-butyl-4-(4-methoxy-3-methylphenyl)-, trans- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 39 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 178542-49-9 CAPLUS
CN Cyclohexanamine, 4-[4-methoxy-3-methylphenyl)-N-(1-methylethyl)-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 178542-5G-2 CAPLUS
CN Cyclohexanamine, 4-[4-methoxy-3-methylphenyl)-N-(2-methylpropyl)-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 178542-51-3 CAPLUS
CN Cyclohexanamine, N-(2,2-dimethylpropyl)-4-(4-methoxy-3-methylphenyl)-, trans- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 39 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 178542-69-4 CAPLUS
CN Cyclohexanamine, N-methyl-4-(3,4,5-trimethoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 178542-61-5 CAPLUS
CN Cyclohexanamine, N-methyl-4-(3,4,5-trimethoxyphenyl)-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 178542-62-6 CAPLUS
CN Cyclohexanamine, 4-(3-fluoro-4-methoxyphenyl)-N-methyl-, trans- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 39 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 178542-52-4 CAPLUS
CN Cyclohexanamine, 4-[4-methoxy-3-methylphenyl)-N-2-propen-1-yl-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 178542-53-5 CAPLUS
CN Benzenamine, N-[4-(4-methoxy-3-methylphenyl)cyclohexyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 178542-54-6 CAPLUS
CN Cyclohexanamine, N-cyclohexyl-4-(4-methoxy-3-methylphenyl)-, trans- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 39 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 178542-63-7 CAPLUS
CN Cyclohexanamine, 4-(3-chloro-4-methoxyphenyl)-N-methyl-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 178542-64-8 CAPLUS
CN Cyclohexanamine, 4-(4-methoxy-3-methylphenyl)-N-(3-methylbutyl)-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 178542-65-9 CAPLUS
CN Cyclohexanamine, N-(3,3-dimethylbutyl)-4-(4-methoxy-3-methylphenyl)-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 178542-66-0 CAPLUS
CN Cyclohexanamine, 4-[4-methoxy-3-methylphenyl)-N-2-propyn-1-yl-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 178737-97-8 CAPLUS
CN Cyclohexanamine, 4-[4-methoxy-3-methylphenyl)-N,2-dimethyl-, (1α,2β,4β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 178737-98-9 CAPLUS
CN Cyclohexanamine, 4-[4-methoxy-3-methylphenyl)-N,2-dimethyl-, (1α,2β,4α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

1996:404621 Document No. 125:581150 Original Reference No. 125:1165a,1166a
Preparation of N-benzyl-N-acylcycloalkylamine-derivative cholesterol biosynthesis inhibitors. Maier, Roland; Wostrow, Eberhard; Mueller, Peter;
Furnau, Rudolf; Mark, Michael; Kisele, Bernhard; Rudzinski, Ralph-Michael
(Dr. Karl Thomae GmbH, Germany). Ger. Offen. DE 4438055 A1 19960502, 31 pp. (German). CODEN: GWXXBX. APPLICATION: DE 1994-4438055 19941025.

GI



AB The title compds. [I; R1 = (un)branched alkyl, PhCH2, (un)substituted Ph, naphthyl, heterocyclyl, etc.; R2a-R2h = H, alkyl, allyl; R3 = H, (un)branched (un)substituted alkyl, (un)substituted alkenyl, etc.; X = O, S, (un)substituted NH; n = 0-1], useful as cholesterol biosynthesis inhibitors (no data) via the inhibition of HMG-CoA reductase (no data), useful for the treatment of hyperlipidemia (no data) and atherosclerosis (no data), are prepared and I-containing formulations presented. Thus, trans-N-benzyl-4-(4-methoxy-3-methylphenyl)cyclohexylamine was amidated with hexanoyl chloride, producing trans-N-benzyl-N-hexanoyl-4-(4-methoxy-3-methylphenyl)cyclohexylamine in 96.3% theor. yield.
IT 178362-85-4P 178363-86-5P 178362-89-8P 178362-90-1P 178363-92-3P 178364-01-7P 178364-02-8P 178364-03-9P 178364-06-2P 178364-07-3P 178364-08-4P 178364-09-5P 178364-10-8P 178364-11-9P 178364-15-3P 178364-16-4P 178364-17-5P 178364-18-6P 178364-22-2P 178364-23-3P 178364-24-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-benzyl-N-acylcycloalkylamine-derivative cholesterol biosynthesis inhibitors)
RN 178363-85-4 CAPLUS
CN Benzeneethanamine, N-[4-(4-methoxy-3-methylphenyl)cyclohexyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 178737-99-0 CAPLUS
CN Cyclohexanamine, 4-[4-methoxy-3-methylphenyl)-N,2-dimethyl-, (1α,2β,4β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 178363-86-5 CAPLUS
CN Benzeneethanamine, N-[4-(4-methoxy-3-methylphenyl)cyclohexyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 178363-89-8 CAPLUS
CN Benzeneethanamine, N-[4-(4-methoxyphenyl)cyclohexyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 178363-90-1 CAPLUS
CN Benzeneethanamine, N-[4-(4-methoxyphenyl)cyclohexyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 46 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 178363-92-3 CAPLUS
CN Benzenemethanamine, N-[4-(3,4-dimethoxyphenyl)cyclohexyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 178364-01-7 CAPLUS
CN Benzenemethanamine, N-[4-(3-methoxyphenyl)cyclohexyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 178364-02-8 CAPLUS
CN Benzenemethanamine, N-[4-(3-methoxyphenyl)cyclohexyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 47 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Relative stereochemistry.



RN 178364-29-5 CAPLUS
CN Benzenemethanamine, N-[4-(3-ethyl-4-methoxyphenyl)cyclohexyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 178364-30-8 CAPLUS
CN Benzenemethanamine, N-[4-(4-methoxy-2-methylphenyl)cyclohexyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 178364-31-9 CAPLUS
CN Benzenemethanamine, N-[4-(4-methoxy-2-methylphenyl)cyclohexyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 48 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 178364-03-9 CAPLUS
CN Benzenemethanamine, N-[4-(4-methoxyphenyl)-3-methylcyclohexyl]- (CA INDEX NAME)



RN 178364-06-2 CAPLUS
CN Benzenemethanamine, N-[4-(4-methoxy-3-methylphenyl)-2-(2-propen-1-yl)cyclohexyl]- (CA INDEX NAME)



RN 178364-07-3 CAPLUS
CN Benzenemethanamine, N-[4-(4-methoxy-3-methylphenyl)-2-methylcyclohexyl]- (CA INDEX NAME)



RN 178364-08-4 CAPLUS
CN Benzenemethanamine, N-[4-(3-ethyl-4-methoxyphenyl)cyclohexyl]-, cis- (9CI) (CA INDEX NAME)

L29 ANSWER 49 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 178364-15-3 CAPLUS
CN Benzenemethanamine, N-[4-[3-(1,1-dimethylethyl)-4-methoxyphenyl]cyclohexyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 178364-16-4 CAPLUS
CN Benzenemethanamine, N-[4-[3-(1,1-dimethylethyl)-4-methoxyphenyl]cyclohexyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 178364-17-5 CAPLUS
CN Benzenemethanamine, N-[4-(4-methoxy-3-propylphenyl)cyclohexyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 40 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 178364-39-6 CAPLUS
CN Benzenemethanamine, N-[4-(4-methoxy-3-propylphenyl)cyclohexyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 178364-22-2 CAPLUS
CN Benzenemethanamine, N-[4-(3,4,5-trimethoxyphenyl)cyclohexyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 178364-23-3 CAPLUS
CN Benzenemethanamine, N-[4-(3-fluoro-4-methoxyphenyl)cyclohexyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 41 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1996:388194 Document No. 125:581240 Original Reference No. 125:112l9a,112?a
Preparation of N-phenyl-N'-cyclohexylureas as cholesterol biosynthesis inhibitors. Hurmis, Rudolf; Meier, Roland; Muehler, Peter; Wolfum, Eberhard; Mark, Michael; Eisele, Bernhard; Budzinski, Ralph-Michael; Kallenmayer, Gerhard (Dr. Karl Thomae GmbH, Germany). Ger. Offen. DE 4438021 A1 19960502, 24 pp. (German). CODEN: GMXXBX.
APPLICATION: DE 1994-4438021 19941025.

GI



AB Title compds. [I; X = O, S; R1 = MeIC, (substituted) Ph; R2 = H, alkyl; R3 = alkyl; R4 = (substituted) alkyl, alkenyl, alkynyl, Ph, cycloalkyl; R5, R6 = H, F, Cl, Br, CF3, alkyl, alkoxy; R5R6 = atoms to form a fused Ph ring], were prepared Thus, N1-(trans-4-tert-butylcyclohexyl)-N3-(3,3-dimethylallyl)-N1-methyl-N3-phenylurea [I; prepared from N1-(trans-4-tert-butylcyclohexyl)-N1-methyl-N3-phenylurea (preparation given) and 3,3-dimethylallyl bromide, gave a50% inhibition of 14C-acetate incorporation into cholesterol in HEP G2 cells. Drug formulations containing I are given.
IT 178162-23-2P
RL: PCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-phenyl-N'-cyclohexylureas as cholesterol biosynthesis inhibitors)
RN 178162-23-2 CAPLUS
CN Cyclohexanamine, 4-(4-methoxy-3-methylphenyl)-N-methyl-, trans- (CA INDEX NAME)

Relative stereochemistry.



IT 178162-48-0P
RL: SPN (Synthetic preparation); PREP (Preparation)

L29 ANSWER 40 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 178364-24-4 CAPLUS
CN Benzenemethanamine, N-[4-(3-chloro-4-methoxyphenyl)cyclohexyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 41 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
[prepn. of N-phenyl-N'-cyclohexylureas as cholesterol biosynthesis inhibitors]

RN 178162-48-0 CAPLUS
CN Cyclohexanamine, 4-(4-methoxy-3-methylphenyl)-N-methyl-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 42 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1995:994202 Document No. 124:175857O Original Reference No.
124:32607a,32610a Preparation of 6-aryl-(methyl- or methylidene)-quinoline derivatives as voltage-gated potassium channel blockers. Crossley, Roger; Opalko, Albert; Langham, Barry John; Meade, Peter Jonathan (John Wyeth and Brother Ltd., UK). PCT Int. Appl. WO 9521823 A1 19950817, 58 pp. DESIGNATED STATES: W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, UG, US, UZ, VN; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1995-GB279 19950210. PRIORITY: GB 1994-2561 19940210; GB 1994-25344 19941215.
GI



I

AB The title compds. I [the dotted lines represent optional bonds ; R3 is an optionally substituted C6-C10 aryl or heteroaryl group; said aryl or heteroaryl radicals being optionally substituted by one or more substituents the same or different; R4 represents hydrogen, or a group of formula CRaRbRc where Ra, Rb and Rc are independently selected from hydrogen, C1-C6 alkyl, optionally substituted C6-C10 aryl, optionally substituted heteroaryl, C1-C6 alkyl substituted by optionally substituted C6-C10 aryl or heteroaryl; R' represents one or more optional substituents the same or different, selected from one or more of the following: halogen, C1-C6 alkyl, C2-C7 alkoxycarbonyl, C1-C6 hydroxyalkyl, CN, aminocarbonyl, C2-C7 alkanoyloxy(C1-C6)alkyl, carboxy, C2-C7 alkanoxyamino, optionally substituted C6-C10 or heteroaryl or an optionally substituted (C6-C10aryl)alkyl or a heteroaryl alkyl radical; said aryl or heteroaryl radicals being optionally substituted by one or more substituents the same of different, and R''represents one or more optional mono- or di- valent substituents in the 5, 7 or 8 positions the same or different: monovalent substituents being selected from the following: C1-C6 alkyl, C2-C7 alkanoyloxy, hydroxy, amino, C2-C7 alkanoylamino, etc.; R'' can also represent hydroxy in the 6 position (when the optional bond is absent); the divalent substituents being selected from oxo and methylene] are prepared 1,2,3,4,4A,5,6,7,8,8a-Decahydro-3-hydroxymethyl-6-((4-methoxyphenyl)methyl)quinoline HCl salt (II) was prepared in a multistep process starting with 4-((4-methoxyphenyl)methyl)cyclohexanone and Et 2-cyanoacrylate. II in vitro at 100 μM gave 55% block of transient outward potassium current in a test using GH3 cells.
IT 172280-57-8P 172280-58-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinoline derivs. as voltage-gated potassium channel blockers)

L29 ANSWER 42 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 172280-57-8 CAPLUS
CN Cyclohexanepropanoic acid, 5-(4-methoxyphenyl)-2-[(1-phenylethyl)amino]-, methyl ester, [1S-[1α,2α(S*),5β]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172280-58-9 CAPLUS
CN Cyclohexanepropanoic acid, 5-(4-methoxyphenyl)-2-[(1-phenylethyl)amino]-, methyl ester, [1S-[1α,2α(S*),5α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L29 ANSWER 43 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1995:810445 Document No. 123:228005O Original Reference No.
123:40726h,40727a Preparation of 4-aminotetrahydroquinolines and analogs as fungicides and pesticides. Jakobi, Harald; Schaper, Wolfgang; Preuss, Rainer; Braun, Peter; Sachse, Burkhard; Luemmen, Peter (Hoechst Schering AgrEvo GmbH, Germany). Ger. Offen. DE 4343250 A1 19950601, 32 pp. (German). CODEN: GWXXBX. APPLICATION: DE 1993-4343250 19931217. PRIORITY: DE 1993-4340738 19931130.
GI



I



II

AB Title compds. [I; R = aryl(oxy), (phenylimino-interrupted)cycloalk(en)yl, etc.; R1 = H, alkyl, alkoxy, etc.; R2 = H, alkyl, alkoxy(carbonyl), etc.; R1R2 = (CH2)3-5; Z = CR5R6; R3-R8 = H, alkyl, alkoxy, etc.; X = O, S, (alkyl)amino, etc.; Y = bond, hydrocarbylene; n = 1-8] were prepared Thus, 4-chloro-5,6,7,8-tetrahydroquinoline was condensed with cis-4-tert-amylcyclohexylamine to give title compound II (R = CMe3Et) which gave complete control of Botrytis cinerea on broad bean seedlings when sprayed at 250mg/L.
IT 168086-38-2P 168086-42-8P 168086-43-9P
168086-48-4P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-aminotetrahydroquinolines and analogs as fungicides and pesticides)
RN 168086-38-2 CAPLUS
CN 4-Quinolinamine, 5,6,7,8-tetrahydro-N-[4-[4-(1-methylethoxy)phenyl]cyclohexyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 43 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 168086-42-8 CAPLUS
CN 4-Quinolinamine, 5,6,7,8-tetrahydro-2-methyl-N-[4-[4-(1-methylethoxy)phenyl]cyclohexyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 168086-43-9 CAPLUS
CN 4-Quinolinamine, 5,6,7,8-tetrahydro-2-methyl-N-[4-[4-(1-methylethoxy)phenyl]cyclohexyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 43 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 169026-48-4 CAPLUS
CN 4-Quinolinamine, N-[4-(4-ethoxyphenyl)cyclohexyl]-5,6,7,8-tetrahydro-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 44 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1995:758105 Document No. 123:217845 Original Reference No. 123:38455a,38458a
Reversal of multidrug resistance by verapamil analogs. Pereira, Elenej; Teodori, Elisabetta; Dei, Silvia; Gualtieri, Fulvio; Garnier-Suillerot, Arlette (Laboratoire de Chimie Bioorganique, Universite Paris Nord, Bobigny, 93012, Fr.). Biochemical Pharmacology, 50(4), 453-7 (English) 1995. CODEN: BCPCA6. ISSN: 0006-2952. Publisher: Elsevier.
AB The basic distinguishing feature of multidrug resistant (MDR) cells is a decrease in steady-state drug levels as compared to drug-sensitive controls. It is well-known that verapamil increases the sensitivity of MDR cells to drugs, thus reverting drug resistance. A limiting factor for its clin. use is the pronounced cardiovascular effects of the calcium channel antagonist which occur at the high plasma concns. required to block P-glycoprotein transport efficiently. From a clin. point of view, it is important to find verapamil deriv. with low calcium channel blocking activity and high reverting activity. This was the aim of the present study. In this context we have investigated the ability of 12 verapamil analogs with restricted mol. flexibility to increase cellular accumulation of anthracycl drugs and overcome resistance, and their inotropic, chronotropic,and slow calcium channel antagonistic activity. In this study an anthracycline derivative 4'-O-tetrahydropyranyl adriamycin, and an erythroleukemia K562 cell line were used. Three of the 30 derivs. checked were completely devoid of calcium channel blocking activity while exhibiting MDR reverting ability comparable to that of verapamil. These deriv. could be useful for the treatment of MDR in cancer patients and for the design and development of other verapamil deriv.
IT 137648-63-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(reversal of multidrug resistance by verapamil analogs)
RN 137648-63-2 CAPLUS
CN Cyclohexaneacetonitrile, 1-[3,4-dimethoxyphenyl)-4-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 45 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L29 ANSWER 46 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1993:664999 Document No. 123:157040 Original Reference No. 123:28027a,28028a
Preparation of substituted pyridines as pesticides and agrochemical fungicides. Reisenberg, Dieter Bernd; Lindner, Adolf Hans; Wehner, Volkmar; Preuss, Rainer; Schaper, Wolfgang; Jakobi, Harald; Braun, Peter; Knauf, Werner; Sachse, Burkhard; et al. (Hoechst Schering AgrEvo GmbH, Germany). Ger. Offen. DE 4231179 A1 19930316, 49 pp. (German). CODEN: GWXXBX. APPLICATION: DE 1993-4231179 19930914.
GI



AB Title compds. [I; R1-R4 = (halo)alkyl, (halo)alkenyl, (halo)alkoxy, (halo)alkenyloxy, NO2, NO2, haloalkoxymethyl, haloalkenyloxyalkenyl, alkylthio, alkenylthio, alkenylsulfonyl, aryl, substituted amino, cyano, halo, H, etc.; R = alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl; X = O, S, NR, YR; Y = bond, (substituted) C1-6 hydrocarbylene in which a CH2 may be replaced by O; Z = (substituted) cycloalkyl, cycloalkenyl in which a CH2 may be replaced by NR5; R5 = (substituted) Ph], were prepared. Thus, title compound (I), prepared by heating 4-chloro-3-methoxy-2-methylpyridine and O-benzylhydroxylamine in PhOH to give 4-(O-benzylhydroxylamino)-3-methoxy-2-methylpyridine, treatment of the latter with 4-trans-O-tosyloxycyclohexylcyclohexane, and hydrogenolysis of the resulting 4-(O-benzyl-N-(4-cis-cyclohexylcyclohexyl)hydroxylamino)-3-methoxy-2-methylpyridine, at 150 mg/L gave complete control of Phytophthora infestans on tomato plants.
IT 164720-54-1P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted pyridines as pesticides and agrochem. fungicides)
RN 164720-54-1 CAPLUS
CN 4-Pyridinamine, N-[4-(4-ethoxyphenyl)cyclohexyl]-3-methoxy-2-methyl-, cis-
(9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 46 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1994:270113 Document No. 120:270113Z Original Reference No. 120:47845a,47845b Antispasmodic flavones. Leonardi, Amedeo; Motta, Gianni; Pirra, Carlo; Guarneri, Luciano (Recordati s.a. Chemical and Pharmaceutical Co., Switz.; Recordati Industria Chimica e Farmaceutica S.p.A.) Eur. Pat. Appl. EP 566288 A1 19931020, 18 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1993-302598 19930401. PRIORITY: IT 1992-MI884 19920410.

GI

I

AB The title compds. I [R = (un)substituted (phenylalkyl)amino, (un)substituted dihydroisoquinolino, etc., X = CO, CO2, CONR, CONRm, CHOH, etc., n = 1-4], which exhibit powerful antispasmodic action and are considerably more stable at physiol. pH than Flavoxate, and which are useful in the treatment of urinary incontinence (no data), are prepared Thus, 4-cyano-4-(3,4-dimethoxyphenyl)-5,5-dimethyl-hexylamine was reacted with 8-(3-bromopropoxy)carbostyril-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran and the free base treated with HCl, producing 8-[3-[4-cyano-4-(3,4-dimethoxyphenyl)-5,5-dimethyl-hexylamino]propoxy]carbostyril-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran hydrochloride (II). II demonstrated 100% stability after 3 h at 37° and pH 7.4, 50% inhibitory concentration of K-induced rat bladder contractions (tonic) 1.3 μmolar, and LD50 (p.o.) >3000 mg/kg (mice), vs. 10, 13.0, and 500, resp., for Flavoxate.

IT 133648-68-7 133648-70-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of flavone antispasmodics)

RN 133648-68-7 CAPLUS
CN Cyclohexanecarbonitrile, 1-[3,4-dimethoxyphenyl)-4-(methylamino)-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 46 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 133648-70-1 CAPLUS
CN Cyclohexanecarbonitrile, 1-[3,4-dimethoxyphenyl)-4-(methylamino)-, trans- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 47 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1994:269828 Document No. 120:269828 Original Reference No. 120:47785a,47786a Cycloheximeneses useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor. Christensen, Siegfried B., IV; Foster, Cornelia Jutta (SmithKline Beckman Corp., USA)
PCT Int. Appl. WO 9319751 A1 19931014, 38 pp. DESIGNATED STATES: W: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, RO, RU, SD, SE, SK, UA; RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1993-US2156 19930305. PRIORITY: US 1992-852111 19920402; US 1992-968761 19921030.

GI

I

AB The title compds. [I; R1 = (un)substituted alkoxycarbonylalkyl, (un)substituted alkylaminocarbonylalkyl, (un)substituted alkoxyalkyl, etc.; R2 = optionally halogen-substituted Me or Et; R3 = H, halogen, C1-4 alkyl, CHNHCOCH3, etc.; X = YR3, halogen, NO2, (un)substituted NH2, etc.; Y = O, SOm; m = 0-2; X2 = O, (un)substituted NH; X3 = H, X; Z = (un)substituted alkoxy, OH, (un)substituted alkylthio, NH, etc.; s = 0-4], which inhibit the biosynthesis of tumor necrosis factor (no data), are prepared 7?is, cis-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexan-1-ol] was reacted with PPh3 and EtOC to the presence of di-Et azodicarboxylate, producing trans-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)-1-form]cyclohexanol.

IT 154284-41-0P 154284-42-1P 154284-51-2P
154284-60-3P 154284-62-5P 154284-64-7P
154284-66-9P 154284-69-2P 154284-70-5P
154284-71-6P 154284-73-8P 154284-74-9P
154284-76-1P 154284-85-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and tissue necrosis factor biosynthesis inhibition of)

RN 154284-41-0 CAPLUS
CN Cyclohexanecarbonitrile, 4-amino-1-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 47 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 154284-42-1 CAPLUS
CN Cyclohexanecarbonitrile, 4-amino-1-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.

RN 154284-51-2 CAPLUS
CN Urea, [4-(3-am-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 47 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 154284-60-3 CAPLUS
CN Acetamide, N-[4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 154284-62-5 CAPLUS
CN Acetic acid, [[4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexyl]amino]oxo-, methyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 47 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 154284-63-6 CAPLUS
CN Cyclohexanecarbonitrile, 1-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-(hydroxyamino)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 154284-70-5 CAPLUS
CN Cyclohexanecarbonitrile, 1-[3-(cyclopentyloxy)-4-methoxyphenyl]-4-(hydroxyamino)-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 154284-71-6 CAPLUS

L29 ANSWER 47 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 154284-64-7 CAPLUS
CN Ethanediamide, N1-[4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexyl]-N2-methyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 154284-66-9 CAPLUS
CN Acetic acid, [[4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexyl]amino]oxo-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 47 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN Cyclohexanecarbonitrile, 1-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-4-(hydroxyamino)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 154284-72-7 CAPLUS
CN Cyclohexanecarbonitrile, 1-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-4-(hydroxyamino)-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 154284-73-8 CAPLUS
CN Cyclohexanecarbonitrile, 1-[3-[(4-fluorophenyl)methoxy]-4-methoxyphenyl]-4-(hydroxyamino)-, cis- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 47 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 154284-74-9 CAPLUS
CN Cyclohexanecarbonitrile,
1-[3-[(4-fluorophenyl)methoxy]-4-methoxyphenyl]-4-(hydroxyamino)-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 154284-84-1 CAPLUS
CN Cyclohexanecarbonitrile, 4-amino-1-[3-(cyclopentyloxy)-4-methoxyphenyl]-, cis- (CA INDEX NAME)

L29 ANSWER 47 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Relative stereochemistry.



RN 154284-85-2 CAPLUS
CN Cyclohexanecarbonitrile, 4-amino-1-[3-(cyclopentyloxy)-4-methoxyphenyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 48 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1993:539078 Document No. 119:139078 Original Reference No. 119:24939a,24942a Preparation of 5-[(aminoaryloxy)methyl]-2-pyrrolidinoneacetates and analogs as drugs. Himmelsbach, Frank; Austel, Volkhard; Pieper, Helmut; Eisert, Wolfgang; Mueller, Thomas; Weisenberger, Johannes; Linz, Guenter; Krueger, Gerd (Thomae, Dr. Karl, G.m.b.H., Germany). Eur. Pat. Appl. EP 483667 A2 19920506, 173 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE. (German). CODEN: EPXXDW. APPLICATION: EP 1991-118148 19911024. PRIORITY: DE 1990-4035961 19901102.
GI


I


III

AB Compds. BXAYE [A = 4- to 7-membered (substituted) alkyleneiminodiyl; B = cyano, NO2, NH2, C(:NH)NH2, NHC(:NH)NH2, etc.; E = vinyl, CH2OH, cyano, SO2H, CO2H, alkoxycarbonyl, etc.; X = X5X4X3X2X1; X1 = bond, alkylene, or arylene which may be linked to X2 by O, SO2, CO, etc.; X2 = fluorenylene, arylene, hydronaphthaleneylene, etc.; X3, X5 = bond, (unsatd.) alkylene, etc.; X4 = bond, arylene, (bi)cycloalkylene; Y = Y1Y2Y3; Y1, Y2 = bond, (unsatd.) alkylene, etc.; Y3 = bond, arylene, alkylenearylene, etc.] were prepared Thus, (S)-5-[(trityloxy)methyl]-2-pyrrolidinone was condensed with Ph(CH2)3Br and the product alkylated with BrCH2CH:CH2 to give, after deprotection and mesylation, pyrrolidinone (3R,5S)-I (II; R1 = CH2CH:CH2, R2 = SO2Me) which was condensed with 4'-cyano-4-hydroxybiphenyl to give, after oxidation and esterification, II (R1 = CH2CO2Me, R2 = 4'-cyano-4-biphenylyl). The latter was converted in 2 steps to title compound (3R,5S)-III (IV; n = 3). IV (n = 0) had IC50 of 0.024 μM against binding of fibrinogen to human thrombocytes in vitro.
IT 149506-06-9P 149506-07-0P 149506-77-4P 149507-41-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of drugs)
RN 149506-06-9 CAPLUS
CN Carbamic acid, [4-(4-hydroxyphenyl)cyclohexyl]-, 1,1-dimethylethyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 48 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 149506-07-0 CAPLUS
CN Carbamic acid, [4-(4-hydroxyphenyl)cyclohexyl]-, 1,1-dimethylethyl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 149506-77-4 CAPLUS
CN Phenol, 4-(cis-4-aminocyclohexyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 149507-41-5 CAPLUS
CN Phenol, 4-(trans-4-aminocyclohexyl)- (CA INDEX NAME)

Relative stereochemistry.



L29 ANSWER 48 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 133648-68-7 CAPLUS
CN Cyclohexanecarbonitrile, 1-[3,4-dimethoxyphenyl)-4-(methylamino)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 133648-70-1 CAPLUS
CN Cyclohexanecarbonitrile, 1-[3,4-dimethoxyphenyl)-4-(methylamino)-, trans- (CA INDEX NAME)

Relative stereochemistry.



1T 133648-64-3P 133648-65-4P 133648-67-6P
133648-69-8P 133648-71-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 133648-64-3 CAPLUS
CN Cyclohexanecarbonitrile, 1-[3,4-dimethoxyphenyl)-4-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-, cis-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

L29 ANSWER 49 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN

1991:449017 Document No. 115:49017 Original Reference No. 115:8493a,8496a
Verapamil analog with restricted molecular flexibility. Dei, Silvia; Romanelli, M. Novella; Scapecchi, Serena; Teodori, Elisabetta; Chiarini, Alberto; Gualtieri, Fulvio (Dip. Sci. Farm., Univ. Firenze, Florence, 50121, Italy). Journal of Medicinal Chemistry, 34(7), 2219-25 (English) 1991. CODEN: JMCMAR. ISSN: 0022-2623. OTHER SOURCES: CASREACT 115:49017.

AB Three analogs with restricted flexibility were designed to study the active conformation of verapamil during interaction with the slow calcium channel. Thus cis- and trans-1-(3,4-dimethoxyphenyl)-4-[N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methylamino]-4-cyclohexanecarbonitrile (I and II), and 4-(3,4-dimethoxyphenyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-4-cyanopiperidine (III) in which the verapamil structure is inserted into a cyclohexane or piperidine ring, were synthesized. Conformational anal. was performed with MMP and theor. methods, and slow calcium channel antagonism was tested on guinea pig aorta strips. The compds. are 100-times less potent than the parent compound even if they are able to reach conformations that are quite close to the lowest energy conformation proposed for verapamil and similar compds. It appears that the flexibility to rotate around the bond between the quaternary atom and the adjacent methylene, a property which is lost in compds. I-III, is a major requisite for the calcium antagonism of verapamil.

IT 133648-63-2P 133648-66-5P 133648-68-7P
133648-70-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and methylation of)

RN 133648-63-2 CAPLUS
CN Cyclohexanecarbonitrile, 1-[3,4-dimethoxyphenyl)-4-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 133648-66-5 CAPLUS
CN Cyclohexanecarbonitrile, 1-[3,4-dimethoxyphenyl)-4-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 49 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

CRN 133648-63-2
CMF C25 H32 N2 O4

Relative stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 133648-65-4 CAPLUS
CN Cyclohexanecarbonitrile, 1-[3,4-dimethoxyphenyl)-4-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-, monohydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 133648-67-6 CAPLUS
CN Cyclohexanecarbonitrile, 1-[3,4-dimethoxyphenyl)-4-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-, trans-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

L29 ANSWER 49 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CRN 133648-66-5
CMF C25 H32 N2 O4

Relative stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 133648-69-8 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3,4-dimethoxyphenyl)-4-(methylamino)-, cis-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133648-68-7
CMF C16 H22 N2 O2

Relative stereochemistry.



CM 2

CRN 144-62-7

L29 ANSWER 49 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CMF C2 H2 O4

RN 133648-71-2 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3,4-dimethoxyphenyl)-4-(methylamino)-, trans-,
ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133648-70-1
CMF C16 H22 N2 O2

Relative stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4

L29 ANSWER 50 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1989:407046 Document No. 111:70460 Original Reference No. 111:1343a,1346a Bisarylamines, their pharmaceutical compositions, and their use as vasodilators. Regan, John R.; Barton, Jeffrey N.; Suh, John T.; Skiles, Jerry W. (Rorer Pharmaceutical Corp., USA). U.S. US 4795757 A 19890103, 7 pp. Cont.-in-part of U.S. Ser. No. 646,735, abandoned. (English). CODEN: USXXAM. APPLICATION: US 1986-932557 19861120. PRIORITY: US 1984-646735 19840904.
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Aromatic amines I [Q = Q1 - Q3; Ar = (un)substituted Ph, naphthyl, heteroaryl, indolyl, fused arylcycloalkyl; A, A1 = H, OH, aryloxy, C1-6 alkyl or alkoxy; X = cyano, NO2, CO2R, SR, SOR, SO2R; R = H, C1-6 alkyl, aryl; n, n', n'' = 0-4; m, m', m'' = 1-4] are prepared and have Ca channel-blocking activity. Michael addition of 3,4-(MeO)2C6H3CH2CN to 2 equiv CH2:CHCO2Me (in refluxing Me3COH containing Triton B) gave 3,4-(MeO)2C6H3C(CN)(CH2CH2CO2Me)2. This was cyclized by treatment with NaH and MeOH in PhMe to give 4-(3,4-dimethoxyphenyl)-4-cyanocyclohexanone (II). Reductive amination of II by 3,4-(MeO)2C6H3CH2CH2NH2 and NaBH3CN in
EtOH, followed by workup and acidification, gave [(dimethoxyphenyl)ethyl]cyano(dimethoxyphenyl)aminocyclohexane hydrochloride III. At 100 mg/kg i.p. in spontaneously hypertensive rats, III gave an 18-19% decrease in arterial pressure lasting for approx. 10 h.
IT 29778-50-5P 121139-53-5P 121139-56-8P
121139-58-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as cardiovascular agent)
RN 29778-50-5 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3,4-dimethoxyphenyl)-4-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 121139-53-5 CAPLUS
CN Cyclohexanecarbonitrile, 4-[(2,3-dihydro-1H-inden-2-yl)amino]-1-(3,4-dimethoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)

L29 ANSWER 50 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 121139-56-8 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3,4-dimethoxyphenyl)-4-[[2-(3,4-dimethoxyphenyl)ethyl]amino]- (CA INDEX NAME)



RN 121139-58-0 CAPLUS
CN Cyclohexanecarbonitrile, 4-[(2,3-dihydro-1H-inden-2-yl)amino]-1-(3,4-dimethoxyphenyl)- (CA INDEX NAME)



L29 ANSWER 51 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1973:58895 Document No. 80:58895 Original Reference No. 80:13761a,13764a
Arylalkylamine derivatives. XIV. Synthesis of some cycloalkane-substituted arylalkylamines. Apakyan, A. A.; Fird'kanov, L. Sh.; Markaryan, K. A. (Inst. Tonkoi Org. Khim. im. Mndzhoyana, Yerevan, USSR). Armyanskii Khimicheskii Zhurnal, 31(9), 689-93 (Russian) 1978. CODEN: ASYZAN ISSN: 0515-9628.

GI



AB Reduction of I (R = MeO) with NiCNEt in presence of Ni-Re at 30-40° gave 82.4% II whereas at 50° III (R = MeO, R1 = CN, R2 = NH2) was formed. Reduction of the last with LiAlH4 gave 77% III (R = MeO, R1 = CH2NH2, R2 = NH2). Reduction of I (R = H, MeO) with NaBH4 gave III (R1 = CN, R2 = OH) which on reduction with LiAlH4 gave III (R1 = CH2NH2, R2 = OH).

IT 68299-13-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)

RN 68299-13-2 CAPLUS

CN Cyclohexanecarbonitrile, 4-amino-1-(3,4-dimethoxyphenyl)- (CA INDEX NAME)

L29 ANSWER 51 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



IT 68299-12-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 68299-12-7 CAPLUS

CN Cyclohexanemethanamine, 4-amino-1-(3,4-dimethoxyphenyl)- (CA INDEX NAME)



L29 ANSWER 52 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1977:453042 Document No. 87:53042 Original Reference No. 87:8399a,8402a
Azabicycloalkanes as analgetics. V.
4-Phenyl-2-azabicyclo[2,2,2]octanes.
Takeda, Hikio; Kavamori, Masatoshi; Inoue, Kiroumi; Noguchi, Katsuyuki; Nurimoto, Seiichi (Res. Lab., Tanabe Seiyaku Co., Ltd., Saitama, Japan). Chemical & Pharmaceutical Bulletin, 25(4), 775-83 (English) 1977
. CODEN: CPBTAL. ISSN: 0009-2363. OTHER SOURCES: CASREACT 87:53042.

GI



AB Seventeen 4-phenyl-2-azabicyclo[2.2.2]octanes I (R = H, Me; R1 = H, Me, allyl, Pr, benzyl, phenethyl, cyclopropylmethyl; R2 = H, HO, MeO) or/and their salts were prepared from the cyclic acetals II for their potential analgesic and narcotic antagonistic activities. I (R=R2 given: H, Me, m-HO; Me, Me, m-HO; H, allyl, m-HO) (III) had analgesic activity in mice comparable to that of pentazocine and I (R-R1 given: H, Me, p-HO; Me, Me, p-HO; H, Pr, m-HO; H, phenethyl, m-HO), III, and the piperidines IV (R3 = H, Me) inhibited morphine-induced respiratory depression in rabbits.

IT 63383-59-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)

RN 63383-59-3 CAPLUS

CN Cyclohexanecarboxylic acid, 1-(3-methoxyphenyl)-4-[(phenylmethyl)amino]-, methyl ester, hydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 52 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

IT 63383-55-1P 63383-56-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and ring closure of)

RN 63383-55-1 CAPLUS

CN Cyclohexanecarboxylic acid, 1-(3-methoxyphenyl)-4-(methylamino)-, methyl ester, cis- (CA INDEX NAME)

Relative stereochemistry.

RN 63383-56-2 CAPLUS

CN Cyclohexanecarboxylic acid, 1-(3-methoxyphenyl)-4-[(phenylmethyl)amino]-, methyl ester, cis- (CA INDEX NAME)

Relative stereochemistry.



IT 63471-30-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 63471-30-7 CAPLUS

CN Cyclohexanecarboxylic acid, 1-(3-methoxyphenyl)-4-(methylamino)-, hydrochloride, trans- (9CI) (CA INDEX NAME)

L29 ANSWER 52 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
Relative stereochemistry.

● HCl

L29 ANSWER 53 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 56326-84-2 CAPLUS
CN 1-Butanone, 4-[[4-[(acetyloxy)methyl]-4-(4-methoxyphenyl)cyclohexyl]amino]-1-(4-fluorophenyl)-, hydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 56327-21-0 CAPLUS
CN Cyclohexanemethanol, 4-amino-1-(4-methoxyphenyl)-, acetate (ester), hydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 61749-28-8 CAPLUS
CN Cyclohexanemethanol, 4-amino-1-(4-methoxyphenyl)-, hydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 53 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1977:72364 Document No. 86:72364 Original Reference No. 86:11423a,11426a
4-Arylcyclohexylamines. Lednicer, Daniel (Upjohn Co., USA). U.S. US 3979444 19760907, 32 pp. (English). CODEN: USXXAM.
APPLICATION: US 1974-474037 19740528.

GI



AB 4-Arylcyclohexylamines I [R = Ph, substituted phenyl, 1-naphthyl; R1 = H, OH, OAc; R2 = H or C1-3 alkyl; R3 = H, C1-3 alkyl, or (CH2)nCOR4 (R4 = Ph or substituted phenyl); or R2R3N = pyrrolidino, piperidino, morpholino, etc.] and their salts, which depress the central nervous system and lower the blood pressure, were prepared by procedures involving up to 17 steps. Thus, PhCH2CN added to CH2:CHCO2Me to give NCCH(CH2CH2CO2Me)2, which was cyclized and decarboxylated to 4-oxo-1-phenylcyclohexanecarbonitrile, the oxo group then protected and the CN group successively hydrolyzed, reduced, and acetylated; the oxo group was then reduced to OH, mesylated, reacted with NaN3 and reduced to convert the mesyloxy group to NH2 (and the AcO group to OH), after which cyclization with Br(CH2)4Br gave I (R = Ph, R1 = OH, R2R3N = pyrrolidino).

IT 56326-80-8P 56326-84-2P 56327-21-0P
61749-28-8P 61749-30-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 56326-80-8 CAPLUS
CN 1-Butanone, 1-(4-fluorophenyl)-4-[[4-(hydroxymethyl)-4-(4-methoxyphenyl)cyclohexyl]amino]-, hydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

L29 ANSWER 53 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 61749-30-2 CAPLUS
CN Cyclohexanemethanol, 4-amino-1-(3,4-dimethoxyphenyl)-, hydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

L29 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1976:159675 Document No. 85:159675 Original Reference No. 85:25549a,25552a
4'-Fluoro-4-[4-[phenyl]-4-alkoxycyclohexyl]amino butyrophenones and salts.
Ledniczer, Daniel (Upjohn Co., USA). U.S. US 3965189 19760622, 24 pp. (English). CODEN: USXAAM. APPLICATION: US 1973-333896 19730220. PRIORITY: US 1971-134459X 19710401.

GI

AB Cyclohexylaminobutyrophenones, e.g. I, central nervous system depressants and tranquilizers, were prepared routinely from simple starting materials.
Thus, Grignard reaction of 4-hydroxycyclohexanone with 4-FC6H4Br gave cis- and trans-1-(4-fluorophenyl)-1,4-cyclohexanediols, which were oxidized with Jones reagent to the cyclohexanone. The latter was converted to the dimethyl acetal, the hydroxy group methylated under reducing conditions with subsequent hydrolysis of the ketal, the amine and then the amine acetate prepared, followed by reduction with RANE to the cyclohexylamine-HCl.
This in DMF was treated with NaNH2, followed with 4-chloro-4'-fluorobutyrophenone 2,2-dimethyl-1,3-propanediol ketal, KI, and K2CO3 to give 54% I.

IT 42020-64-4P 42020-74-6P
RL: SYN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 42020-64-4 CAPLUS
CN Cyclohexanamine, 4-methoxy-4-(2-methoxyphenyl)-, hydrochloride, cis- (8CI) (CA INDEX NAME)

Relative stereochemistry.

● HCl

RN 42020-74-6 CAPLUS

L29 ANSWER 55 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1976:159620 Document No. 85:159620 Original Reference No. 85:25541a,25544a
4'-Fluoro-4-[4-[phenyl]cyclohexyl]amino]butyrophenones and their salts.
Ledniczer, Daniel (Upjohn Co., USA). U.S. US 3940961 19760301, 32 pp. (English). CODEN: USXAAM. APPLICATION: US 1973-329044 19730202.

GI

AB Cis and trans I (R1 = alkyl, halo, alkoxy, NO2; R2, R3 = H, alkyl; R4 = H, alkyl, aryl; NR3R4 = pyrrolidino, piperidino, morpholino), useful as tranquilizers at 0.1-100 mg/kg, were prepared via Grignard reaction from 4-hydroxycyclohexanone with the corresponding R1MgBr. Thus, p-FC6H4MgBr reacted with 4-hydroxycyclohexanone followed by oxidation with Jones reagent, treatment with PTCCOCl3, and reduction with NaBH4 to give 4-(p-fluorophenyl)-3-cyclohexen-1-ol (II). Hydrogenation of II over Pd/C followed by treatment with MeNCO2Cl and NaNH2 in DMF at 95°, and reduction with LiAlH4 gave cis and trans I (R1 = 4-F, R2-R4 = H) (III).

III

reacted with MeNCO to give I (R1 = 4-F, R2 = R3 = H, R4 = CONHMe).

IT 42054-39-0P 42054-40-3P 42553-75-1P
60739-50-6P
RL: SYN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 42054-39-0 CAPLUS
CN 1-Butanone, 1-(4-fluorophenyl)-4-[[4-(2-methoxyphenyl)cyclohexyl]amino]-, hydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

● HCl

RN 42054-40-3 CAPLUS
CN 1-Butanone, 1-(4-fluorophenyl)-4-[[4-(3-methoxyphenyl)cyclohexyl]amino]-, hydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN 1-Butanone, 1-(4-fluorophenyl)-4-[[4-methoxy-4-(2-methoxyphenyl)cyclohexyl]amino]-, hydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

L29 ANSWER 55 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 40553-75-1 CAPLUS
CN 1-Butanone, 1-(4-fluorophenyl)-4-[[4-(4-methoxyphenyl)cyclohexyl]amino]-, hydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 60739-50-6 CAPLUS
CN Acetamide, N-[4-[4-(aminosulfonyl)phenyl]cyclohexyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 56 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1973:126064 Document No. 83:126064 Original Reference No. 83:19718a,19722a
Butyrophenones as hypotensive agents. Derivatives of
4-aryl-4-hydroxymethylcyclohexylamine. Ledniker, Daniel; Emmert, D.
Edward; Podzik, Alan D.; Graham, Boyd E. (Res. Lab., Upjohn Co.,
Kalamazoo, MI, USA). Journal of Medicinal Chemistry, 16(6), 593-9
(English) 1973. CODEN: JMCMAR. ISSN: 0022-2623. OTHER
SOURCES: CASREACT 83:126064.
GI For diagram(s), see printed CA Issue.
AB A series of 14 title compds. was prepared from the arylcyanocyclohexanone
ketal by hydrolysis to the acid, reduction, deketalization, reduction,
mesylation,
and amination via the azide, followed by condensation with the
appropriate
4-chlorobutyrophenone derivative
Cis-4'-fluoro-4-[[4-hydroxymethyl)-4-(p-
methoxyphenyl)cyclohexyl]amino]butyrophenone-HCl (I-HCl), the most active
compound, lowered blood pressure of rats in oral doses as low as 5 mg/kg.
Structure-activity relations are discussed.
IT 56327-32-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and condensation with chlorobutyrophenone derivative)
RN 56327-32-3 CAPLUS
CN Cyclohexanemethanol, 4-amino-1-(4-methoxyphenyl)-, hydrochloride, cis-
(9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

IT 56327-21-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and hydrolysis of)
RN 56327-21-0 CAPLUS
CN Cyclohexanemethanol, 4-amino-1-(4-methoxyphenyl)-, acetate (ester),
hydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 56 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

IT 56326-80-8P 56326-84-2P
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and hypotensive activity of)
RN 56326-80-8 CAPLUS
CN 1-Butanone, 1-(4-fluorophenyl)-4-[[4-(hydroxymethyl)-4-(4-
methoxyphenyl)cyclohexyl]amino]-, hydrochloride, cis- (9CI) (CA INDEX
NAME)

Relative stereochemistry.



● HCl

RN 56326-84-2 CAPLUS
CN 1-Butanone,
4-[[4-[acetyloxy)methyl]-4-(4-methoxyphenyl)cyclohexyl]amino]-
1-(4-fluorophenyl)-, hydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 56 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

● HCl

L29 ANSWER 57 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1973:542794 Document No. 79:142794 Original Reference No. 79:23113a,23116a
Partly reduced biphenyls as central nervous system agents. 3. cis- and
trans-4-Aryl-4-methoxycyclohexylamines. Ledniker, Daniel; Emmert, D.
Edward; Lahti, Robert; Rudzik, Allan D. (Res. Lab., Upjohn Co.,
Kalamazoo,
MI, USA). Journal of Medicinal Chemistry, 16(11), 1251-6 (English)
1973. CODEN: JMCMAR. ISSN: 0022-2623.
AB Trans-4-aryl-4-methoxycyclohexylamines showed 2-20-fold greater central
nervous depressant activity than the corresponding cis isomers. The most
potent compound in the series was
trans-4'-fluoro-4-[[4-(4-fluorophenyl)-4-
methoxycyclohexyl]amino]butyrophenone-HCl (I) [42020-70-2], which e.g.
antagonized nicotine-induced tonic extensor convulsions and death in mice
at 0.4 mg/kg i.p. markedly depressed uptake of norepinephrine by mouse
heart in vivo, but not that of serotonin by the mouse spleen. The
trans-arylmethoxycyclohexylamines were prepared by methylation of
ketal-protected 4-hydroxy-4-arylcyclohexanone, deketalization conversion
to the oxime acetate, reduction with RiNi in THF, treatment with
p-fluoro-4-chlorobutyrophenone neopentyl glycol ketal [36714-65-5], and
deketalization.
IT 42020-74-6P
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological
study, unclassified); SPN (Synthetic preparation); BIOL (Biological
study); PREP (Preparation)
(preparation and central nervous system activity of)
RN 42020-74-6 CAPLUS
CN 1-Butanone, 1-(4-fluorophenyl)-4-[[4-methoxy-4-(2-
methoxyphenyl)cyclohexyl]amino]-, hydrochloride, cis- (9CI) (CA INDEX
NAME)

Relative stereochemistry.



● HCl

IT 42020-64-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 42020-64-4 CAPLUS
CN Cyclohexanamine, 4-methoxy-4-(2-methoxyphenyl)-, hydrochloride, cis-
(9CI)
(CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 57 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

● HCl

L29 ANSWER 58 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1973:452980 Document No. 79:52980 Original Reference No. 79:8544h,8547a
4-[Substituted alkoxy)-4-(substituted phenyl)cyclohexylamines. Ledniker, Daniel (Upjohn Co.). Ger. Offen. DE 2252716 19730510, 98 pp. (German). CODEN: GWXXBX. APPLICATION: DE 1972-2252716 19721027.
AB The title compds. were prepared in a multistep process starting with Grignard arylation in the 4 position of 4-hydroxycyclohexanone, alkylation of the hydroxy group, conversion of the keto group to an oxime followed by acetylation and reduction (and alkylation of the amino group), or reduction of the keto group to a hydroxy group followed by esterification with a sulfonic acid and amination to replace the ester group. The products were hypotensives.
IT 62020-64-4P 62020-74-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 62020-64-4 CAPLUS
CN Cyclohexanamine, 4-methoxy-4-(2-methoxyphenyl)-, hydrochloride, cis- (9CI)
(CA INDEX NAME)

Relative stereochemistry.

● HCl

RN 62020-74-6 CAPLUS
CN 1-Butanone, 1-[4-fluorophenyl)-4-[[4-methoxy-4-(2-methoxyphenyl)cyclohexyl]amino]-, hydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 59 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

L29 ANSWER 59 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1973:37879 Document No. 78:37879 Original Reference No. 78:5916h,5917a
Partly reduced bigbenyls as central nervous system agents. 2. Cis- and trans-4-arylcyclohexylamines. Lednicer, Daniel; Emmert, D. Edward; Lahti, Robert; Rudzik, Allan D. (Res. Lab., Upjohn Co., Kalamazoo, MI, USA). Journal of Medicinal Chemistry, 15(12), 1239-43 (English) 1972. CODEN: JMCMAR. ISSN: 0022-2623.
AB Trans-4'-fluoro-4-[4-(p-fluorophenyl)cyclohexylamine]butyrophenone-HCl (I-HCl) [36771-97-8], administered i.p. to mice, (1) markedly depressed various behavioral parameters, (2) antagonized nicotine-induced tonic extensor convulsions and death, and (3) antagonized uptake of labeled norepinephrine by the heart and of serotonin by the spleen. The cis isomer was .leq.0.1 as active. Several other derivs. variously substituted in the 4-Ph ring were also highly active with low toxicity. To synthesize I, p-hydroxycyclohexanone was condensed in THF with the appropriate Grignard reagent to form 4-(p-fluorophenyl)-4-hydroxycyclohexanone; this was dehydrated with CF3CO2H and hydrogenated over Pd/C to form 4-(p-fluorophenyl)cyclohexanone; this was converted to the oxime, then with Ac2O to the oxime acetate, and by Birch reduction with NH3-Li in tert-BuOH to the trans-amine. The amine hydrochloride was treated with Na, then with KI, K2CO3, and 4-chloro-p-fluorobutyrophenone 2,2-dimethylpropylene ketal, and finally with HCl to yield I-HCl.
IT 40504-26-5P 40504-39-0P 40504-40-3P
40553-75-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and behavioral activity of)
RN 40504-26-5 CAPLUS
CN Cyclohexanamine, 4-(4-methoxyphenyl)-, hydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

● HCl

RN 40504-39-0 CAPLUS
CN 1-Butanone, 1-(4-fluorophenyl)-4-[[4-(2-methoxyphenyl)cyclohexyl]amino]-, hydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 59 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 40504-40-3 CAPLUS
CN 1-Butanone, 1-(4-fluorophenyl)-4-[[4-(3-methoxyphenyl)cyclohexyl]amino]-, hydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 40533-75-1 CAPLUS
CN 1-Butanone, 1-(4-fluorophenyl)-4-[[4-(4-methoxyphenyl)cyclohexyl]amino]-, hydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L29 ANSWER 60 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

IT 40504-21-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 40504-21-9 CAPLUS
CN Cyclohexanamine, 4-(3-methoxyphenyl)-, hydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

L29 ANSWER 60 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1971:488570 Document No. 75:88570 Original Reference No. 75:14029a,14032a
New oral antidiabetic drugs. I. Ambrogi, V.; Bloch, Konrad; Datuzi, S.; Grigg, P.; Logemann, W.; Parenty, M. A.; Rabini, T.; Tommasini, R. (Ist. Carlo Erba Ric. Ter., Milan, Italy). Arzneimittel-Forschung, 21(2), 200-4
(English) 1971. CODEN: ARZNAD. ISSN: 0004-4172.
GI For diagram(s), see printed CA Issue.
AB All of 20 new pyrazinecarboxamidoethylphenylsulfonylureas had hypoglycemic activity in mice, and 19 were active in rats; in rats N - (4 - [β - (5 -methylpyrazine -2-carboxamido)ethyl]phenylsulfonyl)-N'- cyclohexylurea (I) was the most active producing a hypoglycemic activity of 40% at 1.3 mg/kg orally. 4-(4-[β-(5-Methylpyrazine-2-carboxamido)ethyl]phenylsulfonyl)-1,1 - hexamethylenesemicarbazide (II), the only pyrazinecarboxamidoethylphenylsulfonylsemicarbazide tested, was as effective as I at the same dose. Neither of the 2 pyrazinecarboxamidoethylphenylsulfonylureas tested had antidiabetic activity in mice or rats. The sulfonamide were synthesized by reacting pyrazine-, pyridazine-, or pyrimidinecarboxamidobenzenesulfonamides with cyclohexyl isocyanate. Intermediate benzenesulfonamides were prepared by acylation of p-[β-aminoethyl]benzenesulfonamide. II was prepared from Me-4-(β-[5-methylpyrazine-2-carboxamido]ethyl) phenylsulfonylcarbazate and 1-aminohexamethyleneimine.
IT 33282-81-4P 33282-82-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 33282-81-4 CAPLUS
CN 2-Pyrazinecarboxamide, N-[4-[4-[[[cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]cyclohexyl]-5-methyl- (CA INDEX NAME)



RN 33282-82-5 CAPLUS
CN 2-Pyrazinecarboxamide, N-[4-[4-[[[cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]cyclohexyl]-3,6-dimethyl- (CA INDEX NAME)



L29 ANSWER 61 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1970:509530 Document No. 73:109530 Original Reference No. 73:17823a,17826a
4-Cyano-4-phenylamino-cyclohexanes, blood pressure depressants. Treiber, Hans J.; Zimmermann, Frank (Knoll A.-G. Chemische Fabriken). S. African ZA 6906413 19700218, 32 pp. (English). CODEN: SFXXA3.
PRIORITY: DE 19680910.
GI For diagram(s), see printed CA Issue.
AB The base-substituted title compds. [I, where Q, X, S, Q', X', Z', is each H, halo, CF3, lower alkyl or alkoxy, R is H or lower alkyl and A is straight or branched-chain lower alkylene or hydroxy lower alkylene) have spasmolytic, neuroleptic, and coronary-dilating properties. II are reductively condensed with arakyl amines, Q', X', Z', C6H2AlkN2 (III) to yield I. Thus 4-cyano-4-phenylcyclohexanone (IV) (from (MeO2CCH2CH2)2C(Ph)CN) and homoveratrylamine distilled azeotropically in
PhMe
and the product hydrogenated by addition of NaBH4, the product treated with
2N KOH and Et2O, and the product saturated with HCl yielded 73% 4-cyano-4-phenyl[β-(3,4-dimethoxyphenyl)ethylamino]cyclohexane-HCl. Similarly were prepared 25 I (R = H). Reductive condensation of (IV) and PhCH2CH2NH2 gave 4-cyano-4-phenyl-[(β-phenylethyl)amino]cyclohexane, which heated in alc. with 98% HCO2H 30 min, the mixture treated with 38% formalin, the residue treated with 2N KOH, and the product saturated with HCl
yielded 86% 4-cyano-4-phenyl-N-methyl-N-(β-phenylethyl)amino-cyclohexane. Similarly were prepared 4 I (R = Me). The reactions of II and III are carried out on a mole-to-mole ratio in C6H6
at
60° or PhMe at 110°.
IT 29778-49-2P 29778-50-5P 29778-51-6P
29778-52-7P 29778-53-8P 29778-54-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 29778-49-2 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3,4-dimethoxyphenyl)-4-[[(2-phenylethyl)amino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 29778-50-5 CAPLUS
CN Cyclohexanecarbonitrile, 1-[3,4-dimethoxyphenyl)-4-[[2-[3,4-dimethoxyphenyl)ethyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)

L29 ANSWER 61 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 29778-51-6 CAPLUS
CN Cyclohexanecarbonitrile, 1-[3,4-dimethoxyphenyl)-4-[(3-methyl-2-phenylethyl)amino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 29778-52-7 CAPLUS
CN Cyclohexanecarbonitrile, 1-[3,4-diethoxyphenyl)-4-[[2-(3,4,5-trimethoxyphenyl)ethyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 29778-53-8 CAPLUS

L29 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1967:421608 Document No. 67:216090 Original Reference No. 67:4083a
4,4-Diphenylcyclohexylamines. (Hecht, E., A.-G.). Neth. Appl. NL 6515046 19660616, 36 pp. (Dutch). CODEN: NAXXAN. PRIORITY: DE 19641215.
GI For diagram(s), see printed CA Issue.
AB Title compds. Ia (X = H, NR2R3) (I), where R1 is H, alkyl, alkenyl, or alkynyl with 3-6 C, R2 and R3 are H, alkyl and alkenyl with 1-8 C, cycloalkyl with 3-8 C, or aralkyl, are prepared by hydrogenating the corresponding oximes (Ia) (X = NOH) (II) or treating the corresponding ketones (Ia) (X = O) (III) with an amine NHR2R3 (IV). Thus, 2 g. Raney

Ni

was added to a solution of 2 g. PCH, 7.5 g. 4,4-diphenylcyclohex-2-enone

(V)

oxime [m. 142°], and 200 cc. MeOH. The mixture was hydrogenated at 50° and 6 atmospheric. After 3 molar equivs. of H was taken up, the catalyst was filtered, the filtrate acidified with dilute HCl and evaporated, and the residue recrysts. from EtOH to yield 4,4-diphenylcyclohexylamine-HCl, m. 260°. The following compds. were prepared similarly: the hydrochlorides of the following cyclohexylamines: 4,4-di-p-tolyl [m. 240°], 4,4-bis[p-isopropylphenyl] m. 240°, 2-methyl-4,4-diphenyl, α isomer m. 255-6°, β isomer m. 214-15°, 2-methyl-4,4-di-p-tolyl, isomer mixture m. 85°, 2-ethyl-4,4-diphenyl, α isomer m. 270°, β isomer m. 216-18°, isomer mixture m. 245°, 2-isopropyl-4,4-diphenyl, m. 300°, 2-propyl-4,4-diphenyl (m. 264-5°), 2-butyl-4,4-diphenyl (m. 217-18°); the following cyclohexylamines: 4,4-bis[p-methoxyphenyl), bO.03 176-8°, 4,4-diphenyl, bO.05 162-5°, m. 102°, 2-ethyl-4,4-diphenyl, bO.03 164-6°, and 1-amino-4,4-diphenylcyclohex-2-ene, bO.05 158-60°. An autoclave containing 20 g. V, 35 g. isopropylamine (VI), and 50 cc. tetrahydrofuran (VII) was agitated at 200° for 10 hrs. After cooling, VI and VII were distilled, and the residue (Schiff's base) was dissolved in MeOH and hydrogenated with 2 g. PtO2 until a 2 mole equiva. of H was taken up. Removal of the catalyst, acidification with dilute HCl, and removal of

MeOH

gave 17 g. 1-isopropylamino-4,4-diphenylcyclohexane, bO.05 164-5°, HCl salt m. 230°. The following compds. were prepared similarly: hydrochlorides of the following 4,4-diphenylcyclohexanes: 1-isopropylamino, m. 230°, 1-sec-butylamino, m. 170°, 1-pyrrolidyl, m. 264-5°, 1-[3-(3,6-methylenedioxyphenyl)propylamino], m. 214°, 1-(2-phenylbutylamino), m. 171, 1-isopropylamino-2-methyl, m. 198-200°, 1-pyrrolidino-2-allyl, m. 234-5°; 1-isopropylamino-2-allyl, m. 238°, 1-pyrrolidino, m. 242°, the following 4,4-diphenylcyclohexenes: 1-isopropylamino, bO.05 164-5°, and 1-sec-butylamino, bO.05 166-7°; the following hydrochlorides of 4,4-diphenylcyclohex-2-ene: 1-isopropylamine, m. 258-9°, 1-allylamine, m. 213°, 1-[3-(3,4-dichlorophenyl)ethylamino], m. 200°, 1-isopropylamino-4,4-bis[p-isopropylphenyl)cyclohexane-HCl, m. 190°, 1-isopropylamino-4,4-di-p-tolylcyclohexane-HCl, m. 261°; 1-isopropylamino-2-methyl-4,4-di-p-tolylcyclohexane-HCl α isomer m. 242-3, β isomer m. 253-6; and 1-isopropylamino-4,4-bis(p-chlorophenyl)cyclohex-2-ene-HCl, m. 189°. The following compds. were prepared by alkylating several of the above amines: the following 4,4-diphenylcyclohexanes: 1-dimethylamino, HCl salt m. 248°; 1-methylamino, bO.04 151-2°, 1-ethylamino, bO.05 160-2°, HCl salt m. 237-8°, 1-propylamino, bO.05

L29 ANSWER 61 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN Cyclohexanecarbonitrile, 1-(3,4-diethoxyphenyl)-4-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)

● HCl

RN 29778-54-9 CAPLUS
CN Cyclohexanecarbonitrile, 1-(3,4-diethoxyphenyl)-4-[[2-(4-methoxyphenyl)ethyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)

● HCl

L29 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
162-4°, HCl salt m. 210°), 1-butylamine, bO.05 168-70°, HCl salt m. 110°, 1-n-heylamine, bO.05 178-9°, HCl salt m. 120°, 1-n-octylamine, bO.05 190-3°, HCl salt m. 128-30°, 1-isobutylamino, bO.03 171-5°, HCl salt m. 208-9°; 1-(N-methyl-N-isopropylamino), bO.05 164-5°, HCl salt m. 134-5°, 1-(N-methyl-N-sec-butylamino, bO.05 167-7°, HCl salt m. 188-90°; 1-(N-methyl-N-cyclohexylamino), HCl salt m. 234-5°; 1-diethylamino-2-methyl, HCl salt, α isomer m. 230-1°, β isomer m. 160°; 1-diethylamino-2-ethyl, HCl salt α isomer m. 244-5°, β isomer m. 235°; 1-dimethylamino-1-propyl, HCl salt m. 243°; 1-dimethylamino-1-butyl, HCl salt m. 230°; and 1-(N-isopropyl-N-benzylamino), m. 190°; 1-dimethylamino-4,4-di-p-tolylcyclohexane-HCl, m. 232°; 1-(N-methyl-N-isopropylamino)-4,4-di-p-tolylcyclohexane-HCl, m. 245°; 1-(N-methyl-N-isopropylamino)-4,4-bis(p-isopropylphenyl)cyclohexane-HCl, m. 260°, 1-dimethylamino-2-methyl-4,4-di-p-tolylcyclohexane-HCl, isomers mixt. m. 233-5°, 1-(N-methyl-N-isopropylamino)-4,4-diphenylcyclohex-2-ene-HCl m. 244-5°; and 4,4-bis(p-hydroxyphenyl)cyclohexylamine-HBr. The compds. are useful as pharmaceuticals.
IT 14558-32-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 14558-32-8 CAPLUS
CN Cyclohexanamine, 4,4-bis(4-methoxyphenyl)- (CA INDEX NAME)



L29 ANSWER 63 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN
1966:11239 Document No. 64:11239 Original Reference No. 64:2004g-h,2005a-h,2006a Substituted cyclohexylamines. (Cutter Laboratories, Inc.). NL 6500267 19650715, 29 pp. (Unavailable). PRIORITY: US 19640114.
GI For diagram(s), see printed CA Issue.
AB The title compds. with the general formulas I and II are prepared by standard methods; I has local anesthetic and central nervous system stimulating activity; II has local anesthetic, antiinflammatory, antispasmodic, and antilipemic properties. Thus, to a solution of 477 g. diphenylacetaldehyde in 1.5 l. MeOH, cooled to 5°, is added with stirring under N a cold solution of 56 g. Na in 1.51. MeOH. Stirring is continued and a solution of 187 g. methyl vinyl ketone in 1.5 l. MeOH is added in 2 hrs. with cooling in ice. The mixture is kept overnight, heated 4 hrs. at 60°, and worked up. From 2 reactions, 749 g. 4,4-diphenyl-2-cyclohexen-1-one (III), m. 97-9° (EtOH), is obtained. Similarly is prepared 4,4-bis(4-methoxyphenyl)-2-cyclohexen-1-one (IV), (crude) b0.4 206-50°. A mixture of 88.5 g. 4,4'-dimethylbenzoin, 25 g. activated Raney Ni, and 250 ml. absolute EtOH is hydrogenated 15 hrs. at 50-60°/3.43 atmospheric H to yield 89 g. of a mixture of 4,4'-dimethylhydrobenzoin and 4,4'-dimethylisohydrobenzoin, which mixture is heated 3.5 hrs. at 135° with 400 ml. dichloroacetic acid to yield 44.71 g. bis(4-methylphenyl)acetaldehyde (V), b0.25 125-35°. According to the method used for III are prepared: 4,4-bis(4-chlorophenyl)-2-cyclohexen-1-one (VIa), b0.25 165-95°, and (VIb), b0.25 195-225°; (from V) 4,4-bis(4-methylphenyl)-2-cyclohexen-1-one (VII), (crude) b0.3 170-210°. A solution of 100 g. III in 800 ml. EtOAc is hydrogenated with 2.8 atmospheric H 2 hrs. over 1.5 g. 10% Pd-C to yield 83-91% 4,4-diphenylcyclohexanone (VIII), m. 144.5-6.5° (EtOAc). Similarly are prepared the following 4,4-bis(4-substituted phenyl)cyclohexanones (starting compound, substituent, and m.p. given): IV, OMe (IX), 84-6.5° (iso-PrOH); VIa, Cl (Xa), 87-91°; VIb, Cl (Xb), 153-4° (Xa and Xb are polymorphic and have an identical ir spectrum); VII, Me (XI), 173-4.5° (EtOAc). A mixture of 6.1 g. 2,2'-iminodiethanol, 125 ml. C6H6, and 0.25 g. Dowex 50W-X8 (acid form) is refluxed 0.5 hr. (Dean-Stark apparatus). To this mixture is added 12.0 g. VIII, and refluxing (Dean-Stark apparatus) is continued for 20 hrs. to yield 17.45 g. 2,2'-(4,4-diphenylcyclohexenylimino)diethanol (XII) (low m.p.). Similarly are prepared (from VIII) 3-[(4,4-diphenylcyclohexenyl)-(2-hydroxyethyl)amino]-2-propanol (XIII), oil; 2-[(4,4-diphenylcyclohexenyl)methylamino]ethanol (XIV), oil; N,N-bis(2-ethoxyethyl)-4,4-diphenylcyclohexenylamine (XV), oil; (from IX) 2,2' - [4,4 - bis(4 - methoxyphenyl)cyclohexenylimino]diethanol (XVI); and (from XI) 2,2,'-[4,4-bis(4-methylphenyl)cyclohexenylimino]diethanol (XVII). A solution of 17.45 g. XII in 200 ml. MeOH is hydrogenated 40 hrs.

L29 ANSWER 63 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
at 4.2 atm. H over 0.5 g. PtO2 to yield 62% 2,2'-(4,4-diphenylcyclohexylimino)diethanol (XVIII)-HCl, m. 176.5-9.5°. Similarly are prepd.: (from XIII) 1-[(4,4-diphenylcyclohexyl)(2-hydroxyethyl)amino]-2-propanol-HCl, m. 179.5-81.5°; (from XIV) 72% 2-[(4,4-diphenylcyclohexyl)methylamino]ethanol-HCl, m. 200.5-3° (MeOH-Et2O). A soln. of 10.0 g. VIII and 3.05 g. 2-aminoethanol in 100 ml. MeOH is hydrogenated 40 min. with 3.85 atm. H over 0.1 g. PtO2 to yield 82% 2-(4,4-diphenylcyclohexylamino)ethanol-HCl, m. 197-8°. Similarly are prepd.: 3-(4,4-diphenylcyclohexylamino)propanol-HCl, m. 190-1.5° (free base m. 157-60°); 71% 1-(4,4-diphenylcyclohexylamino)-2-propanol-HCl, m. 212-14°, and 45% 3-(4,4-diphenylcyclohexylamino)-1,2-propanediol-HCl, m. 196-202° (MeOH-Et2O) [free base m. 150-4° (MeOH)]; (from XV) 45% N,N-bis(2-ethoxyethyl)-4,4-diphenylcyclohexylamine-HCl, m. 112-13.5°; (from IX) 3-[(4,4-bis(4 - methoxyphenyl)cyclohexyl)(2 - hydroxyethyl)amino] - 1-propanol-HCl, m. 164-5° (MeOH); 2-[(4,4-bis(4-methoxyphenyl)cyclohexyl)methylamino]ethanol-HCl, m. 187-9° (MeOH); N-(2-methoxyethyl)-4,4-bis(4-methoxyphenyl)cyclohexylamine-HCl, m. 152-4° (iso-PrOH); (from X) 2-[4,4-bis(4-chlorophenyl)cyclohexylamino]ethanol-HCl.0.5H2O, m. 135-6° (MeOH); 1-[(4,4-bis(4-chlorophenyl)cyclohexyl)(2-hydroxyethyl)amino]-2-propanol-HCl, m. 243-4° (MeOH-Et2O); 4-[4,4 - bis(4 - chlorophenyl)cyclohexyl]morpholine - HCl.H2O, m. 224-7° (iso-PrOH); 2-[4,4-bis(4-methoxyphenyl)cyclohexylamino]ethanol-HCl, m. 161-3° (iso-PrOH); 1-[4,4-bis(4-methoxyphenyl)cyclohexyl)(2-hydroxyethyl)amino]-2-propanol-C2H2O4, m. 155-7° (MeOH-Et2O); and the following 2,2'-[4,4 - bis(4 - substituted phenyl)cyclohexylimino] diethanol - HCl (substituent and m.p. given): (from XVII), Me, 161-3°; Cl, 190-3° (MeOH-Et2O); (from XVI), OMe, 160.5-2° (iso-PrOH). To a dry soln. of 20.37 g. XVIII and 9.91 g. methyl carbamate in 150 ml. chlorobenzene is added 1.25 g. aluminum isopropoxide and the mixt. is boiled 22 hrs. to yield 2,2'-(4,4-diphenylcyclohexylimino)diethanol monocarbamate-HCl, m. 220.5-4° (also some dicarbamate isolated, no phys. consts.). A soln. of 20.08 g. 2,2-diphenylcyclohexylamine (XIX) and 20.0 g. 2-bromoethanol in 50 ml. abs. EtOH is refluxed 17 hrs. to yield 24.32 g. 2-(2,2-diphenylcyclohexylamino)ethanol (XX)-HBr, m. 203.5-9.5° (Et2O); XX.HCl m. 239-41.5° (MeOH-Et2O). To a mixt. of 25.0 g. XX.HCl in 500 ml. H2O is added 20 g. 37% CH2O soln., and the mixt. is hydrogenated 42 hrs. at 50° and 2.8 atm. H over 5.0 g. 10% Pd-C to yield 14.1 g. 2-[(2,2-diphenylcyclohexyl)methylamino]ethanol-HCl, m. 180-3° (MeOH-Et2O). From 22.0 g. XIX and 14.0 g. 3-bromo-1-propanol is obtained (via the base) 12.25 g. 3-(2,2-diphenylcyclohexylamino)propanol-HCl.H2O, m. 101-5° (decompn.) (MeOH-Et2O). A soln. of 14.65 g. XX.HBr and 34.3 g. PBr3 in 75 ml. CHCl3 is refluxed 1.5 hrs. to yield 15.2 g. N-(2-bromoethyl)-2,2-diphenylcyclohexylamine-HBr, m. 257-9° (decompn.)(EtOH), which is treated in 400 ml. CHCl3 with 12.0 g. freshly prepd. AgOAc. The mixt. is refluxed with stirring 70 hrs. to yield 11.2 g. 2-(2,2-diphenylcyclohexylamino)ethanyl acetate-HCl, m. 197-9° (EtOH-Et2O). To a cooled soln. of XX in 150 ml. dry C6H6 (obtained from 15.0 g. XX.HBr) is added 1.0 g. 1,4-diazabicyclo[2.2.2]octane and 6.0 g. methyl isocyanate to yield after 19 days at 5° 6.5 g.

L29 ANSWER 63 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
2-(2,2-diphenylcyclohexylamino)ethanol methylcarbamate (XXI)-HCl, m. 173-6° (MeOH-Et2O); free XXI m. 146.5-8° (hexane). A mixt. of 25.0 g. XIX, 15.0 g. Na2CO3, 25.0 g. bis(2-chloroethyl) ether (XXII), and 175 ml. dry PhMe is refluxed (Dean-Stark app.) with stirring 3 days to yield 9.0 g. 4-(2,2-diphenylcyclohexyl)morpholine (XXIII), m. 93-6° (MeOH); XXIII.HCl m. 179-83° (decompn.) (MeOH-Et2O). More XXIII.HCl is obtained from the mother liquor by another treatment with XXII.
IT 4538-68-5P, Cyclohexylamine, N-(2-methoxyethyl)-4,4-bis(p-methoxyphenyl)-, hydrochloride
4538-71-0P, Ethanol, 2-[[4,4-bis(p-methoxyphenyl)cyclohexyl]amino]-, hydrochloride
RL: PREP (Preparation)
(preparation of)
RN 4538-68-5 CAPLUS
CN Cyclohexanamine, N-(2-methoxyethyl)-4,4-bis(4-methoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 4538-71-0 CAPLUS
CN Ethanol, 2-[[4,4-bis(4-methoxyphenyl)cyclohexyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L29 ANSWER 63 OF 63 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

10576581.trn

```
=> FIL STNGUIDE
FILE 'STNGUIDE' ENTERED AT 14:36:23 ON 02 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 29, 2009 (20090529/UP).

=> d his

     (FILE 'HOME' ENTERED AT 13:35:47 ON 02 JUN 2009)

     FILE 'REGISTRY' ENTERED AT 13:35:58 ON 02 JUN 2009
L1             STRUCTURE UPLOADED
L2          13 S L1
L3             STRUCTURE UPLOADED
L4          50 S L3
L5       16588 S L3 FULL

     FILE 'STNGUIDE' ENTERED AT 13:43:45 ON 02 JUN 2009

     FILE 'CAPLUS' ENTERED AT 13:49:42 ON 02 JUN 2009

     FILE 'STNGUIDE' ENTERED AT 13:49:49 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 13:55:44 ON 02 JUN 2009
L6             STRUCTURE UPLOADED
```

10576581.trn

```
L18          18 S L17
L19          50 S SAM L18 SUB=L5
L20          50 S SAM L17 SUB=L5
L21             STRUCTURE UPLOADED
L22          26 S L21
L23          42 S SAM L22 SUB=L5
L24         781 S FULL L22 SUB=L5

     FILE 'CAPLUS' ENTERED AT 14:23:31 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 14:23:42 ON 02 JUN 2009

     FILE 'CAPLUS' ENTERED AT 14:23:45 ON 02 JUN 2009

     FILE 'CAPLUS' ENTERED AT 14:24:02 ON 02 JUN 2009
L25          75 S L24
L26          59 S L25 AND PY<=2004
L27          52 S L25 AND PRD<=2004
L28          52 S L25 AND PRY<=2004
L29          63 S L26 OR L27 OR L28

     FILE 'STNGUIDE' ENTERED AT 14:36:23 ON 02 JUN 2009

=> FIL CAPLUS
FILE 'CAPLUS' ENTERED AT 14:38:31 ON 02 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
```

10576581.trn

```
=> s cholesterol
        198942 CHOLESTEROL
           942 CHOLESTEROLS
L30     199139 CHOLESTEROL
                  (CHOLESTEROL OR CHOLESTEROLS)

=> d hi
'HI' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
```

10576581.trn

structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):d his
'D' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)

10576581.trn

```
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):end

=> d his

     (FILE 'HOME' ENTERED AT 13:35:47 ON 02 JUN 2009)
```

10576581.trn

```
     FILE 'REGISTRY' ENTERED AT 14:03:14 ON 02 JUN 2009

     FILE 'HCAPLUS' ENTERED AT 14:03:23 ON 02 JUN 2009
L14             4 S L5 AND L12
L15               STRUCTURE UPLOADED

     FILE 'REGISTRY' ENTERED AT 14:07:39 ON 02 JUN 2009
L16            50 S SAM L15 SUB=L5

     FILE 'STNGUIDE' ENTERED AT 14:18:03 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 14:20:55 ON 02 JUN 2009
L17               STRUCTURE UPLOADED

     FILE 'REGISTRY' ENTERED AT 14:21:18 ON 02 JUN 2009
L18            18 S L17
L19            50 S SAM L18 SUB=L5
L20            50 S SAM L17 SUB=L5
L21               STRUCTURE UPLOADED
L22            26 S L21
L23            42 S SAM L22 SUB=L5
L24           781 S FULL L22 SUB=L5

     FILE 'CAPLUS' ENTERED AT 14:23:31 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 14:23:42 ON 02 JUN 2009
```

10576581.trn

=>
Uploading C:\Program Files\Stnexp\Queries\10576581-7777777.str



chain nodes :
18 19
ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13

10576581.trn

=> file reg
FILE 'REGISTRY' ENTERED AT 14:40:39 ON 02 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 1 JUN 2009 HIGHEST RN 1151607-22-5
DICTIONARY FILE UPDATES: 1 JUN 2009 HIGHEST RN 1151607-22-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

10576581.trn

```
     FILE 'CAPLUS' ENTERED AT 13:58:03 ON 02 JUN 2009
L11             4 S L10
L12          6519 S LDL RECEPTOR

     FILE 'REGISTRY' ENTERED AT 14:02:44 ON 02 JUN 2009

     FILE 'CAPLUS' ENTERED AT 14:02:48 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 14:03:14 ON 02 JUN 2009

     FILE 'HCAPLUS' ENTERED AT 14:03:23 ON 02 JUN 2009
L14             4 S L5 AND L12
L15               STRUCTURE UPLOADED

     FILE 'REGISTRY' ENTERED AT 14:07:39 ON 02 JUN 2009
L16            50 S SAM L15 SUB=L5

     FILE 'STNGUIDE' ENTERED AT 14:18:03 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 14:20:55 ON 02 JUN 2009
L17               STRUCTURE UPLOADED

     FILE 'REGISTRY' ENTERED AT 14:21:18 ON 02 JUN 2009
L18            18 S L17
L19            50 S SAM L18 SUB=L5
L20            50 S SAM L17 SUB=L5
```

10576581.trn

```
     FILE 'CAPLUS' ENTERED AT 14:40:49 ON 02 JUN 2009
L35             TRA L32 1- RN :     8976 TERMS

     FILE 'REGISTRY' ENTERED AT 14:40:56 ON 02 JUN 2009
L36         8976 SEA L35

=> s l36 and l12
            346 LDL
         141349 RECEPTOR
              3 RECEPTORS
         141350 RECEPTOR
                   (RECEPTOR OR RECEPTORS)
            194 LDL RECEPTOR
                   (LDL(W)RECEPTOR)
L37           0 L36 AND L12

=> d his

     (FILE 'HOME' ENTERED AT 13:35:47 ON 02 JUN 2009)

     FILE 'REGISTRY' ENTERED AT 13:35:58 ON 02 JUN 2009
L1                STRUCTURE UPLOADED
L2             13 S L1
L3                STRUCTURE UPLOADED
L4             50 S L3
L5          16588 S L3 FULL
```

10576581.trn

```
     FILE 'REGISTRY' ENTERED AT 14:07:39 ON 02 JUN 2009
L16          50 S SAM L15 SUB=L5

     FILE 'STNGUIDE' ENTERED AT 14:18:03 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 14:20:55 ON 02 JUN 2009
L17             STRUCTURE UPLOADED

     FILE 'REGISTRY' ENTERED AT 14:21:18 ON 02 JUN 2009
L18          18 S L17
L19          50 S SAM L18 SUB=L5
L20          50 S SAM L17 SUB=L5
L21             STRUCTURE UPLOADED
L22          26 S L21
L23          42 S SAM L22 SUB=L5
L24         781 S FULL L22 SUB=L5

     FILE 'CAPLUS' ENTERED AT 14:23:31 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 14:23:42 ON 02 JUN 2009

     FILE 'CAPLUS' ENTERED AT 14:23:45 ON 02 JUN 2009

     FILE 'CAPLUS' ENTERED AT 14:24:02 ON 02 JUN 2009
L25          75 S L24
L26          59 S L25 AND PY<=2004
L27          52 S L25 AND PRD<=2004
```

10576581.trn

100.0% PROCESSED 40 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET): ONLINE **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET): 421 TO 1179
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET): 1 TO 80

L39 1 SEA SUB=L38 SSS SAM L34

=> d scan

10576581.trn

L19 1 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide,
N-[trans-4-[4-(aminocarbonyl)phenyl]cyclohexyl]-N-cyclopropyl-4-
[(1S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]-
MF C26 H29 F3 N2 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

10576581.trn

```
=> d his

     (FILE 'HOME' ENTERED AT 13:35:47 ON 02 JUN 2009)

     FILE 'REGISTRY' ENTERED AT 13:35:58 ON 02 JUN 2009
L1                STRUCTURE UPLOADED
L2             13 S L1
L3                STRUCTURE UPLOADED
L4             50 S L3
L5          16588 S L3 FULL

     FILE 'STNGUIDE' ENTERED AT 13:43:45 ON 02 JUN 2009

     FILE 'CAPLUS' ENTERED AT 13:49:42 ON 02 JUN 2009

     FILE 'STNGUIDE' ENTERED AT 13:49:49 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 13:55:44 ON 02 JUN 2009
L6                STRUCTURE UPLOADED
L7              0 S SAM L6 SUB=L5
L8                STRUCTURE UPLOADED
L9              0 S SAM L8 SUB=L5
L10            16 S FULL L8 SUB=L5

     FILE 'CAPLUS' ENTERED AT 13:58:03 ON 02 JUN 2009
L11             4 S L10
L12          6519 S LDL RECEPTOR

     FILE 'REGISTRY' ENTERED AT 14:02:44 ON 02 JUN 2009

     FILE 'CAPLUS' ENTERED AT 14:02:48 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 14:03:14 ON 02 JUN 2009

     FILE 'HCAPLUS' ENTERED AT 14:03:23 ON 02 JUN 2009
L14             4 S L5 AND L12
L15               STRUCTURE UPLOADED

     FILE 'REGISTRY' ENTERED AT 14:07:39 ON 02 JUN 2009
L16            50 S SAM L15 SUB=L5

     FILE 'STNGUIDE' ENTERED AT 14:18:03 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 14:20:55 ON 02 JUN 2009
L17               STRUCTURE UPLOADED

     FILE 'REGISTRY' ENTERED AT 14:21:18 ON 02 JUN 2009
L18            18 S L17
L19            50 S SAM L18 SUB=L5
L20            50 S SAM L17 SUB=L5
L21               STRUCTURE UPLOADED
L22            26 S L21
L23            42 S SAM L22 SUB=L5
L24           781 S FULL L22 SUB=L5
```

10576581.trn

```
     FILE 'CAPLUS' ENTERED AT 14:23:31 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 14:23:42 ON 02 JUN 2009

     FILE 'CAPLUS' ENTERED AT 14:23:45 ON 02 JUN 2009

     FILE 'CAPLUS' ENTERED AT 14:24:02 ON 02 JUN 2009
L25           75 S L24
L26           59 S L25 AND PY<=2004
L27           52 S L25 AND PRD<=2004
L28           52 S L25 AND PRY<=2004
L29           63 S L26 OR L27 OR L28

     FILE 'STNGUIDE' ENTERED AT 14:36:23 ON 02 JUN 2009

     FILE 'CAPLUS' ENTERED AT 14:38:31 ON 02 JUN 2009
L30       199139 S CHOLESTEROL
L31         3768 S L5
L32           63 S L31 AND L30
L33            8 S L32 AND AMIDE
L34              STRUCTURE UPLOADED

     FILE 'REGISTRY' ENTERED AT 14:40:39 ON 02 JUN 2009

     FILE 'CAPLUS' ENTERED AT 14:40:49 ON 02 JUN 2009
L35              TRA L32 1- RN :     8976 TERMS

     FILE 'REGISTRY' ENTERED AT 14:40:56 ON 02 JUN 2009
L36         8976 SEA L35
L37            0 S L36 AND L12
L38         1173 S L36 AND L5
L39            1 S SAM L34 SUB=L38

=> tra rn l14
L40          TRANSFER L14 1- RN :    1422 TERMS
L41         1422 L40

=> s l41 not l38
L42         1220 L41 NOT L38

=> s l38 not l41
L43          971 L38 NOT L41

=> s sub=l43 sam l38
SUBSET AND SAMPLE ARE IGNORED FOR THIS SEARCH
L44         1173 L36 AND L5

=> s sub=l43 sam l38
SUBSET AND SAMPLE ARE IGNORED FOR THIS SEARCH
L45         1173 L36 AND L5

=> s sub=l43 sam l34
SAMPLE SUBSET SEARCH INITIATED 14:43:45 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED -       37 TO ITERATE
```

10576581.trn

```
100.0% PROCESSED       37 ITERATIONS                                1 ANSWERS
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):           ONLINE  **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):          376 TO     1104
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):               1 TO       80

L46           1 SEA SUB=L43 SSS SAM L34

=> s sub=143 full 134
FULL SUBSET SEARCH INITIATED 14:44:04 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -      769 TO ITERATE

100.0% PROCESSED      769 ITERATIONS                               12 ANSWERS
SEARCH TIME: 00.00.01

L47          12 SEA SUB=L43 SSS FUL L34

=> d scan
```

L47 12 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Acetamide, 2-[methyl[4-[4-[methyl[pentylsulfonyl]amino]cyclohexyl]phenyl]methyl]amino]-, trans-(9CI)
MF C22 H37 N3 O3 S

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1)-200

L47 12 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Acetamide, N-[4-[4-[[2-amino-2-oxoethyl]methylamino]methyl]phenyl]cyclohexyl]-N-(phenylmethyl)-, trans-(9CI)
MF C25 H33 N3 O2

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L47 12 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Acetamide, 2-[[[4-[4-[[4-[(4-fluorophenyl)methyl]methylsulfonyl]amino]cyclohexyl]phenyl]methyl]amino]-, trans-(9CI)
MF C24 H32 F N3 O3 S

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L47 12 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, N-[4-[4-[1-[[2-amino-2-oxoethyl]methylamino]ethyl]phenyl]cyclohexyl]-4-chloro-N-methyl-
MF C25 H32 Cl N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L47 12 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Acetamide, 2-[[3-[4-[4-[[(4-chlorophenyl)sulfonyl]methylamino]cyclohexyl]phenyl]ethyl]methylamino]-
MF C24 H32 Cl N3 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L47 12 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Butenamide, N-[4-[4-[[2-amino-2-oxoethyl)methylamino]methyl]phenyl]cyclohexyl]-N-methyl-4-phenyl-, trans- (9CI)
MF C27 H35 N3 O2

Relative stereochemistry.
Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L47 12 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 1,5(2H)-Pyrimidinedicarboxamide, N1-[2-[(cis-4-cyano-4-phenylcyclohexyl)amino]ethyl]-6-(2,4-difluorophenyl)-4-ethyl-3,6-dihydro-2-oxo-, hydrochloride (1:1), (+)-
MF C29 H32 F2 N6 O3 . Cl H

Rotation (+). Absolute stereochemistry unknown.



● HCl

L47 12 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, N-[trans-4-[4-(aminoacetonitrilyl)phenyl]cyclohexyl]-N-ethyl-4-[(2S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]-
MF C25 H29 F3 N2 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L47 12 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, N-[trans-4-[4-[aminocarbonyl]phenyl]cyclohexyl]-N-cyclopropyl-4-[[(1S)-3,3,3-trifluoro-1-hydroxy-1-methylethyl]-
MF C26 H29 F3 N2 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L47 12 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Acetamide, 2-[[[4-[4-[[4-chlorophenyl]sulfonyl]methylamino]cyclohexyl]phenyl]methyl]methylamino]-, trans- (9CI)
MF C23 H30 Cl N3 O3 S

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L47 12 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, N-[4-[4-[[[2-amino-2-oxoethyl]methylamino]methyl]phenyl]cyclohexyl]-4-chloro-N-methyl-, trans- (9CI)
MF C24 H30 Cl N3 O2

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L47 12 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, N-[4-[4-[[[2-amino-1-methyl-2-oxoethyl]methylamino]methyl]phenyl]cyclohexyl]-4-chloro-N-methyl-
MF C25 H32 Cl N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

10576581.trn

=>
Uploading C:\Program Files\Stnexp\Queries\2356213451234.str





10576581.trn

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 17:CLASS 18:CLASS 19:Atom 20:Atom 21:Atom 22:Atom
23:Atom 24:CLASS 25:Atom 26:Atom 27:CLASS 28:Atom 29:Atom 30:Atom 31:Atom

L48   STRUCTURE UPLOADED

=> d l48
L48 HAS NO ANSWERS
L48   STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> d his

     (FILE 'HOME' ENTERED AT 13:35:47 ON 02 JUN 2009)

     FILE 'REGISTRY' ENTERED AT 13:35:58 ON 02 JUN 2009
L1   STRUCTURE UPLOADED
L2   13 S L1
L3   STRUCTURE UPLOADED

10576581.trn

```
L15             STRUCTURE UPLOADED

     FILE 'REGISTRY' ENTERED AT 14:07:39 ON 02 JUN 2009
L16          50 S SAM L15 SUB=L5

     FILE 'STNGUIDE' ENTERED AT 14:18:03 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 14:20:55 ON 02 JUN 2009
L17             STRUCTURE UPLOADED

     FILE 'REGISTRY' ENTERED AT 14:21:18 ON 02 JUN 2009
L18          18 S L17
L19          50 S SAM L18 SUB=L5
L20          50 S SAM L17 SUB=L5
L21             STRUCTURE UPLOADED
L22          26 S L21
L23          42 S SAM L22 SUB=L5
L24         781 S FULL L22 SUB=L5

     FILE 'CAPLUS' ENTERED AT 14:23:31 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 14:23:42 ON 02 JUN 2009

     FILE 'CAPLUS' ENTERED AT 14:23:45 ON 02 JUN 2009

     FILE 'CAPLUS' ENTERED AT 14:24:02 ON 02 JUN 2009
L25          75 S L24
```

10576581.trn

```
     FILE 'REGISTRY' ENTERED AT 14:42:30 ON 02 JUN 2009
L41         1422 SEA L40
L42         1220 S L41 NOT L38
L43          971 S L38 NOT L41
L44         1173 S SUB=L43 SAM L38
L45         1173 S SUB=L43 SAM L38
L46            1 S SAM L34 SUB=L43
L47           12 S FULL L34 SUB=L43
L48              STRUCTURE UPLOADED

=> s sub=l5 sam l48
SAMPLE SUBSET SEARCH INITIATED 14:48:00 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED -       32 TO ITERATE

100.0% PROCESSED       32 ITERATIONS                              0 ANSWERS
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):           ONLINE  **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):          301 TO      979
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):               0 TO        0

L49            0 SEA SUB=L5 SSS SAM L48

=> s sub=l5 full l48
FULL SUBSET SEARCH INITIATED 14:48:18 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -      521 TO ITERATE
```

10576581.trn



10576581.trn

L51 STRUCTURE UPLOADED

=> d 151
L51 HAS NO ANSWERS
L51 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 151
SAMPLE SEARCH INITIATED 14:52:24 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 8569 TO ITERATE

23.3% PROCESSED 2000 ITERATIONS 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 165831 TO 176929
PROJECTED ANSWERS: 1 TO 209

10576581.trn

```
L11             4 S L10
L12          6519 S LDL RECEPTOR

     FILE 'REGISTRY' ENTERED AT 14:02:44 ON 02 JUN 2009

     FILE 'CAPLUS' ENTERED AT 14:02:48 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 14:03:14 ON 02 JUN 2009

     FILE 'HCAPLUS' ENTERED AT 14:03:23 ON 02 JUN 2009
L14             4 S L5 AND L12
L15               STRUCTURE UPLOADED

     FILE 'REGISTRY' ENTERED AT 14:07:39 ON 02 JUN 2009
L16            50 S SAM L15 SUB=L5

     FILE 'STNGUIDE' ENTERED AT 14:18:03 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 14:20:55 ON 02 JUN 2009
L17               STRUCTURE UPLOADED

     FILE 'REGISTRY' ENTERED AT 14:21:18 ON 02 JUN 2009
L18            18 S L17
L19            50 S SAM L18 SUB=L5
L20            50 S SAM L17 SUB=L5
L21               STRUCTURE UPLOADED
L22            26 S L21
```

10576581.trn

```
L35             TRA L32 1- RN :     8976 TERMS

     FILE 'REGISTRY' ENTERED AT 14:40:56 ON 02 JUN 2009
L36         8976 SEA L35
L37            0 S L36 AND L12
L38         1173 S L36 AND L5
L39            1 S SAM L34 SUB=L38

     FILE 'HCAPLUS' ENTERED AT 14:42:29 ON 02 JUN 2009
L40             TRA L14 1- RN :     1422 TERMS

     FILE 'REGISTRY' ENTERED AT 14:42:30 ON 02 JUN 2009
L41         1422 SEA L40
L42         1220 S L41 NOT L38
L43          971 S L38 NOT L41
L44         1173 S SUB=L43 SAM L38
L45         1173 S SUB=L43 SAM L38
L46            1 S SAM L34 SUB=L43
L47           12 S FULL L34 SUB=L43
L48              STRUCTURE UPLOADED
L49            0 S SAM L48 SUB=L5
L50            0 S FULL L48 SUB=L5
L51              STRUCTURE UPLOADED
L52            1 S L51

=> s sub=l5 sam l52
SAMPLE SUBSET SEARCH INITIATED 14:52:37 FILE 'REGISTRY'
```

10576581.trn

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Jun 2009 VOL 150 ISS 23
FILE LAST UPDATED: 1 Jun 2009 (20090601/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l54
L55 3 L54

L55 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN
2005:1123880 Document No. 143:4059230 Preparation of heterocycle- and benzene-containing sulfonamide derivatives as LDL receptor agonists.
Ban, Hitoshi; Asano, Shigehiro (Sumitomo Pharmaceuticals Co., Ltd., Japan). PCT Int. Appl. WO 2005097738 A1 20051020, 233 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2005-JP6977 20050404. PRIORITY: JP 2004-112503 20040406.
GI



I



II

AB Enhancers for expression of low d. lipoprotein receptor containing the title compds. represented by the formula (I), prodrugs thereof, and their pharmaceutically acceptable salts [m, n, p = 0-4 and 3≤m+n≤8; X = O, S, each (un)substituted NH or CH2; R1 -R3 = H, each (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, arylsulfonyl, heteroarylsulfonyl, arylalkyl, or heteroarylalkyl; Y = SO2, optionally esterified P(O)(OH), CO; Z = O, S, (un)substituted NH, (CH2)q; q = 0-4; a, b, c, d, e, f = H, HO, each (un)substituted alkyl, alkoxy, alkoxycarbonyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, arylalkyl, heteroarylalkyl, arylalkyloxy, or heteroarylalkyloxy; or one or plural combination(s) of a and b, c and d, or e and f represent oxo; e and f

L55 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
represent thioxo; a and c represent alkylene] are disclosed. Drugs for treating hyperlipemia and arteriosclerosis contg. the compds. I are also disclosed. Thus, a soln. of 40 mg tert-Bu [[[2-[cis-4-amino-1-(3-methoxyphenyl)cyclohexyl]methyl]amino]sulfonyl]carbamate and 22.0 mg 1-benzyl-4-piperidone in 2 mL 1,2-dichloroethane was treated with 71.7 mg sodium triacetoxyborohydride and stirred overnight, followed by treatment of the product with CF_3CO_2H in CH_2Cl_2 to give N-[[cis-4-[(1-benzylpiperidin-4-yl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]sulfonamide (II) (R4 = NH2, R5 = 1-benzyl-4-piperidinyl) (III). III and II (R4 = Me, R5 = 1,1'-biphenyl-4-ylmethyl) at 10 μM increased the uptake of 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI)-labeled human low d. lipoprotein in HepG2 cells by 230 and 238%, resp.
IT 867264-21-9P 867264-32-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of heterocycle- and benzene-containing sulfonamide derivs. as LDL receptor agonists for treatment of hyperlipemia and arteriosclerosis)
RN 867264-21-9 CAPLUS
CN Carbamic acid, [[[[cis-4-[([1,1'-biphenyl]-4-ylmethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]amino]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867264-32-2 CAPLUS
CN Carbamic acid, [[[[cis-4-[([1,1'-biphenyl]-4-ylmethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]amino]sulfonyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

L55 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



IT 850886-15-6P 850886-16-7P, N-[[cis-4-[(Biphenyl-4-ylmethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]-4-methylbenzenesulfonamide 867263-53-4P 867263-74-9P 867263-77-2P 867263-78-3P 867263-82-9P 867263-85-2P 867264-17-3P 867264-22-0P 867264-23-1P 867264-27-5P 867264-29-7P 867264-30-0P 867264-31-1P 867264-33-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocycle- and benzene-containing sulfonamide derivs. as LDL receptor agonists for treatment of hyperlipemia and arteriosclerosis)
RN 850886-15-6 CAPLUS
CN Methanesulfonamide, N-[[cis-4-[([1,1'-biphenyl]-4-ylmethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-16-7 CAPLUS
CN Benzenesulfonamide, N-[[cis-4-[([1,1'-biphenyl]-4-ylmethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]-4-methyl- (CA INDEX NAME)

Relative stereochemistry.

L55 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867263-53-4 CAPLUS
CN Methanesulfonamide, N-[cis-4-[([1,1'-biphenyl]-4-ylmethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-74-9 CAPLUS
CN Sulfamide, N-[[cis-4-[(1-[1,1'-biphenyl]-4-ylethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.

L55 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 867263-77-2 CAPLUS
CN Sulfamide, N-[[cis-4-[[1,1'-biphenyl]-4-ylethyl]amino]-1-[3-methoxyphenyl]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-78-3 CAPLUS
CN Sulfamide, N-[2-[trans-4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-[3-methoxyphenyl]cyclohexyl]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.

L55 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 867264-17-3 CAPLUS
CN Methanesulfonamide, N-[[cis-4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-[3-ethoxyphenyl]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867264-22-0 CAPLUS
CN Sulfamide, N-[[cis-4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-[3-methoxyphenyl]cyclohexyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 867264-23-1 CAPLUS
CN Sulfamide, N-[[trans-4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-[3-methoxyphenyl]cyclohexyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.

L55 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 867263-82-9 CAPLUS
CN Sulfamide, N-[[cis-4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-[3-methoxyphenyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-85-2 CAPLUS
CN Benzenesulfonamide, N-[[cis-4-[[1,1'-biphenyl]-4-ylmethyl)amino]-1-[3-methoxyphenyl]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



L55 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 867264-27-5 CAPLUS
CN Sulfamide, N-[[cis-4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-[3-ethoxyphenyl]cyclohexyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 867264-29-7 CAPLUS
CN Acetamide, N-[[[[cis-4-[[[1,1'-biphenyl]-4-ylmethyl)amino]-1-[3-methoxyphenyl]cyclohexyl]methyl]amino]sulfonyl]- (CA INDEX NAME)

Relative stereochemistry.



L55 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867264-30-0 CAPLUS
CN Propanamide, N-[[[cis-4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-[3-methoxyphenyl]cyclohexyl]methyl]amino]sulfonyl]-2-methyl- (CA INDEX NAME)

Relative stereochemistry.



RN 867264-31-1 CAPLUS
CN Carbamic acid, [[[[cis-4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-[3-methoxyphenyl]cyclohexyl]methyl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867264-33-3 CAPLUS
CN Sulfamide, N-[[cis-4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-[3-methoxyphenyl]cyclohexyl]methyl]-N'-methyl-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.

L55 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867264-25-3 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-[3-methoxyphenyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.



IT 850886-32-8P 867263-76-1P 867263-81-8P
867264-38-4P 867264-39-5P 867264-20-8P
867264-24-2P 867264-26-4P 867264-28-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclo- and benzene-containing sulfonamide derivs. as LDL receptor agonists for treatment of hyperlipemia and arteriosclerosis)

RN 850886-32-8 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-[3-methoxyphenyl]-, cis- (CA INDEX NAME)

Relative stereochemistry.



L55 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

IT 850886-11-2, cis-4-(Aminomethyl)-N-(biphenyl-4-ylmethyl)-4-(3-methoxyphenyl)cyclohexanamine 867263-75-0 867264-25-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heterocyclo- and benzene-containing sulfonamide derivs. as LDL receptor agonists for treatment of hyperlipemia and arteriosclerosis)

RN 850886-11-2 CAPLUS
CN [1,1'-Biphenyl]-4-methanamine, N-[cis-4-(aminomethyl)-4-(3-methoxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867263-75-0 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[1-[1,1'-biphenyl]-4-ylethyl]amino]-1-(3-methoxyphenyl)-, trans- (CA INDEX NAME)

Relative stereochemistry.

L55 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867263-76-1 CAPLUS
CN Carbamic acid, [[[[trans-4-[[1-[1,1'-biphenyl]-4-ylethyl]amino]-1-[3-methoxyphenyl]cyclohexyl]methyl]amino]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867263-81-8 CAPLUS
CN Carbamic acid, [[[2-[cis-4-[[1,1'-biphenyl]-4-ylmethyl]amino]-1-[3-methoxyphenyl]cyclohexyl]ethyl]amino]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 867264-18-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[cis-4-cyano-4-(3-methoxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

L55 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 867264-19-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[cis-4-cyano-4-(3-hydroxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867264-20-8 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[cis-4-cyano-4-(3-ethoxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 867264-24-2 CAPLUS
CN [1,1'-Biphenyl]-4-methanamine, N-[trans-4-(aminomethyl)-4-(3-methoxyphenyl)cyclohexyl]- (CA INDEX NAME)

L55 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Relative stereochemistry.



RN 867264-26-4 CAPLUS
CN Carbamic acid, [[[trans-4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]amino]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867264-28-6 CAPLUS
CN Carbamic acid, [[[[cis-4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-(3-ethoxyphenyl)cyclohexyl]methyl]amino]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



L55 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN
2005:369273 Document No. 142:430990 Preparation of novel piperidine and cyclohexanecarbonitrile derivatives effective in enhancing LDL receptor manifestation. Ban, Hitoshi; Uhnuma, Satoshi; Tsuboya, Norie; Asano, Shigehiro (Sumitomo Pharmaceuticals Co., Ltd., Japan). PCT Int. Appl. WO 2005037269 A1 20050428, 209 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DZ, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, NL, MR, NE, NL, PT, SE, SM, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2004-JP15773 20041019. PRIORITY: JP 2003-361254 20031021.

GI



AB Drugs for enhancing LDL receptor manifestation contains compds. represented by the following formula (I), prodrugs thereof, or pharmaceutically acceptable salts of either [n, n, p = 0-4, provided that 3≤n+n≤8; X = N, each (un)substituted CH; Y = each (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, or aromatic group, COY; R1 = H, each (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, 3- to 8-membered saturated heterocyclyl containing one (un)substituted NH or O, aromatic group, COR14; R14 = each (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, or aromatic group; R2-R7 = H, CN, each (un)substituted alkyl, alkoxy, alkoxycarbonyl, aralkyl, heteroarylalkyl, aralkyloxy, or heteroarylalkyloxy; or one or a plural combination of R2 and R3, R4 and R5, or R6 and R7 = oxo; or R2 and R4 together = alkylene; two of R2-R5 are on the adjacent carbon atom to form a double bond; Z = H, CN, CO2H, cyano, phthalimido, halo, each (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, or aromatic group, etc.] as active ingredients. These compds. are effective in enhancing low d. lipoprotein (LDL) receptor manifestation and lowering blood concentration of LDL cholesterol and are useful as therapeutic agents for treating hyperlipemia and arteriosclerosis. Thus, 0.019 mL benzyl bromide was added to a suspension of 60 mg 4-(3-methoxyphenyl)-1,4'-bipiperidine-4-carbonitrile dihydrochloride and 92.6 mg K2CO3 in 1.0 mL DMF under ice-cooling, and the resulting mixture was warmed to room temperature, stirred overnight, and quenched by adding water to

L55 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
give, after workup and silica gel chromatog., 15.4 g 1'-benzyl-4-(3-methoxyphenyl)-3',6'-bipiperidine-4-carbonitrile (II). II at 10 μM and N-benzyl-4-(3-methoxyphenyl)-3-(pyrimidin-2-yl)piperidine-4-carbothioamide at 3 μM enhanced the LDL receptor activity by 135 and 193%, resp.

IT 850886-31-2P, cis-4-(Aminomethyl)-N-(biphenyl-4-ylmethyl)-4-(3-methoxyphenyl)cyclohexanamine 850886-33-4P
RL: PAC (Pharmacological activity); ACT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (Unsa)
(preparation of novel piperidine and cyclohexanecarbonitrile derivs. as

as
enhancers for LDL receptor manifestation, hypolipidemics, and antiatherosclerotics)

RN 850886-33-4 CAPLUS
CN [1,1'-Biphenyl]-4-methanamine, N-[cis-4-(aminomethyl)-4-(3-methoxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-33-9 CAPLUS
CN Cyclohexanecarbonitrile, 4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



IT 850886-33-4P, cis-N-(Biphenyl-4-ylmethyl)-4-[(ethylamino)methyl]-4-(3-methoxyphenyl)cyclohexanamine 850886-34-5P,
Benzyl[cis-4-[(biphenyl-4-ylmethyl)amino]-1-(3-

L55 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN Methanesulfonamide, N-[[cis-4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-16-7 CAPLUS
CN Benzenesulfonamide, N-[[cis-4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]-4-methyl- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-17-8 CAPLUS
CN Acetamide, N-[[cis-4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-18-9 CAPLUS

L55 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
methoxyphenyl)cyclohexyl]methyl]amino 850886-15-6P
850886-16-7P, N-[[cis-4-[(Biphenyl-4-ylmethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]-4-methylbenzenesulfonamide 850886-17-8P 850886-18-9P,
N-[[cis-4-[(Biphenyl-4-ylmethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]benzamide 850886-19-0P,
cis-N-Benzyl-4-[(biphenyl-4-ylmethyl)amino]-1-(3-methoxyphenyl)cyclohexanecarboxamide 850886-22-5P,
cis-4-[(Biphenyl-4-ylmethyl)amino]-1-(3-methoxyphenyl)cyclohexanecarboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of novel piperidine and cyclohexanecarbonitrile derivs. as enhancers for LDL receptor manifestation, hypolipidemics, and antiatherosclerotics)

RN 850886-15-6 CAPLUS
CN [1,1'-Biphenyl]-4-methanamine, N-[cis-4-[(ethylamino)methyl]-4-(3-methoxyphenyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-14-5 CAPLUS
CN [1,1'-Biphenyl]-4-methanamine, N-[cis-4-(3-methoxyphenyl)-4-[[(phenylmethyl)amino]methyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-15-6 CAPLUS

L55 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN Benzamide, N-[[cis-4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-(3-methoxyphenyl)cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-19-0 CAPLUS
CN Cyclohexanecarboxamide, 4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-(3-methoxyphenyl)-N-(phenylmethyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 850886-22-5 CAPLUS
CN Cyclohexanecarboxamide, 4-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-(3-methoxyphenyl)-, cis- (CA INDEX NAME)

Relative stereochemistry.



L55 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN
1996:425152 Document No. 125:86319 Original Reference No. 125:16264a,16268a
Preparation and formulation of N-(4-phenylcyclohexyl)alkanamides and analogs as cholesterol biosynthesis inhibitors. Maier, Roland; Moeller, Peter; Molton, Eberhard; Strnasa, Rodolf; Mark, Michael; Eisele, Bernhard
Boehinski, Ralph-Michael (Dr. Karl Thomas GmbH, Germany). Ger. Offen. DE 4417999 A1 19961021, 40 pp. (German). CODEN: GWXXBX. APPLICATION: DE 1994-4417999 19940525.

GI

AB Title compds. [I; R1 = substituted Ph, pyridyl, pyrimidinyl, etc.; Z = (CR2R2'q)n; R2a-2'b = H, alk(en)yl; R3 = alk(en)yl, alkynyl, Ph, cyclohexyl(methyl); R4 = (O- or S-interrupted) alkyl, alkenyl, phenyl(alkyl), etc.; X = O, S, NPh, NSO2C6H4Me-4; n = 0 or 1] were prepared
Thus, I, e.g., prepared 4-[4-(2-diethylaminoethoxy)-3-methylphenyl]-N-hexanoyl-N-methylcyclohexylamine gave 250% inhibition of cholesterol biosynthesis in human hepatoma cells at 10-6M in vitro.
IT 170540-41-4P 170541-26-2P 170541-96-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and formulation of N-(4-phenylcyclohexyl)alkanamides and analogs as cholesterol biosynthesis inhibitors)
RN 170540-41-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[4-(4-hydroxy-3-methylphenyl)cyclohexyl]-N-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L55 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L55 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 170541-26-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[4-(4-hydroxy-3-methylphenyl)cyclohexyl]-N-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 170541-96-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[4-[4-[2-(diethylamino)ethoxy]-3-methylphenyl]cyclohexyl]-N-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

10576581.trn

=> file reg
FILE 'REGISTRY' ENTERED AT 14:59:47 ON 02 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 1 JUN 2009 HIGHEST RN 1151607-22-5
DICTIONARY FILE UPDATES: 1 JUN 2009 HIGHEST RN 1151607-22-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> file caplus

10576581.trn

This file contains CAS Registry Numbers for easy and accurate
substance identification.

```
=> d his

     (FILE 'HOME' ENTERED AT 13:35:47 ON 02 JUN 2009)

     FILE 'REGISTRY' ENTERED AT 13:35:58 ON 02 JUN 2009
L1             STRUCTURE UPLOADED
L2          13 S L1
L3             STRUCTURE UPLOADED
L4          50 S L3
L5       16588 S L3 FULL

     FILE 'STNGUIDE' ENTERED AT 13:43:45 ON 02 JUN 2009

     FILE 'CAPLUS' ENTERED AT 13:49:42 ON 02 JUN 2009

     FILE 'STNGUIDE' ENTERED AT 13:49:49 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 13:55:44 ON 02 JUN 2009
L6             STRUCTURE UPLOADED
L7           0 S SAM L6 SUB=L5
L8             STRUCTURE UPLOADED
L9           0 S SAM L8 SUB=L5
L10         16 S FULL L8 SUB=L5
```

10576581.trn

```
L23          42 S SAM L22 SUB=L5
L24         781 S FULL L22 SUB=L5

     FILE 'CAPLUS' ENTERED AT 14:23:31 ON 02 JUN 2009

     FILE 'REGISTRY' ENTERED AT 14:23:42 ON 02 JUN 2009

     FILE 'CAPLUS' ENTERED AT 14:23:45 ON 02 JUN 2009

     FILE 'CAPLUS' ENTERED AT 14:24:02 ON 02 JUN 2009
L25          75 S L24
L26          59 S L25 AND PY<=2004
L27          52 S L25 AND PRD<=2004
L28          52 S L25 AND PRY<=2004
L29          63 S L26 OR L27 OR L28

     FILE 'STNGUIDE' ENTERED AT 14:36:23 ON 02 JUN 2009

     FILE 'CAPLUS' ENTERED AT 14:38:31 ON 02 JUN 2009
L30      199139 S CHOLESTEROL
L31        3768 S L5
L32          63 S L31 AND L30
L33           8 S L32 AND AMIDE
L34             STRUCTURE UPLOADED

     FILE 'REGISTRY' ENTERED AT 14:40:39 ON 02 JUN 2009
```

```
10576581.trn


     FILE 'CAPLUS' ENTERED AT 14:52:54 ON 02 JUN 2009
L55             3 S L54

     FILE 'REGISTRY' ENTERED AT 14:59:47 ON 02 JUN 2009

     FILE 'CAPLUS' ENTERED AT 15:00:00 ON 02 JUN 2009

=> s l12 and structure activity
       3298940 STRUCTURE
        893015 STRUCTURES
       3717534 STRUCTURE
                 (STRUCTURE OR STRUCTURES)
       2457890 ACTIVITY
        495701 ACTIVITIES
       2669217 ACTIVITY
                 (ACTIVITY OR ACTIVITIES)
        105391 STRUCTURE ACTIVITY
                 (STRUCTURE(W)ACTIVITY)
L56          19 L12 AND STRUCTURE ACTIVITY

=> d scan ti
```

10576581.trn

L46 19 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI The NMR solution structure of relaxin (RLXP1) receptor lipoprotein receptor class A module and identification of key residues in N-terminal region of module that mediate receptor activation

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L56 19 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Effect of 3-substituted A0(14)-15-ketosterols on cholesterol metabolism in hepatoma Hep G2 cells

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L56 19 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Novel 1,4-diarylpiperidine-4-methylureas as anti-hyperlipidemic agents: Dual effectors on acyl-CoA:cholesterol O-acyltransferase and low-density lipoprotein receptor expression

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L56 19 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Major Involvement of Low-Density Lipoprotein Receptor-Related Protein 1 in the Clearance of Plasma Free Amyloid β-Peptide by the Liver

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10576581.trn

L56 19 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Functional expression of the chicken low density lipoprotein receptor-related protein in a mutant Chinese hamster ovary cell line restores toxicity of Pseudomonas exotoxin A and degradation of α2-macroglobulin

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L56 19 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Anti-Prolll protein antibodies and conjugates for diagnosis and treatment of prostate, lung, colony and pancreatic cancer or metastasis

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L56 19 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Binding effects of β-very LDL with Chinese hamster ovary cells transfected with very LDL receptor containing different repeats deletion

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L56 19 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Dissection of the domain architecture of the α2macroglobulin-receptor-associated protein

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10576581.trn

L46 19 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Growth factor-induced phosphorylation of sterol regulatory element-binding
proteins inhibits sumoylation, thereby stimulating the expression of their
target genes, low d. lipoprotein uptake, and lipid synthesis

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L56 19 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Multivalent recombinant antibodies for treating HIV infection

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L56 19 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Synthesis and Biological Evaluation of a New Series of Sterols as Potential Hypocholesterolemic Agents

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L56 19 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Ursane Triterpenoids Inhibit Atherosclerosis and Xanthoma in LDL Receptor Knockout Mice

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10576581.trn

L56 19 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Ligand-receptor interactions of the low density lipoprotein receptor-related protein, a multi-ligand endocytic receptor

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L56 19 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Berberine Analogues as a Novel Class of the Low-Density-Lipoprotein Receptor Up-Regulators: Synthesis, Structure-Activity Relationships, and Cholesterol-Lowering Efficacy

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L56 19 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Inhibition of nicotinic acetylcholine receptors by apolipoprotein E-derived peptides in rat hippocampal slices

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L56 19 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Dissection of the domain architecture of the alkaroloidvulin-receptor-associated protein. [Erratum to document cited in CA127:2236]

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10576581.trn

L46 19 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI The Epidermal Growth Factor Homology Domain of the LDL
Receptor Drives Lipoprotein Release through an Allosteric
Mechanism Involving H190, H562, and H586

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L56 19 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Requirements of basic amino acid residues within the lectin-like domain
of
LOX-1 for the binding of oxidized low-density lipoprotein

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L56 19 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Substrate-based inhibitors of lanosterol 14a-methyl demethylase: 1.
Assessment of inhibitor structure-activity
relationship and cholesterol biosynthesis inhibition properties

ALL ANSWERS HAVE BEEN SCANNED

10576581.trn

```
=> FIL STNGUIDE
FILE 'STNGUIDE' ENTERED AT 15:01:47 ON 02 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 29, 2009 (20090529/UP).

=>
```